<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Solstice Spatial Document Viewer</title>
    <style>
        /* Global Styles */
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
            margin: 0;
            padding: 0;
            background: #f5f5f5;
            color: #333;
        }
        
        /* Navigation */
        .navbar {
            background: #2c3e50;
            color: white;
            padding: 1rem 2rem;
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 1000;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        
        .navbar h1 {
            margin: 0;
            font-size: 1.5rem;
        }
        
        /* Main Layout */
        .main-content {
            margin-top: 80px;
            padding: 2rem;
        }
        
        /* Document Selector */
        .document-selector {
            background: white;
            padding: 1rem;
            margin-bottom: 2rem;
            border-radius: 8px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.05);
        }
        
        .document-selector select {
            padding: 0.5rem 1rem;
            font-size: 1rem;
            border: 1px solid #ddd;
            border-radius: 4px;
            cursor: pointer;
        }
        
        /* Document Container */
        .document-wrapper {
            display: none;
            background: white;
            padding: 2rem;
            border-radius: 8px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.05);
        }
        
        .document-wrapper.active {
            display: block;
        }
        
        /* Page Container */
        .page-container {
            margin: 2rem auto;
            position: relative;
            background: white;
            box-shadow: 0 4px 8px rgba(0,0,0,0.1);
            overflow: hidden;
        }
        
        /* Block Styling */
        .text-block {
            position: absolute;
            border: 1px solid transparent;
            padding: 2px;
            box-sizing: border-box;
            cursor: pointer;
            transition: all 0.2s ease;
            font-size: 20.0%;
            line-height: 1.2;
            overflow: hidden;
            text-overflow: ellipsis;
        }
        
        .text-block:hover {
            border-color: #3498db;
            background: rgba(52, 152, 219, 0.1);
            z-index: 10;
            overflow: visible;
        }
        
        .text-block.title {
            font-weight: bold;
            color: #2c3e50;
        }
        
        .text-block.list {
            color: #27ae60;
        }
        
        .figure-block, .table-block {
            position: absolute;
            border: 2px dashed #e74c3c;
            background: rgba(231, 76, 60, 0.05);
            display: flex;
            align-items: center;
            justify-content: center;
            text-align: center;
            font-size: 0.8rem;
            color: #e74c3c;
            cursor: pointer;
        }
        
        .table-block {
            border-color: #f39c12;
            background: rgba(243, 156, 18, 0.05);
            color: #f39c12;
        }
        
        /* Page Header */
        .page-header {
            text-align: center;
            padding: 1rem;
            background: #ecf0f1;
            margin: -2rem -2rem 1rem -2rem;
            font-weight: 600;
        }
        
        /* Block Tooltip */
        .block-tooltip {
            position: absolute;
            background: rgba(0, 0, 0, 0.9);
            color: white;
            padding: 0.5rem;
            border-radius: 4px;
            font-size: 0.75rem;
            white-space: nowrap;
            display: none;
            z-index: 1000;
            pointer-events: none;
        }
        
        /* Scale controls */
        .scale-controls {
            position: fixed;
            bottom: 20px;
            right: 20px;
            background: white;
            padding: 1rem;
            border-radius: 8px;
            box-shadow: 0 4px 8px rgba(0,0,0,0.2);
            z-index: 100;
        }
        
        .scale-controls button {
            padding: 0.5rem 1rem;
            margin: 0 0.25rem;
            border: 1px solid #ddd;
            background: white;
            border-radius: 4px;
            cursor: pointer;
        }
        
        .scale-controls button:hover {
            background: #f8f9fa;
        }
        
        .scale-display {
            display: inline-block;
            width: 60px;
            text-align: center;
            font-weight: 600;
        }
    </style>
</head>
<body>

        <nav class="navbar">
            <h1>Solstice Spatial Document Viewer</h1>
            <div style="font-size: 0.9rem; opacity: 0.8; margin-top: 0.5rem;">
                8 documents • 
                85 pages • 
                811 blocks
            </div>
        </nav>
        
<div class="main-content">
<div class="document-selector">
<label for="doc-select">Select Document: </label>
<select id="doc-select" onchange="showDocument(this.value)">
<option value="Zimmerman_et_al.__2023_" selected>Zimmerman_et_al.__2023_</option>
<option value="Treanor_et_al.__2011_" >Treanor_et_al.__2011_</option>
<option value="FlublokPI" >FlublokPI</option>
<option value="CDC_Influenza_vaccines" >CDC_Influenza_vaccines</option>
<option value="Grohskopf_et_al.__2023_" >Grohskopf_et_al.__2023_</option>
<option value="Arunachalam_et_al.__2021_" >Arunachalam_et_al.__2021_</option>
<option value="Hsiao_et_al.__2023_" >Hsiao_et_al.__2023_</option>
<option value="Liu_et_al.__2024_" >Liu_et_al.__2024_</option>
</select>
</div>
<div class="documents-container">
<div class="document-wrapper active" id="doc-Zimmerman_et_al.__2023_">
<h2>Zimmerman_et_al.__2023_</h2>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 1</div>

            <div class="figure-block" 
                 style="left: 46.25633544921875px; top: 70.73579711914063px; width: 571.8089477539063px; height: 106.47339477539063px;"
                 title="[FIGURE 1 - See figure_p1_det_0_004.png]"
                 data-order="0"
                 data-bbox="231.28167724609375,353.6789855957031,3090.326416015625,886.0459594726562">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 191.74639892578125px; top: 142.33236083984374px; width: 278.01575927734376px; height: 12.094775390625001px;"
                 title="tion, egg free vaccines manu fac bin ant technologies have accine; PA-SIIS, Pennsylvania Statewide Randomized controlled trial; RIV4"
                 data-order="1"
                 data-bbox="958.7319946289062,711.6618041992188,2348.810791015625,772.1356811523438">
                tion, egg free vaccines manu fac bin ant technologies have accine; PA-SIIS, Pennsylvania Statewide Randomized controlled trial; RIV4
            </div>
            

            <div class="text-block title" 
                 style="left: 37.66275634765625px; top: 196.15970458984376px; width: 498.8750854492188px; height: 58.247814941406254px;"
                 title="1. Introduction Despite the availability of an array of influenza vaccines and recommendations for vaccination of individuals age 6 months and over, influenza remains a major cause of miz at ions and ..."
                 data-order="2"
                 data-bbox="188.31378173828125,980.7985229492188,2682.689208984375,1272.03759765625">
                1. Introduction Despite the availability of an array of influenza vaccines and recommendations for vaccination of individuals age 6 months and over, influenza remains a major cause of miz at ions and ...
            </div>
            

            <div class="text-block text" 
                 style="left: 46.37858581542969px; top: 260.964892578125px; width: 564.8107208251953px; height: 30.5234619140625px;"
                 title=""
                 data-order="3"
                 data-bbox="231.89292907714844,1304.824462890625,3055.946533203125,1457.4417724609375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 42.01104431152344px; top: 296.14921875px; width: 558.0105865478516px; height: 41.367578125px;"
                 title="Conclusions: Over all adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and t..."
                 data-order="4"
                 data-bbox="210.0552215576172,1480.74609375,3000.108154296875,1687.583984375">
                Conclusions: Over all adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and t...
            </div>
            

            <div class="text-block title" 
                 style="left: 223.77490234375px; top: 361.904736328125px; width: 74.0896728515625px; height: 3.4812988281250004px;"
                 title="65 years or older ("
                 data-order="5"
                 data-bbox="1118.87451171875,1809.523681640625,1489.3228759765625,1826.93017578125">
                65 years or older (
            </div>
            

            <div class="text-block text" 
                 style="left: 200.72769775390626px; top: 374.684765625px; width: 420.8896850585938px; height: 200.25654296875px;"
                 title="i ology, Suite 600 Sc henley Place, 4420 Bayard St., Pittsburgh, PA 15260, USA Division of Infectious Diseases/Pharmacy Department - AMP 5 TH Floor Falk Medical Building, 3601 Fifth Ave, Pittsburgh, P..."
                 data-order="6"
                 data-bbox="1003.6384887695312,1873.423828125,3108.0869140625,2874.70654296875">
                i ology, Suite 600 Sc henley Place, 4420 Bayard St., Pittsburgh, PA 15260, USA Division of Infectious Diseases/Pharmacy Department - AMP 5 TH Floor Falk Medical Building, 3601 Fifth Ave, Pittsburgh, P...
            </div>
            

            <div class="text-block title" 
                 style="left: 40.599307250976565px; top: 639.5003417968751px; width: 69.0638641357422px; height: 14.216064453125px;"
                 title="vaccines atest negat"
                 data-order="7"
                 data-bbox="202.9965362548828,3197.501708984375,548.3158569335938,3268.58203125">
                vaccines atest negat
            </div>
            

            <div class="text-block text" 
                 style="left: 43.45837097167969px; top: 663.5744140625001px; width: 279.1947784423828px; height: 25.4375px;"
                 title="Vaccine effectiveness of recombinant an i i i fl l d h i"
                 data-order="8"
                 data-bbox="217.29185485839844,3317.8720703125,1613.2657470703125,3445.0595703125">
                Vaccine effectiveness of recombinant an i i i fl l d h i
            </div>
            

            <div class="text-block text" 
                 style="left: 42.440896606445314px; top: 703.0451171875001px; width: 278.9897674560547px; height: 76.5244140625px;"
                 title="Va journal homepage: www"
                 data-order="9"
                 data-bbox="212.20448303222656,3515.2255859375,1607.1533203125,3897.84765625">
                Va journal homepage: www
            </div>
            

            <div class="text-block text" 
                 style="left: 50.543817138671876px; top: 788.62734375px; width: 81.18386840820312px; height: 1.5079101562500001px;"
                 title=""
                 data-order="10"
                 data-bbox="252.71908569335938,3943.13671875,658.638427734375,3950.67626953125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 53.41007690429688px; top: 790.8903320312501px; width: 187.76992797851562px; height: 11.357666015625px;"
                 title=""
                 data-order="11"
                 data-bbox="267.0503845214844,3954.45166015625,1205.9000244140625,4011.239990234375">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 39.65040893554688px; top: 810.5495117187501px; width: 177.27734985351563px; height: 20.41474609375px;"
                 title=""
                 data-order="12"
                 data-bbox="198.25204467773438,4052.74755859375,1084.6387939453125,4154.8212890625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 466.6564453125px; top: 584.751806640625px; width: 153.66328125px; height: 2.3017578125px;"
                 title=""
                 data-order="13"
                 data-bbox="2333.2822265625,2923.759033203125,3101.5986328125,2935.267822265625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 339.9715576171875px; top: 636.851318359375px; width: 277.7350341796875px; height: 147.157470703125px;"
                 title="standard dose influenza iz at ion using a retrospective ine evier.com/locate/vaccine"
                 data-order="14"
                 data-bbox="1699.8577880859375,3184.256591796875,3088.532958984375,3920.0439453125">
                standard dose influenza iz at ion using a retrospective ine evier.com/locate/vaccine
            </div>
            
</div>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 2</div>

            <div class="text-block title" 
                 style="left: 37.94064025878907px; top: 50.889312744140625px; width: 176.29202575683595px; height: 11.42579345703125px;"
                 title="influenza vaccine in a season, missing i"
                 data-order="0"
                 data-bbox="189.7032012939453,254.44656372070312,1071.163330078125,311.5755310058594">
                influenza vaccine in a season, missing i
            </div>
            

            <div class="text-block text" 
                 style="left: 42.04608764648438px; top: 65.96302490234375px; width: 279.51128540039065px; height: 206.88074951171876px;"
                 title="2.1. Patients Patients were individuals 18 years and older as of August 1 each season who were hospitalized in one of nineteen UPMC hospitals in central and southwestern Pennsylvania and had atest for..."
                 data-order="1"
                 data-bbox="210.23043823242188,329.81512451171875,1607.786865234375,1364.2188720703125">
                2.1. Patients Patients were individuals 18 years and older as of August 1 each season who were hospitalized in one of nineteen UPMC hospitals in central and southwestern Pennsylvania and had atest for...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.223382568359376px; top: 268.339599609375px; width: 282.12720336914066px; height: 83.4128173828125px;"
                 title="The University of Pittsburgh Institutional Review Board approved this retrospective study using EMR databases. A test negative case control study estimates VE by comparing the odds of vaccination amon..."
                 data-order="2"
                 data-bbox="201.11691284179688,1341.697998046875,1611.7529296875,1758.7620849609375">
                The University of Pittsburgh Institutional Review Board approved this retrospective study using EMR databases. A test negative case control study estimates VE by comparing the odds of vaccination amon...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.31746215820313px; top: 347.99101562500005px; width: 280.7395690917969px; height: 131.822900390625px;"
                 title="bidity and mortality. Additional rVE studies of new vaccine formulations are needed to help determine vaccination best practices. This study is a retrospective test negative case control study of infl..."
                 data-order="3"
                 data-bbox="196.58731079101562,1739.955078125,1600.28515625,2399.069580078125">
                bidity and mortality. Additional rVE studies of new vaccine formulations are needed to help determine vaccination best practices. This study is a retrospective test negative case control study of infl...
            </div>
            

            <div class="text-block title" 
                 style="left: 40.01890563964844px; top: 497.95068359375px; width: 52.10458679199219px; height: 13.8193359375px;"
                 title="influenza co [12], there i"
                 data-order="4"
                 data-bbox="200.0945281982422,2489.75341796875,460.6174621582031,2558.85009765625">
                influenza co [12], there i
            </div>
            

            <div class="text-block text" 
                 style="left: 42.33419189453125px; top: 518.209326171875px; width: 279.06568603515626px; height: 85.647314453125px;"
                 title="Two large studies have explored rVE of recombinant quad riv a lent influenza vaccine (RIV4). The Medicare beneficiaries study [10] using retrospective data as described above, reported significant rVE..."
                 data-order="5"
                 data-bbox="211.67095947265625,2591.046630859375,1606.9993896484375,3019.283203125">
                Two large studies have explored rVE of recombinant quad riv a lent influenza vaccine (RIV4). The Medicare beneficiaries study [10] using retrospective data as described above, reported significant rVE...
            </div>
            

            <div class="text-block title" 
                 style="left: 40.11873474121094px; top: 618.97978515625px; width: 52.28919982910156px; height: 13.74912109375px;"
                 title="laboratory-c fll lt"
                 data-order="6"
                 data-bbox="200.5936737060547,3094.89892578125,462.0396728515625,3163.64453125">
                laboratory-c fll lt
            </div>
            

            <div class="text-block text" 
                 style="left: 41.69203491210938px; top: 639.21279296875px; width: 278.0755187988281px; height: 200.42744140625px;"
                 title="Reasonably accurate VE and relative VE (rVE) estimates depend upon having access to a sufficient number of recipients of any given vaccine type. Research on high dose quad rival ent influenza vaccine ..."
                 data-order="7"
                 data-bbox="208.46017456054688,3196.06396484375,1598.8377685546875,4198.201171875">
                Reasonably accurate VE and relative VE (rVE) estimates depend upon having access to a sufficient number of recipients of any given vaccine type. Research on high dose quad rival ent influenza vaccine ...
            </div>
            

            <div class="text-block title" 
                 style="left: 337.5471923828125px; top: 72.98375854492188px; width: 97.7470458984375px; height: 13.061572265625001px;"
                 title="ditions and influenza...t"
                 data-order="8"
                 data-bbox="1687.7359619140625,364.9187927246094,2176.47119140625,430.2266540527344">
                ditions and influenza...t
            </div>
            

            <div class="text-block text" 
                 style="left: 340.682763671875px; top: 93.91175537109376px; width: 279.80136718750003px; height: 203.36707763671876px;"
                 title="mari zed across variables. We allow a maximum of three splits for each tree in the model, allowing for three way interactions among all covariates to be considered. The shrinkage parameter was set to ..."
                 data-order="9"
                 data-bbox="1703.413818359375,469.55877685546875,3102.420654296875,1486.3941650390625">
                mari zed across variables. We allow a maximum of three splits for each tree in the model, allowing for three way interactions among all covariates to be considered. The shrinkage parameter was set to ...
            </div>
            

            <div class="text-block text" 
                 style="left: 337.5844970703125px; top: 288.728515625px; width: 283.9667236328125px; height: 192.34194335937502px;"
                 title="Standard Dose Flu zone and FlucelVax. HD-IIV4 was High Dose Flu zone, RIV4 was Flublok and Adj-IV was FluAd. Other independent variables were age, influenza season (2018-2019 and 20192020), sex, race ..."
                 data-order="10"
                 data-bbox="1687.9224853515625,1443.642578125,3107.756103515625,2405.352294921875">
                Standard Dose Flu zone and FlucelVax. HD-IIV4 was High Dose Flu zone, RIV4 was Flublok and Adj-IV was FluAd. Other independent variables were age, influenza season (2018-2019 and 20192020), sex, race ...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.3979736328125px; top: 476.22685546875005px; width: 283.9823486328125px; height: 155.9595703125px;"
                 title="and percentages for categorical data. Baseline characteristics between the vaccination groups were compared using chi square or the Fisher’sexact tests for categorical variables and ages were compared..."
                 data-order="11"
                 data-bbox="1691.9898681640625,2381.13427734375,3111.901611328125,3160.93212890625">
                and percentages for categorical data. Baseline characteristics between the vaccination groups were compared using chi square or the Fisher’sexact tests for categorical variables and ages were compared...
            </div>
            

            <div class="text-block text" 
                 style="left: 340.5562255859375px; top: 629.1904296875px; width: 280.1832275390625px; height: 60.623291015625px;"
                 title="respectively, thus these analyses were likely to be underpowered to detect a significant rVE for RIV4 over SD-IIV4. Moreover, rVE estimates by vaccine strain were also precluded by insufficient sample..."
                 data-order="12"
                 data-bbox="1702.7811279296875,3145.9521484375,3103.697265625,3449.068603515625">
                respectively, thus these analyses were likely to be underpowered to detect a significant rVE for RIV4 over SD-IIV4. Moreover, rVE estimates by vaccine strain were also precluded by insufficient sample...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.4243408203125px; top: 686.890185546875px; width: 281.0826416015625px; height: 159.66704101562502px;"
                 title="2.2. Statistical methods For primary analysis, all adults 18 years were included, then for secondary analyses, they were stratified into age groups 65 years, and 18-64 years. Sample size calculations ..."
                 data-order="13"
                 data-bbox="1697.1217041015625,3434.450927734375,3102.534912109375,4232.7861328125">
                2.2. Statistical methods For primary analysis, all adults 18 years were included, then for secondary analyses, they were stratified into age groups 65 years, and 18-64 years. Sample size calculations ...
            </div>
            
</div>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 3</div>

            <div class="text-block title" 
                 style="left: 37.65020751953125px; top: 50.809179687500006px; width: 175.96180419921876px; height: 11.611560058593751px;"
                 title="Fig. 1. Flow chart for primary analyses. The prim"
                 data-order="0"
                 data-bbox="188.25103759765625,254.0458984375,1068.06005859375,312.10369873046875">
                Fig. 1. Flow chart for primary analyses. The prim
            </div>
            

            <div class="text-block text" 
                 style="left: 38.548675537109375px; top: 70.91614990234375px; width: 283.6963684082031px; height: 96.58927001953126px;"
                 title=""
                 data-order="1"
                 data-bbox="192.74337768554688,354.58074951171875,1611.2252197265625,837.527099609375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 40.473391723632815px; top: 165.32540283203127px; width: 282.4328582763672px; height: 129.57342529296875px;"
                 title=""
                 data-order="2"
                 data-bbox="202.36695861816406,826.6270141601562,1614.53125,1474.494140625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 41.88196411132813px; top: 294.5282470703125px; width: 123.72482299804688px; height: 12.708276367187501px;"
                 title=""
                 data-order="3"
                 data-bbox="209.40982055664062,1472.6412353515625,828.033935546875,1536.1826171875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 40.59450988769532px; top: 325.855224609375px; width: 44.69796447753907px; height: 13.12900390625px;"
                 title="analyses a (80%), just"
                 data-order="4"
                 data-bbox="202.97254943847656,1629.276123046875,426.4623718261719,1694.921142578125">
                analyses a (80%), just
            </div>
            

            <div class="text-block text" 
                 style="left: 40.205969238281256px; top: 343.703271484375px; width: 280.75445556640625px; height: 184.30278320312502px;"
                 title="The total number of influenza test results among in patients was 18 467 of which 530 were excluded because of missing vaccination information or vaccination &lt; 14 days before illness, and 3,264 were ex..."
                 data-order="5"
                 data-bbox="201.02984619140625,1718.516357421875,1604.8021240234375,2640.0302734375">
                The total number of influenza test results among in patients was 18 467 of which 530 were excluded because of missing vaccination information or vaccination &lt; 14 days before illness, and 3,264 were ex...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.555300903320315px; top: 525.03173828125px; width: 279.2791229248047px; height: 35.138232421875px;"
                 title="3. Results The total number of influenza test results among inpatients was"
                 data-order="6"
                 data-bbox="202.77650451660156,2625.15869140625,1599.172119140625,2800.849853515625">
                3. Results The total number of influenza test results among inpatients was
            </div>
            

            <div class="figure-block" 
                 style="left: 64.13905029296875px; top: 575.91064453125px; width: 511.8644165039063px; height: 238.42978515625px;"
                 title="[FIGURE 8 - See figure_p3_det_2_002.png]"
                 data-order="7"
                 data-bbox="320.69525146484375,2879.55322265625,2880.017333984375,4071.7021484375">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 520.3677734375px; top: 50.3450927734375px; width: 101.67983398437501px; height: 12.857733154296875px;"
                 title="vaccine (RIV4), standard dose"
                 data-order="8"
                 data-bbox="2601.8388671875,251.7254638671875,3110.238037109375,316.0141296386719">
                vaccine (RIV4), standard dose
            </div>
            

            <div class="text-block text" 
                 style="left: 341.1055419921875px; top: 71.63446655273438px; width: 278.9560791015625px; height: 48.79889526367188px;"
                 title=""
                 data-order="9"
                 data-bbox="1705.5277099609375,358.1723327636719,3100.30810546875,602.1668090820312">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 339.06333007812503px; top: 119.340625px; width: 282.64609375000003px; height: 153.309912109375px;"
                 title=""
                 data-order="10"
                 data-bbox="1695.316650390625,596.703125,3108.547119140625,1363.252685546875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 338.7827392578125px; top: 265.3105712890625px; width: 281.30222167968753px; height: 193.2020263671875px;"
                 title="adults 65 years. Again, having a high risk condition was associated with receipt of one of these vaccines (87.5% combined vs. 78.4% SD-IIV4; P &lt; 0 001. Adjusted VEs for RIV4 for younger adults were si..."
                 data-order="11"
                 data-bbox="1693.9136962890625,1326.5528564453125,3100.4248046875,2292.56298828125">
                adults 65 years. Again, having a high risk condition was associated with receipt of one of these vaccines (87.5% combined vs. 78.4% SD-IIV4; P &lt; 0 001. Adjusted VEs for RIV4 for younger adults were si...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.882763671875px; top: 454.46860351562503px; width: 282.486767578125px; height: 98.0263671875px;"
                 title="white race (83.7% RIV4 vs. 71.8% SD-IIV4; P &lt; 0 001, fewer cases of influenza (9.2% RIV4 vs. 11.9% SD-IIV4; P &lt; 0 041 and having a high risk condition (83.2% RIV4 vs. 66.8% SD-IIV4; P &lt; 0 001. Among o..."
                 data-order="12"
                 data-bbox="1699.413818359375,2272.343017578125,3111.84765625,2762.474853515625">
                white race (83.7% RIV4 vs. 71.8% SD-IIV4; P &lt; 0 001, fewer cases of influenza (9.2% RIV4 vs. 11.9% SD-IIV4; P &lt; 0 041 and having a high risk condition (83.2% RIV4 vs. 66.8% SD-IIV4; P &lt; 0 001. Among o...
            </div>
            

            <div class="text-block text" 
                 style="left: 23.009854125976563px; top: 820.53017578125px; width: 599.4366790771485px; height: 20.32685546875px;"
                 title="R. K. Zimmerman, M. Patricia No walk, K. Dauer et al. Vaccine 41 (2023) 5134-5140"
                 data-order="13"
                 data-bbox="115.04927062988281,4102.65087890625,3112.232666015625,4204.28515625">
                R. K. Zimmerman, M. Patricia No walk, K. Dauer et al. Vaccine 41 (2023) 5134-5140
            </div>
            
</div>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 4</div>

            <div class="figure-block" 
                 style="left: 84.12318725585938px; top: 63.39337158203125px; width: 488.04712524414066px; height: 245.55997314453126px;"
                 title="[FIGURE 1 - See figure_p4_det_3_000.png]"
                 data-order="0"
                 data-bbox="420.6159362792969,316.96685791015625,2860.8515625,1544.7667236328125">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 40.15584716796875px; top: 313.79755859375px; width: 581.5773559570313px; height: 30.4531982421875px;"
                 title="b RIV4: Flublok. c SD-IIV4: Afluria, Fluarix, FluLaval, Standard Dose Flu zone and FlucelVax."
                 data-order="1"
                 data-bbox="200.77923583984375,1568.98779296875,3108.666015625,1721.2537841796875">
                b RIV4: Flublok. c SD-IIV4: Afluria, Fluarix, FluLaval, Standard Dose Flu zone and FlucelVax.
            </div>
            

            <div class="text-block title" 
                 style="left: 40.62521057128907px; top: 364.1339111328125px; width: 26.41202087402344px; height: 10.6451171875px;"
                 title="High"
                 data-order="2"
                 data-bbox="203.1260528564453,1820.6695556640625,335.1861572265625,1873.8951416015625">
                High
            </div>
            

            <div class="text-block text" 
                 style="left: 15.268363952636719px; top: 372.61308593750005px; width: 596.0252883911133px; height: 12.801953125px;"
                 title="65 years 7,694 (53) 1,930 (58) 213 (22) Influenza case, ref. = non case, n (%) 1,803 (12) 291 (9) 114 (12) 0.005"
                 data-order="3"
                 data-bbox="76.3418197631836,1863.0654296875,3056.46826171875,1927.0751953125">
                65 years 7,694 (53) 1,930 (58) 213 (22) Influenza case, ref. = non case, n (%) 1,803 (12) 291 (9) 114 (12) 0.005
            </div>
            

            <div class="table-block" 
                 style="left: 44.290771484375px; top: 386.27250976562505px; width: 577.7255859375px; height: 139.384716796875px;"
                 title="[TABLE 5 - See table_p4_det_3_003.png]"
                 data-order="4"
                 data-bbox="221.453857421875,1931.362548828125,3110.081787109375,2628.2861328125">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 46.9476806640625px; top: 522.873779296875px; width: 391.1326904296875px; height: 31.501074218750002px;"
                 title="uadrivalent influenza vaccine (SD-IIV4), high dose quad rival ent influenza vaccine (HD-IIV4), adjuvanted influenza vtherwise excluded."
                 data-order="5"
                 data-bbox="234.7384033203125,2614.368896484375,2190.40185546875,2771.874267578125">
                uadrivalent influenza vaccine (SD-IIV4), high dose quad rival ent influenza vaccine (HD-IIV4), adjuvanted influenza vtherwise excluded.
            </div>
            

            <div class="text-block text" 
                 style="left: 41.53095397949219px; top: 574.294677734375px; width: 279.66130676269535px; height: 36.31396484375px;"
                 title=""
                 data-order="6"
                 data-bbox="207.65476989746094,2871.473388671875,1605.9613037109375,3053.043212890625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 38.819314575195314px; top: 607.22685546875px; width: 283.2698455810547px; height: 110.05781250000001px;"
                 title=""
                 data-order="7"
                 data-bbox="194.09657287597656,3036.13427734375,1610.44580078125,3586.42333984375">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 40.711795043945315px; top: 728.2666992187501px; width: 59.77098083496094px; height: 13.740869140625001px;"
                 title=""
                 data-order="8"
                 data-bbox="203.55897521972656,3641.33349609375,502.41387939453125,3710.037841796875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 42.18217163085938px; top: 750.6216796875001px; width: 280.2672424316406px; height: 72.57216796875001px;"
                 title="R. K. Zimmerman, M. Patricia No walk, K. Dauer et al."
                 data-order="9"
                 data-bbox="210.91085815429688,3753.1083984375,1612.2470703125,4115.96923828125">
                R. K. Zimmerman, M. Patricia No walk, K. Dauer et al.
            </div>
            

            <div class="text-block text" 
                 style="left: 339.9859619140625px; top: 573.53251953125px; width: 280.6678466796875px; height: 19.356640625px;"
                 title=""
                 data-order="10"
                 data-bbox="1699.9298095703125,2867.66259765625,3103.26904296875,2964.44580078125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 338.48154296875003px; top: 598.3111328125px; width: 283.571826171875px; height: 221.592529296875px;"
                 title=""
                 data-order="11"
                 data-bbox="1692.40771484375,2991.5556640625,3110.266845703125,4099.518310546875">
                
            </div>
            
</div>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 5</div>

            <div class="text-block text" 
                 style="left: 39.814004516601564px; top: 50.89453735351563px; width: 172.81712341308594px; height: 11.003155517578126px;"
                 title="was a retrospective cohort study of Medic f d b i 2019-2020 b I i t"
                 data-order="0"
                 data-bbox="199.0700225830078,254.47268676757812,1063.1556396484375,309.48846435546875">
                was a retrospective cohort study of Medic f d b i 2019-2020 b I i t
            </div>
            

            <div class="text-block title" 
                 style="left: 41.29994506835938px; top: 72.94776000976563px; width: 27.107159423828126px; height: 10.947064208984376px;"
                 title="signific culture"
                 data-order="1"
                 data-bbox="206.49972534179688,364.7388000488281,342.0355224609375,419.47412109375">
                signific culture
            </div>
            

            <div class="text-block text" 
                 style="left: 8.724317169189453px; top: 82.23599243164062px; width: 615.3463859558105px; height: 21.610906982421877px;"
                 title="was not significant for those 65 years for either RT PCR con firmed ILI nor culture positive ILI. For those 50-64 years, rVE was significant against RT-PCR ILI (42%; 95% CI = 15 61) and against limite..."
                 data-order="2"
                 data-bbox="43.621585845947266,411.1799621582031,3120.353515625,519.2344970703125">
                was not significant for those 65 years for either RT PCR con firmed ILI nor culture positive ILI. For those 50-64 years, rVE was significant against RT-PCR ILI (42%; 95% CI = 15 61) and against limite...
            </div>
            

            <div class="table-block" 
                 style="left: 42.51338195800781px; top: 104.23045654296875px; width: 586.5953582763672px; height: 166.81085205078125px;"
                 title="[TABLE 4 - See table_p5_det_4_004.png]"
                 data-order="3"
                 data-bbox="212.56690979003906,521.1522827148438,3145.543701171875,1355.20654296875">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 49.70347290039063px; top: 271.6334228515625px; width: 572.2664001464844px; height: 54.37744140625px;"
                 title="ble 4 djusted vaccine effectiveness (VE) of recombinant quad rival ent influenza vaccine (RIV4), standard dose quad rival ent influenza vaccine (SD-IIV4), and RIV4 + high dose uadrivalent influenza va..."
                 data-order="4"
                 data-bbox="248.51736450195312,1358.1671142578125,3109.849365234375,1630.0543212890625">
                ble 4 djusted vaccine effectiveness (VE) of recombinant quad rival ent influenza vaccine (RIV4), standard dose quad rival ent influenza vaccine (SD-IIV4), and RIV4 + high dose uadrivalent influenza va...
            </div>
            

            <div class="text-block title" 
                 style="left: 40.409426879882815px; top: 356.6399169921875px; width: 27.316513061523438px; height: 10.801049804687501px;"
                 title="c RIV4 d F"
                 data-order="5"
                 data-bbox="202.04713439941406,1783.1995849609375,338.62969970703125,1837.204833984375">
                c RIV4 d F
            </div>
            

            <div class="text-block text" 
                 style="left: 44.69889526367188px; top: 365.223388671875px; width: 574.9886047363282px; height: 21.128027343750002px;"
                 title="a SD-IIV4: Afluria, Fluarix, FluLaval, SD Flu zone and FlucelVax. b For difference between those receiving RIV4 and those receiving SD-IIV4. c RIV4: Flublok; HD IIV4: High dose Flu zone; Adj IV: FluAd"
                 data-order="6"
                 data-bbox="223.49447631835938,1826.116943359375,3098.4375,1931.757080078125">
                a SD-IIV4: Afluria, Fluarix, FluLaval, SD Flu zone and FlucelVax. b For difference between those receiving RIV4 and those receiving SD-IIV4. c RIV4: Flublok; HD IIV4: High dose Flu zone; Adj IV: FluAd
            </div>
            

            <div class="table-block" 
                 style="left: 48.547949218750006px; top: 386.2635498046875px; width: 578.15322265625px; height: 107.3546630859375px;"
                 title="[TABLE 8 - See table_p5_det_4_007.png]"
                 data-order="7"
                 data-bbox="242.73974609375,1931.3177490234375,3133.505859375,2468.091064453125">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 48.55525512695313px; top: 490.12631835937503px; width: 286.8306823730469px; height: 31.02294921875px;"
                 title="able 3 har act eris tics of participants by age group and vaccine received including recombinant qu V4), high dose quad rival ent influenza vaccine (HD-IIV4) and adjuvanted influenza vacci"
                 data-order="8"
                 data-bbox="242.77627563476562,2450.631591796875,1676.9296875,2605.746337890625">
                able 3 har act eris tics of participants by age group and vaccine received including recombinant qu V4), high dose quad rival ent influenza vaccine (HD-IIV4) and adjuvanted influenza vacci
            </div>
            

            <div class="text-block text" 
                 style="left: 56.375274658203125px; top: 532.92822265625px; width: 301.4622253417969px; height: 0.55166015625px;"
                 title=""
                 data-order="9"
                 data-bbox="281.8763732910156,2664.64111328125,1789.1875,2667.3994140625">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 40.97471313476563px; top: 558.611669921875px; width: 27.19124755859375px; height: 10.805419921875px;"
                 title="p Groups)"
                 data-order="10"
                 data-bbox="204.87356567382812,2793.058349609375,340.8298034667969,2847.08544921875">
                p Groups)
            </div>
            

            <div class="text-block text" 
                 style="left: 44.10713806152344px; top: 567.153173828125px; width: 573.2500885009766px; height: 22.282568359375002px;"
                 title="Multivariable logistic regression model adjusted for age, race, sex, season, and high risk conditions, except that the stratified variable is not included as an adjustment in ts own analysis. d Propen..."
                 data-order="11"
                 data-bbox="220.5356903076172,2835.765869140625,3086.7861328125,2947.1787109375">
                Multivariable logistic regression model adjusted for age, race, sex, season, and high risk conditions, except that the stratified variable is not included as an adjustment in ts own analysis. d Propen...
            </div>
            

            <div class="table-block" 
                 style="left: 43.05678100585938px; top: 590.3148925781251px; width: 582.9727600097657px; height: 113.99770507812501px;"
                 title="[TABLE 13 - See table_p5_det_4_005.png]"
                 data-order="12"
                 data-bbox="215.28390502929688,2951.574462890625,3130.147705078125,3521.56298828125">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 42.6228515625px; top: 720.1155761718751px; width: 276.8510986328125px; height: 120.53510742187501px;"
                 title="Table 2 Vaccine effectiveness (VE) of recombinant quad rival ent influenza vaccine (RIV4) a propensity scores and inverse probability weighting (IPW). Group Adjusted RIV4 a VE compared to no vaccinati..."
                 data-order="13"
                 data-bbox="213.1142578125,3600.577880859375,1597.3697509765625,4203.25341796875">
                Table 2 Vaccine effectiveness (VE) of recombinant quad rival ent influenza vaccine (RIV4) a propensity scores and inverse probability weighting (IPW). Group Adjusted RIV4 a VE compared to no vaccinati...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.73381347656255px; top: 720.2490234375px; width: 281.4612060546875px; height: 71.77919921875001px;"
                 title="and ard dose quad rival ent influenza vaccine (SD IIV4) and relative VE of RIV4 using lat ive vaccine effectiveness of RIV4 mpa red to SD-IIV4, % (95% CI) justed using a priori riablesc Adjusted using..."
                 data-order="14"
                 data-bbox="1698.6690673828125,3601.2451171875,3105.97509765625,3960.14111328125">
                and ard dose quad rival ent influenza vaccine (SD IIV4) and relative VE of RIV4 using lat ive vaccine effectiveness of RIV4 mpa red to SD-IIV4, % (95% CI) justed using a priori riablesc Adjusted using...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.654736328125px; top: 788.3667968750001px; width: 281.301513671875px; height: 52.98427734375px;"
                 title="and ard dose quad rival ent influenza vaccine (SD-IIV4) and relative VE of RIV4 using Vaccine 41 (2023) 5134-5140"
                 data-order="15"
                 data-bbox="1698.273681640625,3941.833984375,3104.78125,4206.75537109375">
                and ard dose quad rival ent influenza vaccine (SD-IIV4) and relative VE of RIV4 using Vaccine 41 (2023) 5134-5140
            </div>
            
</div>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 6</div>

            <div class="text-block text" 
                 style="left: 80.06618652343751px; top: 48.08914489746094px; width: 17.970660400390624px; height: 812.6829254150391px;"
                 title="Relative vaccine effectiveness (rVE) of recombinant quad rival ent influenza vaccine (RIV4) aand RIV4 + high dose quad rival ent influenza vaccine (HD-IIV4) b + adjuvanted influenza vaccine (Adj-IV) c..."
                 data-order="0"
                 data-bbox="400.3309326171875,240.4457244873047,490.1842346191406,4303.8603515625">
                Relative vaccine effectiveness (rVE) of recombinant quad rival ent influenza vaccine (RIV4) aand RIV4 + high dose quad rival ent influenza vaccine (HD-IIV4) b + adjuvanted influenza vaccine (Adj-IV) c...
            </div>
            

            <div class="table-block" 
                 style="left: 72.13324584960938px; top: 75.28676757812501px; width: 8.682904052734376px; height: 771.799560546875px;"
                 title="[TABLE 2 - See table_p6_det_5_003.png]"
                 data-order="1"
                 data-bbox="360.6662292480469,376.433837890625,404.08074951171875,4235.431640625">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 261.8546142578125px; top: 206.86770019531252px; width: 19.426025390625px; height: 623.2769287109376px;"
                 title="ne, and cell cultured Flu cel vax. usted for age, race, sex, season, and high risk conditions, except that the stratified variable is not included as an adjustment in its own analysis. ession Method w..."
                 data-order="2"
                 data-bbox="1309.2730712890625,1034.3385009765625,1406.4031982421875,4150.72314453125">
                ne, and cell cultured Flu cel vax. usted for age, race, sex, season, and high risk conditions, except that the stratified variable is not included as an adjustment in its own analysis. ession Method w...
            </div>
            

            <div class="text-block title" 
                 style="left: 520.73857421875px; top: 50.314978027343756px; width: 101.23330078125001px; height: 12.901416015625001px;"
                 title="ntly effective among all li i d i h"
                 data-order="3"
                 data-bbox="2603.69287109375,251.57489013671875,3109.859375,316.08197021484375">
                ntly effective among all li i d i h
            </div>
            

            <div class="text-block text" 
                 style="left: 338.08737792968753px; top: 71.41458129882812px; width: 282.39743652343753px; height: 51.85602416992188px;"
                 title="because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines. 5. Conclusions"
                 data-order="4"
                 data-bbox="1690.4368896484375,357.0729064941406,3102.424072265625,616.35302734375">
                because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines. 5. Conclusions
            </div>
            

            <div class="text-block title" 
                 style="left: 339.1934326171875px; top: 135.44877929687502px; width: 122.1815673828125px; height: 13.7017333984375px;"
                 title="wave precedes the influenza circulation of A (H3 N2) may"
                 data-order="5"
                 data-bbox="1695.9671630859375,677.243896484375,2306.875,745.7525634765625">
                wave precedes the influenza circulation of A (H3 N2) may
            </div>
            

            <div class="text-block text" 
                 style="left: 334.9798583984375px; top: 152.0534912109375px; width: 284.3114013671875px; height: 470.6853759765625px;"
                 title="ond, as an integrated healthcare system, its EMR is robust, with regular uploads of vaccination data from the state immunization registry. In addition, we verified vaccination status through the state..."
                 data-order="6"
                 data-bbox="1674.8992919921875,760.2674560546875,3096.456298828125,3113.6943359375">
                ond, as an integrated healthcare system, its EMR is robust, with regular uploads of vaccination data from the state immunization registry. In addition, we verified vaccination status through the state...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.62373046875px; top: 702.289111328125px; width: 278.462109375px; height: 74.76430664062501px;"
                 title="all adults, and supports its superior effectiveness over SD IIV4 for adults 18-64 years of age. 4.1. Strengths and limitations This study has several strengths and limitations. Firstly, the demographi..."
                 data-order="7"
                 data-bbox="1698.11865234375,3511.445556640625,3090.42919921875,3885.26708984375">
                all adults, and supports its superior effectiveness over SD IIV4 for adults 18-64 years of age. 4.1. Strengths and limitations This study has several strengths and limitations. Firstly, the demographi...
            </div>
            

            <div class="text-block title" 
                 style="left: 338.8572998046875px; top: 793.663232421875px; width: 67.529345703125px; height: 13.56123046875px;"
                 title="ate potential im dd tth id"
                 data-order="8"
                 data-bbox="1694.2864990234375,3968.316162109375,2031.9332275390625,4036.122314453125">
                ate potential im dd tth id
            </div>
            

            <div class="text-block text" 
                 style="left: 342.654296875px; top: 816.490283203125px; width: 279.473388671875px; height: 25.786181640625003px;"
                 title="Vaccine 41 (2023) 5134-5140"
                 data-order="9"
                 data-bbox="1713.271484375,4082.451416015625,3110.638427734375,4211.38232421875">
                Vaccine 41 (2023) 5134-5140
            </div>
            
</div>
<div class="page-container" data-width="3245.543701171875" data-height="4403.8603515625" style="width: 649.1087402343751px; height: 880.7720703125001px;">
<div class="page-header">Page 7</div>

            <div class="text-block title" 
                 style="left: 37.785162353515624px; top: 50.82733764648438px; width: 176.3371520996094px; height: 11.7052001953125px;"
                 title=""
                 data-order="0"
                 data-bbox="188.92581176757812,254.13668823242188,1070.611572265625,312.6626892089844">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 40.716067504882815px; top: 71.73095092773438px; width: 283.5803680419922px; height: 60.090423583984375px;"
                 title=""
                 data-order="1"
                 data-bbox="203.58033752441406,358.6547546386719,1621.482177734375,659.1068725585938">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 39.79103698730469px; top: 144.36856689453126px; width: 75.45737609863282px; height: 13.894067382812501px;"
                 title=""
                 data-order="2"
                 data-bbox="198.95518493652344,721.8428344726562,576.2420654296875,791.3131713867188">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 53.70375366210938px; top: 167.24385986328127px; width: 225.45440063476565px; height: 13.651318359375px;"
                 title=""
                 data-order="3"
                 data-bbox="268.5187683105469,836.2192993164062,1395.790771484375,904.4758911132812">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 39.07934265136719px; top: 191.21441650390625px; width: 158.82278137207032px; height: 13.20948486328125px;"
                 title=""
                 data-order="4"
                 data-bbox="195.39671325683594,956.0720825195312,989.5106201171875,1022.1195068359375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 41.47874755859375px; top: 212.4649169921875px; width: 279.3457885742188px; height: 84.34553222656251px;"
                 title="Infect Dis 2014 58 3 319 27. https://doi.org/10.1093/Cid/Cit736. [2] McLean HQ, Thompson MG, Sunda ram ME, Kieke BA, Gag lani M, Mur thy K, et al. Influenza vaccine effectiveness in the United States ..."
                 data-order="5"
                 data-bbox="207.39373779296875,1062.3245849609375,1604.1226806640625,1484.05224609375">
                Infect Dis 2014 58 3 319 27. https://doi.org/10.1093/Cid/Cit736. [2] McLean HQ, Thompson MG, Sunda ram ME, Kieke BA, Gag lani M, Mur thy K, et al. Influenza vaccine effectiveness in the United States ...
            </div>
            

            <div class="text-block title" 
                 style="left: 40.64517517089844px; top: 307.2470703125px; width: 89.80521545410157px; height: 13.849877929687501px;"
                 title="[1] Ohmit SE, Thompson Influenza vaccine effe h i lti i"
                 data-order="6"
                 data-bbox="203.2258758544922,1536.2353515625,652.251953125,1605.4847412109375">
                [1] Ohmit SE, Thompson Influenza vaccine effe h i lti i
            </div>
            

            <div class="text-block text" 
                 style="left: 40.586395263671875px; top: 330.36455078125005px; width: 279.71245727539065px; height: 36.9691162109375px;"
                 title="the study, procure funding and edited the manuscript. References"
                 data-order="7"
                 data-bbox="202.93197631835938,1651.82275390625,1601.4942626953125,1836.6683349609375">
                the study, procure funding and edited the manuscript. References
            </div>
            

            <div class="text-block title" 
                 style="left: 40.372650146484375px; top: 378.7903564453125px; width: 22.355871582031252px; height: 13.6286376953125px;"
                 title="manu procu"
                 data-order="8"
                 data-bbox="201.86325073242188,1893.9517822265625,313.6426086425781,1962.094970703125">
                manu procu
            </div>
            

            <div class="text-block text" 
                 style="left: 50.32828979492188px; top: 402.250146484375px; width: 239.57600708007814px; height: 12.924072265625px;"
                 title="nd edited the manuscript. GKB oversaw the data preparati nalyses and edited the manuscript MPN drafted and edi"
                 data-order="9"
                 data-bbox="251.64144897460938,2011.250732421875,1449.521484375,2075.87109375">
                nd edited the manuscript. GKB oversaw the data preparati nalyses and edited the manuscript MPN drafted and edi
            </div>
            

            <div class="text-block title" 
                 style="left: 40.63078918457032px; top: 427.37958984375px; width: 96.8334442138672px; height: 13.51474609375px;"
                 title="RKZ i dth"
                 data-order="10"
                 data-bbox="203.15394592285156,2136.89794921875,687.3211669921875,2204.4716796875">
                RKZ i dth
            </div>
            

            <div class="text-block text" 
                 style="left: 42.44756164550782px; top: 448.441162109375px; width: 280.1452606201172px; height: 75.27114257812501px;"
                 title="views of the authors and not San of i. Data Deidentified data may be made available upon request. Author contributions"
                 data-order="11"
                 data-bbox="212.23780822753906,2242.205810546875,1612.964111328125,2618.5615234375">
                views of the authors and not San of i. Data Deidentified data may be made available upon request. Author contributions
            </div>
            

            <div class="text-block title" 
                 style="left: 40.534460449218756px; top: 532.446630859375px; width: 51.07584838867188px; height: 12.176123046875px;"
                 title="This work initiated gra"
                 data-order="12"
                 data-bbox="202.67230224609375,2662.233154296875,458.0515441894531,2723.11376953125">
                This work initiated gra
            </div>
            

            <div class="text-block list" 
                 style="left: 45.224237060546876px; top: 552.35107421875px; width: 278.48906860351565px; height: 74.154296875px;"
                 title="received investigator initiated grant funding from San of i for this project. Drs. No walk and Bala sub ram an i, have grant funding from Merck &amp; Co., Inc. for an unrelated project. Ms. Dauer and Mr. ..."
                 data-order="13"
                 data-bbox="226.12118530273438,2761.75537109375,1618.5665283203125,3132.52685546875">
                received investigator initiated grant funding from San of i for this project. Drs. No walk and Bala sub ram an i, have grant funding from Merck &amp; Co., Inc. for an unrelated project. Ms. Dauer and Mr. ...
            </div>
            

            <div class="text-block title" 
                 style="left: 520.32822265625px; top: 50.45471801757813px; width: 101.18720703125001px; height: 12.76771240234375px;"
                 title=""
                 data-order="14"
                 data-bbox="2601.64111328125,252.27359008789062,3107.5771484375,316.1121520996094">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 332.64931640625px; top: 66.65050659179688px; width: 295.24580078125px; height: 554.3062316894532px;"
                 title="benefits of cell culture isolation and manufacturing. The rap Adv Vacc Immunoth 2020 8 1 10. https doi org 10 1177-2515135520908121. [10] Izuri eta HS, Lu M, Kel man J, Lu Y, Linda as A, Loc J, et al...."
                 data-order="15"
                 data-bbox="1663.24658203125,333.2525329589844,3139.4755859375,3104.78369140625">
                benefits of cell culture isolation and manufacturing. The rap Adv Vacc Immunoth 2020 8 1 10. https doi org 10 1177-2515135520908121. [10] Izuri eta HS, Lu M, Kel man J, Lu Y, Linda as A, Loc J, et al....
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-Treanor_et_al.__2011_">
<h2>Treanor_et_al.__2011_</h2>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 1</div>

            <div class="figure-block" 
                 style="left: 59.124444580078126px; top: 70.44091186523438px; width: 570.1086608886719px; height: 85.83870239257813px;"
                 title="[FIGURE 1 - See figure_p1_det_0_005.png]"
                 data-order="0"
                 data-bbox="295.6222229003906,352.2045593261719,3146.16552734375,781.3980712890625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 203.32991943359377px; top: 139.953271484375px; width: 280.8736938476563px; height: 11.582385253906251px;"
                 title="under the control of the baculovir l i ldifi i f h"
                 data-order="1"
                 data-bbox="1016.6495971679688,699.766357421875,2421.01806640625,757.6782836914062">
                under the control of the baculovir l i ldifi i f h
            </div>
            

            <div class="text-block title" 
                 style="left: 41.65173950195313px; top: 192.61320800781252px; width: 590.9422058105469px; height: 42.638012695312504px;"
                 title="Although embryonated hen’seggs have been used to generate effective influenza vaccines for many years, this system does have several important drawbacks. Vaccine manufacturing using eggs requires spec..."
                 data-order="2"
                 data-bbox="208.25869750976562,963.0660400390625,3162.9697265625,1176.256103515625">
                Although embryonated hen’seggs have been used to generate effective influenza vaccines for many years, this system does have several important drawbacks. Vaccine manufacturing using eggs requires spec...
            </div>
            

            <div class="text-block text" 
                 style="left: 66.21449584960938px; top: 258.12041015625px; width: 539.7898986816407px; height: 27.050952148437503px;"
                 title=""
                 data-order="3"
                 data-bbox="331.0724792480469,1290.60205078125,3030.02197265625,1425.8568115234375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 55.219085693359375px; top: 288.95773925781253px; width: 201.82210083007814px; height: 73.0152099609375px;"
                 title="similar Flublok 62 6 def in it Con clu confirm"
                 data-order="4"
                 data-bbox="276.0954284667969,1444.7886962890625,1285.2059326171875,1809.86474609375">
                similar Flublok 62 6 def in it Con clu confirm
            </div>
            

            <div class="figure-block" 
                 style="left: 51.020727539062506px; top: 375.1768798828125px; width: 182.5076904296875px; height: 257.51267089843753px;"
                 title="[FIGURE 6 - See figure_p1_det_0_027.png]"
                 data-order="5"
                 data-bbox="255.1036376953125,1875.8843994140625,1167.64208984375,3163.44775390625">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 240.80007324218752px; top: 386.30563964843753px; width: 75.1068115234375px; height: 12.6974609375px;"
                 title=") uring the 2007-2008"
                 data-order="6"
                 data-bbox="1204.0003662109375,1931.5281982421875,1579.534423828125,1995.0155029296875">
                ) uring the 2007-2008
            </div>
            

            <div class="text-block text" 
                 style="left: 231.11474609375px; top: 400.6819091796875px; width: 408.170849609375px; height: 200.1139892578125px;"
                 title="s States a b s t r a c t Background: Development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production is ahigh priority. We conducted this study to determine ..."
                 data-order="7"
                 data-bbox="1155.57373046875,2003.4095458984375,3196.427978515625,3003.9794921875">
                s States a b s t r a c t Background: Development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production is ahigh priority. We conducted this study to determine ...
            </div>
            

            <div class="text-block title" 
                 style="left: 55.74872436523438px; top: 631.715380859375px; width: 72.60562133789062px; height: 13.991162109375px;"
                 title=""
                 data-order="8"
                 data-bbox="278.7436218261719,3158.576904296875,641.771728515625,3228.53271484375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 56.495947265625006px; top: 653.6847656250001px; width: 281.1709228515625px; height: 75.21718750000001px;"
                 title="rot ect ive efficacy of a trivalent recombin Flublok® against influenza in healthy ad rial"
                 data-order="9"
                 data-bbox="282.479736328125,3268.423828125,1688.3343505859375,3644.509765625">
                rot ect ive efficacy of a trivalent recombin Flublok® against influenza in healthy ad rial
            </div>
            

            <div class="text-block text" 
                 style="left: 54.60243530273438px; top: 758.771484375px; width: 282.8708801269531px; height: 45.337890625px;"
                 title="Vac"
                 data-order="10"
                 data-bbox="273.0121765136719,3793.857421875,1687.3665771484375,4020.546875">
                Vac
            </div>
            

            <div class="text-block text" 
                 style="left: 67.35003051757813px; top: 803.8231933593751px; width: 217.6890808105469px; height: 4.9452148437500005px;"
                 title="Con ten"
                 data-order="11"
                 data-bbox="336.7501525878906,4019.115966796875,1425.195556640625,4043.842041015625">
                Con ten
            </div>
            

            <div class="text-block text" 
                 style="left: 54.378820800781256px; top: 816.3484375px; width: 247.45611572265625px; height: 21.25166015625px;"
                 title="Vacci"
                 data-order="12"
                 data-bbox="271.89410400390625,4081.7421875,1509.1746826171875,4188.00048828125">
                Vacci
            </div>
            

            <div class="text-block text" 
                 style="left: 356.06533203125px; top: 629.091552734375px; width: 282.42124023437503px; height: 61.476269531250004px;"
                 title="nt hemagglutinin protein vaccine lts: A randomized, placebo controlled h d R i I ik e R b t K hb f"
                 data-order="13"
                 data-bbox="1780.32666015625,3145.457763671875,3192.432861328125,3452.839111328125">
                nt hemagglutinin protein vaccine lts: A randomized, placebo controlled h d R i I ik e R b t K hb f
            </div>
            

            <div class="text-block text" 
                 style="left: 353.901513671875px; top: 685.718017578125px; width: 281.74985351562503px; height: 125.23671875000001px;"
                 title="at Science direct ne vier com locate vaccine nt hemagglutinin protein vaccine"
                 data-order="14"
                 data-bbox="1769.507568359375,3428.590087890625,3178.2568359375,4054.773681640625">
                at Science direct ne vier com locate vaccine nt hemagglutinin protein vaccine
            </div>
            
</div>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 2</div>

            <div class="text-block text" 
                 style="left: 41.98299255371094px; top: 67.99093627929688px; width: 287.9507965087891px; height: 108.32200317382814px;"
                 title="ocal and systemic reactions graded as mild (noticeable but not nterfering with normal activities), “moderate” (some interference with normal activities), and “severe” (symptom prevented normal daily a..."
                 data-order="0"
                 data-bbox="209.9149627685547,339.9546813964844,1649.6689453125,881.564697265625">
                ocal and systemic reactions graded as mild (noticeable but not nterfering with normal activities), “moderate” (some interference with normal activities), and “severe” (symptom prevented normal daily a...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.81911926269532px; top: 172.94205322265626px; width: 280.1551483154297px; height: 50.53302001953125px;"
                 title="udy site. Vaccine was administered as a single intramuscular jection in the upper deltoid. Subjects measured their oral temperature daily and maintained memory aid for 7 days after vaccination on whic..."
                 data-order="1"
                 data-bbox="229.09559631347656,864.7102661132812,1629.871337890625,1117.3753662109375">
                udy site. Vaccine was administered as a single intramuscular jection in the upper deltoid. Subjects measured their oral temperature daily and maintained memory aid for 7 days after vaccination on whic...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.855166625976565px; top: 238.22807617187502px; width: 54.575479125976564px; height: 13.67724609375px;"
                 title="ssigned to rece i"
                 data-order="2"
                 data-bbox="219.2758331298828,1191.140380859375,492.1532287597656,1259.526611328125">
                ssigned to rece i
            </div>
            

            <div class="text-block title" 
                 style="left: 42.32265014648438px; top: 262.1751708984375px; width: 55.04841918945313px; height: 12.828149414062501px;"
                 title="on during the"
                 data-order="3"
                 data-bbox="211.61325073242188,1310.8758544921875,486.8553466796875,1375.0166015625">
                on during the
            </div>
            

            <div class="text-block text" 
                 style="left: 43.178591918945315px; top: 282.813232421875px; width: 282.5401336669922px; height: 209.68754882812502px;"
                 title=". hosp hate buffer pH 7.0 ± 0.4 without a preservative. Genes were cloned into baculo virus using RT-PCR from the same Cd ce rived vaccine seed viruses used for the production of licensed nactivated i..."
                 data-order="4"
                 data-bbox="215.89295959472656,1414.066162109375,1628.5936279296875,2462.50390625">
                . hosp hate buffer pH 7.0 ± 0.4 without a preservative. Genes were cloned into baculo virus using RT-PCR from the same Cd ce rived vaccine seed viruses used for the production of licensed nactivated i...
            </div>
            

            <div class="text-block title" 
                 style="left: 42.62890625px; top: 511.508056640625px; width: 106.5441650390625px; height: 13.417529296875001px;"
                 title="H1 N1), A/Wisconsin/67/20"
                 data-order="5"
                 data-bbox="213.14453125,2557.540283203125,745.8653564453125,2624.6279296875">
                H1 N1), A/Wisconsin/67/20
            </div>
            

            <div class="text-block text" 
                 style="left: 45.02111511230469px; top: 530.879736328125px; width: 282.4197540283203px; height: 155.62905273437502px;"
                 title="rmulation of trivalent rHA0 vaccine in a population of healthy oung adults. Methods 1. Vaccine The vaccine (Flublok used in this study consisted of puried hemagglutinin (HA) proteins produced in insec..."
                 data-order="6"
                 data-bbox="225.10557556152344,2654.398681640625,1637.204345703125,3432.5439453125">
                rmulation of trivalent rHA0 vaccine in a population of healthy oung adults. Methods 1. Vaccine The vaccine (Flublok used in this study consisted of puried hemagglutinin (HA) proteins produced in insec...
            </div>
            

            <div class="text-block text" 
                 style="left: 42.91237182617188px; top: 684.2933105468751px; width: 283.34605102539064px; height: 93.548583984375px;"
                 title="7,8]. These studies have consistently shown excellent to ler a bil yand antibody responses similar to those seen with egg derived nfluenza vaccines. Finally, in a preliminary field efficacy evalation,..."
                 data-order="7"
                 data-bbox="214.56185913085938,3421.466552734375,1631.2921142578125,3889.20947265625">
                7,8]. These studies have consistently shown excellent to ler a bil yand antibody responses similar to those seen with egg derived nfluenza vaccines. Finally, in a preliminary field efficacy evalation,...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.716983032226565px; top: 776.964111328125px; width: 280.47618103027344px; height: 62.636181640625004px;"
                 title="34 J. J. Tre an or et al. / Vaccin oung adults and adults 65 and older [3-5]. More recent studs have evaluated rHA0 vaccine formulations in healthy adults, ubjects aged 50-64 years of age [6] and subj..."
                 data-order="8"
                 data-bbox="223.5849151611328,3884.820556640625,1625.9658203125,4198.00146484375">
                34 J. J. Tre an or et al. / Vaccin oung adults and adults 65 and older [3-5]. More recent studs have evaluated rHA0 vaccine formulations in healthy adults, ubjects aged 50-64 years of age [6] and subj...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.4151611328125px; top: 69.1717041015625px; width: 286.7613525390625px; height: 24.990338134765626px;"
                 title="est. Protective efficacy (PE) was calculated as (1-RR), where RR is he relative risk of having an event compared to the placebo group. Upper and lower confidence limits for the RR were calculated usin..."
                 data-order="9"
                 data-bbox="1697.0758056640625,345.8585205078125,3130.882568359375,470.8102111816406">
                est. Protective efficacy (PE) was calculated as (1-RR), where RR is he relative risk of having an event compared to the placebo group. Upper and lower confidence limits for the RR were calculated usin...
            </div>
            

            <div class="text-block title" 
                 style="left: 341.68461914062505px; top: 108.29006347656251px; width: 126.83168945312501px; height: 13.667871093750001px;"
                 title="etween groups in the prop or tio old increase in HAI antibody w"
                 data-order="10"
                 data-bbox="1708.423095703125,541.4503173828125,2342.58154296875,609.7896728515625">
                etween groups in the prop or tio old increase in HAI antibody w
            </div>
            

            <div class="text-block text" 
                 style="left: 342.0093505859375px; top: 129.46514892578125px; width: 286.35935058593753px; height: 109.64263916015625px;"
                 title="trains comparing pre and 28 day post vaccination samples. The rimary efficacy endpoint was culture documented influenza illess, defined as development of a CDC-defined influenza like lness (CDC ILI as..."
                 data-order="11"
                 data-bbox="1710.0467529296875,647.3257446289062,3141.843505859375,1195.5389404296875">
                trains comparing pre and 28 day post vaccination samples. The rimary efficacy endpoint was culture documented influenza illess, defined as development of a CDC-defined influenza like lness (CDC ILI as...
            </div>
            

            <div class="text-block title" 
                 style="left: 341.47600097656255px; top: 251.67934570312502px; width: 97.48684082031251px; height: 13.780786132812501px;"
                 title="ymary immunogen i city en"
                 data-order="12"
                 data-bbox="1707.3800048828125,1258.396728515625,2194.814208984375,1327.3006591796875">
                ymary immunogen i city en
            </div>
            

            <div class="text-block text" 
                 style="left: 343.8054931640625px; top: 272.4826904296875px; width: 281.1643798828125px; height: 189.6699951171875px;"
                 title="ore activity at 1:10 were assigned a value of 1:5. As says were er formed using turkey red blood cells (Viro med Laboratories, Mine ton ka, MN). Swabs for virus culture were stored at −70 ◦C and shipp..."
                 data-order="13"
                 data-bbox="1719.0274658203125,1362.4134521484375,3124.849365234375,2310.763427734375">
                ore activity at 1:10 were assigned a value of 1:5. As says were er formed using turkey red blood cells (Viro med Laboratories, Mine ton ka, MN). Swabs for virus culture were stored at −70 ◦C and shipp...
            </div>
            

            <div class="text-block text" 
                 style="left: 342.3582275390625px; top: 458.31772460937503px; width: 284.7608642578125px; height: 110.46938476562501px;"
                 title="vail able sera from vaccine recipients, and a randomly selected ubset of approximately 33% of placebo specimens were selected or testing. The antigens used in the as says were baculo virus eri ved rHA..."
                 data-order="14"
                 data-bbox="1711.7911376953125,2291.588623046875,3135.595458984375,2843.935546875">
                vail able sera from vaccine recipients, and a randomly selected ubset of approximately 33% of placebo specimens were selected or testing. The antigens used in the as says were baculo virus eri ved rHA...
            </div>
            

            <div class="text-block title" 
                 style="left: 342.27023925781253px; top: 581.2408203125px; width: 100.4161376953125px; height: 13.235107421875px;"
                 title="yemagglutination-inhibit"
                 data-order="15"
                 data-bbox="1711.3511962890625,2906.2041015625,2213.431884765625,2972.379638671875">
                yemagglutination-inhibit
            </div>
            

            <div class="text-block text" 
                 style="left: 342.42485351562505px; top: 601.69873046875px; width: 284.12421875px; height: 120.02797851562501px;"
                 title="he diary and ascertain the presence or absence of respiratory illess symptoms. Subjects were instructed to return to the clinic for lness evaluations if they observed any acute respiratory sympoms or ..."
                 data-order="16"
                 data-bbox="1712.124267578125,3008.49365234375,3132.745361328125,3608.633544921875">
                he diary and ascertain the presence or absence of respiratory illess symptoms. Subjects were instructed to return to the clinic for lness evaluations if they observed any acute respiratory sympoms or ...
            </div>
            

            <div class="text-block text" 
                 style="left: 342.54770507812503px; top: 718.5819824218751px; width: 282.46171875px; height: 120.508544921875px;"
                 title="(2011) 77337739 enter for review of interim safety data at day 28. A final phone call ccurred at the end of the influenza season. 3. Surveillance for influenza During the influenza season, subjects co..."
                 data-order="17"
                 data-bbox="1712.738525390625,3592.909912109375,3125.047119140625,4195.45263671875">
                (2011) 77337739 enter for review of interim safety data at day 28. A final phone call ccurred at the end of the influenza season. 3. Surveillance for influenza During the influenza season, subjects co...
            </div>
            
</div>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 3</div>

            <div class="text-block title" 
                 style="left: 56.01661987304688px; top: 69.06022338867187px; width: 26.246673583984375px; height: 10.739898681640625px;"
                 title=""
                 data-order="0"
                 data-bbox="280.0830993652344,345.3011169433594,411.31646728515625,399.0006103515625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 58.41075439453125px; top: 77.73407592773438px; width: 306.29176025390626px; height: 12.497027587890626px;"
                 title="(n=2304) (n=2344) even"
                 data-order="1"
                 data-bbox="292.05377197265625,388.6703796386719,1823.5125732421875,451.155517578125">
                (n=2304) (n=2344) even
            </div>
            

            <div class="table-block" 
                 style="left: 55.680267333984375px; top: 93.42468872070313px; width: 585.6572814941406px; height: 148.53305053710938px;"
                 title="[TABLE 3 - See table_p3_det_2_009.png]"
                 data-order="2"
                 data-bbox="278.4013366699219,467.1234436035156,3206.687744140625,1209.7886962890625">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 54.54744873046875px; top: 239.75749511718752px; width: 590.9949340820312px; height: 30.4472900390625px;"
                 title="groups) and fatigue or lack of energy (14.5% in both groups). The majority (76%) of complaints of headache were also mild. There were 17 reports of fever (oral temperature &gt;100.4 F) among Flublok"
                 data-order="3"
                 data-bbox="272.73724365234375,1198.7874755859375,3227.7119140625,1351.02392578125">
                groups) and fatigue or lack of energy (14.5% in both groups). The majority (76%) of complaints of headache were also mild. There were 17 reports of fever (oral temperature &gt;100.4 F) among Flublok
            </div>
            

            <div class="text-block text" 
                 style="left: 56.628900146484376px; top: 284.6476318359375px; width: 281.59495239257814px; height: 84.94216308593751px;"
                 title="p y j g. 1. Of the 4648 enrolled subjects, 2344 were randomized to Subjects enrolled (n=4648)"
                 data-order="4"
                 data-bbox="283.1445007324219,1423.2381591796875,1691.1192626953125,1847.948974609375">
                p y j g. 1. Of the 4648 enrolled subjects, 2344 were randomized to Subjects enrolled (n=4648)
            </div>
            

            <div class="text-block title" 
                 style="left: 55.061004638671875px; top: 380.90546875px; width: 94.05375366210939px; height: 13.353857421875px;"
                 title="tota o 6 8 e g bther Flublok or Placeb"
                 data-order="5"
                 data-bbox="275.3050231933594,1904.52734375,745.5737915039062,1971.296630859375">
                tota o 6 8 e g bther Flublok or Placeb
            </div>
            

            <div class="text-block text" 
                 style="left: 59.1570068359375px; top: 402.754052734375px; width: 280.67770996093753px; height: 49.525585937500004px;"
                 title="ent of subjects. Results"
                 data-order="6"
                 data-bbox="295.7850341796875,2013.770263671875,1699.173583984375,2261.398193359375">
                ent of subjects. Results
            </div>
            

            <div class="text-block title" 
                 style="left: 55.0765380859375px; top: 464.380810546875px; width: 48.894116210937504px; height: 13.696533203125px;"
                 title="he study, and"
                 data-order="7"
                 data-bbox="275.3826904296875,2321.904052734375,519.853271484375,2390.38671875">
                he study, and
            </div>
            

            <div class="text-block text" 
                 style="left: 57.58641357421875px; top: 486.66533203125005px; width: 279.8033813476563px; height: 51.219433593750004px;"
                 title="p y g , sum ing a 5% attrition rate. 6. Informed consent"
                 data-order="8"
                 data-bbox="287.93206787109375,2433.32666015625,1686.948974609375,2689.423828125">
                p y g , sum ing a 5% attrition rate. 6. Informed consent
            </div>
            

            <div class="figure-block" 
                 style="left: 59.738232421875004px; top: 551.28916015625px; width: 276.0821533203125px; height: 267.85634765625px;"
                 title="[FIGURE 10 - See figure_p3_det_2_000.png]"
                 data-order="9"
                 data-bbox="298.691162109375,2756.44580078125,1679.1019287109375,4095.7275390625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 102.29969482421876px; top: 824.73134765625px; width: 189.08133544921876px; height: 11.70029296875px;"
                 title="J. J. Tre a no"
                 data-order="10"
                 data-bbox="511.49847412109375,4123.65673828125,1456.9051513671875,4182.158203125">
                J. J. Tre a no
            </div>
            

            <div class="text-block text" 
                 style="left: 355.2422119140625px; top: 283.8448486328125px; width: 281.8802001953125px; height: 84.18593750000001px;"
                 title="uBlok or placebo are shown in Table 1. Flublok was associated ith local injection site pain and muscle aches that were signifantly more frequent than after saline placebo (P &lt;.03 for pain). owever, 94..."
                 data-order="11"
                 data-bbox="1776.2110595703125,1419.2242431640625,3185.612060546875,1840.1539306640625">
                uBlok or placebo are shown in Table 1. Flublok was associated ith local injection site pain and muscle aches that were signifantly more frequent than after saline placebo (P &lt;.03 for pain). owever, 94...
            </div>
            

            <div class="text-block text" 
                 style="left: 355.10100097656255px; top: 363.68845214843753px; width: 283.5722900390625px; height: 98.4294189453125px;"
                 title="AE), there was 1 death in each group, and 9 and 13 subjects in he Flublok and placebo groups, respectively were discontinued for ther reasons. 1. Assessment of vaccine safety The rates and severities ..."
                 data-order="12"
                 data-bbox="1775.5050048828125,1818.4422607421875,3193.366455078125,2310.58935546875">
                AE), there was 1 death in each group, and 9 and 13 subjects in he Flublok and placebo groups, respectively were discontinued for ther reasons. 1. Assessment of vaccine safety The rates and severities ...
            </div>
            

            <div class="text-block title" 
                 style="left: 354.81596679687505px; top: 476.855615234375px; width: 138.2880859375px; height: 13.055078125000001px;"
                 title="ithdrew consent (22 (1%) and 14"
                 data-order="13"
                 data-bbox="1774.079833984375,2384.278076171875,2465.520263671875,2449.553466796875">
                ithdrew consent (22 (1%) and 14
            </div>
            

            <div class="text-block text" 
                 style="left: 353.3519287109375px; top: 499.901025390625px; width: 285.54416503906253px; height: 342.202294921875px;"
                 title="(2011) 77337739-7735 . verity in each group Placebo (N = 2304) Severe Mild Moderate Severe 34 (1) 567 (25) 130 (6) 30 (1) 4 (&lt;1) 5 (&lt;1) 6 (&lt;1) 1 (&lt;1) 12 (&lt;1) 256 (11) 66 (3) 11 (&lt;1) 6 (&lt;1) 54 (2) 13 (..."
                 data-order="14"
                 data-bbox="1766.7596435546875,2499.505126953125,3194.48046875,4210.5166015625">
                (2011) 77337739-7735 . verity in each group Placebo (N = 2304) Severe Mild Moderate Severe 34 (1) 567 (25) 130 (6) 30 (1) 4 (&lt;1) 5 (&lt;1) 6 (&lt;1) 1 (&lt;1) 12 (&lt;1) 256 (11) 66 (3) 11 (&lt;1) 6 (&lt;1) 54 (2) 13 (...
            </div>
            
</div>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 4</div>

            <div class="text-block title" 
                 style="left: 43.56792907714844px; top: 47.67643737792969px; width: 19.96034851074219px; height: 11.977084350585939px;"
                 title="nd thr"
                 data-order="0"
                 data-bbox="217.8396453857422,238.38218688964844,317.6413879394531,298.2676086425781">
                nd thr
            </div>
            

            <div class="text-block title" 
                 style="left: 43.79157104492188px; top: 69.07118530273438px; width: 28.110968017578127px; height: 10.384521484375px;"
                 title="y p rany a"
                 data-order="1"
                 data-bbox="218.95785522460938,345.3559265136719,359.5126953125,397.2785339355469">
                y p rany a
            </div>
            

            <div class="text-block text" 
                 style="left: 40.91866149902344px; top: 77.60881958007813px; width: 617.5029205322267px; height: 12.950872802734375px;"
                 title="( p ) weekly phone calls and instructed to return to the study clinics ture positive CDC-ILI associated with isolation of H1 N1 viruses"
                 data-order="2"
                 data-bbox="204.5933074951172,388.0440979003906,3292.10791015625,452.7984619140625">
                ( p ) weekly phone calls and instructed to return to the study clinics ture positive CDC-ILI associated with isolation of H1 N1 viruses
            </div>
            

            <div class="table-block" 
                 style="left: 40.38683776855469px; top: 91.40595703125001px; width: 592.0518829345704px; height: 134.135888671875px;"
                 title="[TABLE 4 - See table_p4_det_3_003.png]"
                 data-order="3"
                 data-bbox="201.93418884277344,457.02978515625,3162.193603515625,1127.709228515625">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 44.63144226074219px; top: 221.17851562500002px; width: 190.25244445800783px; height: 30.221850585937503px;"
                 title="Among Flublok recipients, subjects with ase seasonal influenza vaccine in the year prio gher baseline titers of antibody against all thre"
                 data-order="4"
                 data-bbox="223.15721130371094,1105.892578125,1174.41943359375,1257.0018310546875">
                Among Flublok recipients, subjects with ase seasonal influenza vaccine in the year prio gher baseline titers of antibody against all thre
            </div>
            

            <div class="text-block text" 
                 style="left: 40.93087158203125px; top: 263.969482421875px; width: 287.3077758789063px; height: 95.955810546875px;"
                 title="luBlok and placebo recipients are shown in Table 2. Flublok nduced serum antibody responses to all three components of the accine in the majority of recipients, although lower response rates were seen..."
                 data-order="5"
                 data-bbox="204.65435791015625,1319.847412109375,1641.1932373046875,1799.62646484375">
                luBlok and placebo recipients are shown in Table 2. Flublok nduced serum antibody responses to all three components of the accine in the majority of recipients, although lower response rates were seen...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.81094055175782px; top: 357.90080566406255px; width: 281.3529022216797px; height: 121.1520751953125px;"
                 title="mong placebo recipients were uneventful and resulted in the birth a normal infant at 36 weeks gestation or later. Two women in the uBlok and three in the placebo group had associated AEs during heir p..."
                 data-order="6"
                 data-bbox="219.05470275878906,1789.5040283203125,1625.8192138671875,2395.264404296875">
                mong placebo recipients were uneventful and resulted in the birth a normal infant at 36 weeks gestation or later. Two women in the uBlok and three in the placebo group had associated AEs during heir p...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.314208984375px; top: 487.928173828125px; width: 89.3326416015625px; height: 12.913232421875001px;"
                 title="ollow up information wnd 15 in placebo). Ten"
                 data-order="7"
                 data-bbox="216.571044921875,2439.640869140625,663.2342529296875,2504.20703125">
                ollow up information wnd 15 in placebo). Ten
            </div>
            

            <div class="text-block text" 
                 style="left: 46.159158325195314px; top: 509.289990234375px; width: 279.8611053466797px; height: 131.50595703125px;"
                 title="p yver and cough 7 days after vaccination and was hospitalized 11 ys after vaccination with a diagnosis of pericardial effusion and rdiac tampon a de. Peri car dio cent es is showed one colony of Prop..."
                 data-order="8"
                 data-bbox="230.79579162597656,2546.449951171875,1630.101318359375,3203.979736328125">
                p yver and cough 7 days after vaccination and was hospitalized 11 ys after vaccination with a diagnosis of pericardial effusion and rdiac tampon a de. Peri car dio cent es is showed one colony of Prop...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.84592895507813px; top: 634.80107421875px; width: 281.3700866699219px; height: 109.680224609375px;"
                 title="Placebo 127 20.33 18.8 3 21.5 (16.5, 25.0) (15.2, 23.3) (1, 8) (18.1, 25.4 Flublok 448 31.9 349.0 78 22.9 (28.2, 36.1) (316.9, 384 3 (74, 82) (20.7, 25.4 Flublok PVa 93 64.9 235.7 56 47.5 (51.0, 82.7)..."
                 data-order="9"
                 data-bbox="224.22964477539062,3174.00537109375,1631.080078125,3722.406494140625">
                Placebo 127 20.33 18.8 3 21.5 (16.5, 25.0) (15.2, 23.3) (1, 8) (18.1, 25.4 Flublok 448 31.9 349.0 78 22.9 (28.2, 36.1) (316.9, 384 3 (74, 82) (20.7, 25.4 Flublok PVa 93 64.9 235.7 56 47.5 (51.0, 82.7)...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.214636230468756px; top: 755.399462890625px; width: 96.5238037109375px; height: 13.787841796875px;"
                 title="Pre"
                 data-order="10"
                 data-bbox="216.07318115234375,3776.997314453125,698.6921997070312,3845.9365234375">
                Pre
            </div>
            

            <div class="text-block text" 
                 style="left: 45.27607116699219px; top: 776.583154296875px; width: 282.7202911376953px; height: 62.262744140625px;"
                 title="36 J. J. Tre an or et al. / Vaccine ble 2 rum hemagglutination-inhibiting (HAI) antibody titers in all subjects, and in Flublok re Group N Pre (day 0) and post vaccination (day 28) geometric mean a A/..."
                 data-order="11"
                 data-bbox="226.38035583496094,3882.915771484375,1639.9818115234375,4194.2294921875">
                36 J. J. Tre an or et al. / Vaccine ble 2 rum hemagglutination-inhibiting (HAI) antibody titers in all subjects, and in Flublok re Group N Pre (day 0) and post vaccination (day 28) geometric mean a A/...
            </div>
            

            <div class="text-block text" 
                 style="left: 345.9056396484375px; top: 266.147900390625px; width: 278.53562011718753px; height: 37.0387939453125px;"
                 title="ruses (98%) were antigenic ally similar to B/Florida/04/2006, presenting a different clade from the vaccine strain, and one flu enz a B virus could not be antigenic ally characterized. The cumulative ..."
                 data-order="12"
                 data-bbox="1729.5281982421875,1330.739501953125,3122.206298828125,1515.9334716796875">
                ruses (98%) were antigenic ally similar to B/Florida/04/2006, presenting a different clade from the vaccine strain, and one flu enz a B virus could not be antigenic ally characterized. The cumulative ...
            </div>
            

            <div class="text-block text" 
                 style="left: 340.68498535156255px; top: 299.71728515625px; width: 285.53073730468753px; height: 83.5594482421875px;"
                 title="y p pesting. These viruses included 12 H1 N1 viruses antigenic ally esembling H1 drift variant A/Brisbane/59/2007, 41 H3 N2 viruses ntigenically resembling the H3 drift variant A/Brisbane/10/2007, 2 H..."
                 data-order="13"
                 data-bbox="1703.4249267578125,1498.58642578125,3131.07861328125,1916.3836669921875">
                y p pesting. These viruses included 12 H1 N1 viruses antigenic ally esembling H1 drift variant A/Brisbane/59/2007, 41 H3 N2 viruses ntigenically resembling the H3 drift variant A/Brisbane/10/2007, 2 H...
            </div>
            

            <div class="text-block text" 
                 style="left: 344.1169677734375px; top: 379.9727294921875px; width: 282.1815185546875px; height: 98.2062255859375px;"
                 title="ruses were A/Wisconsin/67/2005 like H3 N2 viruses. Two of these ccurred in Flublok recipients and 6 occurred in placebo rec i pints, and among these subjects one Flublok recipient and 5 placebo cipien..."
                 data-order="14"
                 data-bbox="1720.5848388671875,1899.8636474609375,3131.492431640625,2390.894775390625">
                ruses were A/Wisconsin/67/2005 like H3 N2 viruses. Two of these ccurred in Flublok recipients and 6 occurred in placebo rec i pints, and among these subjects one Flublok recipient and 5 placebo cipien...
            </div>
            

            <div class="text-block text" 
                 style="left: 342.943994140625px; top: 473.36396484375px; width: 283.66293945312503px; height: 145.6615234375px;"
                 title="nd point for this study was the development of culture confirmed DC-ILI, and we also assessed the effect of vaccination on rates of ny influenza culture positive illness. A total of 582 subjects were ..."
                 data-order="15"
                 data-bbox="1714.719970703125,2366.81982421875,3133.03466796875,3095.12744140625">
                nd point for this study was the development of culture confirmed DC-ILI, and we also assessed the effect of vaccination on rates of ny influenza culture positive illness. A total of 582 subjects were ...
            </div>
            

            <div class="text-block text" 
                 style="left: 342.5197265625px; top: 614.3541992187501px; width: 282.377197265625px; height: 223.65302734375px;"
                 title="(2011) 77337739 ients with or without self reported history of prior seasonal influenza vaccination. body titer (95% CI) and response rates (95% CI) to the following vaccine antigens 7 2005 (H3 N2) B/..."
                 data-order="16"
                 data-bbox="1712.5986328125,3071.77099609375,3124.484619140625,4190.0361328125">
                (2011) 77337739 ients with or without self reported history of prior seasonal influenza vaccination. body titer (95% CI) and response rates (95% CI) to the following vaccine antigens 7 2005 (H3 N2) B/...
            </div>
            
</div>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 5</div>

            <div class="figure-block" 
                 style="left: 65.01574096679688px; top: 66.56510620117187px; width: 266.07720336914065px; height: 369.78381958007816px;"
                 title="[FIGURE 1 - See figure_p5_det_4_002.png]"
                 data-order="0"
                 data-bbox="325.0787048339844,332.8255310058594,1655.4647216796875,2181.74462890625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 56.25321655273438px; top: 443.182568359375px; width: 279.5747375488281px; height: 32.36220703125px;"
                 title="g 2 Kaplan Meier plots of the cumulative incidence of culture positive CDC ILI"
                 data-order="1"
                 data-bbox="281.2660827636719,2215.912841796875,1679.1397705078125,2377.723876953125">
                g 2 Kaplan Meier plots of the cumulative incidence of culture positive CDC ILI
            </div>
            

            <div class="text-block text" 
                 style="left: 56.250317382812504px; top: 487.96708984375005px; width: 284.950830078125px; height: 49.747802734375px;"
                 title=""
                 data-order="2"
                 data-bbox="281.2515869140625,2439.83544921875,1706.0057373046875,2688.574462890625">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 55.40881958007813px; top: 548.802099609375px; width: 63.260894775390625px; height: 14.280712890625px;"
                 title=""
                 data-order="3"
                 data-bbox="277.0440979003906,2744.010498046875,593.3485717773438,2815.4140625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 55.94279174804688px; top: 570.210791015625px; width: 281.84534301757816px; height: 75.75771484375001px;"
                 title=""
                 data-order="4"
                 data-bbox="279.7139587402344,2851.053955078125,1688.940673828125,3229.842529296875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 56.68896484375px; top: 659.8449218750001px; width: 27.372320556640627px; height: 11.331640625px;"
                 title=""
                 data-order="5"
                 data-bbox="283.44482421875,3299.224609375,420.3064270019531,3355.8828125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 58.23041381835938px; top: 668.4853515625px; width: 278.97022094726566px; height: 21.998339843750003px;"
                 title=""
                 data-order="6"
                 data-bbox="291.1520690917969,3342.4267578125,1686.003173828125,3452.41845703125">
                
            </div>
            

            <div class="table-block" 
                 style="left: 56.993847656250004px; top: 688.707763671875px; width: 278.8663330078125px; height: 128.79521484375002px;"
                 title="[TABLE 8 - See table_p5_det_4_014.png]"
                 data-order="7"
                 data-bbox="284.96923828125,3443.538818359375,1679.3009033203125,4087.514892578125">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 56.52703857421875px; top: 816.466796875px; width: 279.88038330078126px; height: 20.444433593750002px;"
                 title="J. J. Tre an or et al. / Vaccin"
                 data-order="8"
                 data-bbox="282.63519287109375,4082.333984375,1682.037109375,4184.55615234375">
                J. J. Tre an or et al. / Vaccin
            </div>
            

            <div class="text-block text" 
                 style="left: 353.33271484375px; top: 68.05205688476563px; width: 286.292724609375px; height: 95.61868286132812px;"
                 title="nthe 2005-2006 influenza season predominated by influenza B iruses and with overall low attack rates [20], and 49.3% over two easons, 2005-2007 with most cases due to antigenic ally variant iruses [21..."
                 data-order="9"
                 data-bbox="1766.66357421875,340.2602844238281,3198.127197265625,818.3536987304688">
                nthe 2005-2006 influenza season predominated by influenza B iruses and with overall low attack rates [20], and 49.3% over two easons, 2005-2007 with most cases due to antigenic ally variant iruses [21...
            </div>
            

            <div class="text-block text" 
                 style="left: 355.10295410156255px; top: 159.38222656250002px; width: 282.5632568359375px; height: 81.85383300781251px;"
                 title="yhich were mostly vaccine like. In another smaller study done on ollege campuses in Michigan [19], the protective efficacy of TIV gainst culture confirmed illness was 73% (95% CI, 51%, 85%). In hat st..."
                 data-order="10"
                 data-bbox="1775.5147705078125,796.9111328125,3188.3310546875,1206.1802978515625">
                yhich were mostly vaccine like. In another smaller study done on ollege campuses in Michigan [19], the protective efficacy of TIV gainst culture confirmed illness was 73% (95% CI, 51%, 85%). In hat st...
            </div>
            

            <div class="text-block text" 
                 style="left: 354.95024414062505px; top: 239.07229003906252px; width: 280.56220703125px; height: 135.673974609375px;"
                 title="ub st anti ally lower than that against influenza A. Comparisons of these results with the results of other ssess men ts of the protective efficacy of influenza vaccines are omplica ted by differences..."
                 data-order="11"
                 data-bbox="1774.751220703125,1195.3614501953125,3177.562255859375,1873.7313232421875">
                ub st anti ally lower than that against influenza A. Comparisons of these results with the results of other ssess men ts of the protective efficacy of influenza vaccines are omplica ted by differences...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.56059570312505px; top: 368.582763671875px; width: 283.65463867187503px; height: 156.226806640625px;"
                 title="nti body [16]. Consistent with the results of national surveillance in the US uring the 2007-2008 season [17], the majority of influenza A iruses detected in this study were H3 N2 viruses that represe..."
                 data-order="12"
                 data-bbox="1767.802978515625,1842.913818359375,3186.076171875,2624.0478515625">
                nti body [16]. Consistent with the results of national surveillance in the US uring the 2007-2008 season [17], the majority of influenza A iruses detected in this study were H3 N2 viruses that represe...
            </div>
            

            <div class="text-block text" 
                 style="left: 356.13388671875003px; top: 518.685400390625px; width: 280.875048828125px; height: 249.23291015625px;"
                 title="eric ard it is has also been reported previously following vaccina on with licensed, egg derived influenza vaccine with a similar me course [11]. The mechanism and clinical significance of such nassoc..."
                 data-order="13"
                 data-bbox="1780.66943359375,2593.427001953125,3185.044677734375,3839.591552734375">
                eric ard it is has also been reported previously following vaccina on with licensed, egg derived influenza vaccine with a similar me course [11]. The mechanism and clinical significance of such nassoc...
            </div>
            

            <div class="text-block text" 
                 style="left: 355.19804687500005px; top: 764.443115234375px; width: 282.437646484375px; height: 75.470751953125px;"
                 title="(2011) 77337739-7737 HA0 vaccine produced using the baculo virus expression system healthy adults [9]. These vaccines have been well tolerated at all oses administered, and are associated with low rat..."
                 data-order="14"
                 data-bbox="1775.990234375,3822.215576171875,3188.178466796875,4199.5693359375">
                (2011) 77337739-7737 HA0 vaccine produced using the baculo virus expression system healthy adults [9]. These vaccines have been well tolerated at all oses administered, and are associated with low rat...
            </div>
            
</div>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 6</div>

            <div class="text-block text" 
                 style="left: 40.328103637695314px; top: 69.034521484375px; width: 289.1884735107422px; height: 36.565185546875px;"
                 title="lin ical trials from Protein Sciences Corporation, Wyeth, San of i, GlaxoSmithKline, PaxVax, Ligocyte, and Vax innate, and is apaid onsultant to ITS incorporated and Novartis. H. E.-S. has received ra..."
                 data-order="0"
                 data-bbox="201.64051818847656,345.172607421875,1647.5828857421875,527.99853515625">
                lin ical trials from Protein Sciences Corporation, Wyeth, San of i, GlaxoSmithKline, PaxVax, Ligocyte, and Vax innate, and is apaid onsultant to ITS incorporated and Novartis. H. E.-S. has received ra...
            </div>
            

            <div class="text-block text" 
                 style="left: 42.843927001953126px; top: 100.03216552734375px; width: 284.2742858886719px; height: 111.62801513671876px;"
                 title="M. D., Benchmark Research, Sacramento, CA; Keith Reisinger M. D., rimary Physicians Research, Pittsburgh, PA; Robert Rosen M. D., arol in a Medical Trials, Winston-Salem, NC; Gilbert Schiff M. D., ter..."
                 data-order="1"
                 data-bbox="214.21963500976562,500.16082763671875,1635.591064453125,1058.3009033203125">
                M. D., Benchmark Research, Sacramento, CA; Keith Reisinger M. D., rimary Physicians Research, Pittsburgh, PA; Robert Rosen M. D., arol in a Medical Trials, Winston-Salem, NC; Gilbert Schiff M. D., ter...
            </div>
            

            <div class="text-block text" 
                 style="left: 42.115625px; top: 203.75466308593752px; width: 285.4603271484375px; height: 194.13076171875002px;"
                 title="ubjects in this study: Mhorag Hay M. D., University of Rochester chool of Medicine, Rochester, NY; Mark Blatter M. D., Primary hysicians Research, Pittsburgh, PA; Stanley Block M. D., Kentucky ediatri..."
                 data-order="2"
                 data-bbox="210.578125,1018.7733154296875,1637.8797607421875,1989.4271240234375">
                ubjects in this study: Mhorag Hay M. D., University of Rochester chool of Medicine, Rochester, NY; Mark Blatter M. D., Primary hysicians Research, Pittsburgh, PA; Stanley Block M. D., Kentucky ediatri...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.0400634765625px; top: 418.734814453125px; width: 91.1970703125px; height: 13.03974609375px;"
                 title="aFleur, Anthony Meyer gators at the study site"
                 data-order="3"
                 data-bbox="215.2003173828125,2093.674072265625,671.1856689453125,2158.872802734375">
                aFleur, Anthony Meyer gators at the study site
            </div>
            

            <div class="text-block text" 
                 style="left: 45.245950317382814px; top: 440.78369140625px; width: 280.7675018310547px; height: 28.582666015625px;"
                 title="cknowledgements The authors acknowledge the efforts of Kerry Senger, Tam"
                 data-order="4"
                 data-bbox="226.22975158691406,2203.91845703125,1630.0672607421875,2346.831787109375">
                cknowledgements The authors acknowledge the efforts of Kerry Senger, Tam
            </div>
            

            <div class="text-block text" 
                 style="left: 43.84333190917969px; top: 477.17353515625px; width: 287.96697082519535px; height: 287.56904296875px;"
                 title="ponal influenza and supports that significant protection in a primed opulation can be obtained against influenza with apure hemagutinin vaccine. The efficacy results also demonstrate that in dults, th..."
                 data-order="5"
                 data-bbox="219.21665954589844,2385.86767578125,1659.051513671875,3823.712890625">
                ponal influenza and supports that significant protection in a primed opulation can be obtained against influenza with apure hemagutinin vaccine. The efficacy results also demonstrate that in dults, th...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.34076538085938px; top: 776.580126953125px; width: 278.47559204101566px; height: 62.817138671875px;"
                 title="38 J. J. Tre an or et al. / Vaccin eclearly impacted by antigenic differences between vaccine and rculating viruses, with highest levels of effectiveness reported for 1 viruses [25] and lowest levels ..."
                 data-order="6"
                 data-bbox="226.70382690429688,3882.900634765625,1619.081787109375,4196.986328125">
                38 J. J. Tre an or et al. / Vaccin eclearly impacted by antigenic differences between vaccine and rculating viruses, with highest levels of effectiveness reported for 1 viruses [25] and lowest levels ...
            </div>
            

            <div class="text-block text" 
                 style="left: 343.14404296875px; top: 67.18909912109375px; width: 281.52109375000003px; height: 75.69893798828126px;"
                 title="2] Belong i a EA, Kieke BA, Donahue JG, Green lee RT, Balish A, Foust A, et al. Effectiveness of in activated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to ..."
                 data-order="7"
                 data-bbox="1715.72021484375,335.94549560546875,3123.32568359375,714.440185546875">
                2] Belong i a EA, Kieke BA, Donahue JG, Green lee RT, Balish A, Foust A, et al. Effectiveness of in activated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to ...
            </div>
            

            <div class="text-block title" 
                 style="left: 342.5245361328125px; top: 167.57375488281252px; width: 51.669897460937506px; height: 12.428186035156251px;"
                 title="1] Jackson L, Ga ffi d"
                 data-order="8"
                 data-bbox="1712.6226806640625,837.8687744140625,1970.97216796875,900.0097045898438">
                1] Jackson L, Ga ffi d
            </div>
            

            <div class="text-block list" 
                 style="left: 342.215478515625px; top: 188.97147216796876px; width: 284.26103515625px; height: 627.7356079101563px;"
                 title="ants to Protein Sciences and multiple other entities. R. I. and M. C. re employees of Protein Sciences. Financial support: The study was funded by Protein Sciences Corporation, the manufacturers fthe ..."
                 data-order="9"
                 data-bbox="1711.077392578125,944.8573608398438,3132.382568359375,4083.535400390625">
                ants to Protein Sciences and multiple other entities. R. I. and M. C. re employees of Protein Sciences. Financial support: The study was funded by Protein Sciences Corporation, the manufacturers fthe ...
            </div>
            

            <div class="text-block text" 
                 style="left: 344.699462890625px; top: 825.39248046875px; width: 278.78828125px; height: 13.01806640625px;"
                 title="(2011) 77337739"
                 data-order="10"
                 data-bbox="1723.497314453125,4126.96240234375,3117.438720703125,4192.052734375">
                (2011) 77337739
            </div>
            
</div>
<div class="page-container" data-width="3392.10791015625" data-height="4310.5166015625" style="width: 678.4215820312501px; height: 862.1033203125px;">
<div class="page-header">Page 7</div>

            <div class="text-block text" 
                 style="left: 265.7833984375px; top: 47.438531494140626px; width: 159.77519531250002px; height: 11.820745849609375px;"
                 title=""
                 data-order="0"
                 data-bbox="1328.9169921875,237.19265747070312,2127.79296875,296.29638671875">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 59.504815673828126px; top: 66.21965942382813px; width: 578.3415710449219px; height: 65.85001831054687px;"
                 title=""
                 data-order="1"
                 data-bbox="297.5240783691406,331.0982971191406,3189.23193359375,660.348388671875">
                
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-FlublokPI">
<h2>FlublokPI</h2>
<div class="page-container" data-width="3346.028564453125" data-height="4301.60546875" style="width: 669.205712890625px; height: 860.32109375px;">
<div class="page-header">Page 1</div>

            <div class="text-block text" 
                 style="left: 37.21581115722656px; top: 47.709869384765625px; width: 279.5712493896485px; height: 19.1203125px;"
                 title="Guillain-Barré Syndrome (GBS). Evidence for a causal relation of GBS with other in flue vaccines is inconclusive; if an excess risk exists, it is probably slightly more than additional case per 1 mill..."
                 data-order="0"
                 data-bbox="186.0790557861328,238.54934692382812,1583.935302734375,334.1509094238281">
                Guillain-Barré Syndrome (GBS). Evidence for a causal relation of GBS with other in flue vaccines is inconclusive; if an excess risk exists, it is probably slightly more than additional case per 1 mill...
            </div>
            

            <div class="table-block" 
                 style="left: 34.79164428710938px; top: 109.0896484375px; width: 614.4140686035157px; height: 415.85341796875px;"
                 title="[TABLE 2 - See table_p1_mrg_det_0_017.png]"
                 data-order="1"
                 data-bbox="173.95822143554688,545.4482421875,3246.028564453125,2624.71533203125">
                <span>Table</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 41.14046630859375px; top: 535.366064453125px; width: 124.63605957031251px; height: 3.0294921875000003px;"
                 title="2.1 Dosage"
                 data-order="2"
                 data-bbox="205.70233154296875,2676.830322265625,828.8826293945312,2691.977783203125">
                2.1 Dosage
            </div>
            

            <div class="text-block text" 
                 style="left: 37.377716064453125px; top: 557.842919921875px; width: 296.0677917480469px; height: 197.868896484375px;"
                 title="Flublok is a vaccine indicated for active immunization for the prevention of disease caused by influenza A virus subtypes and influenza type B virus contained in the vaccine. Flublok is approved for u..."
                 data-order="3"
                 data-bbox="186.88858032226562,2789.214599609375,1667.2275390625,3778.55908203125">
                Flublok is a vaccine indicated for active immunization for the prevention of disease caused by influenza A virus subtypes and influenza type B virus contained in the vaccine. Flublok is approved for u...
            </div>
            

            <div class="text-block text" 
                 style="left: 36.1211181640625px; top: 780.192529296875px; width: 291.506005859375px; height: 2.848876953125px;"
                 title=""
                 data-order="4"
                 data-bbox="180.6055908203125,3900.962646484375,1638.1356201171875,3915.20703125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 43.37355041503906px; top: 824.79580078125px; width: 286.01416931152346px; height: 12.872460937500001px;"
                 title="HIGHLIGHTS OF PRESCRIBING INFORMATION"
                 data-order="5"
                 data-bbox="216.8677520751953,4123.97900390625,1646.9385986328125,4188.34130859375">
                HIGHLIGHTS OF PRESCRIBING INFORMATION
            </div>
            

            <div class="text-block text" 
                 style="left: 369.840576171875px; top: 44.46328125px; width: 273.50078125px; height: 29.646734619140627px;"
                 title="data for Flublok are presented from four clinical trials (Studies 1, 2, 3, and 4). Data a placebo controlled trial in adults 18 through 49 years of age (Study 1) are nted, followed by data pooled acco..."
                 data-order="6"
                 data-bbox="1849.202880859375,222.31640625,3216.706787109375,370.5500793457031">
                data for Flublok are presented from four clinical trials (Studies 1, 2, 3, and 4). Data a placebo controlled trial in adults 18 through 49 years of age (Study 1) are nted, followed by data pooled acco...
            </div>
            

            <div class="text-block list" 
                 style="left: 343.83566894531253px; top: 536.8265625px; width: 297.4136474609375px; height: 303.49453125px;"
                 title="• If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Flublok should be based on careful consideration of potential benefits and risks...."
                 data-order="7"
                 data-bbox="1719.1783447265625,2684.1328125,3206.24658203125,4201.60546875">
                • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Flublok should be based on careful consideration of potential benefits and risks....
            </div>
            
</div>
<div class="page-container" data-width="3346.028564453125" data-height="4301.60546875" style="width: 669.205712890625px; height: 860.32109375px;">
<div class="page-header">Page 2</div>

            <div class="text-block list" 
                 style="left: 37.16869201660156px; top: 43.992041015625006px; width: 297.5755950927734px; height: 292.08564453125px;"
                 title="Nausea 6 1 &lt;1 5 1 &lt;1 Joint pain 4 &lt;1 &lt;1 4 &lt;1 &lt;1 Chills 3 &lt;1 &lt;1 3 &lt;1 &lt;1 Fever¶ &lt;1 &lt;1 &lt;1 &lt;1 &lt;1 &lt;1 NOTE: Data based on the most severe response reported by subjects. Results ≥1% reported to nearest whole..."
                 data-order="0"
                 data-bbox="185.8434600830078,219.960205078125,1673.721435546875,1680.388427734375">
                Nausea 6 1 &lt;1 5 1 &lt;1 Joint pain 4 &lt;1 &lt;1 4 &lt;1 &lt;1 Chills 3 &lt;1 &lt;1 3 &lt;1 &lt;1 Fever¶ &lt;1 &lt;1 &lt;1 &lt;1 &lt;1 &lt;1 NOTE: Data based on the most severe response reported by subjects. Results ≥1% reported to nearest whole...
            </div>
            

            <div class="text-block text" 
                 style="left: 49.662365722656254px; top: 339.09384765625003px; width: 274.06090087890624px; height: 30.771484375px;"
                 title="Fatigue 15 3 &lt;1 14 3 &lt;1 Muscle Pain 11 2 &lt;1 7 &lt;1 &lt;1"
                 data-order="1"
                 data-bbox="248.31182861328125,1695.46923828125,1618.6163330078125,1849.32666015625">
                Fatigue 15 3 &lt;1 14 3 &lt;1 Muscle Pain 11 2 &lt;1 7 &lt;1 &lt;1
            </div>
            

            <div class="table-block" 
                 style="left: 46.08024291992188px; top: 373.2517333984375px; width: 285.0032531738281px; height: 233.2403564453125px;"
                 title="[TABLE 3 - See table_p2_det_1_011.png]"
                 data-order="2"
                 data-bbox="230.40121459960938,1866.2586669921875,1655.41748046875,3032.46044921875">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 40.630688476562504px; top: 601.480224609375px; width: 286.8230712890625px; height: 132.01650390625px;"
                 title="edpo t Study 1 (NCT00539981) included 4648 subjects 18 through 49 years of age for safety analysis, randomized to receive Flublok (n=2344) or placebo (n=2304) (1) (see Clinic a Studies [14 1. Study 2 ..."
                 data-order="3"
                 data-bbox="203.1534423828125,3007.401123046875,1637.268798828125,3667.483642578125">
                edpo t Study 1 (NCT00539981) included 4648 subjects 18 through 49 years of age for safety analysis, randomized to receive Flublok (n=2344) or placebo (n=2304) (1) (see Clinic a Studies [14 1. Study 2 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 46.559765625000004px; top: 748.8595703125001px; width: 284.40952148437503px; height: 5.903125px;"
                 title="ays following receipt of vaccine. Study 4 also actively solicited pre specified common iti it tti th h 30 d fll ...i"
                 data-order="4"
                 data-bbox="232.798828125,3744.2978515625,1654.846435546875,3773.8134765625">
                ays following receipt of vaccine. Study 4 also actively solicited pre specified common iti it tti th h 30 d fll ...i
            </div>
            

            <div class="text-block text" 
                 style="left: 42.46947937011719px; top: 763.1151855468751px; width: 288.0621368408203px; height: 31.373486328125px;"
                 title="of a memory aid for 7 days following vaccination, and unsolicited adverse reactions were collected for 28-30 days post vaccination. In Studies 1- 3 and 5, SAEs were collected for 6 months post vaccina..."
                 data-order="5"
                 data-bbox="212.34739685058594,3815.575927734375,1652.6580810546875,3972.443359375">
                of a memory aid for 7 days following vaccination, and unsolicited adverse reactions were collected for 28-30 days post vaccination. In Studies 1- 3 and 5, SAEs were collected for 6 months post vaccina...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.8701171875px; top: 805.251611328125px; width: 290.73227539062503px; height: 32.760791015625px;"
                 title="Reactogenicity data from a small Phase 2 trial (Study 5) in adults 18 through 49 years of age, 153 of whom received Flublok 135 mcg, are not presented. However, subjects from Study 5 are included in t..."
                 data-order="6"
                 data-bbox="199.3505859375,4026.258056640625,1653.011962890625,4190.06201171875">
                Reactogenicity data from a small Phase 2 trial (Study 5) in adults 18 through 49 years of age, 153 of whom received Flublok 135 mcg, are not presented. However, subjects from Study 5 are included in t...
            </div>
            

            <div class="text-block text" 
                 style="left: 359.77788085937505px; top: 43.56053161621094px; width: 267.494580078125px; height: 32.74093322753907px;"
                 title="or prescription medicine. ever defined as ≥100.4°F (38°C). Mild (≥100 4 to &lt;101.1°F); Moderate (≥101.2°F 102.2°F); Severe (≥102.2°F)"
                 data-order="7"
                 data-bbox="1798.889404296875,217.8026580810547,3136.3623046875,381.50732421875">
                or prescription medicine. ever defined as ≥100.4°F (38°C). Mild (≥100 4 to &lt;101.1°F); Moderate (≥101.2°F 102.2°F); Severe (≥102.2°F)
            </div>
            

            <div class="table-block" 
                 style="left: 355.78281250000003px; top: 80.76488647460938px; width: 284.76767578125003px; height: 221.89944458007812px;"
                 title="[TABLE 9 - See table_p2_det_1_019.png]"
                 data-order="8"
                 data-bbox="1778.9140625,403.8244323730469,3202.75244140625,1513.3216552734375">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 347.75998535156253px; top: 297.722900390625px; width: 293.9644287109375px; height: 131.568115234375px;"
                 title="Table 3: Frequency of Solicited Local Injection Site Adverse Reactions and Systemic Adverse Reactions within 7 Days of Administration of Flublok or Comparator in Adults ≥65 Years of Age, Studies 3 and..."
                 data-order="9"
                 data-bbox="1738.7999267578125,1488.614501953125,3208.6220703125,2146.455078125">
                Table 3: Frequency of Solicited Local Injection Site Adverse Reactions and Systemic Adverse Reactions within 7 Days of Administration of Flublok or Comparator in Adults ≥65 Years of Age, Studies 3 and...
            </div>
            

            <div class="text-block text" 
                 style="left: 354.6553955078125px; top: 432.04501953125003px; width: 284.4939208984375px; height: 2.45458984375px;"
                 title=""
                 data-order="10"
                 data-bbox="1773.2769775390625,2160.22509765625,3195.74658203125,2172.498046875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 359.8240966796875px; top: 449.126171875px; width: 269.86813964843753px; height: 33.241357421875px;"
                 title="or prescription medicine. ever defined as ≥100.4°F (38°C). Mild (≥100 4 to &lt;101.1°F); Moderate (≥101.2°F 102.2°F); Severe (≥102.2°F) For fever, 12 Flublok recipients and 5 IIV3 recipients we is sing d..."
                 data-order="11"
                 data-bbox="1799.1204833984375,2245.630859375,3148.461181640625,2411.837646484375">
                or prescription medicine. ever defined as ≥100.4°F (38°C). Mild (≥100 4 to &lt;101.1°F); Moderate (≥101.2°F 102.2°F); Severe (≥102.2°F) For fever, 12 Flublok recipients and 5 IIV3 recipients we is sing d...
            </div>
            

            <div class="table-block" 
                 style="left: 351.26420898437505px; top: 487.74321289062505px; width: 291.58188476562503px; height: 220.888134765625px;"
                 title="[TABLE 13 - See table_p2_det_1_017.png]"
                 data-order="12"
                 data-bbox="1756.321044921875,2438.716064453125,3214.23046875,3543.15673828125">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 349.1063232421875px; top: 704.368701171875px; width: 293.3607177734375px; height: 108.55605468750001px;"
                 title="Comparator in Adults 50-64 Years of Age, Studies 2 and 4, Total Vaccinated Cohort*,† Flublok N=972 IIV3† N=967 Any Mod‡ Sev‡ Any Mod‡ Sev‡ Local % Pain 32 2 &lt;1 37 &lt;1 0 Firmness/Swelling 7 2 &lt;1 6 1 &lt;1 ..."
                 data-order="13"
                 data-bbox="1745.5316162109375,3521.843505859375,3212.335205078125,4064.623779296875">
                Comparator in Adults 50-64 Years of Age, Studies 2 and 4, Total Vaccinated Cohort*,† Flublok N=972 IIV3† N=967 Any Mod‡ Sev‡ Any Mod‡ Sev‡ Local % Pain 32 2 &lt;1 37 &lt;1 0 Firmness/Swelling 7 2 &lt;1 6 1 &lt;1 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 365.000634765625px; top: 826.21962890625px; width: 269.10751953125003px; height: 2.1775390625px;"
                 title="Table 2: Frequency of Solicited Local Injection Site Adverse Reactions and"
                 data-order="14"
                 data-bbox="1825.003173828125,4131.09814453125,3170.540771484375,4141.98583984375">
                Table 2: Frequency of Solicited Local Injection Site Adverse Reactions and
            </div>
            
</div>
<div class="page-container" data-width="3346.028564453125" data-height="4301.60546875" style="width: 669.205712890625px; height: 860.32109375px;">
<div class="page-header">Page 3</div>

            <div class="text-block text" 
                 style="left: 40.8550048828125px; top: 44.879711914062504px; width: 288.7697021484375px; height: 18.627490234375px;"
                 title="A developmental study of Flublok has been performed in rats administered 0.5 mL (divided, a single human dose is 0.5 mL) of Flublok prior to mating and during gestation. This study revealed no evidenc..."
                 data-order="0"
                 data-bbox="204.2750244140625,224.3985595703125,1648.12353515625,317.5360107421875">
                A developmental study of Flublok has been performed in rats administered 0.5 mL (divided, a single human dose is 0.5 mL) of Flublok prior to mating and during gestation. This study revealed no evidenc...
            </div>
            

            <div class="text-block text" 
                 style="left: 36.58558654785156px; top: 108.08991699218751px; width: 301.27110290527344px; height: 451.4849365234375px;"
                 title="7 days following vaccination. Of these solicited events, rash was most frequently reported (Flublok 1.3%, IIV3 0.8%) over the 30 day follow up period. Flublok Quad rival ent Flublok Quad rival ent has..."
                 data-order="1"
                 data-bbox="182.9279327392578,540.4495849609375,1689.283447265625,2797.874267578125">
                7 days following vaccination. Of these solicited events, rash was most frequently reported (Flublok 1.3%, IIV3 0.8%) over the 30 day follow up period. Flublok Quad rival ent Flublok Quad rival ent has...
            </div>
            

            <div class="text-block title" 
                 style="left: 41.89610900878907px; top: 563.79677734375px; width: 50.174905395507814px; height: 12.378808593750001px;"
                 title="1.9% and 0.9% 7 days following"
                 data-order="2"
                 data-bbox="209.4805450439453,2818.98388671875,460.3550720214844,2880.8779296875">
                1.9% and 0.9% 7 days following
            </div>
            

            <div class="text-block title" 
                 style="left: 40.50762939453125px; top: 576.7167480468751px; width: 111.722509765625px; height: 12.652392578125001px;"
                 title="actively solicited for 30 days follow i 1.6% of IIV3 recipients reported su"
                 data-order="3"
                 data-bbox="202.53814697265625,2883.583740234375,761.1506958007812,2946.845703125">
                actively solicited for 30 days follow i 1.6% of IIV3 recipients reported su
            </div>
            

            <div class="text-block text" 
                 style="left: 37.875244140625px; top: 599.1110351562501px; width: 297.7127197265625px; height: 213.5087890625px;"
                 title="placebo recipient. Both deaths occurred more than 28 days following vaccination and neither was considered vaccine related. SAEs were reported by 32 Flublok recipients and 35 placebo recipients. One S..."
                 data-order="4"
                 data-bbox="189.376220703125,2995.55517578125,1677.9398193359375,4063.09912109375">
                placebo recipient. Both deaths occurred more than 28 days following vaccination and neither was considered vaccine related. SAEs were reported by 32 Flublok recipients and 35 placebo recipients. One S...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.08284912109375px; top: 822.36611328125px; width: 284.95440673828125px; height: 17.545996093750002px;"
                 title="Among adults 18-49 years of age (Studies 1 and 5 pooled), through 6 months ost vaccination two deaths were reported one in a Flublok recipient and one in a"
                 data-order="5"
                 data-bbox="225.41424560546875,4111.83056640625,1650.186279296875,4199.560546875">
                Among adults 18-49 years of age (Studies 1 and 5 pooled), through 6 months ost vaccination two deaths were reported one in a Flublok recipient and one in a
            </div>
            

            <div class="text-block title" 
                 style="left: 348.89707031250003px; top: 44.336456298828125px; width: 78.287158203125px; height: 11.340570068359376px;"
                 title="headache, chills sweats and throat swab sample"
                 data-order="6"
                 data-bbox="1744.4853515625,221.68228149414062,2135.921142578125,278.3851318359375">
                headache, chills sweats and throat swab sample
            </div>
            

            <div class="text-block text" 
                 style="left: 345.52900390625px; top: 55.8561279296875px; width: 297.14482421875px; height: 680.5325927734375px;"
                 title="development or female fertility were observed in the study. 8.2 Lactation Risk Summary It is not known whether Flublok is excreted in human milk. Data are not available to assess the effects of Flublo..."
                 data-order="7"
                 data-bbox="1727.64501953125,279.2806396484375,3213.369140625,3681.943603515625">
                development or female fertility were observed in the study. 8.2 Lactation Risk Summary It is not known whether Flublok is excreted in human milk. Data are not available to assess the effects of Flublo...
            </div>
            

            <div class="text-block text" 
                 style="left: 349.908935546875px; top: 807.30986328125px; width: 292.275927734375px; height: 30.2919921875px;"
                 title="Clinical Considerations Disease associated Maternal and or Embryo/Fetal Risk Pregnant women are at increased risk of complications associated with influenza infection d P i h i fl b i d"
                 data-order="8"
                 data-bbox="1749.544677734375,4036.54931640625,3210.92431640625,4188.00927734375">
                Clinical Considerations Disease associated Maternal and or Embryo/Fetal Risk Pregnant women are at increased risk of complications associated with influenza infection d P i h i fl b i d
            </div>
            
</div>
<div class="page-container" data-width="3346.028564453125" data-height="4301.60546875" style="width: 669.205712890625px; height: 860.32109375px;">
<div class="page-header">Page 4</div>

            <div class="text-block text" 
                 style="left: 39.23019104003907px; top: 44.652444458007814px; width: 291.3842376708985px; height: 6.836752319335938px;"
                 title="( g ) g p plogical data for the 2014-2015 influenza season indicated that Influenza A (H3 N2) viruses"
                 data-order="0"
                 data-bbox="196.1509552001953,223.26222229003906,1653.0721435546875,257.44598388671875">
                ( g ) g p plogical data for the 2014-2015 influenza season indicated that Influenza A (H3 N2) viruses
            </div>
            

            <div class="text-block text" 
                 style="left: 38.99876708984375px; top: 104.630419921875px; width: 289.30467529296874px; height: 81.84910888671875px;"
                 title="y g ( ) y g p yreaction (rtPCR) -confirmed influenza was assessed by active and passive surveillance for influenza like illness (ILI) beginning 2 weeks post- vaccination until the end of the influenza..."
                 data-order="1"
                 data-bbox="194.99383544921875,523.152099609375,1641.5172119140625,932.3976440429688">
                y g ( ) y g p yreaction (rtPCR) -confirmed influenza was assessed by active and passive surveillance for influenza like illness (ILI) beginning 2 weeks post- vaccination until the end of the influenza...
            </div>
            

            <div class="text-block text" 
                 style="left: 52.285333251953126px; top: 194.71805419921876px; width: 263.2791198730469px; height: 20.28826904296875px;"
                 title="mpa rat or, Fluarix Quad rival ent, manufactured by Glaxo Smith kline) (n 4489). ong randomized subjects, 58% were female, 80% white, 18% black/African-Ameri other races, and 5% of Hispanic/Latino eth..."
                 data-order="2"
                 data-bbox="261.4266662597656,973.5902709960938,1577.822265625,1075.0316162109375">
                mpa rat or, Fluarix Quad rival ent, manufactured by Glaxo Smith kline) (n 4489). ong randomized subjects, 58% were female, 80% white, 18% black/African-Ameri other races, and 5% of Hispanic/Latino eth...
            </div>
            

            <div class="figure-block" 
                 style="left: 40.98052673339844px; top: 208.3248046875px; width: 291.18475646972655px; height: 252.30424804687502px;"
                 title="[FIGURE 4 - See figure_p4_det_3_020.png]"
                 data-order="3"
                 data-bbox="204.9026336669922,1041.6240234375,1660.826416015625,2303.145263671875">
                <span>Figure</span>
            </div>
            

            <div class="text-block list" 
                 style="left: 37.91220703125px; top: 456.514404296875px; width: 296.8914306640625px; height: 113.7333984375px;"
                 title="Any ILI, all matched strains¶,# 2 0.1 6 0.3 67.2 (-83.2, 96.8) Positive culture with any strain, regardless of match to the vaccine CDC-ILI, all strains‡,Þ 44 1.9 78 3.4 44.6 (18.8, 62.6) Sub-Type A 2..."
                 data-order="4"
                 data-bbox="189.56103515625,2282.572021484375,1674.0181884765625,2851.239013671875">
                Any ILI, all matched strains¶,# 2 0.1 6 0.3 67.2 (-83.2, 96.8) Positive culture with any strain, regardless of match to the vaccine CDC-ILI, all strains‡,Þ 44 1.9 78 3.4 44.6 (18.8, 62.6) Sub-Type A 2...
            </div>
            

            <div class="text-block text" 
                 style="left: 42.94859619140625px; top: 574.288916015625px; width: 144.41846923828126px; height: 5.12998046875px;"
                 title="matched strains‡,§"
                 data-order="5"
                 data-bbox="214.74298095703125,2871.444580078125,936.8353271484375,2897.094482421875">
                matched strains‡,§
            </div>
            

            <div class="text-block text" 
                 style="left: 42.29655151367188px; top: 585.646728515625px; width: 286.8253479003906px; height: 24.63759765625px;"
                 title="Positive culture with a strains represented in the vaccine CDC ILI all 1 0 04 4 0 2 75 4 ( 148 0"
                 data-order="6"
                 data-bbox="211.48275756835938,2928.233642578125,1645.6094970703125,3051.421630859375">
                Positive culture with a strains represented in the vaccine CDC ILI all 1 0 04 4 0 2 75 4 ( 148 0
            </div>
            

            <div class="text-block text" 
                 style="left: 48.164736938476565px; top: 612.102587890625px; width: 278.92139587402346px; height: 9.986572265625px;"
                 title="Cases, n Rate, % Cases, n Rate, %"
                 data-order="7"
                 data-bbox="240.8236846923828,3060.512939453125,1635.4306640625,3110.44580078125">
                Cases, n Rate, % Cases, n Rate, %
            </div>
            

            <div class="text-block text" 
                 style="left: 39.50887451171875px; top: 662.4471191406251px; width: 290.02952880859374px; height: 112.46484375px;"
                 title="(n 4648). The pre defined success criterion for the primary efficacy analysis was that the lower bound of the 95% confidence interval (CI) of VE should be at least 40%. Vaccine efficacy against antige..."
                 data-order="8"
                 data-bbox="197.54437255859375,3312.235595703125,1647.6920166015625,3874.559814453125">
                (n 4648). The pre defined success criterion for the primary efficacy analysis was that the lower bound of the 95% confidence interval (CI) of VE should be at least 40%. Vaccine efficacy against antige...
            </div>
            

            <div class="text-block text" 
                 style="left: 42.075164794921875px; top: 811.7068359375px; width: 289.72727661132814px; height: 25.5341796875px;"
                 title="The primary efficacy endpoint of Study 1 was Centers for Disease Control defined nfluenza-like illness (CDC ILI with a positive culture for an influenza virus strain antigenic ally resembling a strain..."
                 data-order="9"
                 data-bbox="210.37582397460938,4058.5341796875,1659.01220703125,4186.205078125">
                The primary efficacy endpoint of Study 1 was Centers for Disease Control defined nfluenza-like illness (CDC ILI with a positive culture for an influenza virus strain antigenic ally resembling a strain...
            </div>
            

            <div class="text-block text" 
                 style="left: 349.44619140625px; top: 44.052285766601564px; width: 287.13144531250003px; height: 20.50795593261719px;"
                 title="17 PATIENT COUNSELING INFORMATION In form the vaccine recipient of the potential benefits and risks of vaccination with Flublok In form the vaccine recipient that:"
                 data-order="10"
                 data-bbox="1747.23095703125,220.2614288330078,3182.88818359375,322.80120849609375">
                17 PATIENT COUNSELING INFORMATION In form the vaccine recipient of the potential benefits and risks of vaccination with Flublok In form the vaccine recipient that:
            </div>
            

            <div class="text-block text" 
                 style="left: 357.04853515625px; top: 69.43662109375px; width: 273.69072265625px; height: 35.69765625px;"
                 title="• Store refrigerated between 2° and 8°C (36° and 46°F). • Do not freeze. Discard if product has been frozen. • Protect syringes from light. • Do not use after expiration date shown on the label."
                 data-order="11"
                 data-bbox="1785.24267578125,347.18310546875,3153.6962890625,525.67138671875">
                • Store refrigerated between 2° and 8°C (36° and 46°F). • Do not freeze. Discard if product has been frozen. • Protect syringes from light. • Do not use after expiration date shown on the label.
            </div>
            

            <div class="figure-block" 
                 style="left: 354.45456542968753px; top: 105.44561767578125px; width: 278.2450439453125px; height: 165.51883544921876px;"
                 title="[FIGURE 13 - See figure_p4_det_3_007.png]"
                 data-order="12"
                 data-bbox="1772.2728271484375,527.2280883789062,3163.498046875,1354.822265625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 350.22617187500003px; top: 270.51689453125px; width: 292.165234375px; height: 180.70708007812502px;"
                 title="§Post hoc analyses. All cases of influenza A were A/H3 N2. Cases of influenza B were not distinguished by lineage. ¶Culture of rtPCR-positive samples was performed in MDCK cells. 15 REFERENCES 1. Tre ..."
                 data-order="13"
                 data-bbox="1751.130859375,1352.58447265625,3211.95703125,2256.119873046875">
                §Post hoc analyses. All cases of influenza A were A/H3 N2. Cases of influenza B were not distinguished by lineage. ¶Culture of rtPCR-positive samples was performed in MDCK cells. 15 REFERENCES 1. Tre ...
            </div>
            

            <div class="text-block title" 
                 style="left: 350.4822021484375px; top: 455.49687500000005px; width: 68.3861083984375px; height: 4.564990234375px;"
                 title="should be not less t §P t h l A"
                 data-order="14"
                 data-bbox="1752.4110107421875,2277.484375,2094.341552734375,2300.309326171875">
                should be not less t §P t h l A
            </div>
            

            <div class="text-block list" 
                 style="left: 346.8281494140625px; top: 463.51127929687505px; width: 295.5767333984375px; height: 214.638037109375px;"
                 title="All rtPCR-positive Influenza A§ 73 1.7 114 2.7 0.64 36 (14, 53) All rtPCR-positive Influenza B§ 23 0.5 24 0.6 0.96 4 (-72, 46) All Culture confirmed Protocol- defined ILI§,¶ 58 1.3 101 2.3 0.57 43 (21..."
                 data-order="15"
                 data-bbox="1734.1407470703125,2317.556396484375,3212.0244140625,3390.74658203125">
                All rtPCR-positive Influenza A§ 73 1.7 114 2.7 0.64 36 (14, 53) All rtPCR-positive Influenza B§ 23 0.5 24 0.6 0.96 4 (-72, 46) All Culture confirmed Protocol- defined ILI§,¶ 58 1.3 101 2.3 0.57 43 (21...
            </div>
            

            <div class="text-block text" 
                 style="left: 357.385498046875px; top: 689.3439453125001px; width: 271.661669921875px; height: 1.480615234375px;"
                 title="nfluenza‡ 96 2 2 138 3 2 0 70 30 (10 47)"
                 data-order="16"
                 data-bbox="1786.927490234375,3446.7197265625,3145.23583984375,3454.122802734375">
                nfluenza‡ 96 2 2 138 3 2 0 70 30 (10 47)
            </div>
            

            <div class="table-block" 
                 style="left: 349.8437744140625px; top: 707.273486328125px; width: 292.8375732421875px; height: 110.65390625px;"
                 title="[TABLE 18 - See table_p4_mrg_det_3_015.png]"
                 data-order="17"
                 data-bbox="1749.2188720703125,3536.367431640625,3213.40673828125,4089.636962890625">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 348.5833984375px; top: 832.405078125px; width: 290.42236328125px; height: 5.948828125px;"
                 title="predominated and that most inflen a A/H3 N2 ir ses ere antigenic all dissimilar hile"
                 data-order="18"
                 data-bbox="1742.9169921875,4162.025390625,3195.02880859375,4191.76953125">
                predominated and that most inflen a A/H3 N2 ir ses ere antigenic all dissimilar hile
            </div>
            
</div>
<div class="page-container" data-width="3346.028564453125" data-height="4301.60546875" style="width: 669.205712890625px; height: 860.32109375px;">
<div class="page-header">Page 5</div>

            <div class="text-block text" 
                 style="left: 43.50316162109375px; top: 47.112176513671876px; width: 289.8761352539063px; height: 26.752917480468753px;"
                 title=""
                 data-order="0"
                 data-bbox="217.51580810546875,235.56088256835938,1666.896484375,369.3254699707031">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 40.066662597656254px; top: 79.928271484375px; width: 293.55738525390626px; height: 101.25111083984376px;"
                 title=""
                 data-order="1"
                 data-bbox="200.33331298828125,399.641357421875,1668.1202392578125,905.8969116210938">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 37.15823669433594px; top: 181.30351562500002px; width: 289.68341369628905px; height: 72.786865234375px;"
                 title=""
                 data-order="2"
                 data-bbox="185.7911834716797,906.517578125,1634.208251953125,1270.451904296875">
                
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-CDC_Influenza_vaccines">
<h2>CDC_Influenza_vaccines</h2>
<div class="page-container" data-width="4550.03125" data-height="6444.39404296875" style="width: 910.00625px; height: 1288.8788085937501px;">
<div class="page-header">Page 1</div>

            <div class="text-block title" 
                 style="left: 43.90618591308594px; top: 320.86520996093753px; width: 838.2513336181642px; height: 83.18813476562501px;"
                 title="Flu zone Quad rival ent (San of i Pasteur) 0.5-mL PFS†† ≥6 mos†† 15 µg/0.5 mL IM 0.5-mL SDV†† ≥6 mos†† 15 µg/0.5 mL IM 5 0-mL MDV†† ≥6 mos†† 7 5 µg/0 25 mL IM 25 ¶ ¶ ¶"
                 data-order="0"
                 data-bbox="219.5309295654297,1604.3260498046875,4410.78759765625,2020.2667236328125">
                Flu zone Quad rival ent (San of i Pasteur) 0.5-mL PFS†† ≥6 mos†† 15 µg/0.5 mL IM 0.5-mL SDV†† ≥6 mos†† 15 µg/0.5 mL IM 5 0-mL MDV†† ≥6 mos†† 7 5 µg/0 25 mL IM 25 ¶ ¶ ¶
            </div>
            

            <div class="figure-block" 
                 style="left: 56.171875px; top: 414.58955078125px; width: 818.4671875px; height: 825.5201171875001px;"
                 title="[FIGURE 2 - See figure_p1_det_0_003.png]"
                 data-order="1"
                 data-bbox="280.859375,2072.94775390625,4373.1953125,6200.54833984375">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 45.35414123535156px; top: 441.0048828125px; width: 654.0673919677735px; height: 25.253955078125003px;"
                 title="( ) FluLaval Quad rival ent 0 5 mL PFS ≥6 mos 15 µg/0 5 mL"
                 data-order="2"
                 data-bbox="226.7707061767578,2205.0244140625,3497.107666015625,2331.294189453125">
                ( ) FluLaval Quad rival ent 0 5 mL PFS ≥6 mos 15 µg/0 5 mL
            </div>
            

            <div class="text-block title" 
                 style="left: 57.69801635742188px; top: 604.7916992187501px; width: 108.97213745117188px; height: 18.4154296875px;"
                 title="(Seqirus)"
                 data-order="3"
                 data-bbox="288.4900817871094,3023.95849609375,833.3507690429688,3116.03564453125">
                (Seqirus)
            </div>
            

            <div class="text-block text" 
                 style="left: 56.94075927734375px; top: 634.5779785156251px; width: 293.25494384765625px; height: 19.423828125px;"
                 title="Afluria Quad rival ent 0.5-mL PFS§"
                 data-order="4"
                 data-bbox="284.70379638671875,3172.889892578125,1750.978515625,3270.009033203125">
                Afluria Quad rival ent 0.5-mL PFS§
            </div>
            

            <div class="text-block text" 
                 style="left: 57.7960693359375px; top: 1046.02978515625px; width: 345.33974609375px; height: 19.18486328125px;"
                 title="nfluenza (Flu)"
                 data-order="5"
                 data-bbox="288.9803466796875,5230.14892578125,2015.6790771484375,5326.0732421875">
                nfluenza (Flu)
            </div>
            

            <div class="text-block title" 
                 style="left: 60.043939208984376px; top: 1141.064453125px; width: 284.06384887695316px; height: 20.926855468750002px;"
                 title=""
                 data-order="6"
                 data-bbox="300.2196960449219,5705.322265625,1720.5389404296875,5809.95654296875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 56.753308105468754px; top: 1198.7048828125px; width: 90.19244384765625px; height: 16.52783203125px;"
                 title=""
                 data-order="7"
                 data-bbox="283.76654052734375,5993.5244140625,734.728759765625,6076.16357421875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 56.803845214843754px; top: 1249.5517578125px; width: 440.0182250976563px; height: 19.32705078125px;"
                 title=""
                 data-order="8"
                 data-bbox="284.01922607421875,6247.7587890625,2484.1103515625,6344.39404296875">
                
            </div>
            

            <div class="figure-block" 
                 style="left: 782.49658203125px; top: 155.12864990234377px; width: 104.3716796875px; height: 110.98780517578126px;"
                 title="[FIGURE 10 - See figure_p1_det_0_011.png]"
                 data-order="9"
                 data-bbox="3912.48291015625,775.6432495117188,4434.34130859375,1330.582275390625">
                <span>Figure</span>
            </div>
            
</div>
<div class="page-container" data-width="4550.03125" data-height="6444.39404296875" style="width: 910.00625px; height: 1288.8788085937501px;">
<div class="page-header">Page 2</div>

            <div class="figure-block" 
                 style="left: 43.49028625488282px; top: 42.30670166015625px; width: 842.0047332763672px; height: 372.0300659179688px;"
                 title="[FIGURE 1 - See figure_p2_det_1_000.png]"
                 data-order="0"
                 data-bbox="217.45143127441406,211.53350830078125,4427.47509765625,2071.683837890625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 57.1704345703125px; top: 245.165283203125px; width: 223.2010009765625px; height: 19.8760986328125px;"
                 title="Flu zone Quad rival ent is approved 0 25 L fill d i"
                 data-order="1"
                 data-bbox="285.8521728515625,1225.826416015625,1401.857177734375,1325.2069091796875">
                Flu zone Quad rival ent is approved 0 25 L fill d i
            </div>
            

            <div class="text-block text" 
                 style="left: 56.60701293945313px; top: 332.6015869140625px; width: 191.2889587402344px; height: 19.276513671875px;"
                 title="Guidelines for Immunization a"
                 data-order="2"
                 data-bbox="283.0350646972656,1663.0079345703125,1239.4798583984375,1759.3905029296875">
                Guidelines for Immunization a
            </div>
            

            <div class="text-block text" 
                 style="left: 45.66918029785157px; top: 427.45268554687505px; width: 819.9250579833985px; height: 67.16835937500001px;"
                 title="IM-administered influenza vaccines should be administered by needle and syringe only, with the exception of the MDV presentation of Afluria Quad rival ent, which may alternatively be given by the Phar..."
                 data-order="3"
                 data-bbox="228.3459014892578,2137.263427734375,4327.97119140625,2473.105224609375">
                IM-administered influenza vaccines should be administered by needle and syringe only, with the exception of the MDV presentation of Afluria Quad rival ent, which may alternatively be given by the Phar...
            </div>
            

            <div class="text-block text" 
                 style="left: 41.03044128417969px; top: 518.02236328125px; width: 814.0074493408204px; height: 38.919628906250004px;"
                 title="The approved dose volume for Afluria Quad rival ent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged ≥3 years. However, 0.25-mL pre filled syringes are no longer available...."
                 data-order="4"
                 data-bbox="205.15220642089844,2590.11181640625,4275.189453125,2784.7099609375">
                The approved dose volume for Afluria Quad rival ent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged ≥3 years. However, 0.25-mL pre filled syringes are no longer available....
            </div>
            

            <div class="text-block text" 
                 style="left: 56.035394287109376px; top: 579.166650390625px; width: 822.7230041503907px; height: 46.477197265625px;"
                 title="that any influenza vaccine (egg based or non egg based) that is otherwise appropriate for the recipient sage and health status can be used (see Persons with a History of Egg Allergy)."
                 data-order="5"
                 data-bbox="280.1769714355469,2895.833251953125,4393.7919921875,3128.21923828125">
                that any influenza vaccine (egg based or non egg based) that is otherwise appropriate for the recipient sage and health status can be used (see Persons with a History of Egg Allergy).
            </div>
            

            <div class="text-block text" 
                 style="left: 48.2117919921875px; top: 647.57548828125px; width: 841.7944580078125px; height: 34.166796875px;"
                 title="Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contra indication to the use of egg based †"
                 data-order="6"
                 data-bbox="241.0589599609375,3237.87744140625,4450.03125,3408.71142578125">
                Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contra indication to the use of egg based †
            </div>
            

            <div class="text-block text" 
                 style="left: 32.98752136230469px; top: 738.613037109375px; width: 847.5981231689453px; height: 295.917724609375px;"
                 title="Flublok Quad rival ent (San of i Pasteur) 0.5 mL PFS ≥18 yrs 45 µg/0.5 mL IM LAIV4 (egg based vaccine ) Flu mist Quad rival ent (Astr a zen eca) 0.2-mL pre filled single use intr a nasal sprayer 2 thr..."
                 data-order="7"
                 data-bbox="164.93760681152344,3693.065185546875,4402.92822265625,5172.65380859375">
                Flublok Quad rival ent (San of i Pasteur) 0.5 mL PFS ≥18 yrs 45 µg/0.5 mL IM LAIV4 (egg based vaccine ) Flu mist Quad rival ent (Astr a zen eca) 0.2-mL pre filled single use intr a nasal sprayer 2 thr...
            </div>
            

            <div class="text-block text" 
                 style="left: 54.53810424804688px; top: 1130.071484375px; width: 167.61441040039062px; height: 2.713671875px;"
                 title=""
                 data-order="8"
                 data-bbox="272.6905212402344,5650.357421875,1110.7625732421875,5663.92578125">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 54.783416748046875px; top: 1049.206640625px; width: 814.5794738769532px; height: 68.10078125px;"
                 title="Q (Seqirus) y µg RIV4 (recombinant HA vaccine)"
                 data-order="9"
                 data-bbox="273.9170837402344,5246.033203125,4346.814453125,5586.537109375">
                Q (Seqirus) y µg RIV4 (recombinant HA vaccine)
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-Grohskopf_et_al.__2023_">
<h2>Grohskopf_et_al.__2023_</h2>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 1</div>

            <div class="figure-block" 
                 style="left: 28.008895874023438px; top: 41.27568664550782px; width: 601.9416900634766px; height: 110.49594421386719px;"
                 title="[FIGURE 1 - See figure_p1_mrg_det_0_007.png]"
                 data-order="0"
                 data-bbox="140.0444793701172,206.37843322753906,3149.7529296875,758.858154296875">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 31.754132080078126px; top: 50.35986938476563px; width: 611.2430358886719px; height: 102.59701538085938px;"
                 title="U.S. Department of Health and Human Services Centers for Disease Control and Prevention"
                 data-order="1"
                 data-bbox="158.77066040039062,251.79934692382812,3214.98583984375,764.784423828125">
                U.S. Department of Health and Human Services Centers for Disease Control and Prevention
            </div>
            

            <div class="text-block title" 
                 style="left: 32.209222412109376px; top: 350.39133300781253px; width: 600.6818420410157px; height: 124.4955810546875px;"
                 title="y Committee on Immunization Practices United States, 2022-23 Influenza Season"
                 data-order="2"
                 data-bbox="161.04611206054688,1751.9566650390625,3164.455322265625,2374.4345703125">
                y Committee on Immunization Practices United States, 2022-23 Influenza Season
            </div>
            

            <div class="figure-block" 
                 style="left: 179.47786865234377px; top: 772.2975585937501px; width: 114.87122802734376px; height: 66.60224609375px;"
                 title="[FIGURE 4 - See figure_p1_det_0_003.png]"
                 data-order="3"
                 data-bbox="897.3893432617188,3861.48779296875,1471.7454833984375,4194.4990234375">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 187.48647460937502px; top: 783.0655273437501px; width: 354.13759765625px; height: 49.81767578125px;"
                 title=""
                 data-order="4"
                 data-bbox="937.432373046875,3915.32763671875,2708.120361328125,4164.416015625">
                
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 2</div>

            <div class="figure-block" 
                 style="left: 42.32906494140625px; top: 69.95228271484375px; width: 591.3476440429688px; height: 742.2783325195313px;"
                 title="[FIGURE 1 - See figure_p2_mrg_det_1_002.png]"
                 data-order="0"
                 data-bbox="211.64532470703125,349.76141357421875,3168.383544921875,4061.153076171875">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 38.59878845214844px; top: 78.792236328125px; width: 60.09292297363282px; height: 5.647906494140625px;"
                 title=""
                 data-order="1"
                 data-bbox="192.9939422607422,393.961181640625,493.45855712890625,422.2007141113281">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 38.88578491210938px; top: 93.7069580078125px; width: 284.08362426757816px; height: 153.3096435546875px;"
                 title="MMWR Editorial an Charlotte K. Kent, PhD, MPH, Editor in Chief Brian A. King, PhD, MPH, Executive Editor Christine G. Casey, MD, Editor Mary Dott, MD, MPH, Online Editor Ter is a F. Rut ledge, Managin..."
                 data-order="2"
                 data-bbox="194.42892456054688,468.5347900390625,1614.8470458984375,1235.0830078125">
                MMWR Editorial an Charlotte K. Kent, PhD, MPH, Editor in Chief Brian A. King, PhD, MPH, Executive Editor Christine G. Casey, MD, Editor Mary Dott, MD, MPH, Online Editor Ter is a F. Rut ledge, Managin...
            </div>
            

            <div class="text-block text" 
                 style="left: 51.41370239257813px; top: 509.960107421875px; width: 561.011883544922px; height: 20.746386718750003px;"
                 title=""
                 data-order="3"
                 data-bbox="257.0685119628906,2549.800537109375,3062.1279296875,2653.532470703125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 248.57294921875px; top: 551.7123535156251px; width: 190.410595703125px; height: 6.791552734375px;"
                 title="Director become ag M bidit d M"
                 data-order="4"
                 data-bbox="1242.86474609375,2758.561767578125,2194.917724609375,2792.51953125">
                Director become ag M bidit d M
            </div>
            

            <div class="text-block text" 
                 style="left: 183.68050537109377px; top: 560.7450683593751px; width: 315.1427856445313px; height: 63.624218750000004px;"
                 title="(AAFP), and the American C Gynecologists (ACOG). Recom vaccinations in adults are harmo of AAFP, ACOG, and the Am (ACP). ACIP recommend at i Director become agency guide lin"
                 data-order="5"
                 data-bbox="918.4025268554688,2803.725341796875,2494.116455078125,3121.846435546875">
                (AAFP), and the American C Gynecologists (ACOG). Recom vaccinations in adults are harmo of AAFP, ACOG, and the Am (ACP). ACIP recommend at i Director become agency guide lin
            </div>
            

            <div class="text-block text" 
                 style="left: 241.97758789062502px; top: 626.6420410156251px; width: 195.801513671875px; height: 11.845166015625px;"
                 title=".................................. 22 Pediatrics (AAP), t (AAFP) d h"
                 data-order="6"
                 data-bbox="1209.887939453125,3133.210205078125,2188.8955078125,3192.43603515625">
                .................................. 22 Pediatrics (AAP), t (AAFP) d h
            </div>
            

            <div class="text-block text" 
                 style="left: 237.858984375px; top: 638.19482421875px; width: 189.104443359375px; height: 11.906591796875px;"
                 title="22 with recommen P di i (AAP)"
                 data-order="7"
                 data-bbox="1189.294921875,3190.97412109375,2134.817138671875,3250.507080078125">
                22 with recommen P di i (AAP)
            </div>
            

            <div class="text-block title" 
                 style="left: 374.15947265625005px; top: 78.91462402343751px; width: 250.023291015625px; height: 33.70169677734375px;"
                 title="MPA H Carlos Roig, MS, MA William Schaffner, MD Morgan Bobb Swanson, BS"
                 data-order="8"
                 data-bbox="1870.79736328125,394.5731201171875,3120.913818359375,563.0816040039062">
                MPA H Carlos Roig, MS, MA William Schaffner, MD Morgan Bobb Swanson, BS
            </div>
            

            <div class="text-block text" 
                 style="left: 350.80893554687503px; top: 109.50642089843751px; width: 290.61025390625px; height: 242.2901611328125px;"
                 title="MWR Recomm Rep 2022 71 no. RR-#):[inclusive page numbers]. trol and Prevention D, MPH, Director g Principal Deputy Director rfor Public Health Science and Surveillance Director, Office of Science uty ..."
                 data-order="9"
                 data-bbox="1754.044677734375,547.5321044921875,3207.095947265625,1758.98291015625">
                MWR Recomm Rep 2022 71 no. RR-#):[inclusive page numbers]. trol and Prevention D, MPH, Director g Principal Deputy Director rfor Public Health Science and Surveillance Director, Office of Science uty ...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 3</div>

            <div class="text-block title" 
                 style="left: 60.728759765625px; top: 78.84786376953126px; width: 559.138525390625px; height: 64.49322509765625px;"
                 title="quad rival ent adjuvant ed in activated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity fo vaccine administration, then any other age appropriate influenza va..."
                 data-order="0"
                 data-bbox="303.643798828125,394.23931884765625,3099.33642578125,716.7054443359375">
                quad rival ent adjuvant ed in activated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity fo vaccine administration, then any other age appropriate influenza va...
            </div>
            

            <div class="text-block text" 
                 style="left: 89.28710327148438px; top: 148.65059814453124px; width: 507.40156860351567px; height: 25.761206054687502px;"
                 title="mends that adults aged ≥65 years preferentially receive any one of the following higher dose or adjuvanted influenza vac valent high dose in activated influenza vaccine (HD-IIV4), quad rival ent recom..."
                 data-order="1"
                 data-bbox="446.4355163574219,743.2529907226562,2983.443359375,872.0590209960938">
                mends that adults aged ≥65 years preferentially receive any one of the following higher dose or adjuvanted influenza vac valent high dose in activated influenza vaccine (HD-IIV4), quad rival ent recom...
            </div>
            

            <div class="text-block text" 
                 style="left: 51.209265136718756px; top: 183.99617919921877px; width: 584.1184692382812px; height: 36.68477783203125px;"
                 title="f f (Victoria lineage like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage like virus. Second, the approved age indication for the cell culture based in activated influenza vaccine, Flu c..."
                 data-order="2"
                 data-bbox="256.04632568359375,919.9808959960938,3176.638671875,1103.40478515625">
                f f (Victoria lineage like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage like virus. Second, the approved age indication for the cell culture based in activated influenza vaccine, Flu c...
            </div>
            

            <div class="text-block title" 
                 style="left: 311.6353271484375px; top: 232.0536865234375px; width: 57.089599609375px; height: 14.818115234375px;"
                 title="arwin/9/2021 d"
                 data-order="3"
                 data-bbox="1558.1766357421875,1160.2684326171875,1843.6246337890625,1234.3590087890625">
                arwin/9/2021 d
            </div>
            

            <div class="text-block text" 
                 style="left: 55.1377197265625px; top: 253.3560546875px; width: 571.6116943359375px; height: 147.3245361328125px;"
                 title="through 8 years need 2 doses; these children should receive the first dose as soon as possible after vaccine is available, including during July and August. Vaccination during July and August can be c..."
                 data-order="4"
                 data-bbox="275.6885986328125,1266.7802734375,3133.7470703125,2003.4029541015625">
                through 8 years need 2 doses; these children should receive the first dose as soon as possible after vaccine is available, including during July and August. Vaccination during July and August can be c...
            </div>
            

            <div class="text-block text" 
                 style="left: 54.7807861328125px; top: 403.229248046875px; width: 562.9513427734375px; height: 46.498388671875006px;"
                 title="October and throughout the season as long as influenza viruses are circulating and unexpired vaccine is available. For most adul (particularly adults aged ≥65 years) and for pregnant persons in the fi..."
                 data-order="5"
                 data-bbox="273.9039306640625,2016.146240234375,3088.66064453125,2248.63818359375">
                October and throughout the season as long as influenza viruses are circulating and unexpired vaccine is available. For most adul (particularly adults aged ≥65 years) and for pregnant persons in the fi...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.22481079101563px; top: 506.97978515625005px; width: 587.5571716308594px; height: 250.34438476562502px;"
                 title="Practices - United States, 2022-23 Influenza Season Lisa A. Grohskopf, MD1; Lenee H. Bl anton, MPH1; Jill M. Ferdinands, PhD1; Jessie R. Chung, MPH1; Karen R. Broder, MD2; H. Keipp Talbot, MD3; Re be ..."
                 data-order="6"
                 data-bbox="221.12405395507812,2534.89892578125,3158.909912109375,3786.620849609375">
                Practices - United States, 2022-23 Influenza Season Lisa A. Grohskopf, MD1; Lenee H. Bl anton, MPH1; Jill M. Ferdinands, PhD1; Jessie R. Chung, MPH1; Karen R. Broder, MD2; H. Keipp Talbot, MD3; Re be ...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.494195556640626px; top: 770.346728515625px; width: 278.1174987792969px; height: 28.5001953125px;"
                 title="Prevention and Control of Se Recommendations of the Advi"
                 data-order="7"
                 data-bbox="222.47097778320312,3851.733642578125,1613.0584716796875,3994.234619140625">
                Prevention and Control of Se Recommendations of the Advi
            </div>
            

            <div class="text-block text" 
                 style="left: 328.82861328125px; top: 776.857568359375px; width: 296.734423828125px; height: 27.728125000000002px;"
                 title="easonal Influenza with Vaccines:"
                 data-order="8"
                 data-bbox="1644.14306640625,3884.287841796875,3127.815185546875,4022.928466796875">
                easonal Influenza with Vaccines:
            </div>
            

            <div class="text-block text" 
                 style="left: 342.8487548828125px; top: 766.39541015625px; width: 101.75612792968751px; height: 9.204394531250001px;"
                 title="ory Committe"
                 data-order="9"
                 data-bbox="1714.2437744140625,3831.97705078125,2223.0244140625,3877.9990234375">
                ory Committe
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 4</div>

            <div class="text-block text" 
                 style="left: 49.9730224609375px; top: 75.80641479492188px; width: 579.3777587890626px; height: 76.56870727539062px;"
                 title="ates a d goba ydu g t e 0 0 ue a sea so 5). This was coincident with widespread implementation non pharmaceutical interventions (e.g., masking, social stan cing, and suspension of in person work and s..."
                 data-order="0"
                 data-bbox="249.8651123046875,379.0320739746094,3146.75390625,761.8756103515625">
                ates a d goba ydu g t e 0 0 ue a sea so 5). This was coincident with widespread implementation non pharmaceutical interventions (e.g., masking, social stan cing, and suspension of in person work and s...
            </div>
            

            <div class="text-block title" 
                 style="left: 133.6025146484375px; top: 175.68377685546875px; width: 98.8739990234375px; height: 17.95479736328125px;"
                 title="viruses) (14). d hll l"
                 data-order="1"
                 data-bbox="668.0125732421875,878.4188842773438,1162.382568359375,968.19287109375">
                viruses) (14). d hll l
            </div>
            

            <div class="text-block text" 
                 style="left: 40.122875976562504px; top: 195.16121826171877px; width: 287.7771484375px; height: 191.65887451171875px;"
                 title="the vaccine (12). During each of the six influenza seasons from 2010-11 through 2015-16, influenza vaccination prevented an estimated 1 6 6 7 million illnesses, 790 000 3 1 million outpatient medical ..."
                 data-order="2"
                 data-bbox="200.6143798828125,975.8060913085938,1639.5001220703125,1934.1004638671875">
                the vaccine (12). During each of the six influenza seasons from 2010-11 through 2015-16, influenza vaccination prevented an estimated 1 6 6 7 million illnesses, 790 000 3 1 million outpatient medical ...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.344311523437504px; top: 380.57553710937503px; width: 286.5462158203125px; height: 318.96489257812505px;"
                 title="Introduction Influenza viruses typically circulate annually in the United States, most commonly from the late fall through the early spring. Most persons who become ill after influenza virus infection..."
                 data-order="3"
                 data-bbox="196.7215576171875,1902.877685546875,1629.45263671875,3497.7021484375">
                Introduction Influenza viruses typically circulate annually in the United States, most commonly from the late fall through the early spring. Most persons who become ill after influenza virus infection...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.52318420410157px; top: 700.6763671875001px; width: 293.60789489746094px; height: 104.6138671875px;"
                 title="2022-23 influenza season in the United States. A brief sum mar Document containing additional information are available at These recommendations apply to U.S.-licensed influenza vac indications. Updat..."
                 data-order="4"
                 data-bbox="192.6159210205078,3503.3818359375,1660.6553955078125,4026.451171875">
                2022-23 influenza season in the United States. A brief sum mar Document containing additional information are available at These recommendations apply to U.S.-licensed influenza vac indications. Updat...
            </div>
            

            <div class="text-block text" 
                 style="left: 308.22470703125003px; top: 832.3658203125001px; width: 337.075146484375px; height: 10.9921875px;"
                 title="mend at ions and Reports"
                 data-order="5"
                 data-bbox="1541.12353515625,4161.8291015625,3226.499267578125,4216.7900390625">
                mend at ions and Reports
            </div>
            

            <div class="text-block text" 
                 style="left: 352.6927001953125px; top: 170.47198486328125px; width: 286.5599365234375px; height: 150.72039794921875px;"
                 title="vacc specific flu html. Methods ACIP provides annual recommendations for the use of influenza vaccines for the prevention and control of seasonal influenza in the United States. The ACIP Influenza Wor..."
                 data-order="6"
                 data-bbox="1763.4635009765625,852.3599243164062,3196.26318359375,1605.9619140625">
                vacc specific flu html. Methods ACIP provides annual recommendations for the use of influenza vaccines for the prevention and control of seasonal influenza in the United States. The ACIP Influenza Wor...
            </div>
            

            <div class="text-block text" 
                 style="left: 351.2266845703125px; top: 318.35202636718753px; width: 286.89475097656253px; height: 131.9010009765625px;"
                 title="summarized (Tables 2 and 3). Abbreviations are used in this report to denote the various types of vaccines (Box). This report focuses on recommendations and guidance for the use of seasonal influenza ..."
                 data-order="7"
                 data-bbox="1756.1334228515625,1591.7601318359375,3190.607177734375,2251.26513671875">
                summarized (Tables 2 and 3). Abbreviations are used in this report to denote the various types of vaccines (Box). This report focuses on recommendations and guidance for the use of seasonal influenza ...
            </div>
            

            <div class="text-block text" 
                 style="left: 351.1289306640625px; top: 444.31499023437505px; width: 287.4787841796875px; height: 120.01088867187501px;"
                 title="p g This report updates the 2021-22 ACIP recommendations regarding the use of seasonal influenza vaccines (17) and provides recommendations and guidance for vaccination providers regarding the use of ..."
                 data-order="8"
                 data-bbox="1755.6446533203125,2221.574951171875,3193.03857421875,2821.62939453125">
                p g This report updates the 2021-22 ACIP recommendations regarding the use of seasonal influenza vaccines (17) and provides recommendations and guidance for vaccination providers regarding the use of ...
            </div>
            

            <div class="text-block title" 
                 style="left: 462.196728515625px; top: 590.0224121093751px; width: 70.33515625px; height: 19.085791015625002px;"
                 title="care system dur dance for vaccin"
                 data-order="9"
                 data-bbox="2310.983642578125,2950.112060546875,2662.659423828125,3045.541015625">
                care system dur dance for vaccin
            </div>
            

            <div class="text-block text" 
                 style="left: 352.2964599609375px; top: 608.2322265625px; width: 288.6134033203125px; height: 161.85942382812502px;"
                 title="sused according to Food and Drug Administration licensed DC’sinfluenza website (https www cdc gov flu. Vaccination dit ion al information. 2021-22 season, although severity indicators (e.g., influenza..."
                 data-order="10"
                 data-bbox="1761.4822998046875,3041.1611328125,3204.54931640625,3850.458251953125">
                sused according to Food and Drug Administration licensed DC’sinfluenza website (https www cdc gov flu. Vaccination dit ion al information. 2021-22 season, although severity indicators (e.g., influenza...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.8476806640625px; top: 769.2023437500001px; width: 288.5268798828125px; height: 31.841064453125px;"
                 title="the recommendations and alink to the most recent Background ps://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. ddi F d d D Ad i i ili d"
                 data-order="11"
                 data-bbox="1764.2384033203125,3846.01171875,3206.872802734375,4005.217041015625">
                the recommendations and alink to the most recent Background ps://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. ddi F d d D Ad i i ili d
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 5</div>

            <div class="text-block text" 
                 style="left: 38.081259155273436px; top: 78.21742553710938px; width: 312.6538482666016px; height: 13.104437255859375px;"
                 title="already recommended for vaccination, and changes that"
                 data-order="0"
                 data-bbox="190.4062957763672,391.0871276855469,1753.675537109375,456.60931396484375">
                already recommended for vaccination, and changes that
            </div>
            

            <div class="table-block" 
                 style="left: 43.85456848144531px; top: 92.69849853515626px; width: 593.2581756591798px; height: 365.40985107421875px;"
                 title="[TABLE 2 - See table_p5_det_4_002.png]"
                 data-order="1"
                 data-bbox="219.27284240722656,463.49249267578125,3185.563720703125,2290.541748046875">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 39.403482055664064px; top: 447.963134765625px; width: 602.498178100586px; height: 257.47392578125px;"
                 title="y g 18 through 64 yrs (jet injector) µg Fluarix Quad rival ent (GlaxoSmithKline) 0.5-mL PFS ≥6 mos 15 µg/0.5 mL IM¶ FluLaval Quad rival ent (GlaxoSmithKline) 0.5-mL PFS ≥6 mos 15 µg/0.5 mL IM¶ Flu zon..."
                 data-order="2"
                 data-bbox="197.0174102783203,2239.815673828125,3209.50830078125,3527.185302734375">
                y g 18 through 64 yrs (jet injector) µg Fluarix Quad rival ent (GlaxoSmithKline) 0.5-mL PFS ≥6 mos 15 µg/0.5 mL IM¶ FluLaval Quad rival ent (GlaxoSmithKline) 0.5-mL PFS ≥6 mos 15 µg/0.5 mL IM¶ Flu zon...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.60520629882813px; top: 715.34560546875px; width: 293.4188903808594px; height: 88.8779296875px;"
                 title="TABLE 1. Influenza vaccines - United States, 2022-23 influenza seas Trade name (manufacturer) Presentations Age indicati IIV4 (standard dose, egg based vaccines†) Afluria Quad rival ent (Seqirus) 0.5-..."
                 data-order="3"
                 data-bbox="193.02603149414062,3576.72802734375,1660.1204833984375,4021.11767578125">
                TABLE 1. Influenza vaccines - United States, 2022-23 influenza seas Trade name (manufacturer) Presentations Age indicati IIV4 (standard dose, egg based vaccines†) Afluria Quad rival ent (Seqirus) 0.5-...
            </div>
            

            <div class="text-block text" 
                 style="left: 349.92563476562503px; top: 715.052978515625px; width: 290.791552734375px; height: 90.235693359375px;"
                 title="µg HA (IIV4 s and RIV4) or virus count (LAIV4) for each vaccine virus (per dose) Route Mercury (from thimerosal, if present), µg/0.5 mL 15 µg/0.5 mL IM¶ -** 7.5 µg/0.25 mL IM¶ 24.5"
                 data-order="4"
                 data-bbox="1749.628173828125,3575.264892578125,3203.5859375,4026.443359375">
                µg HA (IIV4 s and RIV4) or virus count (LAIV4) for each vaccine virus (per dose) Route Mercury (from thimerosal, if present), µg/0.5 mL 15 µg/0.5 mL IM¶ -** 7.5 µg/0.25 mL IM¶ 24.5
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 6</div>

            <div class="text-block text" 
                 style="left: 39.49216918945313px; top: 78.36132202148438px; width: 525.0728698730469px; height: 13.102142333984375px;"
                 title=""
                 data-order="0"
                 data-bbox="197.46084594726562,391.8066101074219,2822.8251953125,457.31732177734375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 216.79008789062502px; top: 95.61610717773438px; width: 72.634765625px; height: 5.71463623046875px;"
                 title=""
                 data-order="1"
                 data-bbox="1083.950439453125,478.0805358886719,1447.124267578125,506.6537170410156">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 66.56943359375px; top: 107.989990234375px; width: 571.740625px; height: 395.916162109375px;"
                 title="medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asp len i a, or functional asp len i a (e.g., due to sickle cell anemia) • Close contacts and caregivers of severel..."
                 data-order="2"
                 data-bbox="332.84716796875,539.949951171875,3191.55029296875,2519.53076171875">
                medications, congenital or acquired immunodeficiency states, HIV infection, anatomic asp len i a, or functional asp len i a (e.g., due to sickle cell anemia) • Close contacts and caregivers of severel...
            </div>
            

            <div class="text-block text" 
                 style="left: 35.035040283203124px; top: 495.42333984375px; width: 621.6438171386719px; height: 39.755908203125px;"
                 title="wheezing episode has occurred during the preceding 12 months • Children and adults who are immunocompromised due to any cause, including but not limited to immunosuppression caused by medications, con..."
                 data-order="3"
                 data-bbox="175.17520141601562,2477.11669921875,3283.394287109375,2675.896240234375">
                wheezing episode has occurred during the preceding 12 months • Children and adults who are immunocompromised due to any cause, including but not limited to immunosuppression caused by medications, con...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.57745056152344px; top: 538.2955078125px; width: 605.9956451416016px; height: 229.86162109375002px;"
                 title="Egg based IIV4 s • History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine† or to a previous dose of any influenza vaccine (i.e., any egg based IIV, ccIIV, RIV, or LAIV..."
                 data-order="4"
                 data-bbox="192.8872528076172,2691.4775390625,3222.865478515625,3840.78564453125">
                Egg based IIV4 s • History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine† or to a previous dose of any influenza vaccine (i.e., any egg based IIV, ccIIV, RIV, or LAIV...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 7</div>

            <div class="text-block text" 
                 style="left: 20.22450103759766px; top: 78.13838500976563px; width: 621.1813095092774px; height: 23.66717529296875px;"
                 title="adults aged ≥65 years. Information relevant to these changes includes the following: vaccines and related biological products advisory committee march 3 2022 meeting announcement."
                 data-order="0"
                 data-bbox="101.12250518798828,390.6919250488281,3207.029052734375,509.0278015136719">
                adults aged ≥65 years. Information relevant to these changes includes the following: vaccines and related biological products advisory committee march 3 2022 meeting announcement.
            </div>
            

            <div class="table-block" 
                 style="left: 42.26393127441406px; top: 100.62598876953126px; width: 589.783090209961px; height: 85.5668701171875px;"
                 title="[TABLE 2 - See table_p7_det_6_000.png]"
                 data-order="1"
                 data-bbox="211.3196563720703,503.12994384765625,3160.235107421875,930.9642944335938">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 40.314752197265626px; top: 189.51492919921876px; width: 608.3620056152344px; height: 41.072424316406256px;"
                 title="y Primary updates and changes to the recommendations described in this report include 1) the vaccine virus composition for 2022-23 U S seasonal influenza vaccines; g y Committee (VRBPAC). This committ..."
                 data-order="2"
                 data-bbox="201.57376098632812,947.5746459960938,3243.3837890625,1152.936767578125">
                y Primary updates and changes to the recommendations described in this report include 1) the vaccine virus composition for 2022-23 U S seasonal influenza vaccines; g y Committee (VRBPAC). This committ...
            </div>
            

            <div class="text-block text" 
                 style="left: 37.61507873535157px; top: 227.82622070312502px; width: 609.5208099365235px; height: 223.941162109375px;"
                 title="reaction (e.g., anaphylaxis) to any ccIIV of any valency, the provider can consider administering RIV4; and 3) for persons with a history of severe allergic reaction (e.g., anaphylaxis) to any RIV of ..."
                 data-order="3"
                 data-bbox="188.0753936767578,1139.131103515625,3235.679443359375,2258.8369140625">
                reaction (e.g., anaphylaxis) to any ccIIV of any valency, the provider can consider administering RIV4; and 3) for persons with a history of severe allergic reaction (e.g., anaphylaxis) to any RIV of ...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.106329345703124px; top: 459.83627929687503px; width: 294.5211853027344px; height: 192.713134765625px;"
                 title="vaccine (any valency); RIV4 = recombinant influenza vaccine, quad rival ent. * Vaccination providers should check FDA-approved prescribing information for 2 (but not limited to) indications, contra in..."
                 data-order="4"
                 data-bbox="190.53164672851562,2299.181396484375,1663.1375732421875,3262.7470703125">
                vaccine (any valency); RIV4 = recombinant influenza vaccine, quad rival ent. * Vaccination providers should check FDA-approved prescribing information for 2 (but not limited to) indications, contra in...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.64979858398438px; top: 649.0369140625px; width: 295.3564025878906px; height: 150.682763671875px;"
                 title="TABLE 3. Influenza vaccine contra indications and precautions for pe influenza vaccine* - United States, 2022-23 influenza season Vaccine (of any valency) associated with previous severe allergic reac..."
                 data-order="5"
                 data-bbox="193.24899291992188,3245.1845703125,1670.031005859375,3998.598388671875">
                TABLE 3. Influenza vaccine contra indications and precautions for pe influenza vaccine* - United States, 2022-23 influenza season Vaccine (of any valency) associated with previous severe allergic reac...
            </div>
            

            <div class="text-block list" 
                 style="left: 354.5484619140625px; top: 455.79736328125px; width: 292.6031005859375px; height: 340.389306640625px;"
                 title="swith a history of severe allergic reaction to a previous dose of an Available 2022-23 influenza vaccines ccIIV4 RIV4 Precaution§ Precaution§ Contra indication Precaution§ Precaution§ Contra indicatio..."
                 data-order="6"
                 data-bbox="1772.7423095703125,2278.98681640625,3235.7578125,3980.933349609375">
                swith a history of severe allergic reaction to a previous dose of an Available 2022-23 influenza vaccines ccIIV4 RIV4 Precaution§ Precaution§ Contra indication Precaution§ Precaution§ Contra indicatio...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 8</div>

            <div class="text-block text" 
                 style="left: 39.99377136230469px; top: 77.60810546875001px; width: 286.47649230957035px; height: 24.79884033203125px;"
                 title="g p g A summary of the ACIP Evidence to Recommendations"
                 data-order="0"
                 data-bbox="199.96885681152344,388.04052734375,1632.351318359375,512.0347290039062">
                g p g A summary of the ACIP Evidence to Recommendations
            </div>
            

            <div class="text-block list" 
                 style="left: 45.20368041992188px; top: 103.7098388671875px; width: 281.3982727050781px; height: 704.4634521484376px;"
                 title="BOX. Abbreviation conventions for influenza vaccines discussed in his report • Main influenza vaccine types: ű IIV = in activated influenza vaccine ű RIV = recombinant influenza vaccine ű LAIV = live ..."
                 data-order="1"
                 data-bbox="226.01840209960938,518.5491943359375,1633.009765625,4040.866455078125">
                BOX. Abbreviation conventions for influenza vaccines discussed in his report • Main influenza vaccine types: ű IIV = in activated influenza vaccine ű RIV = recombinant influenza vaccine ű LAIV = live ...
            </div>
            

            <div class="text-block text" 
                 style="left: 370.9300537109375px; top: 77.7699951171875px; width: 269.7771728515625px; height: 46.835852050781256px;"
                 title="influenza vaccine (RIV), and MF59-adjuvanted in activated influenza vaccine (aIIV), recommendations for influenza vaccination of persons aged ≥65 years"
                 data-order="2"
                 data-bbox="1854.6502685546875,388.8499755859375,3203.5361328125,623.0292358398438">
                influenza vaccine (RIV), and MF59-adjuvanted in activated influenza vaccine (aIIV), recommendations for influenza vaccination of persons aged ≥65 years
            </div>
            

            <div class="text-block title" 
                 style="left: 376.6196533203125px; top: 147.78841552734374px; width: 239.7012939453125px; height: 19.546984863281253px;"
                 title="≥6 months. On the basis of review of evidence concerning high-"
                 data-order="3"
                 data-bbox="1883.0982666015625,738.9420776367188,3081.604736328125,836.677001953125">
                ≥6 months. On the basis of review of evidence concerning high-
            </div>
            

            <div class="text-block list" 
                 style="left: 353.6080322265625px; top: 170.46007080078127px; width: 288.9256103515625px; height: 544.6373413085938px;"
                 title="y g p Routine annual influenza vaccination of all persons aged ≥6 months who do not have contra indications continues to be recommended. Primary updates in this report include the following: 1. The co..."
                 data-order="4"
                 data-bbox="1768.0401611328125,852.3003540039062,3212.668212890625,3575.487060546875">
                y g p Routine annual influenza vaccination of all persons aged ≥6 months who do not have contra indications continues to be recommended. Primary updates in this report include the following: 1. The co...
            </div>
            

            <div class="text-block list" 
                 style="left: 368.5594482421875px; top: 739.27001953125px; width: 272.9430419921875px; height: 52.435693359375px;"
                 title="Framework for this discussion is available at https www. cdc.gov/vaccines/acip/recs/grade/influenza-older-adultsetr.html."
                 data-order="5"
                 data-bbox="1842.7972412109375,3696.35009765625,3207.512451171875,3958.528564453125">
                Framework for this discussion is available at https www. cdc.gov/vaccines/acip/recs/grade/influenza-older-adultsetr.html.
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 9</div>

            <div class="text-block text" 
                 style="left: 40.5612060546875px; top: 78.64302978515626px; width: 304.6887451171875px; height: 667.8556030273438px;"
                 title="q g (HD-IIV4), quad rival ent recombinant influenza vaccine (RIV4), or quad rival ent adjuvant ed in activated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity..."
                 data-order="0"
                 data-bbox="202.8060302734375,393.21514892578125,1726.249755859375,3732.4931640625">
                q g (HD-IIV4), quad rival ent recombinant influenza vaccine (RIV4), or quad rival ent adjuvant ed in activated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity...
            </div>
            

            <div class="text-block text" 
                 style="left: 359.2112060546875px; top: 77.34810791015626px; width: 282.9932861328125px; height: 9.098077392578125px;"
                 title=""
                 data-order="1"
                 data-bbox="1796.0560302734375,386.74053955078125,3211.0224609375,432.2309265136719">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 356.5460205078125px; top: 108.778369140625px; width: 290.6605224609375px; height: 498.897705078125px;"
                 title="vaccine is available) to allow the second dose (which must be administered ≥4 weeks later) to be received, ideally, by the end of October. • Children who require only 1 dose: Vaccination during July a..."
                 data-order="2"
                 data-bbox="1782.7301025390625,543.891845703125,3236.03271484375,3038.38037109375">
                vaccine is available) to allow the second dose (which must be administered ≥4 weeks later) to be received, ideally, by the end of October. • Children who require only 1 dose: Vaccination during July a...
            </div>
            

            <div class="text-block text" 
                 style="left: 351.3377685546875px; top: 610.10703125px; width: 288.9286376953125px; height: 137.34575195312502px;"
                 title="p g ptrimester: Vaccination during July and August should be avoided unless there is concern that vaccination later in the season might not be possible. • Children who require 2 doses: Certain childre..."
                 data-order="3"
                 data-bbox="1756.6888427734375,3050.53515625,3201.33203125,3737.263916015625">
                p g ptrimester: Vaccination during July and August should be avoided unless there is concern that vaccination later in the season might not be possible. • Children who require 2 doses: Certain childre...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 10</div>

            <div class="text-block text" 
                 style="left: 36.92116088867188px; top: 77.96466674804688px; width: 291.1343078613281px; height: 35.663140869140626px;"
                 title="more than one outbreak might occur in a community in a single year. In the United States, localized outbreaks indicating the start of seasonal influenza activity can occur as early as October."
                 data-order="0"
                 data-bbox="184.60580444335938,389.8233337402344,1640.27734375,568.1390380859375">
                more than one outbreak might occur in a community in a single year. In the United States, localized outbreaks indicating the start of seasonal influenza activity can occur as early as October.
            </div>
            

            <div class="figure-block" 
                 style="left: 42.79817810058594px; top: 112.770068359375px; width: 283.5124908447266px; height: 239.117919921875px;"
                 title="[FIGURE 2 - See figure_p10_det_9_000.png]"
                 data-order="1"
                 data-bbox="213.9908905029297,563.850341796875,1631.5533447265625,1759.43994140625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 45.68348999023438px; top: 357.1431396484375px; width: 281.5268127441406px; height: 73.53762207031251px;"
                 title="acc i nation, providers should offer vaccination during routine health care visits and hospitalizations. No recommendation is made for re vaccination (i.e., providing a booster dose) later nthe season..."
                 data-order="2"
                 data-bbox="228.41744995117188,1785.7156982421875,1636.051513671875,2153.40380859375">
                acc i nation, providers should offer vaccination during routine health care visits and hospitalizations. No recommendation is made for re vaccination (i.e., providing a booster dose) later nthe season...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.760614013671876px; top: 437.689404296875px; width: 290.77588500976566px; height: 90.24526367187501px;"
                 title="* Children aged 6 months through 8 years who require 2 doses of influenza vaccine should receive their first dose as soon as possible (including during July and August, if vaccine is available) to all..."
                 data-order="3"
                 data-bbox="193.80307006835938,2188.447021484375,1647.6824951171875,2639.67333984375">
                * Children aged 6 months through 8 years who require 2 doses of influenza vaccine should receive their first dose as soon as possible (including during July and August, if vaccine is available) to all...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.18590087890625px; top: 522.802734375px; width: 291.42786865234376px; height: 277.88525390625px;"
                 title="FIGURE. Influenza vaccine dosing algorithm for children aged 6 months through 8 years* - Advisory Committee on Immunization Practices, United States, 2022-23 influenza season Did the child receive ≥2 ..."
                 data-order="4"
                 data-bbox="190.92950439453125,2614.013671875,1648.06884765625,4003.43994140625">
                FIGURE. Influenza vaccine dosing algorithm for children aged 6 months through 8 years* - Advisory Committee on Immunization Practices, United States, 2022-23 influenza season Did the child receive ≥2 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.47673339843755px; top: 77.81599121093751px; width: 291.5875732421875px; height: 87.90843505859375px;"
                 title="of influenza vaccine effectiveness using the test negative design found a significant decline in effectiveness within 180 days after vaccination against influenza A (H3 N2) and influenza B but not aga..."
                 data-order="5"
                 data-bbox="1762.3836669921875,389.0799560546875,3220.321533203125,828.6221313476562">
                of influenza vaccine effectiveness using the test negative design found a significant decline in effectiveness within 180 days after vaccination against influenza A (H3 N2) and influenza B but not aga...
            </div>
            

            <div class="text-block text" 
                 style="left: 349.98356933593755px; top: 162.0832275390625px; width: 290.1037841796875px; height: 637.2087158203126px;"
                 title="However, in 29 (76%) of 38 influenza seasons from 1982-83 through 2019-20, peak influenza activity (which often is close to the midpoint of influenza activity for the season) has not occurred until Ja..."
                 data-order="6"
                 data-bbox="1749.9178466796875,810.4161376953125,3200.436767578125,3996.459716796875">
                However, in 29 (76%) of 38 influenza seasons from 1982-83 through 2019-20, peak influenza activity (which often is close to the midpoint of influenza activity for the season) has not occurred until Ja...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 11</div>

            <div class="text-block text" 
                 style="left: 42.7635986328125px; top: 77.45040893554688px; width: 284.971337890625px; height: 45.664422607421876px;"
                 title="increased risk for severe illness and complications from influenza and for influenza related outpatient, emergency department, or hospital visits. When vaccine supply is limited, vaccination"
                 data-order="0"
                 data-bbox="213.8179931640625,387.2520446777344,1638.6746826171875,615.5741577148438">
                increased risk for severe illness and complications from influenza and for influenza related outpatient, emergency department, or hospital visits. When vaccine supply is limited, vaccination
            </div>
            

            <div class="text-block text" 
                 style="left: 37.21993408203125px; top: 118.55781250000001px; width: 288.6524291992188px; height: 290.914599609375px;"
                 title="vaccine routinely, and organized vaccination campaigns should continue throughout the influenza season, including after influenza activity has begun in the community. Although vaccination by the end o..."
                 data-order="1"
                 data-bbox="186.09967041015625,592.7890625,1629.36181640625,2047.362060546875">
                vaccine routinely, and organized vaccination campaigns should continue throughout the influenza season, including after influenza activity has begun in the community. Although vaccination by the end o...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.25857849121094px; top: 405.84555664062503px; width: 284.7133453369141px; height: 202.70966796875px;"
                 title="simulated mathematical model examining various scenarios of vaccination timing, timing of onset of the influenza season, vaccine effectiveness, and rate of waning (39). In this model, during an influe..."
                 data-order="2"
                 data-bbox="201.2928924560547,2029.227783203125,1624.859619140625,3042.776123046875">
                simulated mathematical model examining various scenarios of vaccination timing, timing of onset of the influenza season, vaccine effectiveness, and rate of waning (39). In this model, during an influe...
            </div>
            

            <div class="text-block title" 
                 style="left: 58.54376220703125px; top: 629.91435546875px; width: 254.20819091796875px; height: 35.510888671875px;"
                 title="might result in missed opportunities to vaccinate las difficulties in vaccinating a population within amo strained period. The potential contributions of these facto"
                 data-order="3"
                 data-bbox="292.71881103515625,3149.57177734375,1563.759765625,3327.126220703125">
                might result in missed opportunities to vaccinate las difficulties in vaccinating a population within amo strained period. The potential contributions of these facto
            </div>
            

            <div class="text-block title" 
                 style="left: 37.75902099609375px; top: 671.998095703125px; width: 270.76922607421875px; height: 32.301416015625px;"
                 title="dete at o o aopt a t eto vacc ate. og a issues also are a consideration. Although delaying vaccinat might result in greater immunity later in the season, defe"
                 data-order="4"
                 data-bbox="188.79510498046875,3359.990478515625,1542.6412353515625,3521.49755859375">
                dete at o o aopt a t eto vacc ate. og a issues also are a consideration. Although delaying vaccinat might result in greater immunity later in the season, defe
            </div>
            

            <div class="text-block text" 
                 style="left: 37.519580078125px; top: 706.1663574218751px; width: 289.559326171875px; height: 90.39619140625001px;"
                 title="part attributable to bias, unmeasured confounding, or the late season emergence of antigenic drift variants of influenza viruses that are less well matched to the vaccine viruses. Varying data concern..."
                 data-order="5"
                 data-bbox="187.597900390625,3530.831787109375,1635.39453125,3982.812744140625">
                part attributable to bias, unmeasured confounding, or the late season emergence of antigenic drift variants of influenza viruses that are less well matched to the vaccine viruses. Varying data concern...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.97080078125003px; top: 77.93117675781251px; width: 290.60341796875px; height: 54.880139160156254px;"
                 title="personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual staff persons, and others not directly involved in patient care but who might be e..."
                 data-order="6"
                 data-bbox="1769.85400390625,389.6558837890625,3222.87109375,664.0565795898438">
                personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual staff persons, and others not directly involved in patient care but who might be e...
            </div>
            

            <div class="text-block list" 
                 style="left: 354.92033691406255px; top: 153.20683593750002px; width: 288.2051025390625px; height: 262.72470703125003px;"
                 title="these listed groups. Contra indications and precautions for the use of LAIV4 are noted (Tables 2 and 3). Persons Who Live with or Care for Persons at Higher Risk for Influenza-Related Complications Al..."
                 data-order="7"
                 data-bbox="1774.6016845703125,766.0341796875,3215.627197265625,2079.65771484375">
                these listed groups. Contra indications and precautions for the use of LAIV4 are noted (Tables 2 and 3). Persons Who Live with or Care for Persons at Higher Risk for Influenza-Related Complications Al...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.544140625px; top: 408.0947509765625px; width: 291.061474609375px; height: 76.2755126953125px;"
                 title="for adults). An IIV4 or RIV4 (as appropriate for the recipient sage is suitable for persons in all risk groups. LAIV4 is not recommended for certain populations, including certain of these listed grou..."
                 data-order="8"
                 data-bbox="1762.720703125,2040.4737548828125,3218.028076171875,2421.851318359375">
                for adults). An IIV4 or RIV4 (as appropriate for the recipient sage is suitable for persons in all risk groups. LAIV4 is not recommended for certain populations, including certain of these listed grou...
            </div>
            

            <div class="text-block title" 
                 style="left: 350.385693359375px; top: 491.824658203125px; width: 275.41982421875px; height: 30.38134765625px;"
                 title="facilities. • American Indian or Alaska Native persons. • Persons who are extremely obese (body mass index ≥"
                 data-order="9"
                 data-bbox="1751.928466796875,2459.123291015625,3129.027587890625,2611.030029296875">
                facilities. • American Indian or Alaska Native persons. • Persons who are extremely obese (body mass index ≥
            </div>
            

            <div class="text-block text" 
                 style="left: 358.09116210937503px; top: 525.1298339843751px; width: 283.694287109375px; height: 136.716064453125px;"
                 title="metabolic disorders (including diabetes mel lit us). • Persons who are immunocompromised due to any cause (including but not limited to immunosuppression caused by medications or HIV infection). • Per..."
                 data-order="10"
                 data-bbox="1790.455810546875,2625.649169921875,3208.92724609375,3309.2294921875">
                metabolic disorders (including diabetes mel lit us). • Persons who are immunocompromised due to any cause (including but not limited to immunosuppression caused by medications or HIV infection). • Per...
            </div>
            

            <div class="text-block list" 
                 style="left: 362.0418701171875px; top: 653.1285156250001px; width: 278.7591552734375px; height: 148.713623046875px;"
                 title="fforts should focus on vaccination of persons at higher risk for medical complications attributable to severe influenza who do ot have contra indications. These persons include the following no hierar..."
                 data-order="11"
                 data-bbox="1810.2093505859375,3265.642578125,3204.005126953125,4009.210693359375">
                fforts should focus on vaccination of persons at higher risk for medical complications attributable to severe influenza who do ot have contra indications. These persons include the following no hierar...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 12</div>

            <div class="text-block text" 
                 style="left: 60.49708862304688px; top: 79.92758178710938px; width: 266.60369262695315px; height: 17.622076416015627px;"
                 title=""
                 data-order="0"
                 data-bbox="302.4854431152344,399.6379089355469,1635.50390625,487.748291015625">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 35.82175903320313px; top: 128.591162109375px; width: 294.9006286621094px; height: 350.17631835937505px;"
                 title="and that hospital visitors who have received LAIV should avoid contact with such persons for 7 days after vaccination (41). However, such persons need not be restricted from caring for or visiting les..."
                 data-order="1"
                 data-bbox="179.10879516601562,642.955810546875,1653.6119384765625,2393.83740234375">
                and that hospital visitors who have received LAIV should avoid contact with such persons for 7 days after vaccination (41). However, such persons need not be restricted from caring for or visiting les...
            </div>
            

            <div class="text-block list" 
                 style="left: 44.109649658203125px; top: 732.9464843750001px; width: 285.5192077636719px; height: 33.650097656250004px;"
                 title="volunteers). ACIP guidance for vaccination of health care personnel has been published previously (40). • Household contacts (including children aged ≥6 months)"
                 data-order="2"
                 data-bbox="220.54824829101562,3664.732421875,1648.144287109375,3832.98291015625">
                volunteers). ACIP guidance for vaccination of health care personnel has been published previously (40). • Household contacts (including children aged ≥6 months)
            </div>
            

            <div class="text-block title" 
                 style="left: 354.6407470703125px; top: 76.72939453125001px; width: 269.1292236328125px; height: 34.497143554687504px;"
                 title="2022-23 influenza vaccine and 2) the number of doses influenza vaccine received in previous influenza seasons."
                 data-order="3"
                 data-bbox="1773.2037353515625,383.64697265625,3118.849853515625,556.1326904296875">
                2022-23 influenza vaccine and 2) the number of doses influenza vaccine received in previous influenza seasons.
            </div>
            

            <div class="text-block list" 
                 style="left: 353.8189697265625px; top: 112.34284667968751px; width: 288.60104980468753px; height: 245.1575927734375px;"
                 title="the appropriate volume for each dose. For IIV4 s, the recommended volume may be administered from a pre filled syringe containing the appropriate volume (as supplied by the manufacturer), a single dos..."
                 data-order="4"
                 data-bbox="1769.0948486328125,561.7142333984375,3212.10009765625,1787.502197265625">
                the appropriate volume for each dose. For IIV4 s, the recommended volume may be administered from a pre filled syringe containing the appropriate volume (as supplied by the manufacturer), a single dos...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.43283691406253px; top: 378.12253417968753px; width: 287.99460449218753px; height: 8.0657470703125px;"
                 title="(aIIV4) are not approved for persons aged &lt;65 years."
                 data-order="5"
                 data-bbox="1767.1641845703125,1890.6126708984375,3207.13720703125,1930.94140625">
                (aIIV4) are not approved for persons aged &lt;65 years.
            </div>
            

            <div class="text-block text" 
                 style="left: 352.15622558593753px; top: 388.8782958984375px; width: 289.2660400390625px; height: 113.4899169921875px;"
                 title="should receive 0.5 mL per dose. Alternatively, healthy children aged ≥24 months (≥2 years) may receive LAIV4, 0.2 mL in tran a sally (0.1 mL in each nostril). LAIV4 is not recommended for certain popu..."
                 data-order="6"
                 data-bbox="1760.7811279296875,1944.3914794921875,3207.111328125,2511.841064453125">
                should receive 0.5 mL per dose. Alternatively, healthy children aged ≥24 months (≥2 years) may receive LAIV4, 0.2 mL in tran a sally (0.1 mL in each nostril). LAIV4 is not recommended for certain popu...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.28581542968755px; top: 498.79594726562505px; width: 286.1116455078125px; height: 148.18408203125px;"
                 title="2022-23 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multi dose vial (43). • Fluarix Quad rival ent: 0.5 mL per dose. • Flu cel vax Quad rival ent: 0.5 mL per ..."
                 data-order="7"
                 data-bbox="1761.4290771484375,2493.979736328125,3191.9873046875,3234.900146484375">
                2022-23 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multi dose vial (43). • Fluarix Quad rival ent: 0.5 mL per dose. • Flu cel vax Quad rival ent: 0.5 mL per ...
            </div>
            

            <div class="text-block title" 
                 style="left: 351.413330078125px; top: 656.30107421875px; width: 243.21298828125px; height: 30.93310546875px;"
                 title="for children aged 6 through 35 months are as follows • Afluria Quad rival ent: 0.25 mL per dose. However pre filled syringes are not expected to be availab"
                 data-order="8"
                 data-bbox="1757.066650390625,3281.50537109375,2973.131591796875,3436.1708984375">
                for children aged 6 through 35 months are as follows • Afluria Quad rival ent: 0.25 mL per dose. However pre filled syringes are not expected to be availab
            </div>
            

            <div class="text-block text" 
                 style="left: 349.92729492187505px; top: 689.47001953125px; width: 296.15810546875px; height: 100.18813476562501px;"
                 title="g g Vaccine Dose Volumes Five IIV4 s are approved for children aged ≥6 months (Table 1). Four of these vaccines are egg based (Afluria Quad rival ent, Fluarix Quad rival ent, Flu laval Quad rival ent,..."
                 data-order="9"
                 data-bbox="1749.636474609375,3447.35009765625,3230.427001953125,3948.290771484375">
                g g Vaccine Dose Volumes Five IIV4 s are approved for children aged ≥6 months (Table 1). Four of these vaccines are egg based (Afluria Quad rival ent, Fluarix Quad rival ent, Flu laval Quad rival ent,...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 13</div>

            <div class="text-block text" 
                 style="left: 37.67038269042969px; top: 77.03742675781251px; width: 292.18247375488284px; height: 36.783215332031254px;"
                 title="g y yinfluenza vaccine for the 2022-23 season."
                 data-order="0"
                 data-bbox="188.35191345214844,385.1871337890625,1649.2642822265625,569.1032104492188">
                g y yinfluenza vaccine for the 2022-23 season.
            </div>
            

            <div class="table-block" 
                 style="left: 38.84722595214844px; top: 110.46363525390626px; width: 293.6669097900391px; height: 67.1695068359375px;"
                 title="[TABLE 2 - See table_p13_det_12_007.png]"
                 data-order="1"
                 data-bbox="194.2361297607422,552.3181762695312,1662.5706787109375,888.1657104492188">
                <span>Table</span>
            </div>
            

            <div class="text-block list" 
                 style="left: 43.59397583007813px; top: 242.4111083984375px; width: 296.0643005371094px; height: 560.9972900390625px;"
                 title="TABLE 4. Dose volumes for in activated influenza vaccines approved or children aged 6 through 35 months* - United States, 2022-23 nfluenza season Trade name (Manufacturer) Dose volume for children age..."
                 data-order="2"
                 data-bbox="217.96987915039062,1212.0555419921875,1698.2913818359375,4017.0419921875">
                TABLE 4. Dose volumes for in activated influenza vaccines approved or children aged 6 through 35 months* - United States, 2022-23 nfluenza season Trade name (Manufacturer) Dose volume for children age...
            </div>
            

            <div class="text-block title" 
                 style="left: 352.280419921875px; top: 79.05910644531251px; width: 104.969287109375px; height: 16.203936767578124px;"
                 title="receive any one of the"
                 data-order="3"
                 data-bbox="1761.402099609375,395.2955322265625,2286.24853515625,476.3152160644531">
                receive any one of the
            </div>
            

            <div class="text-block text" 
                 style="left: 347.2637451171875px; top: 99.99146118164063px; width: 294.4901611328125px; height: 499.2392028808594px;"
                 title="can be used postpartum. Influenza vaccine can be administered at any time during pregnancy (i.e., during any trimester), before and during the influenza season. Early vaccination (i.e., during July an..."
                 data-order="4"
                 data-bbox="1736.3187255859375,499.9573059082031,3208.76953125,2996.1533203125">
                can be used postpartum. Influenza vaccine can be administered at any time during pregnancy (i.e., during any trimester), before and during the influenza season. Early vaccination (i.e., during July an...
            </div>
            

            <div class="text-block text" 
                 style="left: 350.98203125000003px; top: 599.050048828125px; width: 289.66367187500003px; height: 138.89541015625px;"
                 title="vaccination during pregnancy is associated with reduced risk for respiratory illness and influenza among pregnant and postpartum persons as well as infants during the first several months of life (33 ..."
                 data-order="5"
                 data-bbox="1754.91015625,2995.250244140625,3203.228515625,3689.727294921875">
                vaccination during pregnancy is associated with reduced risk for respiratory illness and influenza among pregnant and postpartum persons as well as infants during the first several months of life (33 ...
            </div>
            

            <div class="text-block title" 
                 style="left: 352.463623046875px; top: 741.208984375px; width: 74.960009765625px; height: 17.1068359375px;"
                 title="higher risk for se particularly dur"
                 data-order="6"
                 data-bbox="1762.318115234375,3706.044921875,2137.1181640625,3791.5791015625">
                higher risk for se particularly dur
            </div>
            

            <div class="text-block text" 
                 style="left: 354.902734375px; top: 761.35380859375px; width: 288.12490234375px; height: 29.910986328125002px;"
                 title="Pregnant Persons Pregnant and postpartum persons have been observed to be at higher risk for severe illness and complications from influenza"
                 data-order="7"
                 data-bbox="1774.513671875,3806.76904296875,3215.13818359375,3956.323974609375">
                Pregnant Persons Pregnant and postpartum persons have been observed to be at higher risk for severe illness and complications from influenza
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 14</div>

            <div class="text-block text" 
                 style="left: 41.4721923828125px; top: 75.20919799804688px; width: 285.5851318359375px; height: 93.65946655273439px;"
                 title="g y, , y HD-IIV, RIV, and aIIV versus non adjuvant ed SD-IIVs and of each of these three vaccines with one another was reviewed, focusing on published studies performed during non pandemic influenza s..."
                 data-order="0"
                 data-bbox="207.3609619140625,376.0459899902344,1635.28662109375,844.3433227539062">
                g y, , y HD-IIV, RIV, and aIIV versus non adjuvant ed SD-IIVs and of each of these three vaccines with one another was reviewed, focusing on published studies performed during non pandemic influenza s...
            </div>
            

            <div class="text-block text" 
                 style="left: 37.886956787109376px; top: 163.29630126953126px; width: 290.1175842285156px; height: 175.95506591796877px;"
                 title="the findings to all or most seasons. Studies directly comparing HD-IIV, RIV, and aIIV with one another are few and do not support a conclusion that any one of these vaccines is consistently superior t..."
                 data-order="1"
                 data-bbox="189.43478393554688,816.4815063476562,1640.022705078125,1696.2568359375">
                the findings to all or most seasons. Studies directly comparing HD-IIV, RIV, and aIIV with one another are few and do not support a conclusion that any one of these vaccines is consistently superior t...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.82001342773438px; top: 335.990234375px; width: 287.44883422851564px; height: 261.608349609375px;"
                 title="for HD-IIV4 and 45 µg for RIV4, compared with 15 µg for standard dose in activated vaccines). The adjuvant ed vaccine contains 15 µg of HA per virus, similarly to non adjuvant ed SD-IIVs, but contains..."
                 data-order="2"
                 data-bbox="194.10006713867188,1679.951171875,1631.34423828125,2987.992919921875">
                for HD-IIV4 and 45 µg for RIV4, compared with 15 µg for standard dose in activated vaccines). The adjuvant ed vaccine contains 15 µg of HA per virus, similarly to non adjuvant ed SD-IIVs, but contains...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.34791870117188px; top: 594.9755371093751px; width: 291.14165649414065px; height: 104.9990234375px;"
                 title="influenza associated illness, hospitalization, and death compared with younger persons (4 16 64. Influenza vaccines are often less effective in this population (65). HD-IIV, RIV, and aIIV have been ev..."
                 data-order="3"
                 data-bbox="196.73959350585938,2974.877685546875,1652.4478759765625,3499.872802734375">
                influenza associated illness, hospitalization, and death compared with younger persons (4 16 64. Influenza vaccines are often less effective in this population (65). HD-IIV, RIV, and aIIV have been ev...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.19456481933594px; top: 699.0867675781251px; width: 292.07496643066406px; height: 102.990234375px;"
                 title="influenza vaccines: quad rival ent high dose in activated influenza vaccine (HD-IIV4), quad rival ent recombinant influenza vaccine (RIV4), or quad rival ent adjuvanted in activated influenza vaccine ..."
                 data-order="4"
                 data-bbox="190.9728240966797,3495.433837890625,1651.34765625,4010.385009765625">
                influenza vaccines: quad rival ent high dose in activated influenza vaccine (HD-IIV4), quad rival ent recombinant influenza vaccine (RIV4), or quad rival ent adjuvanted in activated influenza vaccine ...
            </div>
            

            <div class="text-block title" 
                 style="left: 354.2467041015625px; top: 77.77211914062501px; width: 291.8190185546875px; height: 2.068914794921875px;"
                 title=""
                 data-order="5"
                 data-bbox="1771.2335205078125,388.860595703125,3230.32861328125,399.2051696777344">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 352.68742675781255px; top: 82.79944458007813px; width: 292.4651123046875px; height: 387.7557800292969px;"
                 title="g g g y (relative efficacy: 42%; 95% CI: 9 65 (68). No data are available from randomized trials of aIIV versus non adjuvant ed SD-IIVs against laboratory confirmed influenza outcomes during non pande..."
                 data-order="6"
                 data-bbox="1763.4371337890625,413.9972229003906,3225.7626953125,2352.776123046875">
                g g g y (relative efficacy: 42%; 95% CI: 9 65 (68). No data are available from randomized trials of aIIV versus non adjuvant ed SD-IIVs against laboratory confirmed influenza outcomes during non pande...
            </div>
            

            <div class="text-block text" 
                 style="left: 350.82841796875005px; top: 479.822509765625px; width: 292.863916015625px; height: 326.287353515625px;"
                 title="Randomized Studies Comparing HD-IIV, RIV, and aIIV with Non adjuvant ed SD-IIVs: Prevention of Influenza Illnesses. Randomized studies comparing HD-IIV, RIV, and aIIV with non adjuvant ed SD-IIVs agai..."
                 data-order="7"
                 data-bbox="1754.14208984375,2399.112548828125,3218.461669921875,4030.54931640625">
                Randomized Studies Comparing HD-IIV, RIV, and aIIV with Non adjuvant ed SD-IIVs: Prevention of Influenza Illnesses. Randomized studies comparing HD-IIV, RIV, and aIIV with non adjuvant ed SD-IIVs agai...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 15</div>

            <div class="text-block title" 
                 style="left: 39.170257568359375px; top: 78.02294311523438px; width: 288.23179321289064px; height: 47.051361083984375px;"
                 title="q jamong RIV4 recipients; frequency of fever was similar between the two vaccines. Frequencies of SAEs were similar between the two groups, and none was judged to be related to a study"
                 data-order="0"
                 data-bbox="195.85128784179688,390.1147155761719,1637.01025390625,625.3715209960938">
                q jamong RIV4 recipients; frequency of fever was similar between the two vaccines. Frequencies of SAEs were similar between the two groups, and none was judged to be related to a study
            </div>
            

            <div class="text-block title" 
                 style="left: 41.25328369140625px; top: 134.76982421875002px; width: 287.60167236328124px; height: 3.71373291015625px;"
                 title="f i fli...iil l"
                 data-order="1"
                 data-bbox="206.26641845703125,673.84912109375,1644.2747802734375,692.4177856445312">
                f i fli...iil l
            </div>
            

            <div class="text-block text" 
                 style="left: 37.039862060546874px; top: 178.91374511718752px; width: 293.81238403320316px; height: 488.0635009765625px;"
                 title="influenza seasons. Many of these studies assessed diagnostic code defined (rather than laboratory confirmed outcomes. In these studies, an overall modest relative benefit in prevention of diagnostic c..."
                 data-order="2"
                 data-bbox="185.19931030273438,894.5687255859375,1654.26123046875,3334.88623046875">
                influenza seasons. Many of these studies assessed diagnostic code defined (rather than laboratory confirmed outcomes. In these studies, an overall modest relative benefit in prevention of diagnostic c...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.87465515136719px; top: 666.8724609375px; width: 286.0084259033203px; height: 136.125439453125px;"
                 title="The second noted a benefit of aIIV3 relative to non adjuvant ed SD-IIV3 (adjusted hazard ratio: 0.79; 95% CI: 0 65 0 96; certainty level: 2, moderate) (85). Observational Studies Comparing HD-IIV, RIV..."
                 data-order="3"
                 data-bbox="199.37327575683594,3334.3623046875,1629.4154052734375,4014.989501953125">
                The second noted a benefit of aIIV3 relative to non adjuvant ed SD-IIV3 (adjusted hazard ratio: 0.79; 95% CI: 0 65 0 96; certainty level: 2, moderate) (85). Observational Studies Comparing HD-IIV, RIV...
            </div>
            

            <div class="text-block text" 
                 style="left: 354.95280761718755px; top: 74.95103149414062px; width: 286.5208740234375px; height: 160.58563842773438px;"
                 title="Persons with a History of Guill a in Barré Syndrome After Influenza Vaccination A history of Guillain-Barré syndrome (GBS) within 6 weeks of a previous dose of any type of influenza vaccine is conside..."
                 data-order="4"
                 data-bbox="1774.7640380859375,374.7551574707031,3207.368408203125,1177.683349609375">
                Persons with a History of Guill a in Barré Syndrome After Influenza Vaccination A history of Guillain-Barré syndrome (GBS) within 6 weeks of a previous dose of any type of influenza vaccine is conside...
            </div>
            

            <div class="text-block title" 
                 style="left: 352.26323242187505px; top: 246.4616455078125px; width: 181.16191406250002px; height: 15.021728515625px;"
                 title="immuno suppress ive medications."
                 data-order="5"
                 data-bbox="1761.316162109375,1232.3082275390625,2667.125732421875,1307.4168701171875">
                immuno suppress ive medications.
            </div>
            

            <div class="text-block text" 
                 style="left: 351.70468750000003px; top: 262.75380859375px; width: 291.991943359375px; height: 360.57280273437505px;"
                 title="Immunocompromised Persons ACIP recommends that persons with compromised immunity (including but not limited to persons with congenital and acquired immunodeficiency states, persons who are immunocompr..."
                 data-order="6"
                 data-bbox="1758.5234375,1313.76904296875,3218.483154296875,3116.633056640625">
                Immunocompromised Persons ACIP recommends that persons with compromised immunity (including but not limited to persons with congenital and acquired immunodeficiency states, persons who are immunocompr...
            </div>
            

            <div class="text-block title" 
                 style="left: 350.409912109375px; top: 633.8936523437501px; width: 291.4728515625px; height: 31.703857421875px;"
                 title="SAE determined by study investigators to be related to vaccine within 43 days after vaccination."
                 data-order="7"
                 data-bbox="1752.049560546875,3169.46826171875,3209.413818359375,3327.987548828125">
                SAE determined by study investigators to be related to vaccine within 43 days after vaccination.
            </div>
            

            <div class="text-block text" 
                 style="left: 353.1844482421875px; top: 666.3009765625001px; width: 288.4566650390625px; height: 133.901806640625px;"
                 title="vaccine (68). One postlicensure randomized clinical trial in the United States evaluated the comparative safety of aIIV3 compared with HD-IIV3 in 757 adults aged ≥65 years (88). For the primary outcom..."
                 data-order="8"
                 data-bbox="1765.9222412109375,3331.5048828125,3208.20556640625,4001.013916015625">
                vaccine (68). One postlicensure randomized clinical trial in the United States evaluated the comparative safety of aIIV3 compared with HD-IIV3 in 757 adults aged ≥65 years (88). For the primary outcom...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 16</div>

            <div class="text-block text" 
                 style="left: 39.534814453125px; top: 78.34479370117188px; width: 290.64482421875px; height: 73.35503540039063px;"
                 title="various components that might cause allergic and a nap hy lactic reactions. Most influenza vaccine package inserts list among contra indications to their use a history of previous severe allergic reac..."
                 data-order="0"
                 data-bbox="197.674072265625,391.7239685058594,1650.898193359375,758.4991455078125">
                various components that might cause allergic and a nap hy lactic reactions. Most influenza vaccine package inserts list among contra indications to their use a history of previous severe allergic reac...
            </div>
            

            <div class="text-block title" 
                 style="left: 37.91109924316407px; top: 159.3782470703125px; width: 217.02610778808594px; height: 15.910327148437501px;"
                 title="As is the case for all vaccines influenza va"
                 data-order="1"
                 data-bbox="189.5554962158203,796.8912353515625,1274.68603515625,876.44287109375">
                As is the case for all vaccines influenza va
            </div>
            

            <div class="text-block text" 
                 style="left: 37.169107055664064px; top: 177.97730712890626px; width: 290.68821716308594px; height: 102.95491943359376px;"
                 title="recommended specifically for egg allergic persons. However, ACIP recommends that vaccination providers consider observing patients (seated or supine) for 15 minutes after administration of any vaccine..."
                 data-order="2"
                 data-bbox="185.8455352783203,889.8865356445312,1639.28662109375,1404.6611328125">
                recommended specifically for egg allergic persons. However, ACIP recommends that vaccination providers consider observing patients (seated or supine) for 15 minutes after administration of any vaccine...
            </div>
            

            <div class="text-block text" 
                 style="left: 53.070068359375px; top: 281.1722900390625px; width: 272.52658691406253px; height: 1.9938232421875002px;"
                 title="d d fll fll"
                 data-order="3"
                 data-bbox="265.350341796875,1405.8614501953125,1627.9832763671875,1415.83056640625">
                d d fll fll
            </div>
            

            <div class="text-block list" 
                 style="left: 37.01072998046875px; top: 301.0099609375px; width: 315.14832763671876px; height: 498.7744140625px;"
                 title="anti viral chemoprophylaxis for these persons (91). However, the benefits of influenza vaccination might outweigh the possible risks for certain persons who have a history of GBS within 6 weeks after ..."
                 data-order="4"
                 data-bbox="185.05364990234375,1505.0498046875,1760.7952880859375,3998.921875">
                anti viral chemoprophylaxis for these persons (91). However, the benefits of influenza vaccination might outweigh the possible risks for certain persons who have a history of GBS within 6 weeks after ...
            </div>
            

            <div class="text-block text" 
                 style="left: 351.4390380859375px; top: 74.68032226562501px; width: 289.9749267578125px; height: 279.750634765625px;"
                 title="precaution for the use of ccIIV4. If ccIIV4 is administered in such instances, vaccination should occur in an inpatient or outpatient medical setting and should be supervised by a health care provider..."
                 data-order="5"
                 data-bbox="1757.1951904296875,373.401611328125,3207.06982421875,1772.15478515625">
                precaution for the use of ccIIV4. If ccIIV4 is administered in such instances, vaccination should occur in an inpatient or outpatient medical setting and should be supervised by a health care provider...
            </div>
            

            <div class="text-block list" 
                 style="left: 359.41655273437505px; top: 335.3638427734375px; width: 286.68291015625px; height: 472.2471923828125px;"
                 title="cIIV4 and RIV4, a history of a severe allergic reaction to any accine component is listed as a contra indication; no labeled ont ra indication is specified for a history of allergic reaction to ny oth..."
                 data-order="6"
                 data-bbox="1797.082763671875,1676.8192138671875,3230.497314453125,4038.05517578125">
                cIIV4 and RIV4, a history of a severe allergic reaction to any accine component is listed as a contra indication; no labeled ont ra indication is specified for a history of allergic reaction to ny oth...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 17</div>

            <div class="text-block list" 
                 style="left: 62.434118652343756px; top: 78.74443359375px; width: 268.8362670898438px; height: 87.76101074218751px;"
                 title="mul at ions are not licensed in the United States, and they ypically not commercially available. More information on enza vaccines and travel is available at https://wwwnc.cdc. travel diseases influen..."
                 data-order="0"
                 data-bbox="312.17059326171875,393.72216796875,1656.3519287109375,832.5272216796875">
                mul at ions are not licensed in the United States, and they ypically not commercially available. More information on enza vaccines and travel is available at https://wwwnc.cdc. travel diseases influen...
            </div>
            

            <div class="text-block title" 
                 style="left: 36.701507568359375px; top: 173.25920410156252px; width: 182.94636840820314px; height: 15.86846923828125px;"
                 title="or unavailability of Southern Hemisph United States Most Southern Hemisp"
                 data-order="1"
                 data-bbox="183.50753784179688,866.2960205078125,1098.2393798828125,945.6383666992188">
                or unavailability of Southern Hemisph United States Most Southern Hemisp
            </div>
            

            <div class="text-block text" 
                 style="left: 40.21199035644531px; top: 188.84310302734377px; width: 286.8593475341797px; height: 136.58856201171875px;"
                 title="influenza season’s vaccine is available should receive the current vaccine the following fall or winter. Influenza vaccine formulated for the Southern Hemisphere might differ in viral composition from..."
                 data-order="2"
                 data-bbox="201.05995178222656,944.2155151367188,1635.356689453125,1627.1583251953125">
                influenza season’s vaccine is available should receive the current vaccine the following fall or winter. Influenza vaccine formulated for the Southern Hemisphere might differ in viral composition from...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.626861572265625px; top: 317.905419921875px; width: 285.26527709960936px; height: 264.26010742187503px;"
                 title="(e.g., on cruise ships) that include persons from areas of the world where influenza viruses are circulating (95 98. Travel ers who want to reduce their risk for influenza should consider influenza va..."
                 data-order="3"
                 data-bbox="203.13430786132812,1589.527099609375,1629.460693359375,2910.82763671875">
                (e.g., on cruise ships) that include persons from areas of the world where influenza viruses are circulating (95 98. Travel ers who want to reduce their risk for influenza should consider influenza va...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.29191589355469px; top: 578.155908203125px; width: 288.0996856689453px; height: 195.43754882812502px;"
                 title="p pallergic reaction. ű A history of a severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency or to any component of RIV4 is a contra indication to future receipt of RIV4. Vaccination ..."
                 data-order="4"
                 data-bbox="191.45957946777344,2890.779541015625,1631.9580078125,3867.96728515625">
                p pallergic reaction. ű A history of a severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency or to any component of RIV4 is a contra indication to future receipt of RIV4. Vaccination ...
            </div>
            

            <div class="text-block title" 
                 style="left: 352.51220703125px; top: 77.45885620117188px; width: 222.79946289062502px; height: 17.634814453125px;"
                 title="and should consult updated CDC guida"
                 data-order="5"
                 data-bbox="1762.56103515625,387.2942810058594,2876.558349609375,475.4683532714844">
                and should consult updated CDC guida
            </div>
            

            <div class="text-block text" 
                 style="left: 350.24094238281253px; top: 95.59923706054688px; width: 291.4080810546875px; height: 89.24756469726563px;"
                 title="Current guidance concerning administration of current U.S.approved or -authorized COVID-19 vaccines indicates that these vaccines may be given with influenza vaccines (https:// www.cdc.gov/vaccines/CO..."
                 data-order="6"
                 data-bbox="1751.2047119140625,477.9961853027344,3208.2451171875,924.2340087890625">
                Current guidance concerning administration of current U.S.approved or -authorized COVID-19 vaccines indicates that these vaccines may be given with influenza vaccines (https:// www.cdc.gov/vaccines/CO...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.0073974609375px; top: 177.81011962890625px; width: 287.8769775390625px; height: 335.62806396484376px;"
                 title="a reasonable assumption is that that peramivir might interfere with the mechanism of LAIV4 if administered from 5 days before through 2 weeks after vaccination and baloxavir might interfere if adminis..."
                 data-order="7"
                 data-bbox="1765.0369873046875,889.0505981445312,3204.421875,2567.19091796875">
                a reasonable assumption is that that peramivir might interfere with the mechanism of LAIV4 if administered from 5 days before through 2 weeks after vaccination and baloxavir might interfere if adminis...
            </div>
            

            <div class="text-block title" 
                 style="left: 352.71232910156255px; top: 525.178857421875px; width: 240.85246582031252px; height: 31.77724609375px;"
                 title="been studied, and the ideal intervals between admin is these medications and LAIV4 are not known. As sum in of at least 5 half lives for substantial decrease in drug lev"
                 data-order="8"
                 data-bbox="1763.5616455078125,2625.894287109375,2967.823974609375,2784.780517578125">
                been studied, and the ideal intervals between admin is these medications and LAIV4 are not known. As sum in of at least 5 half lives for substantial decrease in drug lev
            </div>
            

            <div class="text-block text" 
                 style="left: 352.48601074218755px; top: 559.473486328125px; width: 289.80417480468753px; height: 129.500732421875px;"
                 title="The package insert for LAIV4 notes that anti viral agents might reduce the effectiveness of the vaccine if given within the interval from 48 hours before to 14 days after vaccination (99). However, th..."
                 data-order="9"
                 data-bbox="1762.4300537109375,2797.367431640625,3211.450927734375,3444.87109375">
                The package insert for LAIV4 notes that anti viral agents might reduce the effectiveness of the vaccine if given within the interval from 48 hours before to 14 days after vaccination (99). However, th...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.78349609375005px; top: 688.2296875000001px; width: 290.434619140625px; height: 103.99951171875px;"
                 title="Use of Influenza Anti viral Medications Administration of IIV4 or RIV4 to persons receiving influenza anti viral medications for treatment or chemoprophylaxis of influenza is acceptable. Data concerni..."
                 data-order="10"
                 data-bbox="1763.91748046875,3441.1484375,3216.090576171875,3961.14599609375">
                Use of Influenza Anti viral Medications Administration of IIV4 or RIV4 to persons receiving influenza anti viral medications for treatment or chemoprophylaxis of influenza is acceptable. Data concerni...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 18</div>

            <div class="text-block text" 
                 style="left: 39.645788574218756px; top: 79.88856811523438px; width: 287.41766357421875px; height: 213.78626098632813px;"
                 title="PPSV23 (109 110; tetanus toxoid, reduced diphtheria toxoid, and a cellular pertussis (Tdap) vaccine among adults (108); and Tdap in pregnancy (111). Although increased prevalence of injection site or ..."
                 data-order="0"
                 data-bbox="198.22894287109375,399.4428405761719,1635.3172607421875,1468.3741455078125">
                PPSV23 (109 110; tetanus toxoid, reduced diphtheria toxoid, and a cellular pertussis (Tdap) vaccine among adults (108); and Tdap in pregnancy (111). Although increased prevalence of injection site or ...
            </div>
            

            <div class="text-block text" 
                 style="left: 36.8583984375px; top: 283.2063720703125px; width: 296.63681640625003px; height: 389.24113769531255px;"
                 title="p g g ppostvaccination was similar between the co administration group and the group that received the mRNA COVID-19 vaccine alone; reactogenicity rates in the group receiving HD-IIV4 alone were lower..."
                 data-order="1"
                 data-bbox="184.2919921875,1416.0318603515625,1667.47607421875,3362.237548828125">
                p g g ppostvaccination was similar between the co administration group and the group that received the mRNA COVID-19 vaccine alone; reactogenicity rates in the group receiving HD-IIV4 alone were lower...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.82342529296875px; top: 670.487451171875px; width: 289.1461547851563px; height: 119.955859375px;"
                 title="y, COVID-19 vaccines and influenza vaccines that might be more likely to cause an injection site reaction (e.g., aIIV4 or HD-IIV4) should be administered in different limbs, if possible. In an interim..."
                 data-order="2"
                 data-bbox="194.11712646484375,3352.437255859375,1639.847900390625,3952.216552734375">
                y, COVID-19 vaccines and influenza vaccines that might be more likely to cause an injection site reaction (e.g., aIIV4 or HD-IIV4) should be administered in different limbs, if possible. In an interim...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.844482421875px; top: 76.62420043945313px; width: 285.964013671875px; height: 288.1892517089844px;"
                 title="has been studied, and no evidence of decreased immunogen i city or safety concerns was noted (122). The immunogen i city and safety of simultaneous or sequential administration of two non alum in um a..."
                 data-order="3"
                 data-bbox="1769.222412109375,383.1210021972656,3199.04248046875,1824.0672607421875">
                has been studied, and no evidence of decreased immunogen i city or safety concerns was noted (122). The immunogen i city and safety of simultaneous or sequential administration of two non alum in um a...
            </div>
            

            <div class="text-block text" 
                 style="left: 347.23720703125px; top: 356.125927734375px; width: 292.37958984375px; height: 418.7783203125px;"
                 title="( ) g g pbeen noted within days 0-1 after co administration of IIV with PCV7, PCV13, or DTaP vaccines during the 2006-07 through 2010-11 seasons (114) and with PCV13 during the 2014-15 season (115). A..."
                 data-order="4"
                 data-bbox="1736.18603515625,1780.629638671875,3198.083984375,3874.521240234375">
                ( ) g g pbeen noted within days 0-1 after co administration of IIV with PCV7, PCV13, or DTaP vaccines during the 2006-07 through 2010-11 seasons (114) and with PCV13 during the 2014-15 season (115). A...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 19</div>

            <div class="text-block title" 
                 style="left: 46.67776794433594px; top: 77.90662841796876px; width: 272.2558990478516px; height: 42.287792968750004px;"
                 title="censed influenza vaccines are summarized (Table 1). Cur ren re scribing information should be consulted for authoritative p-to-date information. Contra indications and precaution"
                 data-order="0"
                 data-bbox="233.3888397216797,389.53314208984375,1594.6683349609375,600.9721069335938">
                censed influenza vaccines are summarized (Table 1). Cur ren re scribing information should be consulted for authoritative p-to-date information. Contra indications and precaution
            </div>
            

            <div class="text-block title" 
                 style="left: 54.304394531250004px; top: 124.888720703125px; width: 259.532958984375px; height: 35.1015625px;"
                 title="pluenza vaccine that is appropriate for the recipient’s a dhealth status should be used. Specific age indications f d ifl i i d (T bl 1) C"
                 data-order="1"
                 data-bbox="271.52197265625,624.443603515625,1569.186767578125,799.951416015625">
                pluenza vaccine that is appropriate for the recipient’s a dhealth status should be used. Specific age indications f d ifl i i d (T bl 1) C
            </div>
            

            <div class="text-block text" 
                 style="left: 38.88410034179688px; top: 160.9725341796875px; width: 291.46038208007815px; height: 418.75437011718753px;"
                 title="will contain HA derived from • an influenza A/Victoria/2570/2019 (H1 N1) pdm 09 like virus, • an influenza A/Darwin/9/2021 (H3 N2)-like virus, • an influenza B/Austria/1359417/2021 (Victoria lineage) ..."
                 data-order="2"
                 data-bbox="194.42050170898438,804.8626708984375,1651.722412109375,2898.634521484375">
                will contain HA derived from • an influenza A/Victoria/2570/2019 (H1 N1) pdm 09 like virus, • an influenza A/Darwin/9/2021 (H3 N2)-like virus, • an influenza B/Austria/1359417/2021 (Victoria lineage) ...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.7159423828125px; top: 637.0017578125px; width: 293.578125px; height: 29.281005859375px;"
                 title="advisory-committees/advisory-committee-calendar/vaccinesand-related-biological-products-advisory-committee-march-32022 meeting announcement) All influenza vaccines expected"
                 data-order="3"
                 data-bbox="193.5797119140625,3185.0087890625,1661.4703369140625,3331.413818359375">
                advisory-committees/advisory-committee-calendar/vaccinesand-related-biological-products-advisory-committee-march-32022 meeting announcement) All influenza vaccines expected
            </div>
            

            <div class="text-block text" 
                 style="left: 39.60699462890625px; top: 662.1513671875px; width: 287.39830322265624px; height: 134.44091796875px;"
                 title="Influenza Vaccine Composition and Available Vaccines Influenza Vaccine Composition for the 2022-23 Season All influenza vaccines licensed in the United States will contain components derived from infl..."
                 data-order="4"
                 data-bbox="198.03497314453125,3310.7568359375,1635.0264892578125,3982.96142578125">
                Influenza Vaccine Composition and Available Vaccines Influenza Vaccine Composition for the 2022-23 Season All influenza vaccines licensed in the United States will contain components derived from infl...
            </div>
            

            <div class="text-block text" 
                 style="left: 350.94975585937505px; top: 79.95957641601564px; width: 290.27431640625px; height: 21.836419677734376px;"
                 title="and Flu zone Quad rival ent (44), reference vaccine viruses are"
                 data-order="5"
                 data-bbox="1754.748779296875,399.7978820800781,3206.120361328125,508.97998046875">
                and Flu zone Quad rival ent (44), reference vaccine viruses are
            </div>
            

            <div class="text-block text" 
                 style="left: 352.65976562500003px; top: 107.27371826171876px; width: 288.47021484375px; height: 146.05626220703127px;"
                 title="Standard dose, nonadjuvanted IIV4 s contain 15 µg of HA per vaccine virus in a 0.5-mL dose (7.5 µg of HA per vaccine virus in a 0.25-mL dose). For 2022-23, this category is expected to include five di..."
                 data-order="6"
                 data-bbox="1763.298828125,536.3685913085938,3205.64990234375,1266.64990234375">
                Standard dose, nonadjuvanted IIV4 s contain 15 µg of HA per vaccine virus in a 0.5-mL dose (7.5 µg of HA per vaccine virus in a 0.25-mL dose). For 2022-23, this category is expected to include five di...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.9007568359375px; top: 246.95744628906252px; width: 287.1086669921875px; height: 134.6767822265625px;"
                 title="2022 23 (Table 1); all are expected to be quad rival ent (IIV4 s). Standard dose, nonadjuvanted IIV4 s are licensed for persons aged as young as 6 months. However, for certain IIV4 s, the approved dos..."
                 data-order="7"
                 data-bbox="1764.5037841796875,1234.7872314453125,3200.047119140625,1908.171142578125">
                2022 23 (Table 1); all are expected to be quad rival ent (IIV4 s). Standard dose, nonadjuvanted IIV4 s are licensed for persons aged as young as 6 months. However, for certain IIV4 s, the approved dos...
            </div>
            

            <div class="text-block title" 
                 style="left: 376.8927001953125px; top: 402.21767578125px; width: 238.5343017578125px; height: 33.181005859375px;"
                 title="drivalent In activated Influenza Vaccines (IIV ail able Vaccines. As in recent seasons, various inactiv (IIV ) d b lbl"
                 data-order="8"
                 data-bbox="1884.4635009765625,2011.08837890625,3077.135009765625,2176.993408203125">
                drivalent In activated Influenza Vaccines (IIV ail able Vaccines. As in recent seasons, various inactiv (IIV ) d b lbl
            </div>
            

            <div class="text-block title" 
                 style="left: 350.7381103515625px; top: 441.705029296875px; width: 292.2593505859375px; height: 16.187255859375px;"
                 title="Contra indications, and Precautions"
                 data-order="9"
                 data-bbox="1753.6905517578125,2208.525146484375,3214.9873046875,2289.46142578125">
                Contra indications, and Precautions
            </div>
            

            <div class="text-block text" 
                 style="left: 352.8908935546875px; top: 460.31230468750005px; width: 289.55173339843753px; height: 161.27797851562502px;"
                 title="Since the publication of the previous season srecommendations, FDA has approved ala be ling change for Flu cel vax Quad rival ent (see Recent Influenza Vaccine La be ling Changes). Additional new lic ..."
                 data-order="10"
                 data-bbox="1764.4544677734375,2301.5615234375,3212.213134765625,3107.951416015625">
                Since the publication of the previous season srecommendations, FDA has approved ala be ling change for Flu cel vax Quad rival ent (see Recent Influenza Vaccine La be ling Changes). Additional new lic ...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.4570556640625px; top: 614.3424804687501px; width: 287.2014404296875px; height: 178.92431640625px;"
                 title="for the different types of influenza vaccines are summarized (Tables 2 and 3), as are dose volumes (Table 4). Not all influenza vaccines are likely to be uniformly available in any specific practice s..."
                 data-order="11"
                 data-bbox="1767.2852783203125,3071.71240234375,3203.29248046875,3966.333984375">
                for the different types of influenza vaccines are summarized (Tables 2 and 3), as are dose volumes (Table 4). Not all influenza vaccines are likely to be uniformly available in any specific practice s...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 20</div>

            <div class="text-block text" 
                 style="left: 38.648553466796876px; top: 78.02659301757814px; width: 290.9892150878906px; height: 46.757501220703126px;"
                 title="p g Q (HD-IIV4, licensed for persons aged ≥65 years), for which the correct volume is 0.7 mL per dose. If a smaller vaccine dose (e.g., 0.25 mL) is inadvertently administered to a person"
                 data-order="0"
                 data-bbox="193.24276733398438,390.1329650878906,1648.1888427734375,623.9204711914062">
                p g Q (HD-IIV4, licensed for persons aged ≥65 years), for which the correct volume is 0.7 mL per dose. If a smaller vaccine dose (e.g., 0.25 mL) is inadvertently administered to a person
            </div>
            

            <div class="text-block text" 
                 style="left: 40.71814575195313px; top: 121.29976806640626px; width: 284.6125183105469px; height: 118.23988037109376px;"
                 title="of doses. Children in this age group who require 2 doses for 2022-23 need 2 separate doses administered ≥4 weeks apart, regardless of the specific IIV4 used and volume given for each dose (see Childre..."
                 data-order="1"
                 data-bbox="203.59072875976562,606.4988403320312,1626.6533203125,1197.6982421875">
                of doses. Children in this age group who require 2 doses for 2022-23 need 2 separate doses administered ≥4 weeks apart, regardless of the specific IIV4 used and volume given for each dose (see Childre...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.264416503906254px; top: 238.6135986328125px; width: 293.63707275390624px; height: 475.65231933593753px;"
                 title="vaccine (Flu zone High-Dose Quad rival ent; HD-IIV4) contains 60 µg of HA per vaccine virus (240 µg total) in a 0.7-mL dose (126). Quad rival ent adjuvanted in activated influenza vaccine (Fluad Quad ..."
                 data-order="2"
                 data-bbox="196.32208251953125,1193.0679931640625,1664.5074462890625,3571.32958984375">
                vaccine (Flu zone High-Dose Quad rival ent; HD-IIV4) contains 60 µg of HA per vaccine virus (240 µg total) in a 0.7-mL dose (126). Quad rival ent adjuvanted in activated influenza vaccine (Fluad Quad ...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.64509887695313px; top: 710.830615234375px; width: 290.1631774902344px; height: 89.84140625px;"
                 title="propagated in eggs. For Flu cel vax Quad rival ent, reference vaccine viruses are propagated in Madin-Darby canine kidney cells instead of eggs (125). Two additional IIV4 s that will be available for ..."
                 data-order="3"
                 data-bbox="203.22549438476562,3554.153076171875,1654.0413818359375,4003.360107421875">
                propagated in eggs. For Flu cel vax Quad rival ent, reference vaccine viruses are propagated in Madin-Darby canine kidney cells instead of eggs (125). Two additional IIV4 s that will be available for ...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.52685546875px; top: 73.92291259765625px; width: 287.88876953125003px; height: 134.29434814453126px;"
                 title="IIV, RIV, or LAIV of any valency) is a precaution for the use of ccIIV4 (see Persons with Previous Allergic Reactions to Influenza Vaccines) (Tables 2 and 3). If ccIIV4 is administered in such an inst..."
                 data-order="4"
                 data-bbox="1762.63427734375,369.61456298828125,3202.078125,1041.0863037109375">
                IIV, RIV, or LAIV of any valency) is a precaution for the use of ccIIV4 (see Persons with Previous Allergic Reactions to Influenza Vaccines) (Tables 2 and 3). If ccIIV4 is administered in such an inst...
            </div>
            

            <div class="text-block text" 
                 style="left: 351.75798339843755px; top: 205.092626953125px; width: 290.6098876953125px; height: 91.330908203125px;"
                 title="allergic reaction (e.g., anaphylaxis) to a previous dose of any influenza vaccine (any egg based IIV, ccIIV, RIV, or LAIV of any valency). Use of ccIIV4 is contra indicated in persons who have had a s..."
                 data-order="5"
                 data-bbox="1758.7899169921875,1025.463134765625,3211.83935546875,1482.11767578125">
                allergic reaction (e.g., anaphylaxis) to a previous dose of any influenza vaccine (any egg based IIV, ccIIV, RIV, or LAIV of any valency). Use of ccIIV4 is contra indicated in persons who have had a s...
            </div>
            

            <div class="text-block text" 
                 style="left: 352.603515625px; top: 292.443017578125px; width: 290.90029296875px; height: 98.172119140625px;"
                 title="has a labeled contra indication for persons with a history of a severe allergic reaction to any component of that vaccine (Table 2). Although egg is a component of all IIV4 s other than ccIIV4, ACIP m..."
                 data-order="6"
                 data-bbox="1763.017578125,1462.215087890625,3217.51904296875,1953.07568359375">
                has a labeled contra indication for persons with a history of a severe allergic reaction to any component of that vaccine (Table 2). Although egg is a component of all IIV4 s other than ccIIV4, ACIP m...
            </div>
            

            <div class="text-block text" 
                 style="left: 351.64794921875px; top: 409.257275390625px; width: 291.307666015625px; height: 390.28759765625px;"
                 title="aged ≥36 months, the remaining volume needed to make afull dose should be administered during the same vaccination visit or, if measuring the needed remaining volume is a challenge, administering a re..."
                 data-order="7"
                 data-bbox="1758.23974609375,2046.286376953125,3214.778076171875,3997.724365234375">
                aged ≥36 months, the remaining volume needed to make afull dose should be administered during the same vaccination visit or, if measuring the needed remaining volume is a challenge, administering a re...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 21</div>

            <div class="text-block text" 
                 style="left: 41.47233581542969px; top: 76.68505859375px; width: 289.9348175048828px; height: 76.10610351562501px;"
                 title="during the 2022-23 influenza season. LAIV4 is approved for persons aged 2 through 49 years. LAIV4 contains live attenuated influenza viruses that are propagated in eggs. These viruses are cold adapted..."
                 data-order="0"
                 data-bbox="207.36167907714844,383.42529296875,1657.0357666015625,763.955810546875">
                during the 2022-23 influenza season. LAIV4 is approved for persons aged 2 through 49 years. LAIV4 contains live attenuated influenza viruses that are propagated in eggs. These viruses are cold adapted...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.430456542968756px; top: 148.71455078125px; width: 287.02801513671875px; height: 76.4116943359375px;"
                 title="Quad rival ent Live Attenuated Influenza Vaccine (LAIV4) Available Vaccine. One live attenuated influenza vaccine, FluMist Quad rival ent (LAIV4), is expected to be available d i h 2022 23 ifl LAIV4 i..."
                 data-order="1"
                 data-bbox="202.15228271484375,743.57275390625,1637.2923583984375,1125.6312255859375">
                Quad rival ent Live Attenuated Influenza Vaccine (LAIV4) Available Vaccine. One live attenuated influenza vaccine, FluMist Quad rival ent (LAIV4), is expected to be available d i h 2022 23 ifl LAIV4 i...
            </div>
            

            <div class="text-block title" 
                 style="left: 35.052459716796875px; top: 231.32985839843752px; width: 290.99663696289065px; height: 16.186010742187502px;"
                 title="influenza vaccines (Table 2). RIV4 is not licensed for children aged &lt;18 years"
                 data-order="2"
                 data-bbox="175.26229858398438,1156.6492919921875,1630.2454833984375,1237.579345703125">
                influenza vaccines (Table 2). RIV4 is not licensed for children aged &lt;18 years
            </div>
            

            <div class="text-block text" 
                 style="left: 38.21683349609375px; top: 251.7598876953125px; width: 294.35260009765625px; height: 99.9872314453125px;"
                 title="health care provider who is able to recognize and manage severe allergic reactions. Providers can also consider consulting with an allergist to help identify the vaccine component responsible for the ..."
                 data-order="3"
                 data-bbox="191.08416748046875,1258.7994384765625,1662.84716796875,1758.735595703125">
                health care provider who is able to recognize and manage severe allergic reactions. Providers can also consider consulting with an allergist to help identify the vaccine component responsible for the ...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.91335754394532px; top: 351.91765136718755px; width: 290.5633514404297px; height: 43.9718017578125px;"
                 title="is a precaution for the use of RIV4. If RIV4 is administered in such an instance, vaccination should occur in an inpatient or outpatient medical setting and should be supervised by a h l hid h ibl i d"
                 data-order="4"
                 data-bbox="199.56678771972656,1759.5882568359375,1652.383544921875,1979.447265625">
                is a precaution for the use of RIV4. If RIV4 is administered in such an instance, vaccination should occur in an inpatient or outpatient medical setting and should be supervised by a h l hid h ibl i d
            </div>
            

            <div class="text-block text" 
                 style="left: 37.983453369140626px; top: 392.6069580078125px; width: 295.47902221679686px; height: 265.0532470703125px;"
                 title="Quad rival ent Recombinant Influenza Vaccine (RIV4) Available Vaccine. One recombinant influenza vaccine, Flublok Quad rival ent (RIV4), is expected to be available during the 2022-23 influenza season..."
                 data-order="5"
                 data-bbox="189.91726684570312,1963.0347900390625,1667.3123779296875,3288.301025390625">
                Quad rival ent Recombinant Influenza Vaccine (RIV4) Available Vaccine. One recombinant influenza vaccine, Flublok Quad rival ent (RIV4), is expected to be available during the 2022-23 influenza season...
            </div>
            

            <div class="text-block title" 
                 style="left: 39.028533935546875px; top: 662.242822265625px; width: 229.28972778320315px; height: 32.067333984375004px;"
                 title="within 6 weeks after receipt of a previous dose vaccine is considered a precaution for the use of vaccines (Table 2)."
                 data-order="6"
                 data-bbox="195.14266967773438,3311.214111328125,1341.59130859375,3471.55078125">
                within 6 weeks after receipt of a previous dose vaccine is considered a precaution for the use of vaccines (Table 2).
            </div>
            

            <div class="text-block text" 
                 style="left: 38.755035400390625px; top: 692.616357421875px; width: 288.95717163085936px; height: 109.956103515625px;"
                 title="be found in the package inserts for each vaccine. Prophylactic use of anti viral agents is an option that can be considered for preventing influenza among persons who cannot receive vaccine, particula..."
                 data-order="7"
                 data-bbox="193.77517700195312,3463.081787109375,1638.56103515625,4012.8623046875">
                be found in the package inserts for each vaccine. Prophylactic use of anti viral agents is an option that can be considered for preventing influenza among persons who cannot receive vaccine, particula...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.83388671875px; top: 76.1135986328125px; width: 287.296923828125px; height: 74.45743408203126px;"
                 title="caused by medications, congenital or acquired"
                 data-order="8"
                 data-bbox="1769.16943359375,380.5679931640625,3205.654052734375,752.8551635742188">
                caused by medications, congenital or acquired
            </div>
            

            <div class="text-block text" 
                 style="left: 352.00249023437505px; top: 146.2783447265625px; width: 291.870361328125px; height: 198.37404785156252px;"
                 title="However, ACIP makes an exception for allergy to egg (see Persons with a History of Egg Allergy). • Children and adolescents receiving concomitant aspirin- or salicylate-containing medications, because..."
                 data-order="9"
                 data-bbox="1760.012451171875,731.3917236328125,3219.3642578125,1723.261962890625">
                However, ACIP makes an exception for allergy to egg (see Persons with a History of Egg Allergy). • Children and adolescents receiving concomitant aspirin- or salicylate-containing medications, because...
            </div>
            

            <div class="text-block title" 
                 style="left: 358.77878417968753px; top: 352.79973144531255px; width: 284.75925292968753px; height: 4.4094970703125px;"
                 title="p g )"
                 data-order="10"
                 data-bbox="1793.8939208984375,1763.9986572265625,3217.690185546875,1786.046142578125">
                p g )
            </div>
            

            <div class="text-block text" 
                 style="left: 353.4298828125px; top: 367.84050292968755px; width: 288.453515625px; height: 87.0711669921875px;"
                 title="is uncertain but biologically plausible potential risk associated with live viruses or limited data for use of LAIV. Contra indications to use of LAIV4 include the following: • Severe allergic reactio..."
                 data-order="11"
                 data-bbox="1767.1494140625,1839.2025146484375,3209.4169921875,2274.558349609375">
                is uncertain but biologically plausible potential risk associated with live viruses or limited data for use of LAIV. Contra indications to use of LAIV4 include the following: • Severe allergic reactio...
            </div>
            

            <div class="text-block list" 
                 style="left: 355.71074218750005px; top: 451.05229492187505px; width: 289.447021484375px; height: 294.82651367187503px;"
                 title="p ( ) p pother influenza vaccines used within specified indications. Dosage and Administration. LAIV4 is administered in tran a sally using the supplied pre filled, single use sprayer containing 0.2 m..."
                 data-order="12"
                 data-bbox="1778.5537109375,2255.261474609375,3225.788818359375,3729.39404296875">
                p ( ) p pother influenza vaccines used within specified indications. Dosage and Administration. LAIV4 is administered in tran a sally using the supplied pre filled, single use sprayer containing 0.2 m...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 22</div>

            <div class="text-block list" 
                 style="left: 45.32732238769532px; top: 75.543408203125px; width: 287.3310760498047px; height: 451.028466796875px;"
                 title="that delay medication clearance (e.g., renal insufficiency). Precautions for use of LAIV4 include the following: • Moderate or severe acute illness with or without fever. • History of GBS within 6 wee..."
                 data-order="0"
                 data-bbox="226.63661193847656,377.717041015625,1663.2919921875,2632.859375">
                that delay medication clearance (e.g., renal insufficiency). Precautions for use of LAIV4 include the following: • Moderate or severe acute illness with or without fever. • History of GBS within 6 wee...
            </div>
            

            <div class="text-block title" 
                 style="left: 33.98199462890625px; top: 540.487841796875px; width: 292.76268310546874px; height: 47.683984375px;"
                 title="p , p 5 days for peramivir, and previous 17 days for baloxavir. The interval between influenza anti viral receipt and LAIV4 during which interference might potentially occur might"
                 data-order="1"
                 data-bbox="169.90997314453125,2702.439208984375,1633.723388671875,2940.859130859375">
                p , p 5 days for peramivir, and previous 17 days for baloxavir. The interval between influenza anti viral receipt and LAIV4 during which interference might potentially occur might
            </div>
            

            <div class="text-block text" 
                 style="left: 39.31649169921875px; top: 582.778125px; width: 289.41339111328125px; height: 208.1623046875px;"
                 title="u d y , , p , or functional asp len i a (such as that due to sickle cell anemia). • Close contacts and caregivers of severely immu no suppressed persons who require a protected environment. • Pregnanc..."
                 data-order="2"
                 data-bbox="196.58245849609375,2913.890625,1643.6494140625,3954.7021484375">
                u d y , , p , or functional asp len i a (such as that due to sickle cell anemia). • Close contacts and caregivers of severely immu no suppressed persons who require a protected environment. • Pregnanc...
            </div>
            

            <div class="text-block text" 
                 style="left: 348.14335937500005px; top: 75.69564208984376px; width: 297.25537109375px; height: 248.27713623046876px;"
                 title="cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html. Vaccines should not be used beyond the expiration date on the label. In addition to the expiration date, multi dose vials also might have a beyon..."
                 data-order="3"
                 data-bbox="1740.716796875,378.47821044921875,3226.99365234375,1619.8638916015625">
                cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html. Vaccines should not be used beyond the expiration date on the label. In addition to the expiration date, multi dose vials also might have a beyon...
            </div>
            

            <div class="text-block title" 
                 style="left: 401.54091796875px; top: 350.14013671875px; width: 193.08647460937502px; height: 37.75390625px;"
                 title="qerature monitoring. Vaccine that has frozen Specific recommendations for appropriate re era ture monitoring equipment can be fou"
                 data-order="4"
                 data-bbox="2007.70458984375,1750.70068359375,2973.136962890625,1939.47021484375">
                qerature monitoring. Vaccine that has frozen Specific recommendations for appropriate re era ture monitoring equipment can be fou
            </div>
            

            <div class="text-block text" 
                 style="left: 353.04497070312505px; top: 389.7020263671875px; width: 288.883203125px; height: 176.9002685546875px;"
                 title="site and systemic reactions was similar between the two groups. Storage and Handling of Influenza Vaccines In all instances, approved manufacturer packaging information should be consulted for authori..."
                 data-order="5"
                 data-bbox="1765.224853515625,1948.5101318359375,3209.640869140625,2833.011474609375">
                site and systemic reactions was similar between the two groups. Storage and Handling of Influenza Vaccines In all instances, approved manufacturer packaging information should be consulted for authori...
            </div>
            

            <div class="text-block text" 
                 style="left: 356.9935546875px; top: 558.76103515625px; width: 283.92138671875px; height: 238.94970703125px;"
                 title="efficacy trial conducted among 4,514 children aged ≥2 to &lt;18 years over three influenza seasons (Southern Hemisphere 2017 and Northern Hemisphere 2017-18 and 2018 19 (129). Subsequently, in October 20..."
                 data-order="6"
                 data-bbox="1784.9677734375,2793.80517578125,3204.57470703125,3988.5537109375">
                efficacy trial conducted among 4,514 children aged ≥2 to &lt;18 years over three influenza seasons (Southern Hemisphere 2017 and Northern Hemisphere 2017-18 and 2018 19 (129). Subsequently, in October 20...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 23</div>

            <div class="text-block title" 
                 style="left: 53.610955810546876px; top: 77.83826904296876px; width: 256.8262023925781px; height: 58.786083984375004px;"
                 title="tps://www.hrsa.gov/sites/default/files/hrsa/vicp/vaccine-inju ble 01 03 2022 pdf lists the vaccines covered by VICP a eassociated injuries and conditions that might receive ale"
                 data-order="0"
                 data-bbox="268.0547790527344,389.19134521484375,1552.185791015625,683.1217651367188">
                tps://www.hrsa.gov/sites/default/files/hrsa/vicp/vaccine-inju ble 01 03 2022 pdf lists the vaccines covered by VICP a eassociated injuries and conditions that might receive ale
            </div>
            

            <div class="text-block title" 
                 style="left: 64.45809326171876px; top: 145.74586181640626px; width: 238.17445068359376px; height: 34.9574462890625px;"
                 title="mended, is a mechanism through which compensation ovided to persons who might have been injured as a rce i ving a vaccine covered by VICP The Vaccine InjuryT"
                 data-order="1"
                 data-bbox="322.29046630859375,728.7293090820312,1513.1627197265625,903.5165405273438">
                mended, is a mechanism through which compensation ovided to persons who might have been injured as a rce i ving a vaccine covered by VICP The Vaccine InjuryT
            </div>
            

            <div class="text-block text" 
                 style="left: 36.38811950683594px; top: 174.23387451171877px; width: 292.71730041503906px; height: 455.59063720703125px;"
                 title="weekly) and can be viewed in Flu view Interactive (https:// www cdc gov flu weekly flu view interactive htm. In addition, periodic updates regarding influenza are published in MMWR (https://www.cdc.go..."
                 data-order="2"
                 data-bbox="181.9405975341797,871.1693725585938,1645.527099609375,3149.12255859375">
                weekly) and can be viewed in Flu view Interactive (https:// www cdc gov flu weekly flu view interactive htm. In addition, periodic updates regarding influenza are published in MMWR (https://www.cdc.go...
            </div>
            

            <div class="text-block title" 
                 style="left: 54.47446899414063px; top: 658.689990234375px; width: 257.5934753417969px; height: 6.549560546875px;"
                 title="ww cdc gov flu U S surveillance data are updated week"
                 data-order="3"
                 data-bbox="272.3723449707031,3293.449951171875,1560.3397216796875,3326.19775390625">
                ww cdc gov flu U S surveillance data are updated week
            </div>
            

            <div class="text-block text" 
                 style="left: 39.20686950683594px; top: 700.614892578125px; width: 287.8769195556641px; height: 86.783984375px;"
                 title="Additional Sources of Information Regarding Influenza and Influenza Vaccines Influenza Surveillance, Prevention, and Control"
                 data-order="4"
                 data-bbox="196.0343475341797,3503.074462890625,1635.4189453125,3936.994384765625">
                Additional Sources of Information Regarding Influenza and Influenza Vaccines Influenza Surveillance, Prevention, and Control
            </div>
            

            <div class="text-block text" 
                 style="left: 350.9408203125px; top: 75.56260986328125px; width: 293.59501953125px; height: 105.85111083984376px;"
                 title="Vaccine Information Sheets • IIV4 and RIV4: https://www.cdc.gov/vaccines/hcp/vis/ vis statements flu pdf • LAIV4: https://www.cdc.gov/vaccines/hcp/vis/visstatements/flulive.pdf"
                 data-order="5"
                 data-bbox="1754.7041015625,377.81304931640625,3222.67919921875,907.068603515625">
                Vaccine Information Sheets • IIV4 and RIV4: https://www.cdc.gov/vaccines/hcp/vis/ vis statements flu pdf • LAIV4: https://www.cdc.gov/vaccines/hcp/vis/visstatements/flulive.pdf
            </div>
            

            <div class="text-block title" 
                 style="left: 426.43828125000005px; top: 196.31413574218752px; width: 142.2005859375px; height: 17.81904296875px;"
                 title="y-preparedness-and-response 19-COVID-19/COVID-19-vaccines"
                 data-order="6"
                 data-bbox="2132.19140625,981.5706787109375,2843.1943359375,1070.6658935546875">
                y-preparedness-and-response 19-COVID-19/COVID-19-vaccines
            </div>
            

            <div class="text-block title" 
                 style="left: 353.2529296875px; top: 221.65761718750002px; width: 98.80488281250001px; height: 15.88818359375px;"
                 title="• FDA COVID-1"
                 data-order="7"
                 data-bbox="1766.2646484375,1108.2880859375,2260.2890625,1187.72900390625">
                • FDA COVID-1
            </div>
            

            <div class="text-block list" 
                 style="left: 357.47001953125005px; top: 235.65007324218752px; width: 289.32724609375003px; height: 455.62932128906255px;"
                 title="Additional Resources ACIP Statements • General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP): https www cdc gov vaccines..."
                 data-order="8"
                 data-bbox="1787.35009765625,1178.2503662109375,3233.986328125,3456.39697265625">
                Additional Resources ACIP Statements • General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP): https www cdc gov vaccines...
            </div>
            

            <div class="text-block title" 
                 style="left: 350.91520996093755px; top: 695.4101074218751px; width: 165.80251464843752px; height: 16.444140625px;"
                 title="vaccine compensation or by calling 1"
                 data-order="9"
                 data-bbox="1754.5760498046875,3477.050537109375,2583.588623046875,3559.271240234375">
                vaccine compensation or by calling 1
            </div>
            

            <div class="text-block list" 
                 style="left: 359.44475097656255px; top: 714.8202636718751px; width: 283.8233154296875px; height: 58.498730468750004px;"
                 title="prove that the vaccine caused the injury or condition. Claims must be filed with specified time frames. Persons of all ages who ece ive a VICP-covered vaccine might be eligible to file a claim. Additi..."
                 data-order="10"
                 data-bbox="1797.2237548828125,3574.101318359375,3216.34033203125,3866.594970703125">
                prove that the vaccine caused the injury or condition. Claims must be filed with specified time frames. Persons of all ages who ece ive a VICP-covered vaccine might be eligible to file a claim. Additi...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 24</div>

            <div class="text-block list" 
                 style="left: 36.50953063964844px; top: 76.64461059570313px; width: 300.85707092285156px; height: 670.733807373047px;"
                 title="CDC Influenza Anti viral Guidance • Influenza Anti viral Medications: Summary for Clinicians: https www cdc gov flu professionals anti virals/ summary clinicians htm Infectious Diseases Society of Ame..."
                 data-order="0"
                 data-bbox="182.5476531982422,383.2230529785156,1686.8330078125,3736.89208984375">
                CDC Influenza Anti viral Guidance • Influenza Anti viral Medications: Summary for Clinicians: https www cdc gov flu professionals anti virals/ summary clinicians htm Infectious Diseases Society of Ame...
            </div>
            

            <div class="text-block text" 
                 style="left: 357.112255859375px; top: 77.92192993164063px; width: 283.34067382812503px; height: 39.34662475585938px;"
                 title=""
                 data-order="1"
                 data-bbox="1785.561279296875,389.6096496582031,3202.2646484375,586.3427734375">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 348.2080078125px; top: 108.69483642578126px; width: 296.733447265625px; height: 649.7227905273438px;"
                 title="g j 5. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004-2009. Ped i at rics 2013 131 207 16. PMID 23296444 https://doi.org/10.1542/peds.2012-1255 6. Poehling..."
                 data-order="2"
                 data-bbox="1741.0400390625,543.4741821289062,3224.707275390625,3792.088134765625">
                g j 5. Poehling KA, Edwards KM, Griffin MR, et al. The burden of influenza in young children, 2004-2009. Ped i at rics 2013 131 207 16. PMID 23296444 https://doi.org/10.1542/peds.2012-1255 6. Poehling...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 25</div>

            <div class="text-block list" 
                 style="left: 36.21484069824219px; top: 86.3731689453125px; width: 293.51250305175785px; height: 671.6523681640625px;"
                 title="p g j vaccine 2014 06 052 20. Radin JM, Hawks worth AW, Myers CA, Rick etts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons..."
                 data-order="0"
                 data-bbox="181.07420349121094,431.8658447265625,1648.63671875,3790.127685546875">
                p g j vaccine 2014 06 052 20. Radin JM, Hawks worth AW, Myers CA, Rick etts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons...
            </div>
            

            <div class="text-block list" 
                 style="left: 348.64052734375px; top: 77.87344970703126px; width: 295.09765625px; height: 692.6182006835938px;"
                 title="0 5 0 6 to 0 8 0 9, U ted States osp ta ed du tue a Vaccine Effectiveness Network. Clin Infect Dis 2021 73 726 9. PMID 33462610 https://doi.org/10.1093/cid/ciab045 33. Madhi SA, Cut land CL, Ku wanda ..."
                 data-order="1"
                 data-bbox="1743.20263671875,389.36724853515625,3218.69091796875,3852.458251953125">
                0 5 0 6 to 0 8 0 9, U ted States osp ta ed du tue a Vaccine Effectiveness Network. Clin Infect Dis 2021 73 726 9. PMID 33462610 https://doi.org/10.1093/cid/ciab045 33. Madhi SA, Cut land CL, Ku wanda ...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 26</div>

            <div class="text-block list" 
                 style="left: 35.355593872070315px; top: 87.911376953125px; width: 297.1227752685547px; height: 678.7750000000001px;"
                 title="2004-2005 influenza seasons. Ped i at rics 2008 122 911 9. PMID 18977968 https://doi.org/10.1542/peds.2007-3304 49. Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination and effect on inf..."
                 data-order="0"
                 data-bbox="176.77796936035156,439.556884765625,1662.391845703125,3833.431884765625">
                2004-2005 influenza seasons. Ped i at rics 2008 122 911 9. PMID 18977968 https://doi.org/10.1542/peds.2007-3304 49. Eick AA, Uyeki TM, Klimov A, et al. Maternal influenza vaccination and effect on inf...
            </div>
            

            <div class="text-block text" 
                 style="left: 353.553857421875px; top: 77.97855224609376px; width: 284.227001953125px; height: 18.838537597656252px;"
                 title=""
                 data-order="1"
                 data-bbox="1767.769287109375,389.89276123046875,3188.904296875,484.08544921875">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 348.430322265625px; top: 116.87584228515625px; width: 298.401171875px; height: 653.4163940429688px;"
                 title="pd 9 d 7;35 53 PMID 28917295 https://doi.org/10.1016/j.vaccine.2017.06.069 63. Donahue JG, Kieke BA, King JP, et al. In activated influenza vaccine and spontaneous abortion in the Vaccine Safety Data ..."
                 data-order="2"
                 data-bbox="1742.151611328125,584.3792114257812,3234.157470703125,3851.461181640625">
                pd 9 d 7;35 53 PMID 28917295 https://doi.org/10.1016/j.vaccine.2017.06.069 63. Donahue JG, Kieke BA, King JP, et al. In activated influenza vaccine and spontaneous abortion in the Vaccine Safety Data ...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 27</div>

            <div class="text-block list" 
                 style="left: 36.337744140625px; top: 98.4626953125px; width: 295.356494140625px; height: 696.005615234375px;"
                 title="77. Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness of high dose versus standard dose influenza vaccines using an instrumental variable method. Vaccine 2019 37 1484 90. P..."
                 data-order="0"
                 data-bbox="181.688720703125,492.3134765625,1658.47119140625,3972.341552734375">
                77. Young-Xu Y, Snider JT, van Aalst R, et al. Analysis of relative effectiveness of high dose versus standard dose influenza vaccines using an instrumental variable method. Vaccine 2019 37 1484 90. P...
            </div>
            

            <div class="text-block list" 
                 style="left: 347.47165527343753px; top: 58.20167846679688px; width: 299.9383056640625px; height: 711.7510070800781px;"
                 title="www cdc gov flu professionals anti virals/summary clinicians htm. 92. Woo EJ. Allergic reactions after egg free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System...."
                 data-order="1"
                 data-bbox="1737.3582763671875,291.0083923339844,3237.0498046875,3849.763427734375">
                www cdc gov flu professionals anti virals/summary clinicians htm. 92. Woo EJ. Allergic reactions after egg free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting System....
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 28</div>

            <div class="text-block list" 
                 style="left: 37.00713806152344px; top: 45.5268798828125px; width: 290.3131500244141px; height: 564.1872314453125px;"
                 title="26 MMWR / A t 26 2022 / V l 71 / N 1 US D https://doi.org/10.1016/j.vaccine.2006.12.047 109. Nakashima K, Aos him a M, Ohfuji S, et al. Immunogen i city of simultaneous versus sequential administratio..."
                 data-order="0"
                 data-bbox="185.0356903076172,227.6343994140625,1636.6014404296875,3048.570556640625">
                26 MMWR / A t 26 2022 / V l 71 / N 1 US D https://doi.org/10.1016/j.vaccine.2006.12.047 109. Nakashima K, Aos him a M, Ohfuji S, et al. Immunogen i city of simultaneous versus sequential administratio...
            </div>
            

            <div class="text-block list" 
                 style="left: 352.9055908203125px; top: 78.19187622070314px; width: 291.7397705078125px; height: 532.8093444824219px;"
                 title="PMID 20003918 https://doi.org/10.1016/j.vaccine.2009.11.054 119. Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017. 120. Fluad Quad rival ent [Package Insert]. Holly Springs..."
                 data-order="1"
                 data-bbox="1764.5279541015625,390.9593811035156,3223.226806640625,3055.006103515625">
                PMID 20003918 https://doi.org/10.1016/j.vaccine.2009.11.054 119. Shingrix [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017. 120. Fluad Quad rival ent [Package Insert]. Holly Springs...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 29</div>

            <div class="text-block title" 
                 style="left: 217.3863525390625px; top: 77.74395141601563px; width: 244.9171142578125px; height: 15.15894775390625px;"
                 title=""
                 data-order="0"
                 data-bbox="1086.9317626953125,388.7197570800781,2311.517333984375,464.5144958496094">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 37.601513671875004px; top: 91.52997436523438px; width: 606.494677734375px; height: 127.40498657226563px;"
                 title=""
                 data-order="1"
                 data-bbox="188.007568359375,457.6498718261719,3220.48095703125,1094.6748046875">
                
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 30</div>

            <div class="text-block title" 
                 style="left: 118.31317138671875px; top: 77.36466674804689px; width: 440.06915283203125px; height: 16.626708984375px;"
                 title=""
                 data-order="0"
                 data-bbox="591.5658569335938,386.8233337402344,2791.91162109375,469.9568786621094">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 34.08333129882813px; top: 101.73533935546875px; width: 610.015545654297px; height: 109.17161865234375px;"
                 title=""
                 data-order="1"
                 data-bbox="170.41665649414062,508.67669677734375,3220.494384765625,1054.5347900390625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 33.940087890625px; top: 208.038427734375px; width: 628.43359375px; height: 48.9399658203125px;"
                 title="Sheffield, MD, Salt Lake City, Utah; Angela Sinilaite, MPH, Ottawa, Ontario, Canada; Patricia Stinchfield, MS, St. Paul, Minnesota; Peter Szil a gyi, MD, Los Angeles, California; Susan Wollersheim, MD..."
                 data-order="2"
                 data-bbox="169.700439453125,1040.192138671875,3311.868408203125,1284.8919677734375">
                Sheffield, MD, Salt Lake City, Utah; Angela Sinilaite, MPH, Ottawa, Ontario, Canada; Patricia Stinchfield, MS, St. Paul, Minnesota; Peter Szil a gyi, MD, Los Angeles, California; Susan Wollersheim, MD...
            </div>
            

            <div class="text-block text" 
                 style="left: 35.24333801269531px; top: 249.8815673828125px; width: 620.4924530029298px; height: 265.2536865234375px;"
                 title="p , ygg, , , ; , g , , , California; Association of Immunization Managers, Molly Howell, MPH, Bismarck, North Dakota; Association for Prevention Teaching and Research, Richard Zimmerman, MD, Pittsburg..."
                 data-order="3"
                 data-bbox="176.21669006347656,1249.4078369140625,3278.678955078125,2575.67626953125">
                p , ygg, , , ; , g , , , California; Association of Immunization Managers, Molly Howell, MPH, Bismarck, North Dakota; Association for Prevention Teaching and Research, Richard Zimmerman, MD, Pittsburg...
            </div>
            

            <div class="text-block title" 
                 style="left: 245.3831298828125px; top: 512.395654296875px; width: 189.3815673828125px; height: 15.5400390625px;"
                 title="Atlanta, Georgia; American Nurses Association, C DO, Tulsa, Oklahoma; American Pharmacists As"
                 data-order="4"
                 data-bbox="1226.9156494140625,2561.978271484375,2173.823486328125,2639.678466796875">
                Atlanta, Georgia; American Nurses Association, C DO, Tulsa, Oklahoma; American Pharmacists As
            </div>
            

            <div class="text-block title" 
                 style="left: 38.59340209960938px; top: 526.983056640625px; width: 203.73970336914064px; height: 8.70654296875px;"
                 title="Medical Association, Sandra Adamson Fry hofer, MD"
                 data-order="5"
                 data-bbox="192.96701049804688,2634.915283203125,1211.66552734375,2678.447998046875">
                Medical Association, Sandra Adamson Fry hofer, MD
            </div>
            

            <div class="text-block text" 
                 style="left: 38.10765380859375px; top: 540.85205078125px; width: 607.3932250976562px; height: 102.73447265625px;"
                 title="Clark, MD, Durango, Colorado; Office of Infectious Disease and HIV AIDS Policy, David Kim, MD, Washington, DC; National Institutes of Health, John Beigel, MD, Bethesda, Maryland. Liaison Representativ..."
                 data-order="6"
                 data-bbox="190.53826904296875,2704.26025390625,3227.50439453125,3217.9326171875">
                Clark, MD, Durango, Colorado; Office of Infectious Disease and HIV AIDS Policy, David Kim, MD, Washington, DC; National Institutes of Health, John Beigel, MD, Bethesda, Maryland. Liaison Representativ...
            </div>
            
</div>
<div class="page-container" data-width="3411.868408203125" data-height="4316.7900390625" style="width: 682.373681640625px; height: 863.3580078125001px;">
<div class="page-header">Page 32</div>

            <div class="text-block text" 
                 style="left: 23.257476806640625px; top: 87.29322509765626px; width: 616.3390563964845px; height: 175.91177978515626px;"
                 title=""
                 data-order="0"
                 data-bbox="116.28738403320312,436.46612548828125,3197.982666015625,1316.0250244140625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 285.76303710937503px; top: 268.04365234375px; width: 108.9425048828125px; height: 13.8368896484375px;"
                 title=""
                 data-order="1"
                 data-bbox="1428.815185546875,1340.21826171875,1973.5277099609375,1409.4027099609375">
                
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-Arunachalam_et_al.__2021_">
<h2>Arunachalam_et_al.__2021_</h2>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 1</div>

            <div class="text-block title" 
                 style="left: 36.643618774414065px; top: 91.22142333984375px; width: 107.53387145996095px; height: 17.38853759765625px;"
                 title="protein, neuraminidase"
                 data-order="0"
                 data-bbox="183.2180938720703,456.10711669921875,720.887451171875,543.0498046875">
                protein, neuraminidase
            </div>
            

            <div class="text-block title" 
                 style="left: 24.660195922851564px; top: 109.01070556640626px; width: 573.0761810302735px; height: 51.770056152343756px;"
                 title="the viral surface, HA binds to sialic acid on target cells to facilitate host cell entry and mediates the fusion of the viral envelope to the late endo so mal membrane. Neutral ising antibodies that b..."
                 data-order="1"
                 data-bbox="123.30097961425781,545.0535278320312,2988.681884765625,803.90380859375">
                the viral surface, HA binds to sialic acid on target cells to facilitate host cell entry and mediates the fusion of the viral envelope to the late endo so mal membrane. Neutral ising antibodies that b...
            </div>
            

            <div class="text-block text" 
                 style="left: 35.343545532226564px; top: 167.48751220703127px; width: 268.7248138427735px; height: 14.26708984375px;"
                 title="p p g , thus akey vaccine target. Expressed as trim eric glycoproteins"
                 data-order="2"
                 data-bbox="176.7177276611328,837.4375610351562,1520.341796875,908.7730102539062">
                p p g , thus akey vaccine target. Expressed as trim eric glycoproteins
            </div>
            

            <div class="text-block text" 
                 style="left: 76.11048583984375px; top: 240.8590087890625px; width: 513.5759887695312px; height: 36.9990234375px;"
                 title="rise to highly pathogenic viruses through cross over from reservoirs to humans 9. In the past century, four novel a A virus strains have emerged in this way, each leading to pandemic (H1 N1 in 1918; H..."
                 data-order="3"
                 data-bbox="380.55242919921875,1204.2950439453125,2948.432373046875,1389.2901611328125">
                rise to highly pathogenic viruses through cross over from reservoirs to humans 9. In the past century, four novel a A virus strains have emerged in this way, each leading to pandemic (H1 N1 in 1918; H...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.40285949707032px; top: 280.5214111328125px; width: 547.5029510498047px; height: 85.7645263671875px;"
                 title="omplications of influenza infection constitute a further underecognised disease burden 4 5. Overall, such ahigh disease burden arries substantial social and economic cost 6 7. Prevention of easonal in..."
                 data-order="4"
                 data-bbox="227.01429748535156,1402.6070556640625,2964.529052734375,1831.4296875">
                omplications of influenza infection constitute a further underecognised disease burden 4 5. Overall, such ahigh disease burden arries substantial social and economic cost 6 7. Prevention of easonal in...
            </div>
            

            <div class="text-block text" 
                 style="left: 48.44276733398438px; top: 376.81220703125px; width: 298.23967895507815px; height: 13.04052734375px;"
                 title="019-2020 season. These numbers are significantly higher in hild d dlt d 65 dld 1 2 4 E t l T the"
                 data-order="5"
                 data-bbox="242.21383666992188,1884.06103515625,1733.4122314453125,1949.263671875">
                019-2020 season. These numbers are significantly higher in hild d dlt d 65 dld 1 2 4 E t l T the
            </div>
            

            <div class="text-block title" 
                 style="left: 37.545309448242186px; top: 429.06772460937503px; width: 73.13627014160157px; height: 14.319726562500001px;"
                 title="INTRODUCTION Seasonal in flu enz"
                 data-order="6"
                 data-bbox="187.72654724121094,2145.338623046875,553.4078979492188,2216.937255859375">
                INTRODUCTION Seasonal in flu enz
            </div>
            

            <div class="text-block text" 
                 style="left: 37.83914489746094px; top: 441.034375px; width: 279.04237365722656px; height: 125.89985351562501px;"
                 title="antibodies with rare specific i ties observed with RIV4. Furthermo egg proteins, viral RNA or process impurities, typically found in reactions to these components in susceptible individuals with treco..."
                 data-order="7"
                 data-bbox="189.1957244873047,2205.171875,1584.4075927734375,2834.671142578125">
                antibodies with rare specific i ties observed with RIV4. Furthermo egg proteins, viral RNA or process impurities, typically found in reactions to these components in susceptible individuals with treco...
            </div>
            

            <div class="text-block text" 
                 style="left: 37.224978637695315px; top: 563.58779296875px; width: 280.6743865966797px; height: 114.9724609375px;"
                 title="The influenza vaccine field has been constantly evolving to imp improve the breadth and longevity of the protective immune re vaccines in development. Among these, the recombinant influen system to ex..."
                 data-order="8"
                 data-bbox="186.12489318847656,2817.93896484375,1589.496826171875,3392.80126953125">
                The influenza vaccine field has been constantly evolving to imp improve the breadth and longevity of the protective immune re vaccines in development. Among these, the recombinant influen system to ex...
            </div>
            

            <div class="text-block text" 
                 style="left: 36.85676879882813px; top: 675.5932128906251px; width: 283.3859558105469px; height: 104.97763671875px;"
                 title="REVIEW ARTICLE OPEN Unique features of are comb in vaccine that influence vaccine Arun B. Arunachalam 1✉, Penny Post2 and Deborah Rud in 3"
                 data-order="9"
                 data-bbox="184.28384399414062,3377.966064453125,1601.213623046875,3902.854248046875">
                REVIEW ARTICLE OPEN Unique features of are comb in vaccine that influence vaccine Arun B. Arunachalam 1✉, Penny Post2 and Deborah Rud in 3
            </div>
            

            <div class="text-block text" 
                 style="left: 39.01695556640625px; top: 834.80849609375px; width: 242.09388427734376px; height: 11.44931640625px;"
                 title=""
                 data-order="10"
                 data-bbox="195.08477783203125,4174.04248046875,1405.55419921875,4231.2890625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 335.78256835937503px; top: 429.326171875px; width: 276.865625px; height: 56.799755859375004px;"
                 title="budding virus from the infected cells, thus serving as another important vaccine target. Although the presence of NA is not"
                 data-order="11"
                 data-bbox="1678.912841796875,2146.630859375,3063.240966796875,2430.629638671875">
                budding virus from the infected cells, thus serving as another important vaccine target. Although the presence of NA is not
            </div>
            

            <div class="text-block text" 
                 style="left: 333.23283691406255px; top: 484.69755859375005px; width: 280.0360107421875px; height: 238.99711914062502px;"
                 title="ve the speed, scalability, and flexibility of manufacturing, and to nse across age groups, giving rise to an array of next generation vaccine tetra valent (RIV4), using abaculo virus expression vector..."
                 data-order="12"
                 data-bbox="1666.1641845703125,2423.48779296875,3066.34423828125,3618.473388671875">
                ve the speed, scalability, and flexibility of manufacturing, and to nse across age groups, giving rise to an array of next generation vaccine tetra valent (RIV4), using abaculo virus expression vector...
            </div>
            

            <div class="text-block text" 
                 style="left: 334.64243164062503px; top: 718.596337890625px; width: 276.363037109375px; height: 59.902539062500004px;"
                 title="nt hae mag glut in in influenza erformance"
                 data-order="13"
                 data-bbox="1673.212158203125,3592.981689453125,3055.02734375,3892.494384765625">
                nt hae mag glut in in influenza erformance
            </div>
            

            <div class="text-block text" 
                 style="left: 40.060949707031256px; top: 796.2298339843751px; width: 568.5753295898438px; height: 22.814990234375003px;"
                 title=""
                 data-order="14"
                 data-bbox="200.30474853515625,3981.149169921875,3043.181396484375,4095.22412109375">
                
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 2</div>

            <div class="text-block text" 
                 style="left: 46.432470703125006px; top: 58.07841186523438px; width: 279.6523681640625px; height: 339.8071594238281px;"
                 title="POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE A known risk of traditional split or subunit vaccines is the potenti..."
                 data-order="0"
                 data-bbox="232.162353515625,290.3920593261719,1630.4241943359375,1989.4278564453125">
                POTENTIAL ANTIGENIC MISMATCH OF INFLUENZA VACCINE VIRUS GROWN IN EGG OR CELLS DUE TO ADAPTIVE MUTATIONS IN THE HA PRIMARY STRUCTURE A known risk of traditional split or subunit vaccines is the potenti...
            </div>
            

            <div class="text-block text" 
                 style="left: 47.048858642578125px; top: 393.56206054687505px; width: 282.0867858886719px; height: 82.37587890625001px;"
                 title="This review focuses on the structural features of BEVS derived rHA that make RIV4 unique from conventional vaccines, and how these features help to maximise vaccine performance. Notably, the benefits ..."
                 data-order="1"
                 data-bbox="235.24429321289062,1967.810302734375,1645.67822265625,2379.689697265625">
                This review focuses on the structural features of BEVS derived rHA that make RIV4 unique from conventional vaccines, and how these features help to maximise vaccine performance. Notably, the benefits ...
            </div>
            

            <div class="text-block title" 
                 style="left: 49.70955505371094px; top: 492.477490234375px; width: 269.93988342285155px; height: 35.968457031250004px;"
                 title="g g p g filtration for storage and formulation 22. RIV4 has undergon extensive clinical assessment 23, and was first approved by FDA i 2013. It is now licensed in the USA, Canada, Europe, Australia"
                 data-order="2"
                 data-bbox="248.5477752685547,2462.387451171875,1598.2471923828125,2642.229736328125">
                g g p g filtration for storage and formulation 22. RIV4 has undergon extensive clinical assessment 23, and was first approved by FDA i 2013. It is now licensed in the USA, Canada, Europe, Australia
            </div>
            

            <div class="text-block text" 
                 style="left: 50.373266601562506px; top: 523.98857421875px; width: 276.73496093750003px; height: 249.83095703125002px;"
                 title="avian flu pandemics, when egg supply may be impacted. The adoption of alternative vaccine development approaches (including mRNA, vector, and recombinant protein strategies) in the urgent response to ..."
                 data-order="3"
                 data-bbox="251.8663330078125,2619.94287109375,1635.5411376953125,3869.09765625">
                avian flu pandemics, when egg supply may be impacted. The adoption of alternative vaccine development approaches (including mRNA, vector, and recombinant protein strategies) in the urgent response to ...
            </div>
            

            <div class="text-block text" 
                 style="left: 49.131716918945315px; top: 771.3175781250001px; width: 277.4522430419922px; height: 47.13701171875px;"
                 title="and egg free technologies allowing for guaranteed and faster manufacture of influenza vaccines are needed to ensure timely delivery for upcoming epidemic seasons and during potential avian flu pandemi..."
                 data-order="4"
                 data-bbox="245.65858459472656,3856.587890625,1632.9197998046875,4092.27294921875">
                and egg free technologies allowing for guaranteed and faster manufacture of influenza vaccines are needed to ensure timely delivery for upcoming epidemic seasons and during potential avian flu pandemi...
            </div>
            

            <div class="text-block text" 
                 style="left: 343.3873291015625px; top: 60.500457763671875px; width: 279.4303466796875px; height: 237.42810668945313px;"
                 title="responses in healthy adults with favourable to ler ability. The E. coli expression system has been shown to generate ahigh yields of rHA (200 mg/L of purified HA protein) using a minimal number of bio..."
                 data-order="5"
                 data-bbox="1716.9366455078125,302.5022888183594,3114.08837890625,1489.642822265625">
                responses in healthy adults with favourable to ler ability. The E. coli expression system has been shown to generate ahigh yields of rHA (200 mg/L of purified HA protein) using a minimal number of bio...
            </div>
            

            <div class="text-block text" 
                 style="left: 342.48544921875003px; top: 292.3069580078125px; width: 279.6603515625px; height: 138.2537353515625px;"
                 title="RECOMBINANT HA EXPRESSION SYSTEMS Both prokaryotic and eukaryotic expression systems have been used for the manufacture of rHA vaccine antigens. The first candidate recombinant influenza vaccines to b..."
                 data-order="6"
                 data-bbox="1712.42724609375,1461.5347900390625,3110.72900390625,2152.803466796875">
                RECOMBINANT HA EXPRESSION SYSTEMS Both prokaryotic and eukaryotic expression systems have been used for the manufacture of rHA vaccine antigens. The first candidate recombinant influenza vaccines to b...
            </div>
            

            <div class="text-block title" 
                 style="left: 343.624951171875px; top: 447.54643554687505px; width: 192.891943359375px; height: 14.142333984375px;"
                 title="pinfluenza strain selected for vaccines is eli min"
                 data-order="7"
                 data-bbox="1718.124755859375,2237.732177734375,2682.58447265625,2308.44384765625">
                pinfluenza strain selected for vaccines is eli min
            </div>
            

            <div class="text-block text" 
                 style="left: 344.88481445312505px; top: 459.17109375px; width: 277.3916015625px; height: 305.45004882812503px;"
                 title="2016-2017 season, the influenza vaccine was updated to include a clade 3 C.2 a H3 N2 strain (A/Colorado/15/2014) containing the new glycosylation site 26. However, this particular glycosylation site w..."
                 data-order="8"
                 data-bbox="1724.424072265625,2295.85546875,3111.382080078125,3823.105712890625">
                2016-2017 season, the influenza vaccine was updated to include a clade 3 C.2 a H3 N2 strain (A/Colorado/15/2014) containing the new glycosylation site 26. However, this particular glycosylation site w...
            </div>
            

            <div class="text-block text" 
                 style="left: 345.22421875000003px; top: 760.14150390625px; width: 277.6103515625px; height: 59.615283203125px;"
                 title="vaccine strains and circulating strains are thought to have contributed to this reduced vaccine effectiveness 26. During the 2014-2015 influenza season, a clade 3 C.2 a H3 N2 strain possessing anew pr..."
                 data-order="9"
                 data-bbox="1726.12109375,3800.70751953125,3114.1728515625,4098.783935546875">
                vaccine strains and circulating strains are thought to have contributed to this reduced vaccine effectiveness 26. During the 2014-2015 influenza season, a clade 3 C.2 a H3 N2 strain possessing anew pr...
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 3</div>

            <div class="figure-block" 
                 style="left: 101.29156494140625px; top: 61.68636474609375px; width: 460.7182495117188px; height: 212.62174072265626px;"
                 title="[FIGURE 1 - See figure_p3_det_2_001.png]"
                 data-order="0"
                 data-bbox="506.45782470703125,308.43182373046875,2810.049072265625,1371.54052734375">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 38.635656738281256px; top: 291.793896484375px; width: 572.1198120117188px; height: 32.8147216796875px;"
                 title="primarily as a replication defective vector, for gene delivery and trans gene expression of rHA in the host cells. AdV vectors induce both cell mediated and humoral immunity against the expressed prot..."
                 data-order="1"
                 data-bbox="193.17828369140625,1458.969482421875,3053.77734375,1623.0430908203125">
                primarily as a replication defective vector, for gene delivery and trans gene expression of rHA in the host cells. AdV vectors induce both cell mediated and humoral immunity against the expressed prot...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.203582763671875px; top: 331.3390625px; width: 277.0294982910156px; height: 208.87749023437502px;"
                 title="illness and influenza like illness to a quad rival ent in activated influenza vaccine (QIV; Fluarix Quad rival ent, Glaxo smith kline) given at 15 µg dose strain in adults aged 18 to 64 years 37. Howe..."
                 data-order="2"
                 data-bbox="201.01791381835938,1656.6953125,1586.1654052734375,2701.082763671875">
                illness and influenza like illness to a quad rival ent in activated influenza vaccine (QIV; Fluarix Quad rival ent, Glaxo smith kline) given at 15 µg dose strain in adults aged 18 to 64 years 37. Howe...
            </div>
            

            <div class="text-block text" 
                 style="left: 37.68551025390625px; top: 533.050634765625px; width: 276.62572021484374px; height: 150.47832031250002px;"
                 title="illness and influenza like illness to a quad rival ent in activated BV expression vector HA gene TFF=Tangential Flow Filtration Fig. 1 Generation of rHA using the baculo virus insect cell express from..."
                 data-order="3"
                 data-bbox="188.42755126953125,2665.253173828125,1571.55615234375,3417.644775390625">
                illness and influenza like illness to a quad rival ent in activated BV expression vector HA gene TFF=Tangential Flow Filtration Fig. 1 Generation of rHA using the baculo virus insect cell express from...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.727246093750004px; top: 678.5286621093751px; width: 277.27927246093753px; height: 141.28212890625px;"
                 title="Full length cDNA Polyhedrin promoter Transfer plasmid Processing Signals PCR-direct cloning Full length cDNA Linear i zed BV DNA X X Recombination 1. Cell seeding 2 Expa in bio"
                 data-order="4"
                 data-bbox="193.63623046875,3392.643310546875,1580.0325927734375,4099.053955078125">
                Full length cDNA Polyhedrin promoter Transfer plasmid Processing Signals PCR-direct cloning Full length cDNA Linear i zed BV DNA X X Recombination 1. Cell seeding 2 Expa in bio
            </div>
            

            <div class="text-block text" 
                 style="left: 334.7279296875px; top: 329.84611816406255px; width: 276.3068359375px; height: 186.8114013671875px;"
                 title="structures enhanced their immunogen i city, it compromised the purity of the vaccines considerably, as VLP structures also integrated both baculo virus and Sf9 cell proteins. Elimination of these unwa..."
                 data-order="5"
                 data-bbox="1673.6396484375,1649.2305908203125,3055.173828125,2583.28759765625">
                structures enhanced their immunogen i city, it compromised the purity of the vaccines considerably, as VLP structures also integrated both baculo virus and Sf9 cell proteins. Elimination of these unwa...
            </div>
            

            <div class="text-block text" 
                 style="left: 334.40615234375px; top: 509.87373046875px; width: 276.48520507812503px; height: 162.34755859375002px;"
                 title="by integrating HA, cap sid protein (M1) and neuraminidase (NA) expressed in insect cells 44 46. Although presenting proteins in VLP structures enhanced their immunogen i city, it compromised the Captu..."
                 data-order="6"
                 data-bbox="1672.03076171875,2549.36865234375,3054.456787109375,3361.1064453125">
                by integrating HA, cap sid protein (M1) and neuraminidase (NA) expressed in insect cells 44 46. Although presenting proteins in VLP structures enhanced their immunogen i city, it compromised the Captu...
            </div>
            

            <div class="text-block title" 
                 style="left: 330.5260009765625px; top: 690.5741699218751px; width: 284.0250732421875px; height: 24.805957031250003px;"
                 title="ctor"
                 data-order="7"
                 data-bbox="1652.6300048828125,3452.870849609375,3072.75537109375,3576.900634765625">
                ctor
            </div>
            

            <div class="text-block text" 
                 style="left: 334.5369873046875px; top: 713.9427246093751px; width: 278.0626708984375px; height: 105.4931640625px;"
                 title="twith sbank nor Disc stack centrifugation Harvest Extraction Depth Filtration Clarification"
                 data-order="8"
                 data-bbox="1672.6849365234375,3569.713623046875,3062.998291015625,4097.179443359375">
                twith sbank nor Disc stack centrifugation Harvest Extraction Depth Filtration Clarification
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 4</div>

            <div class="figure-block" 
                 style="left: 53.585723876953125px; top: 55.847802734375px; width: 512.0355163574219px; height: 348.899365234375px;"
                 title="[FIGURE 1 - See figure_p4_mrg_det_3_001.png]"
                 data-order="0"
                 data-bbox="267.9286193847656,279.239013671875,2828.106201171875,2023.73583984375">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 31.94288330078125px; top: 412.043701171875px; width: 612.9514526367187px; height: 5.327099609375001px;"
                 title="g p pyp p ( ) qyp q ypaucimannosidic N linked glycans74 HA0 is coloured in turquoise and orange to show HA1 and HA2 segments combined as a single"
                 data-order="1"
                 data-bbox="159.71441650390625,2060.218505859375,3224.4716796875,2086.85400390625">
                g p pyp p ( ) qyp q ypaucimannosidic N linked glycans74 HA0 is coloured in turquoise and orange to show HA1 and HA2 segments combined as a single
            </div>
            

            <div class="text-block text" 
                 style="left: 46.22359924316407px; top: 426.1224609375px; width: 573.9240570068359px; height: 59.200390625000004px;"
                 title="C C Fig. 2 Structural features of native HA expressed on influenza virus and rHA produced in insect cells using the baculo virus expression vector system. a HA protein (shown as monomer) extracted fro..."
                 data-order="2"
                 data-bbox="231.1179962158203,2130.6123046875,3100.73828125,2426.6142578125">
                C C Fig. 2 Structural features of native HA expressed on influenza virus and rHA produced in insect cells using the baculo virus expression vector system. a HA protein (shown as monomer) extracted fro...
            </div>
            

            <div class="text-block text" 
                 style="left: 50.92942504882813px; top: 486.81435546875px; width: 276.4382263183594px; height: 229.359326171875px;"
                 title="Fibrous Stem Poly sia comple Inter disulfide bond HA1 HA2 External Internal Membrane N -S-SN C Cleaved fusion peptide"
                 data-order="3"
                 data-bbox="254.64712524414062,2434.07177734375,1636.8382568359375,3580.868408203125">
                Fibrous Stem Poly sia comple Inter disulfide bond HA1 HA2 External Internal Membrane N -S-SN C Cleaved fusion peptide
            </div>
            

            <div class="text-block text" 
                 style="left: 49.527688598632814px; top: 714.709130859375px; width: 280.1107879638672px; height: 104.04521484375px;"
                 title="Globular Head a"
                 data-order="4"
                 data-bbox="247.63844299316406,3573.545654296875,1648.1923828125,4093.771728515625">
                Globular Head a
            </div>
            

            <div class="text-block text" 
                 style="left: 344.84208984375005px; top: 490.39726562500005px; width: 273.55859375px; height: 330.03154296875005px;"
                 title="ed cans External Internal Membrane N -S-SUncleaved fusion peptide Pau cim an nose glycans Disulfide bond HA0 HA0 b"
                 data-order="5"
                 data-bbox="1724.21044921875,2451.986328125,3092.00341796875,4102.14404296875">
                ed cans External Internal Membrane N -S-SUncleaved fusion peptide Pau cim an nose glycans Disulfide bond HA0 HA0 b
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 5</div>

            <div class="text-block text" 
                 style="left: 38.92153015136719px; top: 62.23926391601563px; width: 278.12322082519535px; height: 49.31178588867188px;"
                 title="aggregate content in the split vaccine are believed to have induced a Type 2 polarised immune response resulting in ORS based on study results from a mouse model 70. Although extremely rare, this is u..."
                 data-order="0"
                 data-bbox="194.60765075683594,311.1963195800781,1585.2237548828125,557.7552490234375">
                aggregate content in the split vaccine are believed to have induced a Type 2 polarised immune response resulting in ORS based on study results from a mouse model 70. Although extremely rare, this is u...
            </div>
            

            <div class="text-block text" 
                 style="left: 39.02815856933594px; top: 107.291796875px; width: 280.16192932128905px; height: 225.8411376953125px;"
                 title="exclusion high performance liquid chromatography is monitored for the release and the stability of RIV4. Further character is ation by cryo-electron microscopy has revealed that the HA rosette cluster..."
                 data-order="1"
                 data-bbox="195.1407928466797,536.458984375,1595.950439453125,1665.6646728515625">
                exclusion high performance liquid chromatography is monitored for the release and the stability of RIV4. Further character is ation by cryo-electron microscopy has revealed that the HA rosette cluster...
            </div>
            

            <div class="text-block title" 
                 style="left: 37.81971130371094px; top: 370.953271484375px; width: 276.40675354003906px; height: 36.5385498046875px;"
                 title="cluster have been observed; the majority have an average diameter of 150 nm, while the remainder are larger (average diameter, 5500 nm)66. However, the rosette clusters in RIV4 are uniform in size and..."
                 data-order="2"
                 data-bbox="189.0985565185547,1854.766357421875,1571.13232421875,2037.4591064453125">
                cluster have been observed; the majority have an average diameter of 150 nm, while the remainder are larger (average diameter, 5500 nm)66. However, the rosette clusters in RIV4 are uniform in size and...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.623040771484376px; top: 405.2676025390625px; width: 274.61289672851564px; height: 156.0490478515625px;"
                 title="emphasised the relevance of these features in determining vaccine efficacy and long term immunity 65. THE HOMOGENEITY OF RECOMBINANT HA ANTIGENS IN RIV4 MAY IMPROVE THE SAFETY PROFILE OVER CONVENTIONA..."
                 data-order="3"
                 data-bbox="203.11520385742188,2026.3380126953125,1576.1796875,2806.583251953125">
                emphasised the relevance of these features in determining vaccine efficacy and long term immunity 65. THE HOMOGENEITY OF RECOMBINANT HA ANTIGENS IN RIV4 MAY IMPROVE THE SAFETY PROFILE OVER CONVENTIONA...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.00719299316406px; top: 556.820166015625px; width: 277.61363220214844px; height: 119.285986328125px;"
                 title="g g y gdomains than egg derived split vaccines 64. Recently Richards et al.65 examined CD4 T-cell and antibody responses in healthy adults who received egg derived split vaccine, cell derived split va..."
                 data-order="4"
                 data-bbox="190.0359649658203,2784.100830078125,1578.1041259765625,3380.53076171875">
                g g y gdomains than egg derived split vaccines 64. Recently Richards et al.65 examined CD4 T-cell and antibody responses in healthy adults who received egg derived split vaccine, cell derived split va...
            </div>
            

            <div class="text-block text" 
                 style="left: 38.90998229980469px; top: 672.5819824218751px; width: 279.88523254394534px; height: 145.87114257812502px;"
                 title="clearly demonstrate structural differences between HA pre fusion and post fusion states, and the presence of unique neutral ising epi to pes in the pre fusion HA0 molecules, which are present in RIV4 ..."
                 data-order="5"
                 data-bbox="194.54991149902344,3362.909912109375,1593.97607421875,4092.265625">
                clearly demonstrate structural differences between HA pre fusion and post fusion states, and the presence of unique neutral ising epi to pes in the pre fusion HA0 molecules, which are present in RIV4 ...
            </div>
            

            <div class="text-block title" 
                 style="left: 332.9184814453125px; top: 62.132562255859376px; width: 273.6179443359375px; height: 35.998175048828124px;"
                 title="t sst a (p 0 003. eest gato ssuggested tat a toug the circulating A/H3 N2 viruses were antigenic ally similar to the cell grown vaccine reference virus, egg propagation of the vaccine strains had led ..."
                 data-order="6"
                 data-bbox="1664.5924072265625,310.6628112792969,3032.68212890625,490.6536865234375">
                t sst a (p 0 003. eest gato ssuggested tat a toug the circulating A/H3 N2 viruses were antigenic ally similar to the cell grown vaccine reference virus, egg propagation of the vaccine strains had led ...
            </div>
            

            <div class="text-block text" 
                 style="left: 335.2387939453125px; top: 87.83181152343751px; width: 279.25437011718753px; height: 180.25400390625px;"
                 title="antigenic drift variants previously observed in clinical trials . RIV4 has a unique ability to induce broadly cross reactive antibody responses to antigenic ally drifted A/H3 N2 viruses in humans. In ..."
                 data-order="7"
                 data-bbox="1676.1939697265625,439.1590576171875,3072.4658203125,1340.4290771484375">
                antigenic drift variants previously observed in clinical trials . RIV4 has a unique ability to induce broadly cross reactive antibody responses to antigenic ally drifted A/H3 N2 viruses in humans. In ...
            </div>
            

            <div class="text-block text" 
                 style="left: 332.8228271484375px; top: 264.3465576171875px; width: 277.4530029296875px; height: 183.31057128906252px;"
                 title="conserved regions of the molecule for the induction of immunity with broader protection 12 71 76 80. In a study by Nach bag auer et al.78, RIV4 induced HA stem specific neutral ising antibodies direct..."
                 data-order="8"
                 data-bbox="1664.1141357421875,1321.7327880859375,3051.379150390625,2238.28564453125">
                conserved regions of the molecule for the induction of immunity with broader protection 12 71 76 80. In a study by Nach bag auer et al.78, RIV4 induced HA stem specific neutral ising antibodies direct...
            </div>
            

            <div class="text-block text" 
                 style="left: 332.946240234375px; top: 443.2275390625px; width: 276.280224609375px; height: 169.75751953125px;"
                 title="y p g y ( g ) The peptide sequences around gly cosy lati on sites are highly conserved and, as such, antibodies directed against these regions could provide broader specificity. Anti ser a raised agai..."
                 data-order="9"
                 data-bbox="1664.731201171875,2216.1376953125,3046.13232421875,3064.92529296875">
                y p g y ( g ) The peptide sequences around gly cosy lati on sites are highly conserved and, as such, antibodies directed against these regions could provide broader specificity. Anti ser a raised agai...
            </div>
            

            <div class="text-block text" 
                 style="left: 333.60239257812503px; top: 608.82841796875px; width: 278.67421875px; height: 209.29238281250002px;"
                 title="THE N-LINKED GLYCAN STRUCTURE OF RECOMBINANT HA PRODUCED IN INSECT CELLS DIFFERS SIGNIFICANTLY FROM HA IN OTHER INFLUENZA VACCINES Influenza HA has a variable number of N-linked glycosylation sites (d..."
                 data-order="10"
                 data-bbox="1668.011962890625,3044.14208984375,3061.383056640625,4090.60400390625">
                THE N-LINKED GLYCAN STRUCTURE OF RECOMBINANT HA PRODUCED IN INSECT CELLS DIFFERS SIGNIFICANTLY FROM HA IN OTHER INFLUENZA VACCINES Influenza HA has a variable number of N-linked glycosylation sites (d...
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 6</div>

            <div class="text-block title" 
                 style="left: 49.00801086425781px; top: 63.28740234375px; width: 279.2911346435547px; height: 22.186987304687502px;"
                 title="The evidence reviewed here demonstrates several advantages of the BEVS used in the manufacture of RIV4 over conventional"
                 data-order="0"
                 data-bbox="245.04005432128906,316.43701171875,1641.4957275390625,427.3719482421875">
                The evidence reviewed here demonstrates several advantages of the BEVS used in the manufacture of RIV4 over conventional
            </div>
            

            <div class="text-block text" 
                 style="left: 48.755908203125px; top: 87.11469726562501px; width: 278.50192871093753px; height: 221.4372314453125px;"
                 title="tur ers showed that the median oval bum in concentration was 350 ng/mL89. Moreover, another study of commercial influenza vaccine preparations detected other viral proteins such as nucleoprotein and m..."
                 data-order="1"
                 data-bbox="243.779541015625,435.573486328125,1636.2891845703125,1542.7596435546875">
                tur ers showed that the median oval bum in concentration was 350 ng/mL89. Moreover, another study of commercial influenza vaccine preparations detected other viral proteins such as nucleoprotein and m...
            </div>
            

            <div class="text-block title" 
                 style="left: 49.75377197265625px; top: 326.8316650390625px; width: 250.28331298828127px; height: 24.504614257812502px;"
                 title="p p p viruses that are grown in embryonated chicken eggs, they co egg proteins. Testing of 58 vaccine lots covering six dif"
                 data-order="2"
                 data-bbox="248.76885986328125,1634.1583251953125,1500.1854248046875,1756.681396484375">
                p p p viruses that are grown in embryonated chicken eggs, they co egg proteins. Testing of 58 vaccine lots covering six dif
            </div>
            

            <div class="text-block text" 
                 style="left: 48.76026306152344px; top: 350.83139648437503px; width: 284.9110015869141px; height: 113.03950195312501px;"
                 title="groups . These modifications often result in changes to protein folding, conformation, and stability 88. Unlike conventional vaccines, RIV4 does not go through an in activation step, thus preserving t..."
                 data-order="3"
                 data-bbox="243.8013153076172,1754.156982421875,1668.3563232421875,2319.3544921875">
                groups . These modifications often result in changes to protein folding, conformation, and stability 88. Unlike conventional vaccines, RIV4 does not go through an in activation step, thus preserving t...
            </div>
            

            <div class="text-block title" 
                 style="left: 49.720733642578125px; top: 480.542431640625px; width: 277.2020690917969px; height: 35.981103515625px;"
                 title="gg or mammalian cells, the antigens are exposed to in activation agents such as formaldehyde or β-propiolactone (BPL). These in activating agents cause numerous modifications to the antigenic i HA h h..."
                 data-order="4"
                 data-bbox="248.60366821289062,2402.712158203125,1634.614013671875,2582.61767578125">
                gg or mammalian cells, the antigens are exposed to in activation agents such as formaldehyde or β-propiolactone (BPL). These in activating agents cause numerous modifications to the antigenic i HA h h...
            </div>
            

            <div class="text-block text" 
                 style="left: 48.91185607910157px; top: 516.6437500000001px; width: 277.73179626464844px; height: 147.685009765625px;"
                 title="gaeur et al. supports the hypothesis that a recombinant vaccine results in increased titre of broadly neutral ising HA stem reactive antibodies and that these immune responses increase with age78. Thi..."
                 data-order="5"
                 data-bbox="244.5592803955078,2583.21875,1633.21826171875,3321.643798828125">
                gaeur et al. supports the hypothesis that a recombinant vaccine results in increased titre of broadly neutral ising HA stem reactive antibodies and that these immune responses increase with age78. Thi...
            </div>
            

            <div class="text-block text" 
                 style="left: 49.585748291015626px; top: 659.6658691406251px; width: 279.09706420898436px; height: 102.28271484375px;"
                 title="pot ect eespo ses aga st bot ccu at g a d dted A/H3 N2 strains, including in older adults who are at a higher risk for influenza and associated medical complications 83 84. This unique characteristic ..."
                 data-order="6"
                 data-bbox="247.92874145507812,3298.329345703125,1643.4140625,3809.742919921875">
                pot ect eespo ses aga st bot ccu at g a d dted A/H3 N2 strains, including in older adults who are at a higher risk for influenza and associated medical complications 83 84. This unique characteristic ...
            </div>
            

            <div class="text-block title" 
                 style="left: 48.6018310546875px; top: 779.644189453125px; width: 68.7860107421875px; height: 14.309912109375px;"
                 title="p In addition to b Shi d"
                 data-order="7"
                 data-bbox="243.0091552734375,3898.220947265625,586.939208984375,3969.7705078125">
                p In addition to b Shi d
            </div>
            

            <div class="text-block text" 
                 style="left: 47.31205444335938px; top: 794.2873046875001px; width: 281.44517211914064px; height: 24.351806640625px;"
                 title="impaired antibody response to circulating viruses, consistent with previous reports 26."
                 data-order="8"
                 data-bbox="236.56027221679688,3971.4365234375,1643.7861328125,4093.195556640625">
                impaired antibody response to circulating viruses, consistent with previous reports 26.
            </div>
            

            <div class="text-block text" 
                 style="left: 343.840283203125px; top: 63.620574951171875px; width: 279.40341796875003px; height: 200.81182250976565px;"
                 title="gg g y g gwith influenza A2 and B viruses. Epi dem iol. Infect. 70, 767-777 (1972). 11. Ohmit, S. E. et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine induced prote..."
                 data-order="9"
                 data-bbox="1719.201416015625,318.1028747558594,3116.218505859375,1322.1619873046875">
                gg g y g gwith influenza A2 and B viruses. Epi dem iol. Infect. 70, 767-777 (1972). 11. Ohmit, S. E. et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine induced prote...
            </div>
            

            <div class="text-block title" 
                 style="left: 344.9749755859375px; top: 281.9500244140625px; width: 93.26105957031251px; height: 14.0831298828125px;"
                 title="8. Krammer, F. et al. Influen 9. Paules, C. &amp; Subbarao, K"
                 data-order="10"
                 data-bbox="1724.8748779296875,1409.7501220703125,2191.18017578125,1480.165771484375">
                8. Krammer, F. et al. Influen 9. Paules, C. &amp; Subbarao, K
            </div>
            

            <div class="text-block title" 
                 style="left: 343.26267089843753px; top: 295.9122802734375px; width: 154.17839355468752px; height: 12.351171875px;"
                 title="Suppl B, 11-15 (1999). 8. Krammer, F. et al. Influenza. Nat. Rev. Dis."
                 data-order="11"
                 data-bbox="1716.3133544921875,1479.5614013671875,2487.205322265625,1541.3172607421875">
                Suppl B, 11-15 (1999). 8. Krammer, F. et al. Influenza. Nat. Rev. Dis.
            </div>
            

            <div class="text-block text" 
                 style="left: 345.791943359375px; top: 318.30412597656255px; width: 229.639013671875px; height: 25.3134765625px;"
                 title="review of the social and economic burden of influenza in low income countries. Vaccine 33, 6537-6544 (2015). 7 Szucs T The socio economic burden of influenza J Antimicrob C"
                 data-order="12"
                 data-bbox="1728.959716796875,1591.5206298828125,2877.15478515625,1718.0880126953125">
                review of the social and economic burden of influenza in low income countries. Vaccine 33, 6537-6544 (2015). 7 Szucs T The socio economic burden of influenza J Antimicrob C
            </div>
            

            <div class="text-block title" 
                 style="left: 345.0307861328125px; top: 371.9378662109375px; width: 57.973950195312504px; height: 13.115771484375001px;"
                 title="5. Sellers, S. A., H"
                 data-order="13"
                 data-bbox="1725.1539306640625,1859.6893310546875,2015.023681640625,1925.2681884765625">
                5. Sellers, S. A., H
            </div>
            

            <div class="text-block text" 
                 style="left: 351.3601318359375px; top: 387.1609130859375px; width: 270.29562988281253px; height: 5.7251953125px;"
                 title="March 2021"
                 data-order="14"
                 data-bbox="1756.8006591796875,1935.8045654296875,3108.27880859375,1964.4305419921875">
                March 2021
            </div>
            

            <div class="text-block list" 
                 style="left: 339.6279541015625px; top: 421.80161132812503px; width: 288.0560791015625px; height: 372.19169921875005px;"
                 title=", p genrichment. The use of recombinant protein technology eliminates the risk of antigenic mismatch due to potential changes in primary HA structure through egg- or cell adaptation. We also describe ..."
                 data-order="15"
                 data-bbox="1698.1397705078125,2109.008056640625,3138.420166015625,3969.966552734375">
                , p genrichment. The use of recombinant protein technology eliminates the risk of antigenic mismatch due to potential changes in primary HA structure through egg- or cell adaptation. We also describe ...
            </div>
            

            <div class="text-block text" 
                 style="left: 349.47397460937503px; top: 812.1632812500001px; width: 273.34443359375px; height: 3.73974609375px;"
                 title="fl ith t l i fl i i t d i"
                 data-order="16"
                 data-bbox="1747.369873046875,4060.81640625,3114.092041015625,4079.51513671875">
                fl ith t l i fl i i t d i
            </div>
            

            <div class="text-block text" 
                 style="left: 361.18266601562505px; top: 834.7361328125px; width: 269.61972656250003px; height: 11.6666015625px;"
                 title=""
                 data-order="17"
                 data-bbox="1805.913330078125,4173.6806640625,3154.011962890625,4232.013671875">
                
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 7</div>

            <div class="text-block text" 
                 style="left: 42.17275695800782px; top: 65.52053222656251px; width: 274.4629852294922px; height: 3.94970703125px;"
                 title=""
                 data-order="0"
                 data-bbox="210.86378479003906,327.6026611328125,1583.1787109375,347.3511962890625">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 33.14998168945313px; top: 93.48599853515626px; width: 579.6163269042969px; height: 722.5811889648438px;"
                 title="18. Raymond, D. D. et al. Conserved epi tope on influenza virus hemagglutinin head defined by a vaccine induced antibody. Proc. Natl Acad. Sci. USA 115, 168-173 (2018). 19. Saut to, G. A., Kir chen ba..."
                 data-order="1"
                 data-bbox="165.74990844726562,467.42999267578125,3063.83154296875,4080.3359375">
                18. Raymond, D. D. et al. Conserved epi tope on influenza virus hemagglutinin head defined by a vaccine induced antibody. Proc. Natl Acad. Sci. USA 115, 168-173 (2018). 19. Saut to, G. A., Kir chen ba...
            </div>
            
</div>
<div class="page-container" data-width="3324.4716796875" data-height="4332.013671875" style="width: 664.8943359375px; height: 866.402734375px;">
<div class="page-header">Page 8</div>

            <div class="text-block text" 
                 style="left: 45.3781005859375px; top: 32.28443298339844px; width: 580.5662353515626px; height: 577.3667877197266px;"
                 title="2176-2185 (2006). 81. Tre an or, J. J. et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (Flublok (R)) against influenza in healthy adults: a randomized, placebo cont..."
                 data-order="0"
                 data-bbox="226.8905029296875,161.4221649169922,3129.7216796875,3048.256103515625">
                2176-2185 (2006). 81. Tre an or, J. J. et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (Flublok (R)) against influenza in healthy adults: a randomized, placebo cont...
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-Hsiao_et_al.__2023_">
<h2>Hsiao_et_al.__2023_</h2>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 1</div>

            <div class="figure-block" 
                 style="left: 72.24444580078125px; top: 59.19588623046875px; width: 365.5701538085938px; height: 152.57452392578125px;"
                 title="[FIGURE 1 - See figure_p1_det_0_017.png]"
                 data-order="0"
                 data-bbox="361.22222900390625,295.97943115234375,2189.072998046875,1058.85205078125">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 81.37509765625px; top: 105.39790039062501px; width: 350.674267578125px; height: 47.8862548828125px;"
                 title="an were the standard dose vaccines. NCLUSIONS ehigh-dose recombinant vaccine conferred more protection against PCR-co med influenza than an egg based standard dose vaccine among adults be twee"
                 data-order="1"
                 data-bbox="406.87548828125,526.989501953125,2160.246826171875,766.4207763671875">
                an were the standard dose vaccines. NCLUSIONS ehigh-dose recombinant vaccine conferred more protection against PCR-co med influenza than an egg based standard dose vaccine among adults be twee
            </div>
            

            <div class="text-block text" 
                 style="left: 84.99232788085938px; top: 156.796826171875px; width: 345.12793579101566px; height: 28.15113525390625px;"
                 title="luenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0 002. The recombinant vacci snot significantly more protective against influenza related hospitalizati th t d d d i"
                 data-order="2"
                 data-bbox="424.9616394042969,783.984130859375,2150.601318359375,924.7398071289062">
                luenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0 002. The recombinant vacci snot significantly more protective against influenza related hospitalizati th t d d d i
            </div>
            

            <div class="text-block title" 
                 style="left: 67.07163696289062px; top: 237.965185546875px; width: 61.959893798828126px; height: 11.6358642578125px;"
                 title="group. Amon (2 00"
                 data-order="3"
                 data-bbox="335.3581848144531,1189.825927734375,645.1576538085938,1248.0052490234375">
                group. Amon (2 00
            </div>
            

            <div class="text-block text" 
                 style="left: 66.65814208984375px; top: 249.094921875px; width: 382.8411743164063px; height: 81.522021484375px;"
                 title="RESULTS The study population included 1 630 328 vaccine es between the ages of 18 and 64 years (632 962 in the recombinant vaccine group and 997 366 in the standard dose group). During this study peri..."
                 data-order="4"
                 data-bbox="333.29071044921875,1245.474609375,2247.49658203125,1653.084716796875">
                RESULTS The study population included 1 630 328 vaccine es between the ages of 18 and 64 years (632 962 in the recombinant vaccine group and 997 366 in the standard dose group). During this study peri...
            </div>
            

            <div class="text-block title" 
                 style="left: 68.10236206054688px; top: 339.14707031250003px; width: 43.940399169921875px; height: 7.1979003906250005px;"
                 title="outco e. ti"
                 data-order="5"
                 data-bbox="340.5118103027344,1695.7353515625,560.2138061523438,1731.724853515625">
                outco e. ti
            </div>
            

            <div class="text-block text" 
                 style="left: 67.71087646484375px; top: 351.11103515625px; width: 378.5538208007813px; height: 159.89321289062502px;"
                 title="METHODS In this cluster randomized observational study, Kaiser Permanente Northern California facilities routinely administered either a high dose recombinant influenza vaccine (Flublok Quad rival ent..."
                 data-order="6"
                 data-bbox="338.55438232421875,1755.55517578125,2231.323486328125,2555.021240234375">
                METHODS In this cluster randomized observational study, Kaiser Permanente Northern California facilities routinely administered either a high dose recombinant influenza vaccine (Flublok Quad rival ent...
            </div>
            

            <div class="text-block title" 
                 style="left: 68.15931396484375px; top: 521.0248046875px; width: 37.297509765625px; height: 7.3181640625px;"
                 title="standard f 65"
                 data-order="7"
                 data-bbox="340.79656982421875,2605.1240234375,527.2841186523438,2641.71484375">
                standard f 65
            </div>
            

            <div class="text-block text" 
                 style="left: 67.87592163085938px; top: 532.942529296875px; width: 377.67559204101565px; height: 183.42177734375002px;"
                 title="BACKGROUND Quad rival ent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard dose egg based vaccines, and the recombinant formulation is not susceptible..."
                 data-order="8"
                 data-bbox="339.3796081542969,2664.712646484375,2227.757568359375,3581.821533203125">
                BACKGROUND Quad rival ent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard dose egg based vaccines, and the recombinant formulation is not susceptible...
            </div>
            

            <div class="text-block text" 
                 style="left: 70.30568847656251px; top: 712.323974609375px; width: 372.4156005859375px; height: 55.569873046875px;"
                 title="Recombinant or Standard-Dose Influenza Original Article"
                 data-order="9"
                 data-bbox="351.5284423828125,3561.619873046875,2213.6064453125,3839.46923828125">
                Recombinant or Standard-Dose Influenza Original Article
            </div>
            

            <div class="text-block title" 
                 style="left: 192.23050537109376px; top: 780.059716796875px; width: 197.80103759765626px; height: 11.188818359375px;"
                 title=""
                 data-order="10"
                 data-bbox="961.1525268554688,3900.298583984375,1950.15771484375,3956.24267578125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 243.541455078125px; top: 796.483544921875px; width: 143.537744140625px; height: 4.454052734375px;"
                 title=""
                 data-order="11"
                 data-bbox="1217.707275390625,3982.417724609375,1935.39599609375,4004.68798828125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 127.63282470703126px; top: 807.4962890625001px; width: 363.27874755859375px; height: 23.38642578125px;"
                 title="The new engl and jour nal of medicine"
                 data-order="12"
                 data-bbox="638.1641235351562,4037.4814453125,2454.557861328125,4154.41357421875">
                The new engl and jour nal of medicine
            </div>
            

            <div class="text-block text" 
                 style="left: 450.1240234375px; top: 250.24904785156252px; width: 146.35810546875px; height: 63.0514404296875px;"
                 title=""
                 data-order="13"
                 data-bbox="2250.6201171875,1251.2452392578125,2982.41064453125,1566.50244140625">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 450.079052734375px; top: 315.46525878906255px; width: 126.624755859375px; height: 33.531567382812504px;"
                 title=""
                 data-order="14"
                 data-bbox="2250.395263671875,1577.3262939453125,2883.51904296875,1744.984130859375">
                
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 2</div>

            <div class="text-block text" 
                 style="left: 106.20941162109375px; top: 59.91676635742188px; width: 228.50755615234377px; height: 157.40679321289065px;"
                 title="whom are adults between the ages of 18 and 64 years. Members receive nearly all their care at system owned facilities, which includes 259 medical clinics and 21 hospitals. The members’ electronic medi..."
                 data-order="0"
                 data-bbox="531.0470581054688,299.5838317871094,1673.5848388671875,1086.6177978515625">
                whom are adults between the ages of 18 and 64 years. Members receive nearly all their care at system owned facilities, which includes 259 medical clinics and 21 hospitals. The members’ electronic medi...
            </div>
            

            <div class="text-block text" 
                 style="left: 109.660498046875px; top: 220.60881347656252px; width: 226.65749511718752px; height: 202.3600830078125px;"
                 title="pgg To estimate the relative effectiveness of the recombinant vaccine as compared with standard dose vaccines against laboratory confirmed influenza and influenza related outcomes, we compared the two..."
                 data-order="1"
                 data-bbox="548.302490234375,1103.0440673828125,1681.5899658203125,2114.844482421875">
                pgg To estimate the relative effectiveness of the recombinant vaccine as compared with standard dose vaccines against laboratory confirmed influenza and influenza related outcomes, we compared the two...
            </div>
            

            <div class="text-block text" 
                 style="left: 110.25631103515626px; top: 520.07109375px; width: 226.77550048828127px; height: 20.66845703125px;"
                 title="vaccine strain 4 The Flublok Quad rival ent influenza vaccine (RIV4 San of i is manufactured"
                 data-order="2"
                 data-bbox="551.2815551757812,2600.35546875,1685.1590576171875,2703.69775390625">
                vaccine strain 4 The Flublok Quad rival ent influenza vaccine (RIV4 San of i is manufactured
            </div>
            

            <div class="text-block title" 
                 style="left: 109.14394531250001px; top: 581.5336425781251px; width: 161.4722412109375px; height: 11.449072265625px;"
                 title="eggs are used to manufacture th"
                 data-order="3"
                 data-bbox="545.7197265625,2907.668212890625,1353.0809326171875,2964.91357421875">
                eggs are used to manufacture th
            </div>
            

            <div class="text-block text" 
                 style="left: 111.925146484375px; top: 593.373388671875px; width: 219.86533203125px; height: 148.17392578125px;"
                 title="g pmillion).1 Influenza vaccination is the primary method for preventing influenza related illnesses 2 although the vaccine effectiveness ranges from 20% in years in which the vaccine is antigenic all..."
                 data-order="4"
                 data-bbox="559.625732421875,2966.866943359375,1658.952392578125,3707.736572265625">
                g pmillion).1 Influenza vaccination is the primary method for preventing influenza related illnesses 2 although the vaccine effectiveness ranges from 20% in years in which the vaccine is antigenic all...
            </div>
            

            <div class="text-block title" 
                 style="left: 239.6042236328125px; top: 779.835693359375px; width: 193.2822998046875px; height: 11.432177734375001px;"
                 title=""
                 data-order="5"
                 data-bbox="1198.0211181640625,3899.178466796875,2164.4326171875,3956.33935546875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 246.4139404296875px; top: 796.1737792968751px; width: 140.83896484375px; height: 5.14365234375px;"
                 title=""
                 data-order="6"
                 data-bbox="1232.0697021484375,3980.868896484375,1936.2645263671875,4006.587158203125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 143.2126220703125px; top: 807.606201171875px; width: 354.3020751953125px; height: 22.829443359375002px;"
                 title="The new engl and jour nal of medicine"
                 data-order="7"
                 data-bbox="716.0631103515625,4038.031005859375,2487.573486328125,4152.17822265625">
                The new engl and jour nal of medicine
            </div>
            

            <div class="text-block text" 
                 style="left: 337.1770751953125px; top: 58.56240234375px; width: 227.3386962890625px; height: 135.14459228515625px;"
                 title="(Fig. 1). We randomly assigned Block A to start with administration of a standard dose vaccine and Block B to start with administration of the recombinant vaccine. Thereafter, each facility alternated..."
                 data-order="8"
                 data-bbox="1685.8853759765625,292.81201171875,2822.578857421875,968.5349731445312">
                (Fig. 1). We randomly assigned Block A to start with administration of a standard dose vaccine and Block B to start with administration of the recombinant vaccine. Thereafter, each facility alternated...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.15251464843755px; top: 189.55087890625px; width: 220.9878662109375px; height: 153.435009765625px;"
                 title="q yexcluded from the analyses because there were too few cases of influenza during the pandemic to be informative. During the study period, influenza vaccination coverage was similar to national cover..."
                 data-order="9"
                 data-bbox="1695.7625732421875,947.75439453125,2800.701904296875,1714.929443359375">
                q yexcluded from the analyses because there were too few cases of influenza during the pandemic to be informative. During the study period, influenza vaccination coverage was similar to national cover...
            </div>
            

            <div class="text-block title" 
                 style="left: 340.353173828125px; top: 354.61962890625px; width: 63.764111328125004px; height: 11.7228515625px;"
                 title="the coronavir"
                 data-order="10"
                 data-bbox="1701.765869140625,1773.09814453125,2020.58642578125,1831.71240234375">
                the coronavir
            </div>
            

            <div class="text-block text" 
                 style="left: 339.6419677734375px; top: 364.9232177734375px; width: 219.43312988281252px; height: 213.8726806640625px;"
                 title="vaccines used during the study seasons were purchased by KPNC. The first author wrote the first draft of the manuscript. The authors vouch for the accuracy and completeness of the data presented and f..."
                 data-order="11"
                 data-bbox="1698.2098388671875,1824.6160888671875,2795.37548828125,2893.9794921875">
                vaccines used during the study seasons were purchased by KPNC. The first author wrote the first draft of the manuscript. The authors vouch for the accuracy and completeness of the data presented and f...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.8999267578125px; top: 580.1521484375px; width: 223.7631591796875px; height: 148.04658203125px;"
                 title="gin other U.S. regions (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).7 Approximately 10% of the members are covered by Medicaid 8 The KPNC institut..."
                 data-order="12"
                 data-bbox="1694.4996337890625,2900.7607421875,2813.3154296875,3640.99365234375">
                gin other U.S. regions (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).7 Approximately 10% of the members are covered by Medicaid 8 The KPNC institut...
            </div>
            

            <div class="text-block text" 
                 style="left: 348.17197265625003px; top: 726.372216796875px; width: 213.71728515625px; height: 14.05576171875px;"
                 title="nd multiracial residents are higher than those"
                 data-order="13"
                 data-bbox="1740.85986328125,3631.861083984375,2809.4462890625,3702.139892578125">
                nd multiracial residents are higher than those
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 3</div>

            <div class="figure-block" 
                 style="left: 72.20919189453126px; top: 57.10752563476563px; width: 445.1457885742188px; height: 490.3278259277344px;"
                 title="[FIGURE 1 - See figure_p3_mrg_det_2_000.png]"
                 data-order="0"
                 data-bbox="361.04595947265625,285.5376281738281,2586.77490234375,2737.1767578125">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 86.90322265625001px; top: 554.290380859375px; width: 301.0797607421875px; height: 7.877783203125px;"
                 title=""
                 data-order="1"
                 data-bbox="434.51611328125,2771.451904296875,1939.9149169921875,2810.8408203125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 77.1177734375px; top: 566.7263671875px; width: 437.267236328125px; height: 47.757763671875004px;"
                 title="to Block A or Block B. Facility 1 Facility 8 Similarly sized"
                 data-order="2"
                 data-bbox="385.5888671875,2833.6318359375,2571.925048828125,3072.420654296875">
                to Block A or Block B. Facility 1 Facility 8 Similarly sized
            </div>
            

            <div class="text-block text" 
                 style="left: 297.877978515625px; top: 645.482666015625px; width: 222.470947265625px; height: 95.4205078125px;"
                 title="Facility 2 Facility 7 Facility 9 Facility 8"
                 data-order="3"
                 data-bbox="1489.389892578125,3227.413330078125,2601.74462890625,3704.515869140625">
                Facility 2 Facility 7 Facility 9 Facility 8
            </div>
            

            <div class="text-block text" 
                 style="left: 68.94257202148438px; top: 647.1676757812501px; width: 222.40310668945312px; height: 93.93178710937501px;"
                 title="Facility Facility 5 Facility 6"
                 data-order="4"
                 data-bbox="344.7128601074219,3235.83837890625,1456.7283935546875,3705.497314453125">
                Facility Facility 5 Facility 6
            </div>
            

            <div class="text-block title" 
                 style="left: 196.15638427734376px; top: 779.6314453125001px; width: 193.21710205078125px; height: 11.826904296875px;"
                 title=""
                 data-order="5"
                 data-bbox="980.7819213867188,3898.1572265625,1946.867431640625,3957.291748046875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 244.880615234375px; top: 796.3268554687501px; width: 142.844189453125px; height: 5.23095703125px;"
                 title=""
                 data-order="6"
                 data-bbox="1224.403076171875,3981.63427734375,1938.6240234375,4007.7890625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 130.278955078125px; top: 807.431298828125px; width: 361.639404296875px; height: 23.508740234375px;"
                 title="Recombinant or Standard-Dose Influenza Vaccine"
                 data-order="7"
                 data-bbox="651.394775390625,4037.156494140625,2459.591796875,4154.7001953125">
                Recombinant or Standard-Dose Influenza Vaccine
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 4</div>

            <div class="text-block text" 
                 style="left: 108.59412841796876px; top: 59.211645507812506px; width: 228.01539306640626px; height: 96.52424316406251px;"
                 title="ness of the recombinant vaccine against secondary outcomes in patients in the primary age group and against secondary outcomes in five pre specified subgroups of patients with preex-"
                 data-order="0"
                 data-bbox="542.9706420898438,296.0582275390625,1683.047607421875,778.679443359375">
                ness of the recombinant vaccine against secondary outcomes in patients in the primary age group and against secondary outcomes in five pre specified subgroups of patients with preex-
            </div>
            

            <div class="text-block title" 
                 style="left: 110.01711425781251px; top: 167.35209960937502px; width: 49.6144287109375px; height: 12.36466064453125px;"
                 title="age group"
                 data-order="1"
                 data-bbox="550.0855712890625,836.760498046875,798.15771484375,898.5838012695312">
                age group
            </div>
            

            <div class="text-block text" 
                 style="left: 109.39110107421875px; top: 179.42598876953127px; width: 224.55723876953127px; height: 108.27904052734375px;"
                 title="y yhad occurred within 14 days after vaccination. Objectives The primary objective was to estimate the relative vaccine effectiveness of the recombinant vaccine as compared with a standard dose vaccin..."
                 data-order="2"
                 data-bbox="546.9555053710938,897.1299438476562,1669.74169921875,1438.525146484375">
                y yhad occurred within 14 days after vaccination. Objectives The primary objective was to estimate the relative vaccine effectiveness of the recombinant vaccine as compared with a standard dose vaccin...
            </div>
            

            <div class="text-block text" 
                 style="left: 109.42255859375001px; top: 283.68063964843753px; width: 221.653662109375px; height: 138.3531005859375px;"
                 title="( ) ( ) Exploratory outcomes were an influenza diagnosis (PCR-confirmed or clinically diagnosed influenza on the basis of ICD-10 codes), non elective hospitalization for any cause, and death from any ..."
                 data-order="3"
                 data-bbox="547.11279296875,1418.4031982421875,1655.381103515625,2110.168701171875">
                ( ) ( ) Exploratory outcomes were an influenza diagnosis (PCR-confirmed or clinically diagnosed influenza on the basis of ICD-10 codes), non elective hospitalization for any cause, and death from any ...
            </div>
            

            <div class="text-block text" 
                 style="left: 108.8683837890625px; top: 419.30205078125005px; width: 223.8456787109375px; height: 147.58115234375px;"
                 title="not performed. Secondary outcomes were PCR-confirmed influenza A, PCR-confirmed influenza B, and hospitalization for PCR-confirmed influenza, for community acquired pneumonia, and for car dio respirat..."
                 data-order="4"
                 data-bbox="544.3419189453125,2096.51025390625,1663.5703125,2834.416015625">
                not performed. Secondary outcomes were PCR-confirmed influenza A, PCR-confirmed influenza B, and hospitalization for PCR-confirmed influenza, for community acquired pneumonia, and for car dio respirat...
            </div>
            

            <div class="text-block title" 
                 style="left: 110.13764648437501px; top: 580.8013671875px; width: 51.039685058593754px; height: 12.595263671875001px;"
                 title="tests at the"
                 data-order="5"
                 data-bbox="550.688232421875,2904.0068359375,805.8866577148438,2966.983154296875">
                tests at the
            </div>
            

            <div class="text-block text" 
                 style="left: 111.84437255859376px; top: 591.6427734375001px; width: 219.35614013671875px; height: 150.847998046875px;"
                 title="..., facilities administered primarily high dose vaccines to adults who were 65 years of age or older, which made it infeasible to include those members in the study randomization. Outcomes The primar..."
                 data-order="6"
                 data-bbox="559.2218627929688,2958.2138671875,1656.0025634765625,3712.453857421875">
                ..., facilities administered primarily high dose vaccines to adults who were 65 years of age or older, which made it infeasible to include those members in the study randomization. Outcomes The primar...
            </div>
            

            <div class="text-block title" 
                 style="left: 240.46494140625px; top: 780.21337890625px; width: 192.9162109375px; height: 11.021142578125001px;"
                 title=""
                 data-order="7"
                 data-bbox="1202.32470703125,3901.06689453125,2166.90576171875,3956.172607421875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 245.76882324218752px; top: 796.3067382812501px; width: 142.8909912109375px; height: 5.0818359375px;"
                 title=""
                 data-order="8"
                 data-bbox="1228.8441162109375,3981.53369140625,1943.299072265625,4006.94287109375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 143.06436767578126px; top: 807.3747070312501px; width: 354.07899169921876px; height: 23.107226562500003px;"
                 title="The new engl and jour nal of medicine"
                 data-order="9"
                 data-bbox="715.3218383789062,4036.87353515625,2485.716796875,4152.40966796875">
                The new engl and jour nal of medicine
            </div>
            

            <div class="text-block text" 
                 style="left: 336.1311767578125px; top: 59.388928222656254px; width: 226.52077636718752px; height: 69.86666259765626px;"
                 title="p y pcine rather than a standard dose vaccine with respect to sex, race, age, coexisting illnesses,"
                 data-order="10"
                 data-bbox="1680.6558837890625,296.94464111328125,2813.259765625,646.2779541015625">
                p y pcine rather than a standard dose vaccine with respect to sex, race, age, coexisting illnesses,
            </div>
            

            <div class="text-block title" 
                 style="left: 340.074462890625px; top: 141.38554687500002px; width: 96.734912109375px; height: 11.812036132812501px;"
                 title="derived by logistic r"
                 data-order="11"
                 data-bbox="1700.372314453125,706.927734375,2184.046875,765.9879150390625">
                derived by logistic r
            </div>
            

            <div class="text-block text" 
                 style="left: 339.40715332031255px; top: 152.00029296875002px; width: 222.03264160156252px; height: 198.960302734375px;"
                 title="occurred in either study group. Each risk set contained every participant in follow up on that calendar date. Most of the participants had been vaccinated before the beginning of the influenza season ..."
                 data-order="12"
                 data-bbox="1697.0357666015625,760.00146484375,2807.198974609375,1754.802978515625">
                occurred in either study group. Each risk set contained every participant in follow up on that calendar date. Most of the participants had been vaccinated before the beginning of the influenza season ...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.8403564453125px; top: 346.1330810546875px; width: 220.43557128906252px; height: 219.9015869140625px;"
                 title="study with 86% power to detect a relative vaccine effectiveness of 10.0% against PCR-confirmed influenza. On the basis of previous data, we estimated the occurrence of 2.18 PCR-confirmed influenza cas..."
                 data-order="13"
                 data-bbox="1699.2017822265625,1730.6654052734375,2801.379638671875,2830.17333984375">
                study with 86% power to detect a relative vaccine effectiveness of 10.0% against PCR-confirmed influenza. On the basis of previous data, we estimated the occurrence of 2.18 PCR-confirmed influenza cas...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.9891357421875px; top: 564.83916015625px; width: 221.7626708984375px; height: 176.77900390625px;"
                 title="p y g g pestimates of relative vaccine effectiveness were considered to be exploratory. Statistical Analysis We tested the null hypotheses that the recombinant vaccine would not be any more or any les..."
                 data-order="14"
                 data-bbox="1699.9456787109375,2824.19580078125,2808.759033203125,3708.0908203125">
                p y g g pestimates of relative vaccine effectiveness were considered to be exploratory. Statistical Analysis We tested the null hypotheses that the recombinant vaccine would not be any more or any les...
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 5</div>

            <div class="text-block text" 
                 style="left: 295.742724609375px; top: 59.579278564453126px; width: 226.800390625px; height: 81.38073120117188px;"
                 title="y jinfluenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0.002; the P value was below Holm’smultiplicity-adjusted threshold of an alpha level of"
                 data-order="0"
                 data-bbox="1478.713623046875,297.8963928222656,2612.715576171875,704.800048828125">
                y jinfluenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0.002; the P value was below Holm’smultiplicity-adjusted threshold of an alpha level of
            </div>
            

            <div class="text-block text" 
                 style="left: 66.81011352539063px; top: 60.301770019531254px; width: 224.80587768554688px; height: 53.438879394531256px;"
                 title="and Table S6). In both seasons, delays in ship-"
                 data-order="1"
                 data-bbox="334.0505676269531,301.50885009765625,1458.0799560546875,568.7032470703125">
                and Table S6). In both seasons, delays in ship-
            </div>
            

            <div class="text-block text" 
                 style="left: 68.20418090820313px; top: 111.7345947265625px; width: 226.5770202636719px; height: 122.429736328125px;"
                 title="Results Study Participants The study population included 1 630 328 participants during influenza seasons in 2018-2019 and 2019-2020. Of these participants, 632 962 (38 8 received the recombinant vacci..."
                 data-order="2"
                 data-bbox="341.0209045410156,558.6729736328125,1473.906005859375,1170.8216552734375">
                Results Study Participants The study population included 1 630 328 participants during influenza seasons in 2018-2019 and 2019-2020. Of these participants, 632 962 (38 8 received the recombinant vacci...
            </div>
            

            <div class="text-block text" 
                 style="left: 295.6887939453125px; top: 138.82989501953125px; width: 223.84938964843752px; height: 108.02586669921875px;"
                 title="compared with 925 (2.34 per 1000) in the standard dose group (Table 2). For the primary objective, the relative vaccine effectiveness of the recombinant vaccine as compared with standard dose vaccines..."
                 data-order="3"
                 data-bbox="1478.4439697265625,694.1494750976562,2597.69091796875,1234.27880859375">
                compared with 925 (2.34 per 1000) in the standard dose group (Table 2). For the primary objective, the relative vaccine effectiveness of the recombinant vaccine as compared with standard dose vaccines...
            </div>
            

            <div class="text-block text" 
                 style="left: 67.88662719726562px; top: 233.46630859375px; width: 222.7473571777344px; height: 148.782568359375px;"
                 title="pcine and RSV infection would suggest bias in our estimate of the relative vaccine effectiveness against influenza. Conversely, a finding of no association between receipt of the recombinant vaccine a..."
                 data-order="4"
                 data-bbox="339.4331359863281,1167.33154296875,1453.169921875,1911.244384765625">
                pcine and RSV infection would suggest bias in our estimate of the relative vaccine effectiveness against influenza. Conversely, a finding of no association between receipt of the recombinant vaccine a...
            </div>
            

            <div class="text-block text" 
                 style="left: 296.19130859375px; top: 243.6532958984375px; width: 225.63046875px; height: 166.51865234375px;"
                 title="tic i pants at baseline were similar in the two vaccine groups and in the two age groups (Table 1 and Table S6). There was some variation in the timing of the administration of the two vaccines accord..."
                 data-order="5"
                 data-bbox="1480.95654296875,1218.2664794921875,2609.10888671875,2050.8597412109375">
                tic i pants at baseline were similar in the two vaccine groups and in the two age groups (Table 1 and Table S6). There was some variation in the timing of the administration of the two vaccines accord...
            </div>
            

            <div class="text-block text" 
                 style="left: 66.9020751953125px; top: 379.2078369140625px; width: 224.389599609375px; height: 224.19645996093752px;"
                 title="For secondary objectives in participants between the ages of 50 and 64 years, we adjusted for multiplicity by Holm’smethod.10 Subgroup analyses involving participants with preexisting conditions were ..."
                 data-order="6"
                 data-bbox="334.5103759765625,1896.0391845703125,1456.4583740234375,3017.021484375">
                For secondary objectives in participants between the ages of 50 and 64 years, we adjusted for multiplicity by Holm’smethod.10 Subgroup analyses involving participants with preexisting conditions were ...
            </div>
            

            <div class="text-block text" 
                 style="left: 295.8169677734375px; top: 406.77978515625px; width: 224.6608642578125px; height: 120.098974609375px;"
                 title="2337 (61 2 in patients between the ages of 18 and 49 years. Among the participants with PCRconfirmed influenza, hospitalization occurred in 248 of 1484 participants (16 7 among those between the ages ..."
                 data-order="7"
                 data-bbox="1479.0848388671875,2033.89892578125,2602.38916015625,2634.393798828125">
                2337 (61 2 in patients between the ages of 18 and 49 years. Among the participants with PCRconfirmed influenza, hospitalization occurred in 248 of 1484 participants (16 7 among those between the ages ...
            </div>
            

            <div class="text-block title" 
                 style="left: 297.390869140625px; top: 541.228125px; width: 156.388427734375px; height: 11.670068359375001px;"
                 title="enza cases, 1484 (38 8 were dia"
                 data-order="8"
                 data-bbox="1486.954345703125,2706.140625,2268.896484375,2764.490966796875">
                enza cases, 1484 (38 8 were dia
            </div>
            

            <div class="text-block text" 
                 style="left: 294.97287597656253px; top: 554.3139160156251px; width: 228.25808105468752px; height: 129.788818359375px;"
                 title="64 years of age, 279 400 (41 4 received the recombinant vaccine and 395 852 (58 6 received a standard dose vaccine (Table 1). Among the 955 076 patients between 18 and 49 years of age, 353 562 (37 0 r..."
                 data-order="9"
                 data-bbox="1474.8643798828125,2771.569580078125,2616.15478515625,3420.513671875">
                64 years of age, 279 400 (41 4 received the recombinant vaccine and 395 852 (58 6 received a standard dose vaccine (Table 1). Among the 955 076 patients between 18 and 49 years of age, 353 562 (37 0 r...
            </div>
            

            <div class="text-block title" 
                 style="left: 151.33470458984377px; top: 626.723388671875px; width: 52.564160156250004px; height: 12.2375px;"
                 title="rtional-haza nwas eva lua"
                 data-order="10"
                 data-bbox="756.6735229492188,3133.616943359375,1019.4943237304688,3194.804443359375">
                rtional-haza nwas eva lua
            </div>
            

            <div class="text-block title" 
                 style="left: 67.76741333007813px; top: 648.269580078125px; width: 91.97117309570314px; height: 11.751318359375px;"
                 title="as compared with"
                 data-order="11"
                 data-bbox="338.8370666503906,3241.347900390625,798.6929321289062,3300.1044921875">
                as compared with
            </div>
            

            <div class="text-block text" 
                 style="left: 67.08760375976563px; top: 659.5775878906251px; width: 223.14545288085938px; height: 81.35488281250001px;"
                 title="gdata were not imputed. The relative vaccine effectiveness was based on the hazard ratio (1 minus the hazard ratio, expressed as a percentage). This calculation estimated the percent reduction in the ..."
                 data-order="12"
                 data-bbox="335.4380187988281,3297.887939453125,1451.165283203125,3704.662353515625">
                gdata were not imputed. The relative vaccine effectiveness was based on the hazard ratio (1 minus the hazard ratio, expressed as a percentage). This calculation estimated the percent reduction in the ...
            </div>
            

            <div class="text-block text" 
                 style="left: 296.3906494140625px; top: 680.245166015625px; width: 225.3836181640625px; height: 61.345263671875px;"
                 title="p yly schedule, so standard dose vaccines were then administered to prevent interruptions in patient care. Among the 675 252 patients between 50 and 64 years of age 279 400 (41 4%) received the"
                 data-order="13"
                 data-bbox="1481.9532470703125,3401.225830078125,2608.871337890625,3707.9521484375">
                p yly schedule, so standard dose vaccines were then administered to prevent interruptions in patient care. Among the 675 252 patients between 50 and 64 years of age 279 400 (41 4%) received the
            </div>
            

            <div class="text-block title" 
                 style="left: 196.11385498046877px; top: 779.6356933593751px; width: 193.21658935546876px; height: 11.8203125px;"
                 title=""
                 data-order="14"
                 data-bbox="980.5692749023438,3898.178466796875,1946.6522216796875,3957.280029296875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 244.8779296875px; top: 796.3212890625px; width: 142.88935546875px; height: 5.228710937500001px;"
                 title=""
                 data-order="15"
                 data-bbox="1224.3896484375,3981.6064453125,1938.83642578125,4007.75">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 130.3067626953125px; top: 807.42724609375px; width: 361.3928466796875px; height: 23.508886718750002px;"
                 title="Recombinant or Standard-Dose Influenza Vaccine"
                 data-order="16"
                 data-bbox="651.5338134765625,4037.13623046875,2458.498046875,4154.6806640625">
                Recombinant or Standard-Dose Influenza Vaccine
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 6</div>

            <div class="figure-block" 
                 style="left: 37.82227478027344px; top: 53.64313354492188px; width: 517.2260650634765px; height: 568.0807922363282px;"
                 title="[FIGURE 1 - See figure_p6_det_5_000.png]"
                 data-order="0"
                 data-bbox="189.1113739013672,268.2156677246094,2775.24169921875,3108.61962890625">
                <span>Figure</span>
            </div>
            

            <div class="text-block title" 
                 style="left: 39.4747802734375px; top: 618.254150390625px; width: 248.011572265625px; height: 12.764599609375px;"
                 title=""
                 data-order="1"
                 data-bbox="197.3739013671875,3091.270751953125,1437.4317626953125,3155.09375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 35.86388244628906px; top: 627.4535644531251px; width: 527.2397308349609px; height: 117.2837890625px;"
                 title="944 692 Were vaccinated in 2019-2020 season 967 083 Were vaccinated in 2020-2021 season 1 018 043 Received recombinant vaccine 1 758 235 Received a standard dose vaccine 33 133 Were not KPNC members a..."
                 data-order="2"
                 data-bbox="179.3194122314453,3137.267822265625,2815.51806640625,3723.686767578125">
                944 692 Were vaccinated in 2019-2020 season 967 083 Were vaccinated in 2020-2021 season 1 018 043 Received recombinant vaccine 1 758 235 Received a standard dose vaccine 33 133 Were not KPNC members a...
            </div>
            

            <div class="text-block title" 
                 style="left: 239.16943359375px; top: 780.1351074218751px; width: 192.78740234375002px; height: 11.1748046875px;"
                 title=""
                 data-order="3"
                 data-bbox="1195.84716796875,3900.675537109375,2159.7841796875,3956.549560546875">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 244.8430908203125px; top: 796.544677734375px; width: 142.87468261718752px; height: 11.1705078125px;"
                 title="new engl and jour nal of"
                 data-order="4"
                 data-bbox="1224.2154541015625,3982.723388671875,1938.5888671875,4038.575927734375">
                new engl and jour nal of
            </div>
            

            <div class="text-block text" 
                 style="left: 124.898681640625px; top: 804.4197753906251px; width: 379.46391601562505px; height: 27.345068359375002px;"
                 title="The new engl and jour nal of medicine"
                 data-order="5"
                 data-bbox="624.493408203125,4022.098876953125,2521.81298828125,4158.82421875">
                The new engl and jour nal of medicine
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 7</div>

            <div class="text-block text" 
                 style="left: 79.73419189453125px; top: 66.2417724609375px; width: 282.38323974609375px; height: 6.53289794921875px;"
                 title=""
                 data-order="0"
                 data-bbox="398.67095947265625,331.2088623046875,1810.587158203125,363.87335205078125">
                
            </div>
            

            <div class="table-block" 
                 style="left: 76.7179931640625px; top: 77.87673950195312px; width: 441.16520996093755px; height: 419.6556823730469px;"
                 title="[TABLE 2 - See table_p7_det_6_004.png]"
                 data-order="1"
                 data-bbox="383.5899658203125,389.3836975097656,2589.416015625,2487.662109375">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 74.07517700195312px; top: 489.00327148437503px; width: 440.7250671386719px; height: 40.41201171875px;"
                 title="Hispanic ethnic group - no. (%)† Yes 46 318 (17) 65 868 (17) 112 186 (17) No or unknown 233 082 (83) 329 984 (83) 563 066 (83)"
                 data-order="2"
                 data-bbox="370.3758850097656,2445.016357421875,2574.001220703125,2647.076416015625">
                Hispanic ethnic group - no. (%)† Yes 46 318 (17) 65 868 (17) 112 186 (17) No or unknown 233 082 (83) 329 984 (83) 563 066 (83)
            </div>
            

            <div class="text-block text" 
                 style="left: 295.48046875px; top: 552.0966308593751px; width: 223.188232421875px; height: 162.018505859375px;"
                 title="no. of participants (%) 0 (45) 175 600 (44) 300 140 (44) 0 (55) 220 252 (56) 375 112 (56) 7 (51) 198 434 (50) 341 191 (51) 3 (5) 20 814 (5) 34 507 (5) 6 (21) 84 154 (21) 142 570 (21) 6 (1) 2,363 (1) 4..."
                 data-order="3"
                 data-bbox="1477.40234375,2760.483154296875,2593.343505859375,3570.57568359375">
                no. of participants (%) 0 (45) 175 600 (44) 300 140 (44) 0 (55) 220 252 (56) 375 112 (56) 7 (51) 198 434 (50) 341 191 (51) 3 (5) 20 814 (5) 34 507 (5) 6 (21) 84 154 (21) 142 570 (21) 6 (1) 2,363 (1) 4...
            </div>
            

            <div class="text-block text" 
                 style="left: 67.62542724609375px; top: 554.7733886718751px; width: 222.14176025390626px; height: 131.59257812500002px;"
                 title="( ) Male 124,5 Female 154,8 Race or ethnic group - no. (%)† White 142,7 Black 13,6 Asian 58,4 Pacific Islander 1,6 Native American 1,2 M l i i l 7 2"
                 data-order="4"
                 data-bbox="338.12713623046875,2773.866943359375,1448.8359375,3431.829833984375">
                ( ) Male 124,5 Female 154,8 Race or ethnic group - no. (%)† White 142,7 Black 13,6 Asian 58,4 Pacific Islander 1,6 Native American 1,2 M l i i l 7 2
            </div>
            

            <div class="text-block title" 
                 style="left: 66.38098754882813px; top: 701.091796875px; width: 177.18463745117188px; height: 9.985205078125px;"
                 title=""
                 data-order="5"
                 data-bbox="331.9049377441406,3505.458984375,1217.828125,3555.385009765625">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 68.98184204101562px; top: 713.088037109375px; width: 437.5364196777344px; height: 42.377490234375px;"
                 title="Characteristic Recombinant Vaccine (N = 279 400 Standard-Dose Vaccine (N = 395 852 All Vaccinees (N = 675 252"
                 data-order="6"
                 data-bbox="344.9092102050781,3565.440185546875,2532.59130859375,3777.32763671875">
                Characteristic Recombinant Vaccine (N = 279 400 Standard-Dose Vaccine (N = 395 852 All Vaccinees (N = 675 252
            </div>
            

            <div class="text-block title" 
                 style="left: 198.30559082031252px; top: 779.729296875px; width: 192.9933837890625px; height: 11.675390625px;"
                 title=""
                 data-order="7"
                 data-bbox="991.5279541015625,3898.646484375,1956.494873046875,3957.0234375">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 245.10417480468752px; top: 796.366357421875px; width: 142.4441162109375px; height: 6.3182617187500005px;"
                 title=""
                 data-order="8"
                 data-bbox="1225.5208740234375,3981.831787109375,1937.741455078125,4013.423095703125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 130.76341552734377px; top: 807.4603027343751px; width: 353.06202392578126px; height: 23.073193359375px;"
                 title="Recombinant or Standard-Dose Influenza Vaccine"
                 data-order="9"
                 data-bbox="653.8170776367188,4037.301513671875,2419.127197265625,4152.66748046875">
                Recombinant or Standard-Dose Influenza Vaccine
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 8</div>

            <div class="text-block text" 
                 style="left: 38.59794921875px; top: 66.50167846679688px; width: 448.937451171875px; height: 5.292370605468751px;"
                 title=""
                 data-order="0"
                 data-bbox="192.98974609375,332.5083923339844,2437.677001953125,358.9702453613281">
                
            </div>
            

            <div class="table-block" 
                 style="left: 34.00323181152344px; top: 77.7955810546875px; width: 527.2972564697266px; height: 226.847900390625px;"
                 title="[TABLE 2 - See table_p8_det_7_002.png]"
                 data-order="1"
                 data-bbox="170.0161590576172,388.9779052734375,2806.50244140625,1523.2174072265625">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 32.065747070312504px; top: 308.86228027343753px; width: 526.0188720703126px; height: 66.60576171875px;"
                 title="10.8% (95% CI, 6.6 to 14.7) against diagnosed influenza, and 19.5% (95% CI, 5.4 to 31.5) against influenza A in the subgroup with obesity (Tables S7 and S8). In the younger age group, the only explort..."
                 data-order="2"
                 data-bbox="160.3287353515625,1544.3114013671875,2790.423095703125,1877.3402099609375">
                10.8% (95% CI, 6.6 to 14.7) against diagnosed influenza, and 19.5% (95% CI, 5.4 to 31.5) against influenza A in the subgroup with obesity (Tables S7 and S8). In the younger age group, the only explort...
            </div>
            

            <div class="text-block text" 
                 style="left: 108.802734375px; top: 391.67038574218753px; width: 227.313720703125px; height: 123.65607910156251px;"
                 title="cine group as compared with 1510 participants (2.51 cases per 1000) in the standard dose group (Table S8). For three exploratory objectives in this age group, the relative vaccine effectiveness was iv..."
                 data-order="3"
                 data-bbox="544.013671875,1958.3519287109375,1680.582275390625,2576.63232421875">
                cine group as compared with 1510 participants (2.51 cases per 1000) in the standard dose group (Table S8). For three exploratory objectives in this age group, the relative vaccine effectiveness was iv...
            </div>
            

            <div class="text-block text" 
                 style="left: 110.16109619140626px; top: 512.7460449218751px; width: 223.82025146484375px; height: 204.66079101562502px;"
                 title="no. of cases per 1000 luenza 559 (2.00) 925 (2.34) 0.8 es luenza A 522 (1.87) 862 (2.18) 0.8 luenza B 37 (0.13) 64 (0.16) 0.8 r PCRuenza 95 (0.34) 153 (0.39) 0.8 rcommunitymonia 106 (0.38) 183 (0.46) ..."
                 data-order="4"
                 data-bbox="550.8054809570312,2563.730224609375,1669.90673828125,3587.0341796875">
                no. of cases per 1000 luenza 559 (2.00) 925 (2.34) 0.8 es luenza A 522 (1.87) 862 (2.18) 0.8 luenza B 37 (0.13) 64 (0.16) 0.8 r PCRuenza 95 (0.34) 153 (0.39) 0.8 rcommunitymonia 106 (0.38) 183 (0.46) ...
            </div>
            

            <div class="text-block text" 
                 style="left: 111.65241699218751px; top: 715.3954589843751px; width: 228.928564453125px; height: 38.2318359375px;"
                 title="Recombinant Vaccine (N = 279 400 Standard-Dose Vaccine (N = 395 852 Unadjus Rate Ra"
                 data-order="5"
                 data-bbox="558.2620849609375,3576.977294921875,1702.9049072265625,3768.136474609375">
                Recombinant Vaccine (N = 279 400 Standard-Dose Vaccine (N = 395 852 Unadjus Rate Ra
            </div>
            

            <div class="text-block title" 
                 style="left: 238.912939453125px; top: 780.14296875px; width: 193.57158203125002px; height: 11.22431640625px;"
                 title=""
                 data-order="6"
                 data-bbox="1194.564697265625,3900.71484375,2162.422607421875,3956.83642578125">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 246.05461425781252px; top: 796.491455078125px; width: 142.76630859375px; height: 4.599462890625px;"
                 title=""
                 data-order="7"
                 data-bbox="1230.2730712890625,3982.457275390625,1944.1046142578125,4005.45458984375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 127.46064453125001px; top: 807.6015136718751px; width: 372.533447265625px; height: 22.984130859375px;"
                 title="The new engl and jour nal of medicine"
                 data-order="8"
                 data-bbox="637.30322265625,4038.007568359375,2499.970458984375,4152.92822265625">
                The new engl and jour nal of medicine
            </div>
            

            <div class="text-block text" 
                 style="left: 339.69755859375005px; top: 391.3677490234375px; width: 222.37465820312502px; height: 69.7616943359375px;"
                 title="S11). For the outcome of PCR-confirmed influenza among patients in the older age group, relative vaccine effectiveness was 14.4% (95% CI, −1.1 to 27.5) during 2018-2019 and 16.1% (95%"
                 data-order="9"
                 data-bbox="1698.48779296875,1956.8387451171875,2810.361083984375,2305.647216796875">
                S11). For the outcome of PCR-confirmed influenza among patients in the older age group, relative vaccine effectiveness was 14.4% (95% CI, −1.1 to 27.5) during 2018-2019 and 16.1% (95%
            </div>
            

            <div class="text-block text" 
                 style="left: 337.956689453125px; top: 459.96025390625005px; width: 224.55092773437502px; height: 94.450927734375px;"
                 title="weighting with stabilized facility specific propensity scores. ering according to facility and yielded results similar to use of Holm’sadjustment method. The P values that were or responding adjusted ..."
                 data-order="10"
                 data-bbox="1689.783447265625,2299.80126953125,2812.5380859375,2772.055908203125">
                weighting with stabilized facility specific propensity scores. ering according to facility and yielded results similar to use of Holm’sadjustment method. The P values that were or responding adjusted ...
            </div>
            

            <div class="text-block title" 
                 style="left: 405.7734619140625px; top: 573.772265625px; width: 85.01691894531251px; height: 12.883251953125px;"
                 title="o 1.06) 16.7 ( 5.6 to 3"
                 data-order="11"
                 data-bbox="2028.8673095703125,2868.861328125,2453.951904296875,2933.277587890625">
                o 1.06) 16.7 ( 5.6 to 3
            </div>
            

            <div class="text-block text" 
                 style="left: 335.412255859375px; top: 590.919775390625px; width: 225.74257812500002px; height: 161.97597656250002px;"
                 title="usted Ratio Adjusted Hazard Ratio (95% CI)† Relative Vaccine Effectiveness (95% CI) P Value‡ % 6 0.85 (0.76 to 0.94) 15.3 (5.9 to 23.8) 0.002 6 0.84 (0.76 to 0.94) 15.7 (6.0 to 24.5) 0.002 2 0.90 (0.6..."
                 data-order="12"
                 data-bbox="1677.061279296875,2954.598876953125,2805.774169921875,3764.478759765625">
                usted Ratio Adjusted Hazard Ratio (95% CI)† Relative Vaccine Effectiveness (95% CI) P Value‡ % 6 0.85 (0.76 to 0.94) 15.3 (5.9 to 23.8) 0.002 6 0.84 (0.76 to 0.94) 15.7 (6.0 to 24.5) 0.002 2 0.90 (0.6...
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 9</div>

            <div class="figure-block" 
                 style="left: 65.6097412109375px; top: 55.60742797851563px; width: 448.8548095703125px; height: 295.1219421386719px;"
                 title="[FIGURE 1 - See figure_p9_det_8_000.png]"
                 data-order="0"
                 data-bbox="328.0487060546875,278.0371398925781,2572.32275390625,1753.6468505859375">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 68.1307861328125px; top: 365.0099609375px; width: 441.02580566406255px; height: 70.1080078125px;"
                 title="fer red more protection against influenza than nant vaccine group than in the standard do vaccine against influenza as confirmed by polymerase chain reaction (PCR) assay, hospitalization for PCR-confi..."
                 data-order="1"
                 data-bbox="340.6539306640625,1825.0498046875,2545.782958984375,2175.58984375">
                fer red more protection against influenza than nant vaccine group than in the standard do vaccine against influenza as confirmed by polymerase chain reaction (PCR) assay, hospitalization for PCR-confi...
            </div>
            

            <div class="text-block text" 
                 style="left: 294.2954833984375px; top: 459.98344726562505px; width: 227.5649169921875px; height: 295.79853515625px;"
                 title="ess against Influenza among Participants between 50 −10 0 10 20 −20 15 −15 5 −5 25 −25 40 35 45 30 55 50 Percentage"
                 data-order="2"
                 data-bbox="1471.4774169921875,2299.917236328125,2609.302001953125,3778.909912109375">
                ess against Influenza among Participants between 50 −10 0 10 20 −20 15 −15 5 −5 25 −25 40 35 45 30 55 50 Percentage
            </div>
            

            <div class="text-block text" 
                 style="left: 72.75403442382813px; top: 461.36650390625005px; width: 230.8978210449219px; height: 37.891650390625px;"
                 title="Figure 3. Subgroup Analysis of Relative Vaccine Effectiveness d 64 Y f A A di t P iti C diti"
                 data-order="3"
                 data-bbox="363.7701721191406,2306.83251953125,1518.25927734375,2496.290771484375">
                Figure 3. Subgroup Analysis of Relative Vaccine Effectiveness d 64 Y f A A di t P iti C diti
            </div>
            

            <div class="text-block text" 
                 style="left: 68.24349975585938px; top: 494.83232421875005px; width: 220.48621215820313px; height: 192.04726562500002px;"
                 title="−40 −35 −45 Any of the above conditions Hospitalization for PCR-confirmed influenza Cardiovascular disease Respiratory disease Car dio respiratory disease Obesity Diabetes Any of the above conditions ..."
                 data-order="4"
                 data-bbox="341.2174987792969,2474.16162109375,1443.6485595703125,3434.39794921875">
                −40 −35 −45 Any of the above conditions Hospitalization for PCR-confirmed influenza Cardiovascular disease Respiratory disease Car dio respiratory disease Obesity Diabetes Any of the above conditions ...
            </div>
            

            <div class="text-block text" 
                 style="left: 67.0373291015625px; top: 686.2076171875001px; width: 222.605908203125px; height: 67.1017578125px;"
                 title="PCR-confirmed influenza Cardiovascular disease Respiratory disease Car dio respiratory disease Obesity Diabetes"
                 data-order="5"
                 data-bbox="335.1866455078125,3431.0380859375,1448.2161865234375,3766.546875">
                PCR-confirmed influenza Cardiovascular disease Respiratory disease Car dio respiratory disease Obesity Diabetes
            </div>
            

            <div class="text-block title" 
                 style="left: 197.93508300781252px; top: 779.7133300781251px; width: 193.9141845703125px; height: 11.666064453125001px;"
                 title=""
                 data-order="6"
                 data-bbox="989.6754150390625,3898.566650390625,1959.246337890625,3956.89697265625">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 245.22575683593752px; top: 796.375634765625px; width: 142.5263671875px; height: 6.4464355468750005px;"
                 title=""
                 data-order="7"
                 data-bbox="1226.1287841796875,3981.878173828125,1938.7606201171875,4014.1103515625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 131.456201171875px; top: 807.4781250000001px; width: 352.48798828125px; height: 23.0400390625px;"
                 title="Recombinant or Standard-Dose Influenza Vaccine"
                 data-order="8"
                 data-bbox="657.281005859375,4037.390625,2419.720947265625,4152.5908203125">
                Recombinant or Standard-Dose Influenza Vaccine
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 10</div>

            <div class="text-block text" 
                 style="left: 110.06534423828126px; top: 60.80281372070313px; width: 224.26273193359376px; height: 55.36110229492188px;"
                 title="pgraphic characteristics, coexisting illnesses,"
                 data-order="0"
                 data-bbox="550.3267211914062,304.0140686035156,1671.640380859375,580.819580078125">
                pgraphic characteristics, coexisting illnesses,
            </div>
            

            <div class="text-block text" 
                 style="left: 108.16005859375001px; top: 113.99239501953126px; width: 225.143017578125px; height: 134.38919677734376px;"
                 title="g gall associated with its higher dose of hemagglutinin antigen. A strength of our study is that the two study vaccine formulations were alternated in weekly intervals of time at each facility, which ..."
                 data-order="1"
                 data-bbox="540.80029296875,569.9619750976562,1666.515380859375,1241.907958984375">
                g gall associated with its higher dose of hemagglutinin antigen. A strength of our study is that the two study vaccine formulations were alternated in weekly intervals of time at each facility, which ...
            </div>
            

            <div class="text-block text" 
                 style="left: 110.2956298828125px; top: 244.343017578125px; width: 225.9242919921875px; height: 379.13349609375px;"
                 title="through influenza by 15% would provide asub stantial public health benefit, especially during more severe influenza seasons. Several studies have shown benefit for the recombinant vaccine and other hi..."
                 data-order="2"
                 data-bbox="551.4781494140625,1221.715087890625,1681.099609375,3117.382568359375">
                through influenza by 15% would provide asub stantial public health benefit, especially during more severe influenza seasons. Several studies have shown benefit for the recombinant vaccine and other hi...
            </div>
            

            <div class="text-block text" 
                 style="left: 110.4156982421875px; top: 619.2930664062501px; width: 221.6040771484375px; height: 124.254443359375px;"
                 title="mortality at KPNC and nationwide in a similar age group 11 12 If standard dose vaccines were already preventing most cases of influenza and breakthrough cases were uncommon, preventing 15% of breakthr..."
                 data-order="3"
                 data-bbox="552.0784912109375,3096.46533203125,1660.098876953125,3717.737548828125">
                mortality at KPNC and nationwide in a similar age group 11 12 If standard dose vaccines were already preventing most cases of influenza and breakthrough cases were uncommon, preventing 15% of breakthr...
            </div>
            

            <div class="text-block title" 
                 style="left: 240.0472412109375px; top: 779.87978515625px; width: 192.26848144531252px; height: 11.38095703125px;"
                 title=""
                 data-order="4"
                 data-bbox="1200.2362060546875,3899.39892578125,2161.57861328125,3956.3037109375">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 245.118994140625px; top: 796.682177734375px; width: 143.067236328125px; height: 4.412109375px;"
                 title=""
                 data-order="5"
                 data-bbox="1225.594970703125,3983.410888671875,1940.93115234375,4005.471435546875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 143.6383056640625px; top: 807.6638671875px; width: 353.76115722656255px; height: 22.899707031250003px;"
                 title="The new engl and jour nal of medicine"
                 data-order="6"
                 data-bbox="718.1915283203125,4038.3193359375,2486.997314453125,4152.81787109375">
                The new engl and jour nal of medicine
            </div>
            

            <div class="text-block text" 
                 style="left: 338.00778808593753px; top: 60.538812255859376px; width: 225.2259521484375px; height: 214.72984008789064px;"
                 title="y p g seasons, participants between the ages of 50 and 64 years who received the recombinant vaccine had more protection against confirmed influenza than those who received a standard dose vaccine. Su..."
                 data-order="7"
                 data-bbox="1690.0389404296875,302.6940612792969,2816.168701171875,1376.34326171875">
                y p g seasons, participants between the ages of 50 and 64 years who received the recombinant vaccine had more protection against confirmed influenza than those who received a standard dose vaccine. Su...
            </div>
            

            <div class="text-block text" 
                 style="left: 327.98312988281253px; top: 270.33740234375px; width: 234.03151855468752px; height: 281.66728515625px;"
                 title="......e rin our real world setting, compliance with the weekly assigned vaccine schedule occasionally varied because of logistic con strains ts, including supply chain issues for the recombinant vacci..."
                 data-order="8"
                 data-bbox="1639.9156494140625,1351.68701171875,2810.0732421875,2760.0234375">
                ......e rin our real world setting, compliance with the weekly assigned vaccine schedule occasionally varied because of logistic con strains ts, including supply chain issues for the recombinant vacci...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.81201171875px; top: 552.48291015625px; width: 222.16025390625px; height: 68.995458984375px;"
                 title="p gweek (to compare between facilities) showed a relative vaccine effectiveness of approximately 15%, similar to the findings of our primary analysis. Our study also has several limitations. First,"
                 data-order="9"
                 data-bbox="1699.06005859375,2762.41455078125,2809.861328125,3107.391845703125">
                p gweek (to compare between facilities) showed a relative vaccine effectiveness of approximately 15%, similar to the findings of our primary analysis. Our study also has several limitations. First,
            </div>
            

            <div class="text-block title" 
                 style="left: 348.6494384765625px; top: 628.70361328125px; width: 75.19118652343751px; height: 9.7603515625px;"
                 title="hat were stratifie ith"
                 data-order="10"
                 data-bbox="1743.2471923828125,3143.51806640625,2119.203125,3192.31982421875">
                hat were stratifie ith
            </div>
            

            <div class="text-block text" 
                 style="left: 341.4966552734375px; top: 638.042138671875px; width: 221.6966552734375px; height: 20.533203125px;"
                 title="tering according to facility. Sensitivity analyses that were stratified either according to facility"
                 data-order="11"
                 data-bbox="1707.4832763671875,3190.210693359375,2815.966552734375,3292.876708984375">
                tering according to facility. Sensitivity analyses that were stratified either according to facility
            </div>
            

            <div class="text-block text" 
                 style="left: 340.61320800781255px; top: 662.89296875px; width: 220.61794433593752px; height: 80.18085937500001px;"
                 title="g p y , handling of potential confounding bias has not been formally studied. Our intent was to minimize imbalances between the participants who received each vaccine, both within and between faciliti..."
                 data-order="12"
                 data-bbox="1703.0660400390625,3314.46484375,2806.15576171875,3715.369140625">
                g p y , handling of potential confounding bias has not been formally studied. Our intent was to minimize imbalances between the participants who received each vaccine, both within and between faciliti...
            </div>
            
</div>
<div class="page-container" data-width="3082.41064453125" data-height="4258.82421875" style="width: 616.4821289062501px; height: 851.7648437500001px;">
<div class="page-header">Page 11</div>

            <div class="text-block title" 
                 style="left: 67.80874023437501px; top: 62.12703247070313px; width: 48.623852539062504px; height: 5.36429443359375px;"
                 title=""
                 data-order="0"
                 data-bbox="339.043701171875,310.6351623535156,582.1629638671875,337.4566345214844">
                
            </div>
            

            <div class="text-block list" 
                 style="left: 218.9972900390625px; top: 71.61393432617187px; width: 150.6355712890625px; height: 365.26228637695317px;"
                 title="cines worked better than reported &amp; ACIP recommends specific vaccines for seniors. June 23, 2022 (https www cdc gov flu"
                 data-order="1"
                 data-bbox="1094.9864501953125,358.0696716308594,1848.164306640625,2184.381103515625">
                cines worked better than reported &amp; ACIP recommends specific vaccines for seniors. June 23, 2022 (https www cdc gov flu
            </div>
            

            <div class="text-block list" 
                 style="left: 67.83775024414062px; top: 72.06294555664063px; width: 147.0526550292969px; height: 113.59038696289063px;"
                 title=""
                 data-order="2"
                 data-bbox="339.1887512207031,360.3147277832031,1074.4520263671875,928.2666625976562">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 68.12047119140625px; top: 179.56557617187502px; width: 144.82281494140625px; height: 136.74040527343752px;"
                 title=""
                 data-order="3"
                 data-bbox="340.60235595703125,897.827880859375,1064.7164306640625,1581.5299072265625">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 68.45338745117188px; top: 311.12680664062503px; width: 144.60012817382812px; height: 113.125732421875px;"
                 title="8. Davis AC, Voelkel JL, Rem mers CL, Adams JL, McGlynn EA. Comparing Kai-"
                 data-order="4"
                 data-bbox="342.2669372558594,1555.634033203125,1065.267578125,2121.2626953125">
                8. Davis AC, Voelkel JL, Rem mers CL, Adams JL, McGlynn EA. Comparing Kai-
            </div>
            

            <div class="text-block text" 
                 style="left: 68.48516845703125px; top: 429.038720703125px; width: 142.63577880859376px; height: 4.931689453125px;"
                 title="resources/chis)."
                 data-order="5"
                 data-bbox="342.42584228515625,2145.193603515625,1055.604736328125,2169.85205078125">
                resources/chis).
            </div>
            

            <div class="text-block title" 
                 style="left: 197.98992919921875px; top: 779.771533203125px; width: 192.47694091796876px; height: 11.80771484375px;"
                 title=""
                 data-order="6"
                 data-bbox="989.9496459960938,3898.857666015625,1952.3343505859375,3957.896240234375">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 244.048193359375px; top: 796.246142578125px; width: 142.4988525390625px; height: 4.500244140625px;"
                 title=""
                 data-order="7"
                 data-bbox="1220.240966796875,3981.230712890625,1932.7352294921875,4003.73193359375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 123.12115478515625px; top: 807.3366210937501px; width: 371.35267333984376px; height: 23.53994140625px;"
                 title="Recombinant or Standard-Dose Influenza Vaccine"
                 data-order="8"
                 data-bbox="615.6057739257812,4036.68310546875,2472.369140625,4154.3828125">
                Recombinant or Standard-Dose Influenza Vaccine
            </div>
            

            <div class="text-block text" 
                 style="left: 373.944580078125px; top: 71.83564453125px; width: 139.072900390625px; height: 18.785040283203127px;"
                 title=""
                 data-order="9"
                 data-bbox="1869.722900390625,359.17822265625,2565.08740234375,453.1034240722656">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 375.22333984375px; top: 95.09088745117188px; width: 143.128125px; height: 43.92560424804688px;"
                 title=""
                 data-order="10"
                 data-bbox="1876.11669921875,475.4544372558594,2591.75732421875,695.0824584960938">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 374.86708984375px; top: 165.202099609375px; width: 147.17998046875002px; height: 272.24521484375003px;"
                 title="recombinant hemagglutinin. Clin Infect Dis 2021 73 11: e4312-e4320. Copyright © 2023 Massachusetts Medical Society."
                 data-order="11"
                 data-bbox="1874.33544921875,826.010498046875,2610.2353515625,2187.236572265625">
                recombinant hemagglutinin. Clin Infect Dis 2021 73 11: e4312-e4320. Copyright © 2023 Massachusetts Medical Society.
            </div>
            
</div>
</div>
<div class="document-wrapper" id="doc-Liu_et_al.__2024_">
<h2>Liu_et_al.__2024_</h2>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 1</div>

            <div class="text-block title" 
                 style="left: 42.789794921875px; top: 102.88679199218751px; width: 36.80716552734375px; height: 15.851916503906251px;"
                 title="United S cine seed"
                 data-order="0"
                 data-bbox="213.948974609375,514.4339599609375,397.98480224609375,593.6935424804688">
                United S cine seed
            </div>
            

            <div class="text-block title" 
                 style="left: 31.086279296875002px; top: 121.19583740234376px; width: 582.826953125px; height: 132.58675537109374px;"
                 title="year 1, but there was no significant difference in HA stalk antibody fold rise among vaccine groups in either year 1 or year 2. Multiple seasons of non-eg based vaccination may be needed to redirect a..."
                 data-order="1"
                 data-bbox="155.431396484375,605.9791870117188,3069.566162109375,1268.9129638671875">
                year 1, but there was no significant difference in HA stalk antibody fold rise among vaccine groups in either year 1 or year 2. Multiple seasons of non-eg based vaccination may be needed to redirect a...
            </div>
            

            <div class="text-block text" 
                 style="left: 237.6986083984375px; top: 287.427734375px; width: 391.04753417968755px; height: 444.610009765625px;"
                 title="tibody responses from egg pes following repeat vaccinambinant or cell culture based ed influenza vaccines Feng Liu 1, F. Lia in i Gross 1, Sneha Joshi 1, Man jus ha Gag la ni 2,3,4, Allison L. Naleway..."
                 data-order="2"
                 data-bbox="1188.4930419921875,1437.138671875,3143.730712890625,3660.188720703125">
                tibody responses from egg pes following repeat vaccinambinant or cell culture based ed influenza vaccines Feng Liu 1, F. Lia in i Gross 1, Sneha Joshi 1, Man jus ha Gag la ni 2,3,4, Allison L. Naleway...
            </div>
            

            <div class="table-block" 
                 style="left: 43.038552856445314px; top: 296.9488037109375px; width: 210.2274627685547px; height: 415.13547363281253px;"
                 title="[TABLE 4 - See table_p1_det_0_013.png]"
                 data-order="3"
                 data-bbox="215.19276428222656,1484.7440185546875,1266.330078125,3560.42138671875">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 41.96261291503907px; top: 730.309814453125px; width: 287.4570648193359px; height: 63.413525390625004px;"
                 title="Article Redirecting antibody r"
                 data-order="4"
                 data-bbox="209.8130645751953,3651.549072265625,1647.098388671875,3968.61669921875">
                Article Redirecting antibody r
            </div>
            

            <div class="text-block text" 
                 style="left: 38.20923767089844px; top: 814.9892578125px; width: 326.8017242431641px; height: 11.67978515625px;"
                 title=""
                 data-order="5"
                 data-bbox="191.0461883544922,4074.9462890625,1825.0548095703125,4133.34521484375">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 340.33688964843753px; top: 728.976318359375px; width: 285.5381591796875px; height: 63.82744140625px;"
                 title="https://doi.org/10.1038/s41467-023-44551-xresponses from egg-"
                 data-order="6"
                 data-bbox="1701.6844482421875,3644.881591796875,3129.375244140625,3964.018798828125">
                https://doi.org/10.1038/s41467-023-44551-xresponses from egg-
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 2</div>

            <div class="text-block text" 
                 style="left: 41.909802246093754px; top: 49.51056518554688px; width: 288.1579223632813px; height: 134.36054077148438px;"
                 title="n=318 (*139) IIV4-ccIIV4 n=106 (*51) IIV4-RIV4 n=104 (*44) IIV4-IIV4 n=103 (*41) Excluded n=5 Did not meet per protocol criteria Fig. 1 | CONSORT diagrams for screening and Enrollment of participants ..."
                 data-order="0"
                 data-bbox="209.54901123046875,247.55282592773438,1650.338623046875,919.3555297851562">
                n=318 (*139) IIV4-ccIIV4 n=106 (*51) IIV4-RIV4 n=104 (*44) IIV4-IIV4 n=103 (*41) Excluded n=5 Did not meet per protocol criteria Fig. 1 | CONSORT diagrams for screening and Enrollment of participants ...
            </div>
            

            <div class="text-block text" 
                 style="left: 42.75210876464844px; top: 178.72539062500002px; width: 286.3318267822266px; height: 260.23916015625px;"
                 title="during the preceding five seasons. Year 1 (2018-201 ccIIV4 n=283 18-44 years: n=135 45-64 years: n=148 Completed day 0 (n=283) 1 month (n=280) and 6 months (n=266) visit RIV n=198 18-44 years: n=99 45..."
                 data-order="1"
                 data-bbox="213.7605438232422,893.626953125,1645.419677734375,2194.82275390625">
                during the preceding five seasons. Year 1 (2018-201 ccIIV4 n=283 18-44 years: n=135 45-64 years: n=148 Completed day 0 (n=283) 1 month (n=280) and 6 months (n=266) visit RIV n=198 18-44 years: n=99 45...
            </div>
            

            <div class="figure-block" 
                 style="left: 60.51461181640625px; top: 462.127880859375px; width: 543.6122436523438px; height: 333.58984375px;"
                 title="[FIGURE 3 - See figure_p2_mrg_det_1_000.png]"
                 data-order="2"
                 data-bbox="302.57305908203125,2310.639404296875,3020.63427734375,3978.588623046875">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 282.19580078125px; top: 470.91831054687503px; width: 155.18706054687502px; height: 10.814453125px;"
                 title="vaccination (Fig. 1). The A (H1 N1) pd"
                 data-order="3"
                 data-bbox="1410.97900390625,2354.591552734375,2186.914306640625,2408.663818359375">
                vaccination (Fig. 1). The A (H1 N1) pd
            </div>
            

            <div class="text-block text" 
                 style="left: 72.17094116210937px; top: 615.813525390625px; width: 65.04972534179687px; height: 12.831103515625001px;"
                 title="ation reduced an ccine componen"
                 data-order="4"
                 data-bbox="360.8547058105469,3079.067626953125,686.1033325195312,3143.22314453125">
                ation reduced an ccine componen
            </div>
            

            <div class="text-block text" 
                 style="left: 250.83537597656252px; top: 617.6355957031251px; width: 276.2325439453125px; height: 9.761376953125001px;"
                 title="othe HA antigens of ulture based and n 723) and 2019-2020 (Year 2, n 684) influ year 1 HCP were randomized to receive one"
                 data-order="5"
                 data-bbox="1254.1768798828125,3088.177978515625,2635.339599609375,3136.98486328125">
                othe HA antigens of ulture based and n 723) and 2019-2020 (Year 2, n 684) influ year 1 HCP were randomized to receive one
            </div>
            

            <div class="text-block text" 
                 style="left: 41.75011901855469px; top: 787.440185546875px; width: 286.1549102783203px; height: 32.691748046875px;"
                 title="acell culture based influenza vaccine (Flu cel vax Quad rival ent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quad rival ent by SanofiPasteur, RIV4). RIV4 contains 3 times t..."
                 data-order="6"
                 data-bbox="208.75059509277344,3937.200927734375,1639.525146484375,4100.65966796875">
                acell culture based influenza vaccine (Flu cel vax Quad rival ent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quad rival ent by SanofiPasteur, RIV4). RIV4 contains 3 times t...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.72856445312505px; top: 49.760980224609376px; width: 285.64794921875px; height: 124.56947631835938px;"
                 title="RIV4-RIV4 n=74 ccIIV4-RIV4 n=106 ccIIV4-ccIIV4 n=101 RIV4-ccIIV4 n=73 Excluded n=12 Did not meet per protocol criteria (Flu cel vax Quad rival ent; RIV4: recombinant hemagglutinin influenza vaccine (F..."
                 data-order="7"
                 data-bbox="1693.642822265625,248.80490112304688,3121.882568359375,871.6522827148438">
                RIV4-RIV4 n=74 ccIIV4-RIV4 n=106 ccIIV4-ccIIV4 n=101 RIV4-ccIIV4 n=73 Excluded n=12 Did not meet per protocol criteria (Flu cel vax Quad rival ent; RIV4: recombinant hemagglutinin influenza vaccine (F...
            </div>
            

            <div class="text-block title" 
                 style="left: 339.41606445312505px; top: 182.0291259765625px; width: 43.34228515625px; height: 15.19080810546875px;"
                 title=""
                 data-order="8"
                 data-bbox="1697.080322265625,910.1456298828125,1913.791748046875,986.0996704101562">
                
            </div>
            

            <div class="text-block title" 
                 style="left: 334.4124267578125px; top: 195.44638671875px; width: 253.5395263671875px; height: 17.37822265625px;"
                 title=""
                 data-order="9"
                 data-bbox="1672.0621337890625,977.23193359375,2939.759765625,1064.123046875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 337.60498046875px; top: 220.58046875000002px; width: 286.60390625px; height: 229.0162109375px;"
                 title="sas/14/2017 (H3 N2) like virus respectively while the B/Victoria and B/ Yamagata components remained the same (Table 1). Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years..."
                 data-order="10"
                 data-bbox="1688.02490234375,1102.90234375,3121.04443359375,2247.9833984375">
                sas/14/2017 (H3 N2) like virus respectively while the B/Victoria and B/ Yamagata components remained the same (Table 1). Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years...
            </div>
            

            <div class="text-block text" 
                 style="left: 334.8525390625px; top: 786.302392578125px; width: 285.13349609375px; height: 22.69013671875px;"
                 title="epi to pes could be preferentially boosted from repeat vaccination with egg based vaccines 3. The potential of non egg based vaccines to miti gate the impact of prior egg based a cci nation remains nc..."
                 data-order="11"
                 data-bbox="1674.2626953125,3931.511962890625,3099.93017578125,4044.962646484375">
                epi to pes could be preferentially boosted from repeat vaccination with egg based vaccines 3. The potential of non egg based vaccines to miti gate the impact of prior egg based a cci nation remains nc...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 3</div>

            <div class="text-block text" 
                 style="left: 45.31313781738282px; top: 52.543695068359376px; width: 573.8619110107422px; height: 25.615997314453125px;"
                 title=", g y ymotif at HA position 197; whereas egg based B/Yamagata vaccine had g y g (p ) pantibody responses to both egg- (GMT 122) and cell- (GMT 137"
                 data-order="0"
                 data-bbox="226.56568908691406,262.7184753417969,3095.875244140625,390.7984619140625">
                , g y ymotif at HA position 197; whereas egg based B/Yamagata vaccine had g y g (p ) pantibody responses to both egg- (GMT 122) and cell- (GMT 137
            </div>
            

            <div class="table-block" 
                 style="left: 44.40605773925782px; top: 81.09437866210938px; width: 595.4764617919922px; height: 413.8128967285156px;"
                 title="[TABLE 2 - See table_p3_det_2_003.png]"
                 data-order="1"
                 data-bbox="222.03028869628906,405.4718933105469,3199.41259765625,2474.536376953125">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 45.483496093750006px; top: 487.74326171875003px; width: 452.12216796875003px; height: 80.40522460937501px;"
                 title="Year 2 A/Kansas/14/2017 cell a, d N N A S G K N (CHO-) S K N A/Kansas/14/2017 egg b N N A S G K N (CHO-) S K N B/Victoria lineage 129 197 199 Year 1 &amp; 2 B/Colorado/06/2017 cell G N T B/Colorado/06/201..."
                 data-order="2"
                 data-bbox="227.41748046875,2438.71630859375,2488.0283203125,2840.742431640625">
                Year 2 A/Kansas/14/2017 cell a, d N N A S G K N (CHO-) S K N A/Kansas/14/2017 egg b N N A S G K N (CHO-) S K N B/Victoria lineage 129 197 199 Year 1 &amp; 2 B/Colorado/06/2017 cell G N T B/Colorado/06/201...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.83888244628906px; top: 587.8669921875px; width: 284.3939544677734px; height: 26.247265625px;"
                 title="egg CVV (EPI 1082512 A/Singapore/INFIMH-16-0019/2016 NIB-104 egg CVV (EPI 1151864 c S K T"
                 data-order="3"
                 data-bbox="219.1944122314453,2939.3349609375,1641.1641845703125,3070.5712890625">
                egg CVV (EPI 1082512 A/Singapore/INFIMH-16-0019/2016 NIB-104 egg CVV (EPI 1151864 c S K T
            </div>
            

            <div class="text-block text" 
                 style="left: 42.742922973632815px; top: 609.09599609375px; width: 285.0256805419922px; height: 206.72465820312502px;"
                 title="| gg pthe study Viruses Amino acids difference A (H1 N1) pdm09 45 74 120 Year 1 A/Michigan/45/2015 cell a R S T A/Michigan/45/2015 egg R S T A/Michigan/45/2015 X-275 egg CVV (EPI 830246 b R S T A/Sing..."
                 data-order="4"
                 data-bbox="213.71461486816406,3045.47998046875,1638.843017578125,4079.103271484375">
                | gg pthe study Viruses Amino acids difference A (H1 N1) pdm09 45 74 120 Year 1 A/Michigan/45/2015 cell a R S T A/Michigan/45/2015 egg R S T A/Michigan/45/2015 X-275 egg CVV (EPI 830246 b R S T A/Sing...
            </div>
            

            <div class="text-block text" 
                 style="left: 333.6992431640625px; top: 587.747607421875px; width: 293.19699707031253px; height: 26.217578125000003px;"
                 title="A G S N (CHO-) Y K K D F P G N H"
                 data-order="5"
                 data-bbox="1668.4962158203125,2938.738037109375,3134.481201171875,3069.825927734375">
                A G S N (CHO-) Y K K D F P G N H
            </div>
            

            <div class="text-block title" 
                 style="left: 335.513623046875px; top: 624.28447265625px; width: 284.166796875px; height: 24.565869140625px;"
                 title="A G S N (CHO) Y T K D F L D N H A G S N (CHO-) Y K K D F P D/G¶ N H A G S N (CHO-) Y K K D F P G N H"
                 data-order="6"
                 data-bbox="1677.568115234375,3121.42236328125,3098.402099609375,3244.251708984375">
                A G S N (CHO) Y T K D F L D N H A G S N (CHO-) Y K K D F P D/G¶ N H A G S N (CHO-) Y K K D F P G N H
            </div>
            

            <div class="text-block text" 
                 style="left: 337.80961914062505px; top: 645.2624023437501px; width: 287.615625px; height: 170.8609375px;"
                 title="gg g y yon the HA head domain 164 183 209 223 225 282 295 298 S S K Q G P I I S S K R G P I I S S M R G P I I S S K Q A P I I T P K Q G P V I T P K R G A V V 138 142 144 158 159 160 171 190 193 194 22..."
                 data-order="7"
                 data-bbox="1689.048095703125,3226.31201171875,3127.126220703125,4080.61669921875">
                gg g y yon the HA head domain 164 183 209 223 225 282 295 298 S S K Q G P I I S S K R G P I I S S M R G P I I S S K Q A P I I T P K Q G P V I T P K R G A V V 138 142 144 158 159 160 171 190 193 194 22...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 4</div>

            <div class="figure-block" 
                 style="left: 54.792822265625006px; top: 45.35241394042969px; width: 548.830322265625px; height: 348.05066223144536px;"
                 title="[FIGURE 1 - See figure_p4_det_3_002.png]"
                 data-order="0"
                 data-bbox="273.964111328125,226.76206970214844,3018.11572265625,1967.015380859375">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 45.401849365234376px; top: 401.23666992187503px; width: 285.90586547851564px; height: 102.46791992187501px;"
                 title="Day 0 1 m 6 m 5 10 H Day 0 1 m 6 m 5 10 Fig. 2 | MN or HI Antibody responses to egg- and cell propagated vaccine viruses at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1. A..."
                 data-order="1"
                 data-bbox="227.00924682617188,2006.183349609375,1656.53857421875,2518.52294921875">
                Day 0 1 m 6 m 5 10 H Day 0 1 m 6 m 5 10 Fig. 2 | MN or HI Antibody responses to egg- and cell propagated vaccine viruses at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1. A...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.24520263671875px; top: 512.51865234375px; width: 285.4083618164063px; height: 172.59599609375002px;"
                 title="B/VIC B/YAM Day 0 1 m 6 m 5 10 20 40 80 HI titers Day 0 1 m 6 m 5 10 20 40 80 Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280..."
                 data-order="2"
                 data-bbox="221.22601318359375,2562.59326171875,1648.267822265625,3425.5732421875">
                B/VIC B/YAM Day 0 1 m 6 m 5 10 20 40 80 HI titers Day 0 1 m 6 m 5 10 20 40 80 Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.448159790039064px; top: 680.0690429687501px; width: 280.23731384277346px; height: 148.6642578125px;"
                 title="A (H3 N2) A (H1 N1) pdm09 18-44 yrs egg virus 18-44 yrs cell virus Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 MN titers (Log2 scale) 0.003 0.014 &lt;0 0001 0 0008 0.044 &lt;0 0001 Day 0 1 m 6 m ..."
                 data-order="3"
                 data-bbox="217.2407989501953,3400.34521484375,1618.4273681640625,4143.66650390625">
                A (H3 N2) A (H1 N1) pdm09 18-44 yrs egg virus 18-44 yrs cell virus Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 MN titers (Log2 scale) 0.003 0.014 &lt;0 0001 0 0008 0.044 &lt;0 0001 Day 0 1 m 6 m ...
            </div>
            

            <div class="text-block text" 
                 style="left: 340.68540039062503px; top: 398.731591796875px; width: 288.12060546875px; height: 93.22675781250001px;"
                 title="Day 0 1 m 6 m Day 0 1 m 6 mccIIV4 45−64 years: Day 0 (n = 148), 1 m (n = 147), 6 m (n = 142); RIV4 18−44 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45−64 years: Day 0 (n = 98), 1 m (n = 9..."
                 data-order="4"
                 data-bbox="1703.427001953125,1993.657958984375,3144.030029296875,2459.791748046875">
                Day 0 1 m 6 m Day 0 1 m 6 mccIIV4 45−64 years: Day 0 (n = 148), 1 m (n = 147), 6 m (n = 142); RIV4 18−44 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45−64 years: Day 0 (n = 98), 1 m (n = 9...
            </div>
            

            <div class="text-block text" 
                 style="left: 340.28166503906255px; top: 516.031787109375px; width: 285.48020019531253px; height: 61.362158203125006px;"
                 title="Day 0 1 m 6 m 5 Day 0 1 m 6 m 5 80 160 320 640 1280-2560 5120 0.018 80 160 320 640 1280-2560 5120"
                 data-order="5"
                 data-bbox="1701.4083251953125,2580.158935546875,3128.809326171875,2886.9697265625">
                Day 0 1 m 6 m 5 Day 0 1 m 6 m 5 80 160 320 640 1280-2560 5120 0.018 80 160 320 640 1280-2560 5120
            </div>
            

            <div class="text-block text" 
                 style="left: 345.20283203125px; top: 568.04423828125px; width: 277.1453125px; height: 257.0009765625px;"
                 title="45-64 yrs egg virus 45-64 yrs cell virus Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 0.045 0 0046 &lt;0 0001 0.03 0 0074 Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 Flu zone IIV4 Fl..."
                 data-order="6"
                 data-bbox="1726.01416015625,2840.22119140625,3111.74072265625,4125.22607421875">
                45-64 yrs egg virus 45-64 yrs cell virus Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 0.045 0 0046 &lt;0 0001 0.03 0 0074 Day 0 1 m 6 m 5 10 20 40 80 160 320 640 1280-2560 5120 Flu zone IIV4 Fl...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 5</div>

            <div class="figure-block" 
                 style="left: 51.045910644531254px; top: 48.22684936523438px; width: 555.0992553710938px; height: 197.78750610351562px;"
                 title="[FIGURE 1 - See figure_p5_det_4_000.png]"
                 data-order="0"
                 data-bbox="255.22955322265625,241.13424682617188,3030.725830078125,1230.07177734375">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 44.19689636230469px; top: 257.12138671875px; width: 283.4685333251953px; height: 59.1228271484375px;"
                 title="Antibody responses to egg adapted epi to pes measured by antibody GMT egg cell titer ratio in year 1 To assess the levels of antibody responses targeting the egg adapted epi to pes, we used the antibo..."
                 data-order="1"
                 data-bbox="220.98448181152344,1285.60693359375,1638.3271484375,1581.2210693359375">
                Antibody responses to egg adapted epi to pes measured by antibody GMT egg cell titer ratio in year 1 To assess the levels of antibody responses targeting the egg adapted epi to pes, we used the antibo...
            </div>
            

            <div class="text-block text" 
                 style="left: 46.939111328125px; top: 341.5489501953125px; width: 277.6434326171875px; height: 8.397021484375001px;"
                 title="year 1, a total of 26 breakthrough infection cases were identified with"
                 data-order="2"
                 data-bbox="234.695556640625,1707.7447509765625,1622.9127197265625,1749.7298583984375">
                year 1, a total of 26 breakthrough infection cases were identified with
            </div>
            

            <div class="text-block text" 
                 style="left: 43.74236145019532px; top: 371.87314453125003px; width: 282.2457489013672px; height: 143.9px;"
                 title="Pre existing A (H3 N2) and A (H1 N1) pdm09 HA stalk antibodies were detected in participants at varies levels. Comparing HA stalk antibody titers at 1 month post vaccination versus day 0, vaccination ..."
                 data-order="3"
                 data-bbox="218.71180725097656,1859.36572265625,1629.9405517578125,2578.86572265625">
                Pre existing A (H3 N2) and A (H1 N1) pdm09 HA stalk antibodies were detected in participants at varies levels. Comparing HA stalk antibody titers at 1 month post vaccination versus day 0, vaccination ...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.5338134765625px; top: 516.45830078125px; width: 285.65380859375px; height: 36.7017578125px;"
                 title="(n = 98)) age groups respectively (A, B). Antibody waning was expressed as the GM fold reduction of titers from 1 month to 6 months (1 m/6 m) post vaccination for"
                 data-order="4"
                 data-bbox="222.6690673828125,2582.29150390625,1650.9381103515625,2765.80029296875">
                (n = 98)) age groups respectively (A, B). Antibody waning was expressed as the GM fold reduction of titers from 1 month to 6 months (1 m/6 m) post vaccination for
            </div>
            

            <div class="text-block title" 
                 style="left: 45.48583068847657px; top: 563.6822265625px; width: 265.98059997558596px; height: 26.1595703125px;"
                 title="mean (GM) fold rise of antibody titers (1 m/Day 0) from each of the four vacc groups were calculated for egg- and cell propagated vaccine viruses, and for 18 years (Flu zone IIV4 (n = 52), Fluarix IIV..."
                 data-order="5"
                 data-bbox="227.4291534423828,2818.4111328125,1557.3321533203125,2949.208984375">
                mean (GM) fold rise of antibody titers (1 m/Day 0) from each of the four vacc groups were calculated for egg- and cell propagated vaccine viruses, and for 18 years (Flu zone IIV4 (n = 52), Fluarix IIV...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.31932067871094px; top: 584.950830078125px; width: 284.8626617431641px; height: 212.65151367187502px;"
                 title="0 1 2 3 4 5 6 y 0 0058 0 0088 0 0001 &lt;0 0001 &lt;0 0001 &lt;0 0001 &lt;0 0001 0 0006 0.021 0.047 0.034 0.004 0.005 0 0035 0.017 0 0003 0.024 0.01 0 1 2 3 4 5 6 45-64 years Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV..."
                 data-order="6"
                 data-bbox="216.5966033935547,2924.754150390625,1640.909912109375,3988.01171875">
                0 1 2 3 4 5 6 y 0 0058 0 0088 0 0001 &lt;0 0001 &lt;0 0001 &lt;0 0001 &lt;0 0001 0 0006 0.021 0.047 0.034 0.004 0.005 0 0035 0.017 0 0003 0.024 0.01 0 1 2 3 4 5 6 45-64 years Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.558816528320314px; top: 802.61650390625px; width: 288.7825164794922px; height: 24.8263671875px;"
                 title="Flu zone IIV4 1 month fold rise (1 m/Day 0)"
                 data-order="7"
                 data-bbox="227.79408264160156,4013.08251953125,1671.7066650390625,4137.21435546875">
                Flu zone IIV4 1 month fold rise (1 m/Day 0)
            </div>
            

            <div class="text-block text" 
                 style="left: 340.88376464843753px; top: 257.32666015625px; width: 284.1003662109375px; height: 92.09697265625px;"
                 title="participants had GMT egg cell ratio ≥4 to A (H3 N2) and B/Victoria viruses, suggesting ahigh prevalence of pre existing neutralizing antibodies targeting HA egg adapted epi to pes in this highly vacci..."
                 data-order="8"
                 data-bbox="1704.4188232421875,1286.63330078125,3124.920654296875,1747.1181640625">
                participants had GMT egg cell ratio ≥4 to A (H3 N2) and B/Victoria viruses, suggesting ahigh prevalence of pre existing neutralizing antibodies targeting HA egg adapted epi to pes in this highly vacci...
            </div>
            

            <div class="text-block text" 
                 style="left: 337.14453125px; top: 372.76303710937503px; width: 287.85732421875px; height: 72.24453125000001px;"
                 title="RIV4 recipients from the 45−64 years group (Fig. 5 B). Next, to assess whether vaccination with non egg based vaccines can overcome the impact of egg adaptation and reduce the GMT egg/ cell ratio in t..."
                 data-order="9"
                 data-bbox="1685.72265625,1863.815185546875,3125.00927734375,2225.037841796875">
                RIV4 recipients from the 45−64 years group (Fig. 5 B). Next, to assess whether vaccination with non egg based vaccines can overcome the impact of egg adaptation and reduce the GMT egg/ cell ratio in t...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.11572265625px; top: 443.635205078125px; width: 286.403125px; height: 310.9486328125px;"
                 title="A (H1 N1) pdm09 and B/Yamagata, the post vaccination HI antibody GMT egg cell titer ratios were all &lt;2 and similar (p &gt; 0.05) among the vaccine groups (Fig. 5 A, B). For B/Victoria, the post vaccinati..."
                 data-order="10"
                 data-bbox="1695.57861328125,2218.176025390625,3127.59423828125,3772.919189453125">
                A (H1 N1) pdm09 and B/Yamagata, the post vaccination HI antibody GMT egg cell titer ratios were all &lt;2 and similar (p &gt; 0.05) among the vaccine groups (Fig. 5 A, B). For B/Victoria, the post vaccinati...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.6680419921875px; top: 754.022265625px; width: 283.2318115234375px; height: 73.33076171875px;"
                 title="2 3 4 18-44 years Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0.049 0.015 0.03 Waning 6 month fold reduction (1 m/6 m) ters 6 month C"
                 data-order="11"
                 data-bbox="1698.3402099609375,3770.111328125,3114.499267578125,4136.76513671875">
                2 3 4 18-44 years Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0.049 0.015 0.03 Waning 6 month fold reduction (1 m/6 m) ters 6 month C
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 6</div>

            <div class="figure-block" 
                 style="left: 35.81841125488281px; top: 42.10523986816406px; width: 582.0723114013672px; height: 342.89947204589845px;"
                 title="[FIGURE 1 - See figure_p6_det_5_006.png]"
                 data-order="0"
                 data-bbox="179.09205627441406,210.5261993408203,3089.45361328125,1925.0235595703125">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 43.68345642089844px; top: 393.47722167968755px; width: 286.5223785400391px; height: 23.696459960937503px;"
                 title="(n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38). A: HA (A (H1 N1) pdm 09 or HA head (A (H3 N2), B/ VIC B/YAM) bi di ib di B..."
                 data-order="1"
                 data-bbox="218.4172821044922,1967.3861083984375,1651.0291748046875,2085.868408203125">
                (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38). A: HA (A (H1 N1) pdm 09 or HA head (A (H3 N2), B/ VIC B/YAM) bi di ib di B...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.886199951171875px; top: 422.326806640625px; width: 283.0908996582031px; height: 68.372509765625px;"
                 title="Fig. 4 | Total HA binding antibody and HA stalk antibody responses measured by ELISA at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1. Antibody titers from each of the four..."
                 data-order="2"
                 data-bbox="224.43099975585938,2111.634033203125,1639.885498046875,2453.49658203125">
                Fig. 4 | Total HA binding antibody and HA stalk antibody responses measured by ELISA at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1. Antibody titers from each of the four...
            </div>
            

            <div class="text-block text" 
                 style="left: 40.606597900390625px; top: 552.58876953125px; width: 287.7778747558594px; height: 36.490087890625px;"
                 title="ELIS e) Day 0 1 m 6 m 400 800 Day 0 1 m 400 800 51200 &lt;0 0001 &lt;0 0001 0 0011 0 0008 0 0002 &lt;0 0001 0 0081 0.018 &lt;0 0001-51200 &lt;0 0001 &lt;0 0001 0.005 0.004 &lt;0 0001 &lt;0 0001 &lt;0"
                 data-order="3"
                 data-bbox="203.03298950195312,2762.94384765625,1641.92236328125,2945.394287109375">
                ELIS e) Day 0 1 m 6 m 400 800 Day 0 1 m 400 800 51200 &lt;0 0001 &lt;0 0001 0 0011 0 0008 0 0002 &lt;0 0001 0 0081 0.018 &lt;0 0001-51200 &lt;0 0001 &lt;0 0001 0.005 0.004 &lt;0 0001 &lt;0 0001 &lt;0
            </div>
            

            <div class="text-block title" 
                 style="left: 39.82737426757813px; top: 599.5956542968751px; width: 293.8377136230469px; height: 35.67958984375px;"
                 title="B/VIC ers (Log2 scale) 3200-6400 12800-25600 51200 0.036 1600-3200 6400-12800 25600"
                 data-order="4"
                 data-bbox="199.13687133789062,2997.978271484375,1668.325439453125,3176.376220703125">
                B/VIC ers (Log2 scale) 3200-6400 12800-25600 51200 0.036 1600-3200 6400-12800 25600
            </div>
            

            <div class="text-block text" 
                 style="left: 45.25413208007813px; top: 634.0739257812501px; width: 282.6525817871094px; height: 49.529345703125px;"
                 title="ELISA titer ) Day 0 1 m 6 m 400 800 1600-3200 Day 0 1 m 400 800 1600-51200 0.019 &lt;0 0001 &lt;0 0001 0 0088 0 0004 0 0007 0.036 0.015 51200 0 0011 &lt;0 0001 0 0011 0.005 0.02 &lt;0"
                 data-order="5"
                 data-bbox="226.27066040039062,3170.36962890625,1639.5335693359375,3418.016357421875">
                ELISA titer ) Day 0 1 m 6 m 400 800 1600-3200 Day 0 1 m 400 800 1600-51200 0.019 &lt;0 0001 &lt;0 0001 0 0088 0 0004 0 0007 0.036 0.015 51200 0 0011 &lt;0 0001 0 0011 0.005 0.02 &lt;0
            </div>
            

            <div class="text-block text" 
                 style="left: 43.852612304687504px; top: 678.8916015625px; width: 282.5664794921875px; height: 148.61279296875px;"
                 title="A (H3 N2) A (H1 N1) pdm09 Egg virus HA Cell viru ELISA titers (Log2 scale) ters (Log2 scale) A Day 0 1 m 400 800 1600-3200 6400-12800 25600-51200 0.006 &lt;0.000 &lt;0.00 3200-6400 12800-25600 51200 0.047 0..."
                 data-order="6"
                 data-bbox="219.2630615234375,3394.4580078125,1632.095458984375,4137.52197265625">
                A (H3 N2) A (H1 N1) pdm09 Egg virus HA Cell viru ELISA titers (Log2 scale) ters (Log2 scale) A Day 0 1 m 400 800 1600-3200 6400-12800 25600-51200 0.006 &lt;0.000 &lt;0.00 3200-6400 12800-25600 51200 0.047 0...
            </div>
            

            <div class="text-block text" 
                 style="left: 337.18259277343753px; top: 391.89243164062503px; width: 291.6078369140625px; height: 124.42353515625001px;"
                 title="0 1 Geome ELISA tite H3 stalk H1 stalk 6 mcorrected for multiple comparisons (Tukey’stest) was used to compare the GMTs of each time point among the 4 vaccine groups (A, C). One way ANOVA non parametr..."
                 data-order="7"
                 data-bbox="1685.9129638671875,1959.462158203125,3143.9521484375,2581.579833984375">
                0 1 Geome ELISA tite H3 stalk H1 stalk 6 mcorrected for multiple comparisons (Tukey’stest) was used to compare the GMTs of each time point among the 4 vaccine groups (A, C). One way ANOVA non parametr...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.67338867187505px; top: 549.552978515625px; width: 283.010009765625px; height: 192.72763671875px;"
                 title="Day 0 1 m 6 m 200 400 800 1600-3200 6400 Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0.02 0.043 0 0046 0.007 0.038 &lt;0.000 1 0.044 * * * Day 0 1 m 6 m 200 400 800 1600-3200 6400-12800 25600 0 0036 &lt;0 0001 0..."
                 data-order="8"
                 data-bbox="1698.366943359375,2747.764892578125,3113.4169921875,3711.403076171875">
                Day 0 1 m 6 m 200 400 800 1600-3200 6400 Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0.02 0.043 0 0046 0.007 0.038 &lt;0.000 1 0.044 * * * Day 0 1 m 6 m 200 400 800 1600-3200 6400-12800 25600 0 0036 &lt;0 0001 0...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.3689697265625px; top: 738.952197265625px; width: 285.4771728515625px; height: 86.80463867187501px;"
                 title="A Geometric mean ratio of ELISA titer egg cell HA (95% CI) B H3 HA H1 HA B/VIC HA B/YAM HA 6 m Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0.02 &lt;0 0001 0 0002 0 1 2 3 4 Flu zone IIV4 Fluarix IIV4 ccIIV4 RI..."
                 data-order="9"
                 data-bbox="1696.8448486328125,3694.760986328125,3124.230712890625,4128.7841796875">
                A Geometric mean ratio of ELISA titer egg cell HA (95% CI) B H3 HA H1 HA B/VIC HA B/YAM HA 6 m Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0.02 &lt;0 0001 0 0002 0 1 2 3 4 Flu zone IIV4 Fluarix IIV4 ccIIV4 RI...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 7</div>

            <div class="figure-block" 
                 style="left: 52.81986694335938px; top: 47.008093261718756px; width: 553.4539123535156px; height: 279.42945556640626px;"
                 title="[FIGURE 1 - See figure_p7_mrg_det_6_003.png]"
                 data-order="0"
                 data-bbox="264.0993347167969,235.04046630859375,3031.368896484375,1632.187744140625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 66.61202392578126px; top: 107.74737548828125px; width: 7.9292846679687505px; height: 167.58436279296876px;"
                 title="g p 4 aeg pin egg od od Tot ana ind pt cng ced tha od"
                 data-order="1"
                 data-bbox="333.06011962890625,538.7368774414062,372.70654296875,1376.65869140625">
                g p 4 aeg pin egg od od Tot ana ind pt cng ced tha od
            </div>
            

            <div class="text-block text" 
                 style="left: 43.71563415527344px; top: 335.1304931640625px; width: 281.6190093994141px; height: 57.053808593750006px;"
                 title="virus in the 45−64 years group, suggesting repeated boost to antibodies targeting egg adapted epi to pes in these participants after receiving consecutive egg based IIV4 vaccination. In contrast, amon..."
                 data-order="2"
                 data-bbox="218.5781707763672,1675.6524658203125,1626.6732177734375,1960.9215087890625">
                virus in the 45−64 years group, suggesting repeated boost to antibodies targeting egg adapted epi to pes in these participants after receiving consecutive egg based IIV4 vaccination. In contrast, amon...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.5814453125px; top: 390.46953125000005px; width: 280.46518554687503px; height: 53.299902343750006px;"
                 title="A (H3 N2) and B/VIC in the 18−44 years group, B/VIC virus and B/YAM virus in the 45−64 years group suggesting repeated boost to anti each vaccine group. Proportions of participants who had ≥4 -fold re..."
                 data-order="3"
                 data-bbox="227.9072265625,1952.34765625,1630.233154296875,2218.84716796875">
                A (H3 N2) and B/VIC in the 18−44 years group, B/VIC virus and B/YAM virus in the 45−64 years group suggesting repeated boost to anti each vaccine group. Proportions of participants who had ≥4 -fold re...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.955029296875004px; top: 467.944775390625px; width: 284.0715576171875px; height: 221.74589843750002px;"
                 title="A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM g e f ooit ...mcirt e m o e G B 0 1 2 3 4 5 6 45-64 years Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 &lt;0 0001 &lt;0 0001 0 0084 0.011 Fig. 5 | Difference in MN or HI anti..."
                 data-order="4"
                 data-bbox="219.775146484375,2339.723876953125,1640.1329345703125,3448.453369140625">
                A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM g e f ooit ...mcirt e m o e G B 0 1 2 3 4 5 6 45-64 years Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 &lt;0 0001 &lt;0 0001 0 0084 0.011 Fig. 5 | Difference in MN or HI anti...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.34466552734375px; top: 681.2610839843751px; width: 278.3434204101563px; height: 134.26518554687502px;"
                 title="A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM ) I C % 5 9 ( r etit s uriv lle c/ g g e f A 0 1 2 3 4 5 6 Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0 0014 0 0021 0.03"
                 data-order="5"
                 data-bbox="221.72332763671875,3406.305419921875,1613.4404296875,4077.63134765625">
                A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM ) I C % 5 9 ( r etit s uriv lle c/ g g e f A 0 1 2 3 4 5 6 Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 0 0014 0 0021 0.03
            </div>
            

            <div class="text-block text" 
                 style="left: 340.13120117187503px; top: 330.5462890625px; width: 287.3568359375px; height: 113.32636718750001px;"
                 title="Comparing pre- and 1 month post vaccination, A (H3 N2) HA stalk binding antibodies were significantly boosted in ccIIV4-RIV4, RIV4-RIV4, IIV4-ccIIV4, and IIV4-RIV4 arms, while A (H1 N1) pdm09 HA stalk..."
                 data-order="6"
                 data-bbox="1700.656005859375,1652.7314453125,3137.440185546875,2219.36328125">
                Comparing pre- and 1 month post vaccination, A (H3 N2) HA stalk binding antibodies were significantly boosted in ccIIV4-RIV4, RIV4-RIV4, IIV4-ccIIV4, and IIV4-RIV4 arms, while A (H1 N1) pdm09 HA stalk...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.7496337890625px; top: 470.13916015625px; width: 286.7335205078125px; height: 84.55605468750001px;"
                 title="cell vaccine virus (egg cell titer ratio) at pre- and 1 month post vaccination were presented for each vaccine component among the 4 vaccine groups for 18−44 years (C) and 45−64 years (D). Fisher’sexa..."
                 data-order="7"
                 data-bbox="1693.7481689453125,2350.69580078125,3127.415771484375,2773.47607421875">
                cell vaccine virus (egg cell titer ratio) at pre- and 1 month post vaccination were presented for each vaccine component among the 4 vaccine groups for 18−44 years (C) and 45−64 years (D). Fisher’sexa...
            </div>
            

            <div class="text-block title" 
                 style="left: 339.35563964843755px; top: 562.789208984375px; width: 61.7659912109375px; height: 7.85166015625px;"
                 title="0"
                 data-order="8"
                 data-bbox="1696.7781982421875,2813.946044921875,2005.608154296875,2853.204345703125">
                0
            </div>
            

            <div class="text-block text" 
                 style="left: 338.73720703125px; top: 577.6240234375px; width: 284.12099609375px; height: 143.553466796875px;"
                 title="0 Proportion of ≥4 -fold reduced titer to cell vac 20 40 60 80 100 40% 21% Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM Pre Post Pre Post Pre Post Pre Post 45-64 years ..."
                 data-order="9"
                 data-bbox="1693.68603515625,2888.1201171875,3114.291015625,3605.887451171875">
                0 Proportion of ≥4 -fold reduced titer to cell vac 20 40 60 80 100 40% 21% Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM Pre Post Pre Post Pre Post Pre Post 45-64 years ...
            </div>
            

            <div class="text-block text" 
                 style="left: 336.78837890625005px; top: 716.5968750000001px; width: 288.514111328125px; height: 100.779345703125px;"
                 title="20 40 60 80 100 58% 26% Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 accine virus (egg cell p=0.0001 A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM 18-44 years C"
                 data-order="10"
                 data-bbox="1683.94189453125,3582.984375,3126.512451171875,4086.881103515625">
                20 40 60 80 100 58% 26% Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 accine virus (egg cell p=0.0001 A (H3 N2) A (H1 N1) pdm09 B/VIC B/YAM 18-44 years C
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 8</div>

            <div class="figure-block" 
                 style="left: 51.822583007812504px; top: 45.46437072753906px; width: 545.2421630859375px; height: 354.24827575683594px;"
                 title="[FIGURE 1 - See figure_p8_mrg_det_7_005.png]"
                 data-order="0"
                 data-bbox="259.1129150390625,227.3218536376953,2985.32373046875,1998.563232421875">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 42.65858764648438px; top: 396.4622802734375px; width: 284.17478637695314px; height: 5.500195312500001px;"
                 title=""
                 data-order="1"
                 data-bbox="213.29293823242188,1982.3114013671875,1634.1668701171875,2009.8123779296875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 43.35899353027344px; top: 421.48300781250003px; width: 287.5394195556641px; height: 53.591162109375006px;"
                 title="Fig. 6 | HI antibody responses to egg and cell propagated vaccine viruses at pre- and 1 month post vaccination in year 2 stratified by 7 repeat vaccination arms. HI antibody titers from each of the 7 ..."
                 data-order="2"
                 data-bbox="216.7949676513672,2107.4150390625,1654.4920654296875,2375.370849609375">
                Fig. 6 | HI antibody responses to egg and cell propagated vaccine viruses at pre- and 1 month post vaccination in year 2 stratified by 7 repeat vaccination arms. HI antibody titers from each of the 7 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.691201782226564px; top: 490.363720703125px; width: 283.11219177246096px; height: 151.25810546875002px;"
                 title="B/VIC B/YAM Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 0.001 0.014 0 0003 Day 0 1 m 5 10 20 40 80 160 320 640 1280-256..."
                 data-order="3"
                 data-bbox="218.4560089111328,2451.818603515625,1634.0169677734375,3208.109130859375">
                B/VIC B/YAM Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 0.001 0.014 0 0003 Day 0 1 m 5 10 20 40 80 160 320 640 1280-256...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.29273986816406px; top: 631.1895507812501px; width: 283.1022064208984px; height: 197.54853515625px;"
                 title="A (H3 N2) A (H1 N1) pdm09 18-44 yrs egg virus 18-44 yrs cell virus Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 &lt;0 0001 ..."
                 data-order="4"
                 data-bbox="221.4636993408203,3155.94775390625,1636.9747314453125,4143.6904296875">
                A (H3 N2) A (H1 N1) pdm09 18-44 yrs egg virus 18-44 yrs cell virus Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 &lt;0 0001 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.18625488281253px; top: 395.26853027343753px; width: 285.9964599609375px; height: 68.8024169921875px;"
                 title="(n 45), RIV4 RIV4 (n 44), IIV4 ccIIV4 (n 57), IIV4 RIV4 (n 56), IIV4 IIV4 (n 56). Unpaired ttest (two tailed was used to compare the post vaccination GMTs to cell vaccine viruses between IIV4-IIV4 (Fl..."
                 data-order="5"
                 data-bbox="1695.9312744140625,1976.3426513671875,3125.91357421875,2320.354736328125">
                (n 45), RIV4 RIV4 (n 44), IIV4 ccIIV4 (n 57), IIV4 RIV4 (n 56), IIV4 IIV4 (n 56). Unpaired ttest (two tailed was used to compare the post vaccination GMTs to cell vaccine viruses between IIV4-IIV4 (Fl...
            </div>
            

            <div class="text-block text" 
                 style="left: 336.1788330078125px; top: 491.441357421875px; width: 288.0139892578125px; height: 73.544189453125px;"
                 title="Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 &lt;0 0001 0.007 0 0006 &lt;0 0001"
                 data-order="6"
                 data-bbox="1680.8941650390625,2457.206787109375,3120.964111328125,2824.927734375">
                Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 &lt;0 0001 0.007 0 0006 &lt;0 0001
            </div>
            

            <div class="text-block text" 
                 style="left: 337.86044921875003px; top: 563.907373046875px; width: 288.905908203125px; height: 166.990185546875px;"
                 title="Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 0.01 0.004 0.01 Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titer..."
                 data-order="7"
                 data-bbox="1689.30224609375,2819.536865234375,3133.831787109375,3654.48779296875">
                Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 0.01 0.004 0.01 Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titer...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.5493408203125px; top: 723.7638671875001px; width: 286.8440673828125px; height: 103.45244140625px;"
                 title="45-64 yrs egg virus 45-64 yrs cell virus Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 ccIIV4-ccIIV4 ccIIV4-RIV4 RIV4-ccI..."
                 data-order="8"
                 data-bbox="1692.7467041015625,3618.8193359375,3126.967041015625,4136.08154296875">
                45-64 yrs egg virus 45-64 yrs cell virus Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 HI titers (Log2 scale) Day 0 1 m 5 10 20 40 80 160 320 640 1280-2560 5120 ccIIV4-ccIIV4 ccIIV4-RIV4 RIV4-ccI...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 9</div>

            <div class="figure-block" 
                 style="left: 50.465057373046875px; top: 51.499847412109375px; width: 546.0111633300781px; height: 306.67839965820315px;"
                 title="[FIGURE 1 - See figure_p9_det_8_005.png]"
                 data-order="0"
                 data-bbox="252.32528686523438,257.4992370605469,2982.381103515625,1790.8912353515625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 46.84069519042969px; top: 355.41599121093753px; width: 289.6593780517578px; height: 55.151123046875px;"
                 title="g y ggg years, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A). However, for A (H1 N1) pdm09 and B viruses, the difference in ..."
                 data-order="1"
                 data-bbox="234.20347595214844,1777.0799560546875,1682.5003662109375,2052.8355712890625">
                g y ggg years, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A). However, for A (H1 N1) pdm09 and B viruses, the difference in ...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.827639770507815px; top: 429.12387695312503px; width: 284.4061004638672px; height: 221.722412109375px;"
                 title="IIV4 and ccIIV4 (15 µg HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody Fig. 7 | Dynamics of proportion of participants with HI GM..."
                 data-order="2"
                 data-bbox="219.13819885253906,2145.619384765625,1641.168701171875,3254.2314453125">
                IIV4 and ccIIV4 (15 µg HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody Fig. 7 | Dynamics of proportion of participants with HI GM...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.12918395996094px; top: 646.4378417968751px; width: 282.31153869628906px; height: 182.35024414062502px;"
                 title=""
                 data-order="3"
                 data-bbox="220.6459197998047,3232.189208984375,1632.20361328125,4143.9404296875">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 337.4097900390625px; top: 354.0916748046875px; width: 290.5261962890625px; height: 55.7203369140625px;"
                 title="have reported that Q223 R egg adapted change at the HA head domain of A (H1 N1) pdm09 virus can promote virus replication in eggs, alter antigen i city and influence immune response 37 42. In this stu..."
                 data-order="4"
                 data-bbox="1687.0489501953125,1770.4583740234375,3139.679931640625,2049.06005859375">
                have reported that Q223 R egg adapted change at the HA head domain of A (H1 N1) pdm09 virus can promote virus replication in eggs, alter antigen i city and influence immune response 37 42. In this stu...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.53549804687503px; top: 432.268017578125px; width: 287.454248046875px; height: 207.33085937500002px;"
                 title="The impact of egg adaptation was the least profound on the years age group. Fisher’sexact test (two tailed was performed for comparing proportions of ≥4 -fold reduced titer to cell vaccine virus betwe..."
                 data-order="5"
                 data-bbox="1692.677490234375,2161.340087890625,3129.94873046875,3197.994384765625">
                The impact of egg adaptation was the least profound on the years age group. Fisher’sexact test (two tailed was performed for comparing proportions of ≥4 -fold reduced titer to cell vaccine virus betwe...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.5611572265625px; top: 630.506640625px; width: 286.2127197265625px; height: 194.16455078125px;"
                 title=""
                 data-order="6"
                 data-bbox="1692.8057861328125,3152.533203125,3123.869384765625,4123.35595703125">
                
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 10</div>

            <div class="figure-block" 
                 style="left: 63.22056274414063px; top: 47.23918151855469px; width: 545.2701599121094px; height: 350.4983673095703px;"
                 title="[FIGURE 1 - See figure_p10_mrg_det_9_004.png]"
                 data-order="0"
                 data-bbox="316.1028137207031,236.19590759277344,3042.45361328125,1988.687744140625">
                <span>Figure</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 43.904553222656254px; top: 406.217041015625px; width: 284.3302368164063px; height: 57.472851562500004px;"
                 title="g | g y p ypre- and 1 month post vaccination in 7 repeat vaccination arms. Antibody titers from each of the 7 vaccine arms were presented as geometric mean titers (GMTs) with 95% confidence interval (..."
                 data-order="1"
                 data-bbox="219.52276611328125,2031.085205078125,1641.1739501953125,2318.449462890625">
                g | g y p ypre- and 1 month post vaccination in 7 repeat vaccination arms. Antibody titers from each of the 7 vaccine arms were presented as geometric mean titers (GMTs) with 95% confidence interval (...
            </div>
            

            <div class="text-block text" 
                 style="left: 45.66031188964844px; top: 455.596923828125px; width: 280.7110992431641px; height: 85.28427734375px;"
                 title="B/YAM Day 0 1 m 400 800 1600-3200 6400-12800 25600 ELISA titers (Log2 sca Day 0 1 m 400 800 1600-3200 6400-12800 25600 Fig. 8 | HA head and stalk binding antibody responses measured by ELISA at pre- a..."
                 data-order="2"
                 data-bbox="228.3015594482422,2277.984619140625,1631.8570556640625,2704.406005859375">
                B/YAM Day 0 1 m 400 800 1600-3200 6400-12800 25600 ELISA titers (Log2 sca Day 0 1 m 400 800 1600-3200 6400-12800 25600 Fig. 8 | HA head and stalk binding antibody responses measured by ELISA at pre- a...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.330874633789065px; top: 559.9555175781251px; width: 281.53880310058594px; height: 209.67910156250002px;"
                 title="A (H1 N1) pdm09 B/VIC Day 0 1 m 400 800 1600 ELISA tite Day 0 1 m 400 800 1600-3200 Day 0 1 m 400 800 1600-3200 6400-12800 25600-51200 ELISA titers (Log2 scale) Day 0 1 m 400 800 1600-3200 6400-12800 ..."
                 data-order="3"
                 data-bbox="221.6543731689453,2799.777587890625,1629.348388671875,3848.173095703125">
                A (H1 N1) pdm09 B/VIC Day 0 1 m 400 800 1600 ELISA tite Day 0 1 m 400 800 1600-3200 Day 0 1 m 400 800 1600-3200 6400-12800 25600-51200 ELISA titers (Log2 scale) Day 0 1 m 400 800 1600-3200 6400-12800 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 44.532449340820314px; top: 766.679443359375px; width: 284.0390838623047px; height: 61.820751953125004px;"
                 title="A (H3 N2) A Egg virus HA Cell virus HA 3200-6400 12800-25600 51200 ters (Log2 scale) 3200-6400 12800-25600 51200 0.039"
                 data-order="4"
                 data-bbox="222.66224670410156,3833.397216796875,1642.857666015625,4142.5009765625">
                A (H3 N2) A Egg virus HA Cell virus HA 3200-6400 12800-25600 51200 ters (Log2 scale) 3200-6400 12800-25600 51200 0.039
            </div>
            

            <div class="text-block text" 
                 style="left: 337.23491210937505px; top: 405.35712890625px; width: 290.8322265625px; height: 123.57680664062501px;"
                 title="0 1 2 3 RIV4-ccIIV4 RIV4-RIV4 IIV4-ccIIV4 IIV4-RIV4 IIV4-IIV4 H3 stalk H1 stalk Geometric mean fold titers to HA stalk within the same age group (A). One way ANOVA corrected for multiple comparisons (..."
                 data-order="5"
                 data-bbox="1686.174560546875,2026.78564453125,3140.335693359375,2644.669677734375">
                0 1 2 3 RIV4-ccIIV4 RIV4-RIV4 IIV4-ccIIV4 IIV4-RIV4 IIV4-IIV4 H3 stalk H1 stalk Geometric mean fold titers to HA stalk within the same age group (A). One way ANOVA corrected for multiple comparisons (...
            </div>
            

            <div class="text-block text" 
                 style="left: 340.9273681640625px; top: 559.698974609375px; width: 282.1392822265625px; height: 171.620947265625px;"
                 title="Day 0 1 m 200 400 800 1600-3200 6400 ELISA titers (Log2 scale) IIV4-ccIIV4 IIV4-RIV4 IIV4-IIV4 ccIIV4-ccIIV4 ccIIV4-RIV4 RIV4-ccIIV4 RIV4-RIV4 * * * * Day 0 1 m 200 400 800 1600-3200 6400-12800 25600 ..."
                 data-order="6"
                 data-bbox="1704.6368408203125,2798.494873046875,3115.333251953125,3656.599609375">
                Day 0 1 m 200 400 800 1600-3200 6400 ELISA titers (Log2 scale) IIV4-ccIIV4 IIV4-RIV4 IIV4-IIV4 ccIIV4-ccIIV4 ccIIV4-RIV4 RIV4-ccIIV4 RIV4-RIV4 * * * * Day 0 1 m 200 400 800 1600-3200 6400-12800 25600 ...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.07021484375px; top: 729.87724609375px; width: 288.3708984375px; height: 97.71572265625001px;"
                 title="B 0 1 2 3 4 ccIIV4-ccIIV4 ccIIV4-RIV4 RIV4-ccIIV4 RIV4-RIV4 IIV4-ccIIV4 IIV4-RIV4 IIV4-IIV4 H3 HA H1 HA B/VIC HA B/YAM HA Geometric mean ratio of ELISA titer egg cell HA (95% CI) ccIIV4-ccIIV4 ccIIV4-..."
                 data-order="7"
                 data-bbox="1690.35107421875,3649.38623046875,3132.20556640625,4137.96484375">
                B 0 1 2 3 4 ccIIV4-ccIIV4 ccIIV4-RIV4 RIV4-ccIIV4 RIV4-RIV4 IIV4-ccIIV4 IIV4-RIV4 IIV4-IIV4 H3 HA H1 HA B/VIC HA B/YAM HA Geometric mean ratio of ELISA titer egg cell HA (95% CI) ccIIV4-ccIIV4 ccIIV4-...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 11</div>

            <div class="text-block title" 
                 style="left: 42.378787231445315px; top: 51.65144653320313px; width: 209.7574676513672px; height: 14.375714111328126px;"
                 title="p g y y y"
                 data-order="0"
                 data-bbox="211.89393615722656,258.2572326660156,1260.6812744140625,330.13580322265625">
                p g y y y
            </div>
            

            <div class="table-block" 
                 style="left: 46.94664611816407px; top: 70.84563598632813px; width: 281.77532653808595px; height: 274.6375671386719px;"
                 title="[TABLE 2 - See table_p11_det_10_013.png]"
                 data-order="1"
                 data-bbox="234.7332305908203,354.2281799316406,1643.60986328125,1727.416015625">
                <span>Table</span>
            </div>
            

            <div class="text-block text" 
                 style="left: 45.092935180664064px; top: 360.6898193359375px; width: 283.404623413086px; height: 38.0136474609375px;"
                 title="y p pblinding were previously described 27 29. Participant characterisitcs in year 1 are described in Table 2. During Year 1, HCP were stratified by two age groups (18−44 years and 45−64 years) and ra..."
                 data-order="2"
                 data-bbox="225.4646759033203,1803.4490966796875,1642.48779296875,1993.517333984375">
                y p pblinding were previously described 27 29. Participant characterisitcs in year 1 are described in Table 2. During Year 1, HCP were stratified by two age groups (18−44 years and 45−64 years) and ra...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.89830627441407px; top: 407.3362060546875px; width: 130.6973602294922px; height: 25.6208740234375px;"
                 title="United States during the Norther 2019-2020 (Year 2) influenza s l i h dil d i i"
                 data-order="3"
                 data-bbox="219.4915313720703,2036.6810302734375,872.9783325195312,2164.785400390625">
                United States during the Norther 2019-2020 (Year 2) influenza s l i h dil d i i
            </div>
            

            <div class="text-block text" 
                 style="left: 42.94656677246094px; top: 429.63056640625px; width: 284.4756744384766px; height: 186.2763671875px;"
                 title="findings from comparative immunogen i city studies and provide additional information to identify optimal vaccination strategies to prevent influenza. Materials and methods Study design The original s..."
                 data-order="4"
                 data-bbox="214.7328338623047,2148.15283203125,1637.1112060546875,3079.53466796875">
                findings from comparative immunogen i city studies and provide additional information to identify optimal vaccination strategies to prevent influenza. Materials and methods Study design The original s...
            </div>
            

            <div class="text-block text" 
                 style="left: 43.073123168945315px; top: 610.7828125px; width: 288.2364227294922px; height: 121.45712890625px;"
                 title="g, y ( ) (11) (11) (11) (12) Age Group 18−44 years 57 47 55 46 135 48 99 50 45−64 years 65 53 65 54 148 52 99 50 Female 107 88 103 86 233 82 157 79 White 110 90 94 78 232 82 148 75 Hispanic 13 11 19 1..."
                 data-order="5"
                 data-bbox="215.36561584472656,3053.9140625,1656.5477294921875,3661.19970703125">
                g, y ( ) (11) (11) (11) (12) Age Group 18−44 years 57 47 55 46 135 48 99 50 45−64 years 65 53 65 54 148 52 99 50 Female 107 88 103 86 233 82 157 79 White 110 90 94 78 232 82 148 75 Hispanic 13 11 19 1...
            </div>
            

            <div class="text-block title" 
                 style="left: 43.50586853027344px; top: 742.5789550781251px; width: 264.05335998535156px; height: 26.0546875px;"
                 title="n % n % n % n Demographic characteristics"
                 data-order="6"
                 data-bbox="217.5293426513672,3712.894775390625,1537.796142578125,3843.168212890625">
                n % n % n % n Demographic characteristics
            </div>
            

            <div class="text-block text" 
                 style="left: 44.989599609375006px; top: 764.2873046875001px; width: 282.5989013671875px; height: 51.346484375px;"
                 title="| p y Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 n = 122 n = 120 n = 283 n = 198"
                 data-order="7"
                 data-bbox="224.947998046875,3821.4365234375,1637.9425048828125,4078.1689453125">
                | p y Flu zone IIV4 Fluarix IIV4 ccIIV4 RIV4 n = 122 n = 120 n = 283 n = 198
            </div>
            

            <div class="text-block text" 
                 style="left: 336.73588867187505px; top: 50.66380004882813px; width: 286.76279296875003px; height: 125.13455200195312px;"
                 title="Statistical analyses Geometric mean titers (GMTs) at day 0, 1 month and 6 months, geometric mean fold rise (GMFR) of antibody titers at 1 month versus day 0, and geometric mean fold reduction of antib..."
                 data-order="8"
                 data-bbox="1683.679443359375,253.31900024414062,3117.493408203125,878.9917602539062">
                Statistical analyses Geometric mean titers (GMTs) at day 0, 1 month and 6 months, geometric mean fold rise (GMFR) of antibody titers at 1 month versus day 0, and geometric mean fold reduction of antib...
            </div>
            

            <div class="text-block text" 
                 style="left: 338.6759765625px; top: 171.68850097656252px; width: 284.119287109375px; height: 135.17412109375002px;"
                 title="(HRP) conjugated goat anti human pan immunoglobulin conjugate to detect total binding antibodies. ELISA was performed based on previously described procedures 46 47. The ELISA titers were determined a..."
                 data-order="9"
                 data-bbox="1693.3798828125,858.4425048828125,3113.976318359375,1534.3131103515625">
                (HRP) conjugated goat anti human pan immunoglobulin conjugate to detect total binding antibodies. ELISA was performed based on previously described procedures 46 47. The ELISA titers were determined a...
            </div>
            

            <div class="text-block title" 
                 style="left: 338.10820312500005px; top: 313.90988769531253px; width: 207.54360351562502px; height: 8.314013671875001px;"
                 title="serial dilution. Antibodies were detected by hors"
                 data-order="10"
                 data-bbox="1690.541015625,1569.5494384765625,2728.259033203125,1611.1195068359375">
                serial dilution. Antibodies were detected by hors
            </div>
            

            <div class="text-block text" 
                 style="left: 340.1687744140625px; top: 328.100537109375px; width: 285.6532470703125px; height: 295.9212890625px;"
                 title="0019-2016 viruses were tested in MN as says in year 1 using MDCK-SIAT1 cells using methods as previously described 44. In Year 2, egg- and cell propagated A/Kansas/14/2017 viruses were tested by HI as..."
                 data-order="11"
                 data-bbox="1700.8438720703125,1640.502685546875,3129.110107421875,3120.109130859375">
                0019-2016 viruses were tested in MN as says in year 1 using MDCK-SIAT1 cells using methods as previously described 44. In Year 2, egg- and cell propagated A/Kansas/14/2017 viruses were tested by HI as...
            </div>
            

            <div class="text-block title" 
                 style="left: 338.9541748046875px; top: 635.8085449218751px; width: 85.61110839843751px; height: 13.160449218750001px;"
                 title="gg g MDCK cells with c"
                 data-order="12"
                 data-bbox="1694.7708740234375,3179.042724609375,2122.826416015625,3244.844970703125">
                gg g MDCK cells with c
            </div>
            

            <div class="text-block text" 
                 style="left: 337.1602783203125px; top: 647.7689453125px; width: 288.6873779296875px; height: 49.507861328125px;"
                 title="y p ( ) y yas says in year 1 (the cell grown vaccine antigen of the study year does not hemagglutinate in the HI as says, and HI as says in year 2. Egg grown A (H3 N2) viruses were propagated in 10 da..."
                 data-order="13"
                 data-bbox="1685.8013916015625,3238.8447265625,3129.23828125,3486.384033203125">
                y p ( ) y yas says in year 1 (the cell grown vaccine antigen of the study year does not hemagglutinate in the HI as says, and HI as says in year 2. Egg grown A (H3 N2) viruses were propagated in 10 da...
            </div>
            

            <div class="text-block title" 
                 style="left: 338.08720703125005px; top: 706.1263671875px; width: 88.3388671875px; height: 14.248437500000001px;"
                 title="were tested in year 2"
                 data-order="14"
                 data-bbox="1690.43603515625,3530.6318359375,2132.13037109375,3601.8740234375">
                were tested in year 2
            </div>
            

            <div class="text-block text" 
                 style="left: 337.81369628906253px; top: 716.7545898437501px; width: 287.72702636718753px; height: 100.19428710937501px;"
                 title="p p g y ygg g A (H1 N1) pdm09 and influenza B viruses were propagated in MadinDarby canine kidney (MDCK) cells. Influenza B antigens were ether treated prior to use in the HI as says. Egg- and cell (M..."
                 data-order="15"
                 data-bbox="1689.0684814453125,3583.77294921875,3127.70361328125,4084.744384765625">
                p p g y ygg g A (H1 N1) pdm09 and influenza B viruses were propagated in MadinDarby canine kidney (MDCK) cells. Influenza B antigens were ether treated prior to use in the HI as says. Egg- and cell (M...
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 12</div>

            <div class="text-block list" 
                 style="left: 44.893960571289064px; top: 51.041601562500006px; width: 304.163412475586px; height: 35.721197509765624px;"
                 title="vated influenza vaccine in children. Vaccine 38, 5171-5177 (2020). 12. Hart vick son, R. et al. Non inferiority of mammalian cell derived quad rival ent subunit influenza virus vaccines compared to tr..."
                 data-order="0"
                 data-bbox="224.4698028564453,255.2080078125,1745.286865234375,433.8139953613281">
                vated influenza vaccine in children. Vaccine 38, 5171-5177 (2020). 12. Hart vick son, R. et al. Non inferiority of mammalian cell derived quad rival ent subunit influenza virus vaccines compared to tr...
            </div>
            

            <div class="text-block list" 
                 style="left: 42.4886474609375px; top: 209.67473144531252px; width: 583.8827880859375px; height: 618.9877685546876px;"
                 title="with MN or HI GMT egg cell titer ratio ≥4 fold was calculated to quantify the percent of participants with antibodies predominantly targeting egg adapted epi topes per vaccine group. One way ANOVA cor..."
                 data-order="1"
                 data-bbox="212.4432373046875,1048.3736572265625,3131.857177734375,4143.3125">
                with MN or HI GMT egg cell titer ratio ≥4 fold was calculated to quantify the percent of participants with antibodies predominantly targeting egg adapted epi topes per vaccine group. One way ANOVA cor...
            </div>
            

            <div class="text-block text" 
                 style="left: 362.0299072265625px; top: 53.5526123046875px; width: 251.51442871093752px; height: 4.4814697265625005px;"
                 title="vaccines who recommendations."
                 data-order="2"
                 data-bbox="1810.1495361328125,267.7630615234375,3067.7216796875,290.17041015625">
                vaccines who recommendations.
            </div>
            
</div>
<div class="page-container" data-width="3299.41259765625" data-height="4243.9404296875" style="width: 659.8825195312501px; height: 848.7880859375px;">
<div class="page-header">Page 13</div>

            <div class="text-block title" 
                 style="left: 42.85700073242188px; top: 24.154620361328128px; width: 37.516717529296876px; height: 15.039889526367189px;"
                 title="Nature Co"
                 data-order="0"
                 data-bbox="214.28500366210938,120.77310180664062,401.86859130859375,195.97254943847656">
                Nature Co
            </div>
            

            <div class="text-block list" 
                 style="left: 36.872805786132815px; top: 45.63726806640625px; width: 549.2675750732423px; height: 126.6885986328125px;"
                 title="Acknowledgements We thank the staff from Baylor Scott &amp; White Health and Kaiser Permanente Northwest for their participation and support of the study. We © This is a U.S. Government work and not under..."
                 data-order="1"
                 data-bbox="184.36402893066406,228.18634033203125,2930.701904296875,861.6293334960938">
                Acknowledgements We thank the staff from Baylor Scott &amp; White Health and Kaiser Permanente Northwest for their participation and support of the study. We © This is a U.S. Government work and not under...
            </div>
            

            <div class="text-block text" 
                 style="left: 58.002960205078125px; top: 398.789501953125px; width: 268.7261413574219px; height: 33.67578125px;"
                 title="California 7 09 (H1 N1) vaccines with high yield in embryonated chicken eggs. J. Virol. 84, 44-51 (2010). Caton, A. J., Brown lee, G. G., Yew dell, J. W. &amp; Gerhard, W. The"
                 data-order="2"
                 data-bbox="290.0148010253906,1993.947509765625,1633.6455078125,2162.326416015625">
                California 7 09 (H1 N1) vaccines with high yield in embryonated chicken eggs. J. Virol. 84, 44-51 (2010). Caton, A. J., Brown lee, G. G., Yew dell, J. W. &amp; Gerhard, W. The
            </div>
            

            <div class="text-block text" 
                 style="left: 65.17725219726563px; top: 670.945361328125px; width: 259.5188659667969px; height: 24.993994140625002px;"
                 title="nfluenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303, 1-8 (2002)."
                 data-order="3"
                 data-bbox="325.8862609863281,3354.726806640625,1623.4805908203125,3479.69677734375">
                nfluenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303, 1-8 (2002).
            </div>
            

            <div class="text-block text" 
                 style="left: 42.70801696777344px; top: 719.4909179687501px; width: 284.1009918212891px; height: 24.02587890625px;"
                 title="G. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta analysis. Lancet Res pir. Med. 11,"
                 data-order="4"
                 data-bbox="213.5400848388672,3597.45458984375,1634.0450439453125,3717.583984375">
                G. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta analysis. Lancet Res pir. Med. 11,
            </div>
            

            <div class="text-block text" 
                 style="left: 339.29477539062503px; top: 172.32586669921875px; width: 284.64794921875px; height: 34.32479248046875px;"
                 title="holder. To view acopy of this licence, visit http creative commons org licenses by 4 0."
                 data-order="5"
                 data-bbox="1696.473876953125,861.6293334960938,3119.713623046875,1033.2532958984375">
                holder. To view acopy of this licence, visit http creative commons org licenses by 4 0.
            </div>
            

            <div class="text-block text" 
                 style="left: 343.28583984375px; top: 240.1082763671875px; width: 279.29150390625px; height: 4.4230712890625px;"
                 title="...’ C i C li d i d d"
                 data-order="6"
                 data-bbox="1716.42919921875,1200.5413818359375,3112.88671875,1222.65673828125">
                ...’ C i C li d i d d
            </div>
            

            <div class="text-block text" 
                 style="left: 339.69589843750003px; top: 266.607470703125px; width: 284.97578125px; height: 47.1330810546875px;"
                 title="adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author (s) and the source, provide alink to the Creative Commons licence, and ..."
                 data-order="7"
                 data-bbox="1698.4794921875,1333.037353515625,3123.3583984375,1568.7027587890625">
                adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author (s) and the source, provide alink to the Creative Commons licence, and ...
            </div>
            

            <div class="text-block text" 
                 style="left: 339.38400878906253px; top: 339.3760009765625px; width: 230.4828857421875px; height: 14.7527587890625px;"
                 title="isdictional claims in published maps and institutional affili"
                 data-order="8"
                 data-bbox="1696.9200439453125,1696.8800048828125,2849.33447265625,1770.643798828125">
                isdictional claims in published maps and institutional affili
            </div>
            

            <div class="text-block text" 
                 style="left: 356.08134765625005px; top: 362.66525878906253px; width: 164.20156250000002px; height: 12.0276611328125px;"
                 title="lisher’snote Springer Nature remains neu"
                 data-order="9"
                 data-bbox="1780.40673828125,1813.3262939453125,2601.41455078125,1873.464599609375">
                lisher’snote Springer Nature remains neu
            </div>
            

            <div class="text-block text" 
                 style="left: 337.59746093750005px; top: 385.8724609375px; width: 287.553466796875px; height: 24.920361328125px;"
                 title="Reprints and permissions information is available at http www nature com reprints"
                 data-order="10"
                 data-bbox="1687.9873046875,1929.3623046875,3125.754638671875,2053.964111328125">
                Reprints and permissions information is available at http www nature com reprints
            </div>
            

            <div class="text-block text" 
                 style="left: 336.82780761718755px; top: 422.36386718750003px; width: 287.2728271484375px; height: 36.065869140625004px;"
                 title="Peer review information Nature Communications thanks Sure nder Khurana and the other, anonymous, reviewer (s) for their contribution to the peer review of this work."
                 data-order="11"
                 data-bbox="1684.1390380859375,2111.8193359375,3120.503173828125,2292.148681640625">
                Peer review information Nature Communications thanks Sure nder Khurana and the other, anonymous, reviewer (s) for their contribution to the peer review of this work.
            </div>
            

            <div class="text-block title" 
                 style="left: 338.97409667968753px; top: 469.675537109375px; width: 209.9163818359375px; height: 24.357275390625002px;"
                 title="Correspondence and requests for materials should b Z. Levine."
                 data-order="12"
                 data-bbox="1694.8704833984375,2348.377685546875,2744.452392578125,2470.1640625">
                Correspondence and requests for materials should b Z. Levine.
            </div>
            

            <div class="text-block text" 
                 style="left: 337.862255859375px; top: 504.786376953125px; width: 271.356591796875px; height: 26.314599609375px;"
                 title="pp ysupplementary material available at https://doi.org/10.1038/s41467-023-44551-x."
                 data-order="13"
                 data-bbox="1689.311279296875,2523.931884765625,3046.09423828125,2655.5048828125">
                pp ysupplementary material available at https://doi.org/10.1038/s41467-023-44551-x.
            </div>
            

            <div class="text-block list" 
                 style="left: 339.994775390625px; top: 532.4770019531251px; width: 287.1478515625px; height: 153.47368164062502px;"
                 title="p g , , , , , M. G. W., L. J. E., L. G., S. S. K., S. S., S. G., performed the studies and acquired the data. F. L. and S. J. analyzed the data. F. L. and M. Z. L. wrote the manuscript. M. Z. L. super..."
                 data-order="14"
                 data-bbox="1699.973876953125,2662.385009765625,3135.713134765625,3429.75341796875">
                p g , , , , , M. G. W., L. J. E., L. G., S. S. K., S. S., S. G., performed the studies and acquired the data. F. L. and S. J. analyzed the data. F. L. and M. Z. L. wrote the manuscript. M. Z. L. super...
            </div>
            

            <div class="text-block title" 
                 style="left: 340.58469238281253px; top: 693.994873046875px; width: 69.9366943359375px; height: 2.5592773437500003px;"
                 title=""
                 data-order="15"
                 data-bbox="1702.9234619140625,3469.974365234375,2052.60693359375,3482.770751953125">
                
            </div>
            

            <div class="text-block text" 
                 style="left: 340.73691406250003px; top: 707.297412109375px; width: 282.40458984375px; height: 24.774658203125px;"
                 title="Author contributions"
                 data-order="16"
                 data-bbox="1703.6845703125,3536.487060546875,3115.70751953125,3660.3603515625">
                Author contributions
            </div>
            

            <div class="text-block text" 
                 style="left: 44.398233032226564px; top: 769.448486328125px; width: 579.5559661865235px; height: 37.13515625px;"
                 title="States During the 2018-2019 Influenza Season. Clin. Infect. Dis. 71, e368-e376 (2020). 32. Ramsay, L. C. et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic revi..."
                 data-order="17"
                 data-bbox="221.9911651611328,3847.242431640625,3119.77099609375,4032.918212890625">
                States During the 2018-2019 Influenza Season. Clin. Infect. Dis. 71, e368-e376 (2020). 32. Ramsay, L. C. et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic revi...
            </div>
            
</div>
</div>
</div>
</div>

        <div class="scale-controls">
            <button onclick="adjustScale(-0.05)">-</button>
            <span class="scale-display" id="scale-display">20%</span>
            <button onclick="adjustScale(0.05)">+</button>
            <button onclick="resetScale()">Reset</button>
        </div>
        
        <div class="block-tooltip" id="tooltip"></div>
        
        <script>
        let currentScale = 0.2;
        
        function showDocument(docName) {
            // Hide all documents
            document.querySelectorAll('.document-wrapper').forEach(doc => {
                doc.classList.remove('active');
            });
            
            // Show selected document
            const selectedDoc = document.getElementById('doc-' + docName);
            if (selectedDoc) {
                selectedDoc.classList.add('active');
            }
        }
        
        function adjustScale(delta) {
            currentScale = Math.max(0.1, Math.min(1.0, currentScale + delta));
            updateScale();
        }
        
        function resetScale() {
            currentScale = 0.2;
            updateScale();
        }
        
        function updateScale() {
            document.getElementById('scale-display').textContent = Math.round(currentScale * 100) + '%';
            
            // Update all page containers and blocks
            document.querySelectorAll('.page-container').forEach(page => {
                const baseWidth = parseFloat(page.getAttribute('data-width')) || (8.5 * 400);
                const baseHeight = parseFloat(page.getAttribute('data-height')) || (11 * 400);

                page.style.width = (baseWidth * currentScale) + 'px';
                page.style.height = (baseHeight * currentScale) + 'px';
            });
            
            // Update all blocks
            document.querySelectorAll('.text-block, .figure-block, .table-block').forEach(block => {
                const bbox = block.getAttribute('data-bbox');
                if (bbox) {
                    const [x1, y1, x2, y2] = bbox.split(',').map(Number);
                    block.style.left = (x1 * currentScale) + 'px';
                    block.style.top = (y1 * currentScale) + 'px';
                    block.style.width = ((x2 - x1) * currentScale) + 'px';
                    block.style.height = ((y2 - y1) * currentScale) + 'px';
                    block.style.fontSize = (currentScale * 100) + '%';
                }
            });
        }
        
        // Show reading order on hover
        document.addEventListener('DOMContentLoaded', function() {
            const tooltip = document.getElementById('tooltip');
            
            document.querySelectorAll('.text-block, .figure-block, .table-block').forEach(block => {
                // Store original bbox for scaling
                const style = block.style;
                const x1 = parseFloat(style.left) / currentScale;
                const y1 = parseFloat(style.top) / currentScale;
                const x2 = x1 + parseFloat(style.width) / currentScale;
                const y2 = y1 + parseFloat(style.height) / currentScale;
                block.setAttribute('data-bbox', `${x1},${y1},${x2},${y2}`);
                
                // Tooltip on hover
                block.addEventListener('mouseenter', function(e) {
                    const order = this.getAttribute('data-order');
                    tooltip.textContent = `Reading Order: ${parseInt(order) + 1}`;
                    tooltip.style.display = 'block';
                });
                
                block.addEventListener('mousemove', function(e) {
                    tooltip.style.left = (e.pageX + 10) + 'px';
                    tooltip.style.top = (e.pageY - 30) + 'px';
                });
                
                block.addEventListener('mouseleave', function() {
                    tooltip.style.display = 'none';
                });
            });
        });
        </script>
        
</body></html>